annual report scienceled global healthcare company performance summary bn bn aer aer group turnover cer new specialty medicines cer bn bn aer aer total operating profit cer adjusted operating profit cer p p aer aer total earnings per share cer adjusted earnings per share cer p st nd major pipeline dividend access pharmaceutical approvals medicine index industry dow jones sustainability index contents strategic report business model board roles responsibilities financial statements chairmans statement board activity principal decisions glaxosmithkline plc prepared ceos statement purpose values culture uk gaap financial performance boards approach engagement investor information longterm priorities board performance culture board committee information quarterly trend key performance indicators board committee reports fiveyear record industry trends section statement product development pipeline stakeholder engagement directors report products competition innovation intellectual property remuneration report performance principal risks uncertainties trust chairmans annual statement share capital share price risk management annual report remuneration dividends group financial review remuneration policy summary financial calendar annual general meeting corporate governance financial statements tax information shareholders chairmans governance statement directors statement shareholder services contacts board responsibilities us law regulation corporate executive team independent auditors report group companies board architecture financial statements glossary terms notes financial statements cautionary statement see inside back cover document cautionary statement regarding forwardlooking statements nonifrs measures use number adjusted nonifrs measures report performance business total reported results represent group 's overall performance ifrs adjusted results proforma growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs adjusted results nonifrs measures defined pages reconciliations nearest ifrs measures pages strategic report governance remuneration financial statements investor information business model every day help improve health millions people around world discovering developing manufacturing innovative medicines vaccines consumer healthcare products operations span value chain identifying performance delivered investing effectively researching developing testing ground breaking business people executing competitively discoveries regulatory approval manufacturing ability launch new products successfully commercialisation remained resilient grow sales existing portfolio key challenging year world agile maintaining commercial success focus purpose strategic longterm priorities trust also critical success responsible central success people experts company commit use science technology science technology regulation intellectual property address health needs make products affordable commercialisation also collaborate worldleading available modern employer public experts form strategic partnerships complement commitments support trust priority cover broad existing capabilities range environmental social governance esg aspects commitments designed help us respond esg purpose strategy challenges opportunities within industry society purpose improve quality human life broadly contribute many un sustainable helping people feel better live longer guides development goals particularly goal ensure healthy lives actions key delivery strategy promote wellbeing bring differentiated highquality needed healthcare products many people possible preventing value create treating disease keeping people well scientific delivering purpose greatest contribution technical knowhow talented people make improve health people around world included delivering billion packs medicines longterm priorities million vaccine doses billion consumer priorities innovation performance trust healthcare products underpinned ambition build purpose performance driven culture aligned values patient shareholders part capital allocation focus transparency respect integrity expectations framework invest business provide shareholder courage accountability development teamwork returns paid dividend p per share delivered billion free cash flow innovation critical improve health create financial value total rd expenditure billion make positive contribution communities turnover increase aer operate employ people across cer previous year adjusted basis rd countries work directly suppliers expenditure billion turnover higher paid billion corporation tax also aer higher cer proforma basis pay significant amount business employment adjusted rd expenditure grew cer compared related taxes aim modern employer offer broad range employee benefits including preventative pharmaceuticals vaccines focus science healthcare services able attract related immune system human genetics advanced retain best people technology consumer healthcare leverage scientific expertise deep consumer insights create healthcare products meet consumer demands researchbased healthcare company rely intellectual property protection help ensure reasonable return investments continue research develop new innovative medicines gsk annual report business model continued preparing future creating two new companies year achieved important milestone early consistent strategic priorities launch one development organisation rd previous announcements started twoyear programme already enabling us even effective allocate prepare gsk separation two new leading companies budget share technical scientific expertise deliver new gsk new biopharma company focused specialty pipeline regardless modality medicines vaccines rd approach focused programme seeking improve science related immune system use human capabilities create efficiencies global support genetics new technologies new leader consumer functions continuing simplify focus manufacturing healthcare categoryleading power brands innovation network ensuring supply chain ready launch new based science consumer insights specialty medicines rationalising portfolio track separation new standalone biopharma divestments consumer healthcare companies new consumer healthcare company programme programme using unique catalyst separation supporting building key technology infrastructure reset capabilities cost base companies expertise necessary operate standalone company help support delivery significant value creation believe increased investment pipeline new opportunities see new gsk new consumer products together effective implementation twoyear healthcare programme set new company strong new gsk see clear opportunity drive common foundations future performance approach rd science related immune system financial benefits costs reporting associated converges across pharmaceuticals vaccines programme set pages capital allocation capital allocation framework key priorities capital invest business rd pipeline including business development vaccines capacity innovation new products improved shareholder returns dividends performance cash target x x cover generation returning dividend growth trust strict discipline returns gsk annual report strategic report governance remuneration financial statements investor information chairmans statement extraordinary challenging year continued progress strategy towards creation two new companies covid pandemic dominated aspects life importance businesses acting responsibly central business gsk exception impacts felt increasingly broad range stakeholders view operationally among people face huge companies part global health always challenges delivered financial guidance year important element gsks trust priority board continued make progress strategy pleased see gsk topped access medicine index environmental social governance esg testament leadership emma increasingly focus investors stakeholders management team navigated company board fully supports ambitious new environmental year ensured people across gsk remained focused goals climate nature new inclusion diversity purpose delivery performance id targets including race ethnicity management strategy announced board pleased see continued progress board also supports managements efforts contribute made companys strategic goals covid including progression potential vaccines disappointing yet translated improved total therapeutic treatments company world leading shareholder returns tsr progress made reinforces infectious diseases portfolio scientific expertise gsk boards confidence direction company opportunity contribute meaningfully current eventual split next year two new companies biopharma response pandemic work global institutions consumer healthcare combined meaningful support better longterm preparedness planning improvements operating performance onwards provides significant opportunity create value shareholders board changes board continues adapt support companys strengthening biopharma pipeline remains company 's priorities ensure effective delivery specifically new number one priority continued despite committee established oversee separation pandemic nine significant approvals nine pivotal trial transformation two companies corporate starts pipeline consisting potential medicines responsibility committee taken expanded remit vaccines focused infectious diseases oncology line greater focus esg science committee immunemediated diseases number assets could continues provide excellent oversight direction significant launches next five years rd strategy potential change medical practice provide material value company boards scientific committee may charles bancroft joined board nonexecutive closely involved hal team pipeline director charlie succeed judy lewent chair audit risk committee completion annual reporting operational financial performance resilient cycle judy steps board agm would year importantly seeing evidence significantly like thank enormous contribution gsk improved commercial capability execution years also grateful lynn elsenhans agreed driving good expansion key growth products stay board year ensure management also maintained strong focus cost continuity important work corporate responsibility controls cash generation see pipeline committee investment continued shortterm disruption adult vaccines business reflected earnings finally would like thank gsks employees partners guidance year shareholders customers support unprecedented year gsks capital allocation framework focuses investing rd pipeline new product launches vaccine supply capacity disciplined business development paid p per share shareholders expect intend implement new distribution policy dividends year sir jonathan symonds separate two new companies ensure chairman businesses competitive right capital structure capacity invest deliver growth shareholder returns overall expect aggregate distributions gsk across two new companies lower p per share currently paid gsk annual report ceos statement innovation healthcare impact heart purpose made significant progress continuing build highvalue biopharma pipeline focused vaccines specialty medicines remarkable year us despite challenges continued rd delivery also year progress gsk im proud way innovation healthcare impact heart purpose company responded support patients healthcare strengthening rd pipeline remains first priority systems people also delivering good financial made significant progress continuing performance advancing strategic transformation build highvalue biopharma pipeline focused vaccines speciality medicines harnessing science related progress means high confidence ability immune system use human genetics launch new competitive standalone biopharma advanced technologies consumer healthcare companies achieve meaningful global impact health opportunity nine major approvals medicines create significant value shareholders respiratory oncology hiv immunoinflammation remarkable achievement included zejulas expanded growth sales label ovarian cancer making potentially available group sales grew actual exchange rates aer women cabenuva worlds first longacting constant exchange rates cer billion injectable treatment hiv allows patients testament increased focus continued injections year instead taking daily pills place improving commercial execution nine pivotal trials started year including new speciality products drove growth sales vaccine candidate rsv virus high unmet need billion aer cer group causes thousands deaths hospitalisations innovative products account half year successful vaccine could play significant role pharmaceutical sales easing burden start late stage trials respiratory saw strong growth nucala biologic year including new longacting asthma medicine asthma trelegy inhaler asthma copd successful would given every six months hiv new twodrug regimens dovato juluca testament put patients heart rd doubled sales million oncology portfolio overall assets late stage continued grow zejula ovarian cancer significantly development many could transformational growing market share launch blenrep heavily patients products could launch pretreated multiple myeloma patients shingrix successful believe data positive potential vaccine shingles continued grow sales significant commercially billion despite significant disruption adult last year also executed business development vaccinations covid pandemic also saw deals strengthening capabilities acquisition new strong consumer health performance sales antibody mrna genetic platforms technologies cer proforma basis excluding brands divested review reflecting underlying strength brands continue use science contribute covid across portfolio response multiple fronts course disappointed delay vaccine developed sanofi strong performance growth drivers disciplined continue progress along others well cost control allowed us deliver guidance year inhouse externallypartnered therapeutics importantly set pandemic total earnings per share looking ahead potential need next generation p aer cer adjusted covid vaccines use emerging variants earnings per share p aer booster delighted recent collaboration cer curevac research develop several mrna vaccines strong cash generation free cash flow including covid billion declared dividend p per share expect pay gsk annual report strategic report governance remuneration financial statements investor information ceo 's statement continued separation preparation continued work partners longterm remain firmly track intention separate urgent global health needs following positive data two new exciting companies next year new gsk single dose treatment p vivax strain malaria biopharma new world leader consumer healthcare filed alongside partners medicines malaria venture mmv use children population disproportionately met first year targets separation affected disease licensed tb candidate programme integration consumer jv vaccine bill melinda gates research institute substantially complete second year twoyear continued development potential use lowincome transformation see investment pipeline countries high tb burdens pleased behind successfully launching new products sustain commitment important work recognised longterm competitive growth shortterm disruption access medicines index pandemic vaccines business reflected financial topped seventh time row guidance set continue expect meaningful improvement performance onwards people culture people shown remarkable dedication agility building trust resilience year unprecedented circumstances building trust stakeholders addition delivering included thousands employees sustainable financial returns critical pandemic continued work manufacturing facilities throughout highlighted need businesses operate responsible pandemic ensure vital medicines vaccines way life sciences companies ensure consumer products continued reach patients consumers widespread access medicines efforts meant despite challenges enter investor interest environmental social governance esg pipeline stronger commercial execution issues increased significantly last year believe sharper confidence higher ability deliver need transition net zero economy want sustainable longterm growth post separation play part protecting restoring peoples planets health november set ambitious industry leading want thank fantastic people partners environmental targets netzero impact climate without would succeed count change netpositive impact nature prepare exciting future gsk firmly believes value inclusion diversity set aspirational targets proportion ethnically diverse leaders vp level us uk reset gender target aiming increase female representation vp level globally also focusing improving diversity clinical trials emma walmsley ensure represent medicines safe chief executive officer effective realworld patient communities gsk annual report financial performance operating performance reported consumer healthcare sales grew aer cer million full year largely driven turnover inclusion pfizer portfolio partly offset brands divestedunder review proforma basis sales declined proforma growth growth growth cer grew cer excluding brands divestedunder cer cer review reflecting underlying strength brands across pharmaceuticals portfolio categories strong growth ecommerce vaccines successful execution meeting evolving consumer demand consumer healthcare result pandemic corporate operating profit unallocated turnover total operating profit million compared group turnover million total operating margin reflected profit disposal horlicks financial results consumer healthcare brands resultant sale shares hindustan unilever well increased income asset proforma disposals partly offset higher remeasurement growth growth charges contingent consideration liabilities cer cer turnover adjusted operating profit million lower total operating profit aer higher cer turnover increase total earnings per share p cer proforma adjusted operating profit declined adjusted operating profit primarily reflected adverse impact reduction adjusted earnings per sales vaccines result covid pandemic share p investment rd investments promotional product net cash operating support particularly new launches vaccines hiv activities respiratory partly offset effective cost control free cash flow including reduced promotional variable spending across proforma cer growth rates calculated equivalent seven three businesses result covid lockdowns months pfizer consumer healthcare business results reported pfizer included comparative period please see continuing benefit restructuring pharmaceuticals information consumer healthcare earnings per share turnover total eps p compared p strong sales performance key growth drivers hiv increase eps primarily reflected net profit disposal respiratory oncology consumer healthcare offset horlicks consumer healthcare brands well disruption covid adult vaccinations increased income asset disposals partly offset higher group turnover million year aer remeasurement charges contingent consideration cer proforma basis group turnover liabilities higher major restructuring charges oneoff cer cer excluding impact divestments benefit increased share tax profits vaccines brands divested review consumer associate innoviva healthcare adjusted eps p compared p pharmaceuticals turnover year million aer cer cer increase adjusted aer cer respiratory sales aer operating profit reduction primarily resulted higher cer million growth trelegy nucala relvar noncontrolling interest allocation consumer healthcare breo hiv sales flat aer cer million profits higher investment rd reduced share growth juluca dovato partly offset declines tax profits associates resulting nonrecurring income tivicay triumeq sales established pharmaceuticals tax benefit innoviva declined aer cer million cash flow vaccines turnover declined aer cer net cash inflow operating activities year million primarily driven adverse impact covid million million free cash flow pandemic hepatitis vaccines dtpacontaining vaccines million year million synflorix bexsero together divestment rabipur increase free cash flow primarily reflected increased encepur decline partly offset higher sales proceeds disposal intangible assets beneficial timing influenza vaccines across regions shingrix growth payments returns rebates reduced legal payments europe china us together strong improved operating profits partly offset higher dividends performance cervarix china noncontrolling interests increase trade receivables increased tax payments including tax disposals adverse exchange impacts gsk annual report strategic report governance remuneration financial statements investor information financial performance continued total adjusted results total reported results represent groups overall gsk encourages investors analysts rely performance single financial measure review gsks annual reports including financial statements notes entirety gsk uses number adjusted nonifrs measures report performance business adjusted results gsk undertaking number boardapproved major nonifrs measures may considered addition restructuring programmes response significant changes substitute superior information presented groups trading environment overall strategy accordance ifrs see fuller definition following material acquisitions costs cash noncash programmes provided individual elements gsk believes adjusted results considered approved meet accounting recognition criteria together total results provide investors analysts stakeholders helpful complementary information result charges may incurred number years understand better financial performance position following initiation major restructuring programme group period period allow groups gsks reported results year ended december performance easily compared majority included five months results former pfizer consumer peer companies measures also used healthcare business compared twelve months management planning reporting purposes may proforma growth rates cer calculated directly comparable similarly described measures including equivalent seven months results period used companies july former pfizer consumer healthcare business fully described divestments intangible intangible significant total asset asset major transaction legal separation adjusted adjusting items results amortisation impairment restructuring related items costs results turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p intangible asset amortisation impairment divestments significant legal items amortisation impairment intangible assets goodwill proceeds costs disposals associates products excludes computer software businesses significant legal charges net insurance recoveries expenses settlement litigation major restructuring government investigations operating income major restructuring costs include impairments tangible royalty income items assets computer software specific boardapproved programmes structural significant scale separation costs costs individual related projects exceed million additional costs prepare consumer healthcare including integration costs following material acquisitions separation transactionrelated transactionrelated accounting adjustments related significant acquisitions gsk annual report financial performance continued adjusted results proforma growth growth turnover turnover cer cer turnover cost sales gross profit selling general administration research development royalty income operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p performed operating profit adjusted operating profit million lower cost sales aer higher cer turnover increase adjusted cost sales percentage turnover cer adjusted operating margin flat aer percentage points lower cer compared percentage points lower aer percentage points proforma basis adjusted cost sales lower cer basis proforma basis percentage turnover percentage points adjusted operating profit lower cer turnover lower cer compared reflected decrease cer adjusted proforma operating favourable product mix pharmaceuticals margin percentage points lower cer contribution restructuring integration savings partly basis offset adverse product mix vaccines continued adverse pricing pressure pharmaceuticals reduction proforma adjusted operating profit reflects adverse impact reduction sales vaccines selling general administration investment rd continuing price pressure investments adjusted sga costs percentage turnover promotional product support particularly new launches percentage points lower aer offset reduced promotional variable spending percentage points lower cer basis proforma basis oneoff benefit restructuring postretirement benefits adjusted sga costs percentage turnover continuing benefit restructuring tight control percentage points lower cer compared ongoing costs growth adjusted sga costs although flat aer tax grew cer proforma basis costs reduced cer tax adjusted profit amounted million reflected benefits restructuring including oneoff represented effective adjusted tax rate benefits restructuring postretirement benefits reduced reflecting impact settlement number variable spending across three businesses tight open issues tax authorities cancellation control ongoing costs partly offset increased investment uk government reduction uk corporation tax rate promotional product support noncontrolling interests research development allocation adjusted earnings noncontrolling interests adjusted rd expenditure million amounted million million increase turnover higher aer higher cer allocation primarily reflected increased allocation proforma basis adjusted rd expenditure grew consumer healthcare profits cer primarily driven significant increase investment earnings per share oncology well progression covid treatment adjusted eps p compared p programmes partly offset reduction aer cer cer increase adjusted investment research several specialty primary operating profit reduction primarily resulted higher care programmes well efficiency savings noncontrolling interest allocation consumer healthcare implementation separation preparation restructuring profits reduced share tax profits associates programme reductions variable spending resulting nonrecurring income tax benefit innoviva gsk annual report strategic report governance remuneration financial statements investor information longterm priorities believe gsks longterm priorities create lasting value patients consumers shareholders despite challenging operating environment delivered resilient performance strategic objectives remain track innovation performance trust invest scientific technical deliver growth investing responsible company excellence develop launch effectively business commit use science pipeline new products developing people technology address health meet needs patients executing competitively needs make products payers consumers affordable available modern employer objectives objectives objectives deliver innovation sales excellent prioritise spending deliver growth continue deliver ontime infull supply commercial rd supply chain return investment products execution successful consumer healthcare jv build reputation focus innovation accelerate strengthen pipeline integration including driving growth deliver progress trust commitments six potential approvals expected delivering synergies deliver capability building specialty pharmaceuticals deliver twoyear programme prepare gsk separation two new companies progress progress progress strong performance new innovations strong sales performance key growth sector leading positions esg indices including shingrix trelegy juluca dovato drivers hiv respiratory oncology including st access medicine zejula consumer healthcare reflecting index nine major regulatory approvals including resource focus therapy areas markets despite pandemic hiv oncology respiratory brands greatest potential able maintain supply extended indications across portfolio advanced consumer healthcare pharmaceutical vaccine consumer including shingrix bexsero trelegy integration track million healthcare products continue ellipta benlysta annual cost savings manufacturing without significant disruption accelerated pipeline nine pivotal billion divestment proceeds achieved fda ema approved paediatric study starts assets advanced specialty medicine capabilities dolutegravir latestage development new hires oncology joined global efforts develop covid established multiple partnerships programme separate gsk two solutions supported partners develop covid solutions including leading businesses remains track set ambitious new environmental curevac develop next generation mrna sustainability goals climate nature covid vaccines vir biotechnology introduced allemployee mandatory therapeutic antibody treatments inclusion diversity training strengthened capabilities business development deals firstmarket launches consumer healthcare priority objectives priority objectives priority objectives deliver innovation sales excellent continue prioritise spending deliver continue deliver ontime infull supply commercial rd supply chain growth return investment products execution oncology hiv vaccines continue deliver twoyear programme improve manager capability motivate accelerate strengthen pipeline prepare gsk separation two focus develop care people robust commercial input including new leading companies continue deliver progress trust business development build stronger diverse workforce commitments two new leading companies culture move towards creation two new leading companies continue focus performance driven remaining firmly purpose led values based track cultural change range indicators board receives regular updates see pages principal risks principal risks patient safety product quality financial controls reporting antibribery corruption commercial practices pricing nonpromotional engagement privacy research practices environment health safety environmental sustainability information security supply continuity transformation risk management framework designed support longterm priorities see pages gsk annual report culture building stronger purpose performance culture inspire people power delivery longterm priorities people inspired purpose help people living working pandemic also making feel better live longer purpose performance progress transformation programme future ready culture underpinned values patient focus respect brought change personal challenges transparency integrity move towards creation employees support period ensured two new leading companies critical us focus employee health wellbeing services fully performance driven remaining firmly accessible see purpose led values based pandemic meant also much flexible track cultural change range indicators got work done support implemented focused embedding culture prioritises innovation new principles employees carry officebased work competitive edge speed agility deliver growth work place way enables orientated performance employee trust including perform best based role team personal pride purpose embedding values expectations circumstances principles performance choice accountability courage development teamwork anchored driving individual collective performance progress modern employer creating flexibility employees perform work check health culture range indicators making good progress addition company respect people challenging year everyone survey saw highest core takes pride providing access medicines response rate date main measure culture vaccines consumer products opportunity employee engagement reported highest scores obligation build inclusive culture internally since inception survey increase since force good improving diversity inclusion last survey improvements across society focused building inclusive innovation scores average performance culture including inclusion training employees alongside scores showing largest overall improvements across work evolve policies processes practices questions average scores employee also set new aspirational targets gender trust also scored strongly average race ethnicity see way working covid leaders played crucial role know pandemic led positive changes culture rolemodel culture one biggest drivers close three quarters employees moved remote culture change continue build expertise senior working around quarter continued work leaders new appointments top leaders essential sites ensuring medicines vaccines everyday effectiveness global manager population healthcare products reached millions patients measured annual one feedback tool see consumers needed period year saw continued improvements manager seen deeper connection purpose greater focus scores managers seen highly work matters deliver priorities dynamic effective people manage teams moving pace clear accountabilities greater connectivity care continue focus positives throughout part culture ambition long term gsk annual report strategic report governance remuneration financial statements investor information key performance indicators track progress longterm priorities ten operating key performance indicators measure performance group level across three businesses operating key performance indicators kpis reviewed track operating kpis internally regularly corporate executive team board provide performance data report externally employees updated progress every due commercial sensitivities publish data quarter performance system aligns employees bonuses operating kpis indicated nr use number adjusted relevant subset ten indicators remuneration noninternational financial reporting standards ifrs policy used reward performance executives also measures report business performance described includes measures linked kpis see pages pages include adjusted results free cash flow cer growth rates innovation innovation sales r pharmaceuticals vaccines sales products launched last five years bn bna bna consumer healthcare sales products new market last three years total sales pipeline value progress value products pipeline rd milestones achieved nr nr nr performance group turnover r aer cer bn bn bn profit r total operating profit aer cer bn bn bn adjusted operating profit aer cer bn bn bn total operating margin adjusted operating margin free cash flow r bn bn bn market share market share relation competitors nr nr nr top talent succession plans key roles talented employees key roles succession plans place nr nr nr trust employee feedback employee engagement scores global employee survey supply service level percentage orders delivered ontime infull nr nr nr corporate reputation reputation index among stakeholders informed public measured globally top markets nr nr nr r linked executive lti awards bonus see pages comparative information reflects sales products meet definition nr reported externally due commercial sensitivities gsk annual report industry trends operating dynamic environment shaped fastchanging interdependent global trends many accelerated covid pandemic continue respond changing environment advancing strategy longterm priorities global economy significantly affected covid covid pandemic underlined centrality pandemic year economic uncertainty health security stability prosperity nations continued january global economy forecast need strengthen approaches preventing identifying grow impact covid containment managing future pandemics already industry measures stalled economies many countries engaging key partners consider work collectively global economy facing deep recession develop sustainable solutions enhance pandemic preparedness strengthen global health security overall investment covid solutions healthcare systems economic support national lockdowns global healthcare market significant longterm effect global economy government finances fiscal challenge likely global healthcare market grown year lasting impact national healthcare budgets markets worldwide pharmaceutical sales totalling billion outofpocket patient payments personal budgets september north america remains pandemic put healthcare industry centre stage largest pharmaceutical market share global sales demonstrated vital role powerful force good europe representing china second largest discovering developing supplying essential medicines individual country pharmaceutical sales representing vaccines consumer healthcare products need global sales global vaccine sales remained flat rapid solutions pandemic prompted unprecedented approximately billion global consumer technological acceleration collaboration healthcare market estimated valued companies governments regulators international billion organisations mobilise rd deliver novel products speed prescription medicines consumer products proved largely regulatory processes scale manufacturing capacity resilient economic effects pandemic common covid dominated peoples lives discussions trends stockpiling issuing longterm prescriptions safe effective innovation particularly around vaccines dramatic increases purchasing followed falls rose high public agenda industry united around demand driven fewer consultations lockdowns common commitment apply highest levels rigour vaccines market however impacted significantly safety standards potential covidrelated solutions global vaccination rates fell sharply patients unable pandemic also raised questions around affordability visit healthcare professionals rates recovered lockdowns equality access healthcare demands eased middle year declined pandemic licensed covid vaccines medicines became conditions worsened commentators predict widely available multistakeholder organisations economic recession suppress pharmaceutical growth covax critical helping navigate challenges potential countries private funds underpin significant governments looked secure access citizens proportion healthcare costs well ensuring global access pressure governments global trends opportunities challenges seek domestic healthcare supply chains particularly covid solutions became pressing issue disruption changing demographics international logistics systems impacted security supply demographic change increasing demand preventive therapeutic healthcare products global population predicted grow billion estimated billion virtually countries experiencing population ageing proportion projected double imf annual report people living cities becoming iqvia data affluent particularly china experiencing worlds internal data fastestever expansion middle class iqvia impact covid global pharmaceutical growth billion people projected middle class one quarter june worlds total united nations department economic social affairs world population prospects united nations department economic social affairs world population ageing brookings chinas influence global middle class october gsk annual report strategic report governance remuneration financial statements investor information industry trends continued response gsk moved swiftly join global efforts covid factors contributing rising demand pandemic companywide used science technology healthcare including areas focus vaccines portfolio resources could biggest specialty medicines well general medicines impact progress promising vaccines medicines pressure healthcare systems restrain growth spending could produced scale prevent treat virus line innovation priority investing developing see details launching pipeline new products meet pricing access changing needs patients payers consumers see pages pricing healthcare products increasing pressure global health pricing strategies ensure fund highcost innovative therapies continue attract products serve broad demographic see pages significant attention governments public advances science technology scrutiny access innovation pandemic rapid advances innovative science technology particularly intense transforming sector new advances functional genomics governments long sought control healthcare crispr changing possible drug expenditure particularly around pharmaceuticals growing discovery enable researchers pinpoint novel targets populations increased comorbidities improved screening higher probability success cell therapy technologies escalated demand medicines vaccines consumer cells become living medicines altering definition healthcare products parallel new innovative medicines profile medicine scale data genetic libraries complex better targeting diseases genomics requires artificial intelligence ai interpret machine learning helping design new experiments increase governments payers increasingly cooperating across likelihood success growth data also improving jurisdictions ever restrictive measures control healthcare ecosystem helping build virtuous cycle growth pharmaceutical expenditure cases data technology rd regulators purchasers led reimbursement hurdles consequent delays harness technologies track product effectiveness making innovative medicines vaccines available patients researchers build better understanding genetics us controlling pandemic stimulating economy disease consumer use digital tools manage addressing environmental issues expected health determine genetic profiles biden administrations key priorities administration covid demonstrated advanced technology plans expand federal governments role covid accelerating enabling innovation entire industry response proposing major stimulus bill nationwide unprecedented government funding collaborations testing vaccine distribution strategy rejoining world companies research institutes health organization healthcare biden administration especially true rapid acceleration vaccine innovation expected seek expand access affordable care including mrna technology enables specific proteins act comprehensive reforms including prescription drugs antigens produced bodys cells enabling unlikely implemented short term human immune system prevent fight disease remains intense public scrutiny cost prescription advance vaccine innovation likely implications medicines american citizens biden administration beyond current pandemic resulting new range expected pay attention course term highly innovative technologies mark step change prior leaving office trump administration announced able fight infectious disease several regulatory changes address healthcare costs response notably restructuring pharmaceutical rebates benefit application advanced technologies central rd patients pharmacy counter intention proceed approach part innovation priority developing international reference pricing irp mostfavoured core capabilities ai machine learning functional genomics nation pricing policy indefinitely hold pending cell therapy accelerate pace identify resolution legal challenges industry though exact develop novel targets medicines vaccines leadership shape impact measures yet finalised platform technologies continues play central role implemented potential significantly change example adjuvants also mrna technology industrys operating environment us long term pursue inhouse selfamplifying mrna sam platform strategic mrna technology collaboration curevac clinical stage biotechnology company see details february announced additional new agreement curevac jointly develop next generation mrna vaccines covid also established dedicated central london hub ai team complement two collaborations focused applying crispr gene editing technologies drug discovery laboratory genomics research partnership broad institute worldleading genomics centre gsk annual report industry trends continued us determination control costs improve beyond europe many countries implementing various access healthcare address outofpocket patient reforms ranging regulatory pathways cost containment payments countering growing recognition china key changes include alignment drug regulatory importance innovation earlier access us review approval processes international standards versus markets restricted access improved government reimbursement innovative medicines pricing access environment also continues europe although markets established price evolve move towards evidencebased assessments control processes national healthcare authorities continually however irp still used instrument control costs looking sharpen tools disparity access supply additionally although latest national reimbursement drugs availability across eu markets recurring topic debate list negotiations reduced prices offered member states repeatedly raising concerns medicine opportunity improved access innovative medicines shortages concern heightened sharply crisis phase evidence access oncology medicines pandemic although companies mitigated risk particular improving reacting quickly cooperating eu national authorities covid created impetus greater japan htas introduced april centralised procurement vaccines medicines pharmaceutical industry remains concerned use eu level november european commission ec assessments pricing control rather value published pharmaceutical strategy focused improving assessment number latin american nations including patient access affordable medicines also strengthening colombia mexico uruguay central american regions competitive pharmaceutical industry strategy countries also increasingly engaging htas includes legislative nonlegislative proposals spanning considering establishing strengthening existing assessments access affordability innovation competitiveness touching response whole legislative framework pharmaceutical aim improve health millions people year companies operate europe eu commission also making products available responsible prices announced plans improve crossborder preparedness sustainable business health emergencies creation new agency health emergency response authority hera modelled getting balance right responsible pricing us biomedical advanced research development sustainable business fundamental innovation authority barda would build reserves medicines performance trust priorities setting price equipment 'surge capacity ' support manufacturing medicines developed markets apply valuebased approach balance reward innovation access growing calls transparency prices development affordability see aim provide truly differentiated costs public subsidies draft legislation france innovative products deliver effective health outcomes italy requiring publication rd investment costs ability patients payers even highcost products deliver manage unexpected supply constraints details prices value investing genetics genomics big data ai jurisdictions various crossborder alliances accelerating pace develop transformational valletta declaration group beneluxa initiative medicines prioritising molecules higher nordic council visegrad group emerged probability success genetically validated drug candidates exert greater leverage price negotiations twice likely become registered medicines europe well many emerging markets irp continues investments also improving productivity rd gain traction markets using investment primary lever pricing control increasingly countries also cooperating health technology assessments htas new eu hta regulation proposal aiming centralise clinical assessments new medicines medical devices gsk annual report strategic report governance remuneration financial statements investor information industry trends continued regulatory environment societal expectations healthcare highly regulated industry reflecting public societal expectations business continue evolve time expectations products comply stringent levels quality expected progress global development safety efficacy slowed political economic challenges pandemic covid presented number challenges concern around issues grows financial community regulators industry maintain supplies shown increasing interest corporate management essential medicines vaccines continue development environmental social governance esg risks programmes new products support accelerate opportunities better foundation longterm growth development solutions covid many necessary also rise civic protest movements aiming adaptations based important regulatory efforts hold companies governments account social initiatives already underway included work issues racial gender inequality novel regulatory approaches encourage biopharmaceutical pandemic rising scrutiny innovation including addressing new technologies companies supported employees suppliers digital healthcare cell gene therapies complex clinical wider communities crisis environmental trials big data real world evidence agenda growing sense urgency around pace regulators recognised need increased cooperation scale action needed address climate change industry tackle pandemic one increasing focus degradation natural world key enablers acceleration timelines pandemic biodiversity loss together deeper understanding innovation regulators built existing interactions planetary health linked human health supranational bodies international coalition response medicines regulatory authorities response covid trust priority approach esg designed create presents opportunities well challenges longterm value shareholders society potential permanent application regulatory adaptations set public commitments across material issues support development approval broader range support trust priority making good progress new medicines vaccines simplification see pages recognise expectations regulatory processes moving quickly need respond accordingly parallel challenges posed covid industry outlined new global approach continued prepare end transition period inclusion diversity announced two ambitious new uks exit eu development uks future environmental goals net zero impact climate net regulatory framework medicines healthcare positive impact nature see pages products regulatory agency mhra independent response pandemic gsk taken agile regulator peoplecentric approach including strong focus supporting employees suppliers response gsk closely monitors relevant appropriate engages ways improve regulation particularly uk europe us china japan example scientific innovation moves beyond scope current regulation standards learn experience covid working peers engage governments exploring new policies processes incentives would support discovery delivery medicines vaccines developed emerging technologies techniques addition working sector realise opportunities mhra establish new enhanced partnerships regulators outside eu lead globally creation balanced regulatory framework supports innovation gsk annual report stakeholder engagement engaging building trust broad range stakeholders interact impacted business key delivering strategy ensuring success long term approach enable management board understand consider stakeholder views part oversight decision making explained section statement set full incorporated reference strategic report summarise key stakeholder groups engage issues matter response patients insights patients consumers enable us matters consumers develop products better meet needs differentiated product innovation based patient engage consumer needs advisory boards diseasespecific patient panels access reliable supply highquality safe products patient advocacy leaders summits provide patient pricing healthcare products particularly outofpocket insights expenses engagement support patient groups disclosed gskcom initiatives empower patients strengthening pipeline innovative products get involved medicine development maintaining high standards product quality safety market research including consumer sensory labs continuing take valuebased approach pricing balance reward innovation access affordability investors maintain regular constructive dialogue matters investors communicate strategy performance financial performance commercial success order promote investor confidence ensure understanding rd strategy successfully continued access capital developing pipeline engage increasing importance good management esg issues ongoing communications including agm quarterly results calls inperson virtual roadshows good financial performance transparent reporting detailed company information online business rd updates events key pipeline onetoone meetings board members milestones senior executives institutional investors increasing engagement esg matters biennial investors analysts perception study healthcare work healthcare professionals hcps matters professionals medical experts understand patient needs ensure access product scientific information medical products administered right way responsible sales marketing practices experts engage safety efficacy differentiated innovation scientific dialogue increase understanding disease management patient experience increasing use digital channels deliver providing highquality balanced information personalised effective sharing information hcps medicines vaccines ensuring attract retain best talent upholding collaborating clinical trials research responsible sales marketing standards using hcp insights disease management patient experience inform development medicines rd partners partner scientific institutions national health matters academia systems business partners academia help finding right partner accelerate potential ensure develop differentiated healthcare products medicine vaccine approval reach patients engage pushing science far go advance collaborating outstanding scientists human health organisations across globe dissemination advancement scientific knowledge establishing joint ventures strengthen innovation efficiency working worldleading experts biotechs universities working academic institutions accelerate scientific institutions improve drug discovery discovery development new medicines increase productivity rd pipeline collaborating partners curevac mrna technology vir biotechnology new antibody therapies expanding genetic genomics collaborations broad institute gsk annual report strategic report governance remuneration financial statements investor information stakeholder engagement continued governments work governments regulators advocate matters regulators policies encourage innovation promote investment innovation life sciences efficient management healthcare spending scientific funding collaboration give patients support need medicines pricing reimbursement engage public health threats covid antimicrobial meeting regulatory bodies throughout resistance amr development process ensure highquality investment preventive health strengthening health systems safe new products engaging government health agencies working uk eu policymakers ensure postbrexit demonstrate value products patients remains sustained flow goods investment capital economies talent life sciences innovation working governments protect strengthen engaging us policy pricingreimbursement debates right operating environment life sciences phrma commenting legislative proposals innovation launches healthcare reform participating international efforts address global partnering across industry governments tackle amr health threats covid pandemic engaging governments including us uk eu canada regarding production procurement covid vaccines ngos work partners improve access healthcare matters multilateral services products advocate access medicines vaccines organisations policy environment successful un sdgs targets specific disease areas engage universal health coverage future health systems working nongovernmental organisations ngos financing global health including covid solutions partners research develop products address global health challenges focusing unique role global health partner collaborating ngos generic manufacturers develop products scientific expertise sustainably supply products developing countries partnering organisations complementary partnering strengthen health systems developing capabilities reach create sustainable models countries drive progress global health priorities share risk including partnership gavi support access vaccines low lower middleincome countries leveraging community investment programmes support scientific expertise deliver greater impact patients suppliers work thousands suppliers large small matters provide goods services support us prompt payment smaller suppliers delivering reliable supply highquality safe understanding gsk policies ensure compliance products patients consumers opportunities innovate grow relationship engage regular direct engagement suppliers ensure engaging suppliers throughout covid support gsk 's strategies targets pandemic understand operating financial status engaging suppliers thirdparty offering support necessary oversight programme conducting indepth audits engaging suppliers develop improvement plans participating forums pharmaceutical track progress identify areas improvement supply chain initiative consumer goods forum providing proactive support thirdparty ehs improve supply chain sustainability team countries priority suppliers located employees involve listen employees help us maintain matters strong employee engagement retain talented people purpose able see difference make engage great line manager regular lets talk lets listen events feeling understood valued corporate executive team senior leaders part inclusive diverse workplace facilitating dialogue collaboration internal communications platform delivering frequent authentic communications works councils employee forums pandemic employee resource groups clarifying expectations managers motivate global allemployee survey one survey focus care develop employees employees provide feedback line managers supporting employee safety mental wellbeing enabling worklife balance expanded id commitments setting aspirational targets improve ethnic gender diversity leadership gsk annual report innovation year significant progress rd across biopharma portfolio achieved substantial number new launches regulatory filings latestage research milestones consumer healthcare delivered first market launches new innovations across categories progress strengthened biopharma fast tracked covid solutions invested significantly strategic pipeline nine major approvals three vaccine approaches partnerships including immunology nine pivotal study starts clinic three therapeutics company vir biotechnology accelerated portfolio clinical studies mrna technology specialist approvals oncology blenrep started phase iii trials rsv curevac zejula hiv rukobia maternal rsv older adults consumer healthcare cabenuvavocabriarekambys menabcwy candidate vaccines firstmarket launches new specialty duvroq launched first clinical trial innovations rolled assets latestage asset andme collaboration recent innovations development many could new markets potentially significantly change consumer healthcare read medical practice pharmaceuticals vaccines approach rd focuses science related lifecycle innovation focus evolving increasing immune system use human genetics application impact existing products also key component advanced technologies ai machine learning strengthening pipeline ensures vaccines deliver transformational medicines vaccines distinctive medicines reach protect people continue play approach enabled us strengthen pipeline vaccines strong role business performance specialty medicines accelerate pace made significant progress across biopharma discover develop deliver patients embedding portfolio nine major gsk assets targeting unmet medical agile performancedriven culture encouraging clear need gaining regulatory approval infectious diseases accountability incentivising people pursue bold portfolio received approvals hiv firstinclass research backed data strong science also partner attachment inhibitor rukobia us europe hire outstanding talent cuttingedge fields longacting regimen cabenuva canada us outside pharmaceutical industry technology data europe licensed vocabria rekambys also science academia time ambitious received european regulatory approval extend use collaborations worldclass companies institutions several vaccines infectious diseases shingrix partnering research accessing advanced technologies expand use people aged crispr mrna deliver higher number increased risk shingles boostrix tetanus differentiated medicines vaccines diphtheria pertussis vaccine expanded indication gsks biopharma rd pipeline contains potential new include maternal immunisation bexsero europewide medicines candidate vaccines focus immunology label update schedule starting infants two strengthening diversifying portfolio promising months oncology received significant us european clinical assets immunemediated diseases infectious approvals first zejula approved expanded diseases oncology research targets indication ovarian cancer secondly blenrep genetically validated novel targets identified firstinclass antibcma bcell maturation antigen treatment collaboration consumer genetics research multiple myeloma respiratory nucala firstinclass company andme based current projections antiil biologic approved us hypereosinophilic potential launch numerous new vaccines syndrome trelegy ellipta oncedaily single inhaler triple medicines well new indications existing assets therapy approved us asthma duvroq chronic data positive could highpotential kidney diseaserelated anaemia approved japan latestage assets could significantly change medical benlysta approved us expanded indication practice continue focus pipeline assets lupus nephritis greatest probability success gsk annual report strategic report governance remuneration financial statements investor information innovation continued nine assets entered pivotal studies including one fundamentally believe person living hiv take covid vaccine collaborations therapeutic medicines need twodrug regimen dr covid antibody treatment codeveloping treatments dovato juluca shown vir biotechnology candidate vaccine safe effective threedrug regimens allow people living five neisseria serotypes b c w causing meningitis hiv maintain viral suppression taking fewer hiv well candidate vaccine respiratory syncytial drugs lifetime virus rsv maternal immunisation dovato oncedaily singlepill containing dolutegravir successful progression pipeline ability lamivudine treatment adults living hiv fast track covid solutions achieved despite disruption following launch us europe dovato international lockdowns throughout pandemic received marketing approval treatment nave adults continued deliver trial drugs thousands patients hiv japan us japan australia received approval within sealedoff healthcare systems assured patient switch indication third quarter longterm employee safety study integrity resilience data gemini tango studies showed operations supply chains allowed majority dovato effective number threedrug regimens clinical studies remain open data stat clinical trial also demonstrated dovato effective well tolerated treatment rapid initiation infectious diseases diagnosis dovato included international guidelines initial therapy hiv switch option gsk worldleading infectious diseases portfolio medicines vaccines clinical testing reflects received approval rukobia fostemsavir focus immunology gsks year track record firstinclass attachment inhibitor us followed using pioneering research methods novel technologies approval europe february rukobia approved find solutions diseases caused bacteria viruses us fast tracked fda breakthrough parasites information response covid therapy designation therapy provides option heavily see treatmentexperienced adults hiv infection including failing current antiretroviral regimens hiv exhausted treatment options previously delivered around million people across world live hiv positive results week phase iii brighte study including approximately million children although sub saharan africa remains affected region number viiv healthcare also received regulatory approval worlds cases globally continues grow approximately first complete longacting injectable regimen treatment new infections year us alone people living hiv regimen contains cabotegravir rilpivirine reduces number treatment gsk long committed combatting preventing dosing days per year potential ultimately curing hiv thereby limiting impact extend six approved canada peoples lives hiv business managed viiv us cabenuva europe vocabria cabotegravir healthcare sole global specialist hiv pharmaceutical rekambys rilpivirine company majority owned gsk pfizer shionogi shareholders business underpinned complementary approvals aligned goal mission leave person living hiv behind providing convenient simplified treatments people living hiv advancing research longacting whilst curing hiv remains viiv healthcares ultimate aim therapies september began oneyear study portfolio approved antiretroviral medicines offers range identify evaluate approaches integrating every therapeutic options people living hiv include two months injectable cabotegravir rilpivirine hiv treatment tivicay triumeq contain medicine dolutegravir european healthcare practices october completed widely prescribed integrase inhibitor worldwide final study visits yearlong customize study believe around million people living hiv globally investigated best ways implementing oncemonthly hiv taking dolutegravirbased regimen ensuring child regimen clinical practice across us results indicate living hiv left behind june received us high level patient preference longacting injectable food drug administration fda approval followed offers potential reduce frequency dosing european medicines agency ema approval january effective daily oral threedrug regimens maintaining firstever dispersible tablet formulation dolutegravir viral suppression among adults living hiv tivicay children four weeks age gsk annual report innovation continued around million people newly diagnosed hiv gsk 's maternal candidate based recombinant every year focus developing effective prevention essential prefusion f antigen boost preexisting immune response reported positive results trials vaccinated mother whose protective antibodies would investigational longacting injectable cabotegravir treatment transferred unborn child paediatric hiv acquisition interim analysis global hiv candidate harnesses adenovirus vector technology prevention trials network hptn study showed contains three rsv antigens aiming induce active immunity every two months treatment effective extend protection infants first two years life superior daily preexposure prophylaxis pills preventing older adult candidate leverages recombinant prefusion hiv acquisition men results released earlier f antigen combined adjuvant system anticipated following outcome similarly results key ingredient successful shingles vaccine shingrix released earlier anticipated second hptn study enhance immune response population naturally women showed cabotegravir effective declining immune system daily oral standard care preexposure prophylaxis prep intend apply marketing authorisation promising phase iii data older adults maternal therapy regulators first half rsv candidate vaccines showed assets triggered robust immune response welltolerated began shingles phase iii trial maternal candidate vaccine november launch shingrix late signalled step change phase iii programme older adults february prevention shingles painful potentially serious phase iii studies paediatric rsv candidate illness approximately one three people develop shingles vaccine ongoing safety immunogenicity data lifetime vaccine addresses agerelated decline seronegative infants expected may immunity achieving efficacy across age groups first nonlive shingles vaccine combine meningitis specific subunit antigen adjuvant sustain approximately million people develop invasive meningococcal immune response disease imd every year infants young children adolescents particularly vulnerable even disease received european approval expand use diagnosed early adequate treatment started shingrix people aged patients die often within hours onset increased risk shingles also applied broaden symptoms untreated meningococcal meningitis fatal indication us include adults immunodeficiency cases may result brain damage hearing loss immunosuppression likely contract shingles disability survivors respiratory syncytial virus rsv gsk market leader vaccines imd based one innovation priorities development novel revenue complementary portfolio bexsero prophylactic vaccines diseases significant unmet marketleading meningitis b vaccine menveo medical need rsv meningitis acwy vaccine helps protect majority rsv leading cause lower respiratory tract infection imd cases pneumonia bronchiolitis infants older saw publication multiple studies realworld adults risk currently vaccine licensed protect evidence bexseros effectiveness different settings virus every year estimated hospitalise including europe serogroup b prevalent million underfives globally older adults public health englands bexsero immunisation programme us alone uk demonstrated reduction expected cases gsk company develop portfolio three fully vaccineeligible infants evidence led europewide dedicated rsv candidate vaccines label update bexseros schedule starting infants fast tracked fda candidate vaccines two months tailored needs vulnerable populations meanwhile phase ii trials liquid presentation menveo infants complementary maternal paediatric completed december new format aims simplify candidate vaccines older adults candidate vaccine preparation steps healthcare providers vaccine targeted people aged august began phase iii clinical trials menabcwy pentavalent vaccine candidate vaccine builds successful technology used bexsero menveo favourable safety efficacy profiles currently meningitis vaccine exists five serogroups abcwy vaccine would require one vaccine rather two fewer injections internal data gsk annual report strategic report governance remuneration financial statements investor information innovation continued new antibiotics amrrelated vaccines also investigating therapeutic candidate vaccine aim tackle urgent threat antimicrobial resistance chronic hepatitis b infections currently phase iii amr organisms recognised centers disease trials work chronic hepatitis b part focus control cdc world health organization progress therapeutic vaccines help immune system better significant negative impact global public health respond existing diseases help reduce chronic diseases reflects strategic commitment develop novel exacerbations slow progress hopefully improve targeted solutions new areas high medical need quality life growing number people suffering gepotidacin potential firstinclass antibiotic distinct chronic diseases worldwide mechanism action phase iii studies urogenital boostrix tetanus diphtheria pertussis vaccine gonorrhoea uncomplicated urinary tract infection received approval europe expanded indication first data expected first half marks include maternal immunisation immunisation pregnant first time infections addressed new mothers enable mothers immune system make oral antibiotics years transfer antibodies help protect unborn child began phase study candidate vaccine pertussis whooping cough expansion preventing primary recurrent softskin tissue infections supported robust data largest phase iv randomised caused staphylococcus aureus staphylococcus aureus placebocontrolled clinical trial ever performed pertussis pathogen swiftly acquires antibiotic resistance multi maternal immunisation drugresistant strains serious threat human health rotarix vaccine rotavirus infections received us alone methicillinresistant strains staphylococcus european approval porcine circovirusfree presentation aureus annually cause cases hospitalised patients estimated deaths information malaria vaccines see global health also progressing phase study vaccine section another pathogen frequently displaying amr clostridium difficile bacterium causes cases oncology hospitalised patients leading estimated deaths us every year work oncology focused maximising patient survival discovery development transformational support antibacterial research accelerator carbx medicines portfolio oncology assets helped us development new drug treat clinical development individually novel combination prevent recurrent urinary tract infections caused studies across four areas focus first escherichia coli e coli bacteria project aims immunooncology uses human immune system explore safety tolerability pharmacokinetics treat cancer portfolio nine assets includes fimh antagonist phase study initiated blenrep dostarlimab feladilimab next synthetic lethality september due finish support concept two mechanisms work together destroy also enable us scale drug future clinical cancerous cells lead asset area zejula nonclinical studies third cell therapy human tcells engineered information work amr see trust target disease nyeso asset leads portfolio section lastly cancer epigenetics generegulatory system infectious diseases epigenome modulated curb cancer hepatitis b virus hbv chronically infect liver leading two assets field type prmt inhibitor serious health conditions including cirrhosis liver failure prmt inhibitor liver cancer despite existing treatment options almost starting immunooncology received regulatory approval people die hbv year us europe blenrep belantamab mafodotin started phase iib study gsk firstinclass humanised antibody drug conjugate investigational antisense oligonucleotide drug bcma relapsed refractory multiple myeloma multiple hbv inlicensed ionis data myeloma third common blood cancer phase iia study suggested gsk currently cure blenrep first antibcma potential suppress hepatitis b surface antigen therapy approved could provide treatment option four weeks treatment patients relapsed refractory myeloma currently limited treatment options approval followed positive results pivotal dreamm study gsk annual report innovation continued continue progress blenreps extensive clinical originally approved us europe patients development programme enable us advance recurrent ovarian cancer first expanded zejulas earlier lines treatment began two pivotal secondline indication october us lateline treatment multiple myeloma studies dreamm blenrep advanced ovarian cancer associated homologous combination bortezomib dexamethasone recombination deficiency pursuing number dreamm blenrep combination pomalidomide clinical studies zejula alone combination dexamethasone also initiated pivotal thirdline therapies include combination therapy firstline multiple myeloma study dreamm blenrep ovarian cancer pd inhibitor dostarlimab monotherapy phase ib combination study evaluating initiation zeal trial combination pembrolizumab asset combination nirogacestat springworks nonsmall cell lung cancer strengthen pipeline investigational gamma secretase inhibitor relapsed capabilities synthetic lethality agreed broad refractory multiple myeloma latter combination strategic partnership ideaya biosciences oncology substudy ongoing dreamm trial focused precision medicine company dostarlimab investigational antiprogrammed death lead oncology cell therapy asset tcell immunotherapy pd inhibitor evaluating potential letetresgene autoleucel letecel gsk treatment endometrial cancer filed european genetically modified express tcell receptor tcr targeting regulatory approval dostarlimab monotherapy nyeso antigen present across multiple cancer types secondline endometrial cancer based upon data including various solid tumours began garnet trial dostarlimab also phase iii study ruby registrational trial secondline advancedmetastatic synovial firstline recurrent primary advanced endometrial cancer sarcoma therapy accelerated development path combination standard care chemotherapy received european prime fda breakthrough without zejula status two next generation tcell immunotherapies gsk gsk transitioned continue progress feladilimab humanised nont cell preclinical clinical development therapies build depleting igg antibody engineered enhance tcell driven tcr platform utilise enhancements improve antitumour responses activating immune costimulatory cell efficacy persistence also announced strategic receptor icos studying antibody alone collaboration biopharmaceutical company immatics combination therapies due potential across biotechnologies enhance capabilities cell range tumour types first patient enrolment achieved therapy working immatics identify research induce second phase iiiii gated study feladilimab develop novel adoptive cell therapies focus solid combination pembrolizumab chemotherapy tumours work complements existing relationships recurrentmetastatic head neck squamous cell carcinoma cell therapy lyell immunopharma adaptimmune expanding active trial programmes molecule also announced new addition immuno respiratory oncology pipeline anticd gsk immune checkpoint receptor expressed tcells natural killer gsk extending years leadership respiratory medicine cells potential firstinclass antibody first molecule continued innovation development treatments codeveloped andme early began asthma chronic obstructive pulmonary disease copd phase study asset monotherapy combination debilitating respiratory conditions portfolio three dostarlimab patients advanced solid tumours candidate vaccines respiratory syncytial virus mentioned earlier one example worldleading rd area zejula lead synthetic lethal asset expanded since launched five new inhaled therapies indication approval us europe firstinclass biologic nucala giving us one broadest oncedaily oral poly adpribose polymerase parp portfolios respiratory medicines industry new inhibitor firstline monotherapy maintenance treatment respiratory products made portfolio compared patients platinumresponsive advanced ovarian cancer growth offset decline followed positive results phase iii prima study advairseretide moved portfolio showed significant reduction disease progression period patients regardless biomarker status gsk annual report strategic report governance remuneration financial statements investor information innovation continued recognising potential medicines help many priority assets patients possible worked deliver lifecycle immunoinflammation innovations marketleading treatments single inhaler focus science immune system supports triple therapy trelegy ellipta nucala trelegy ellipta received development medicines immunemediated diseases regulatory approval us japan treatment lupus rheumatoid arthritis ra source adults asthma following earlier positive results significant morbidity patients considerable public phase iii captain study expanded trelegy elliptas health burden society emphasis reflects aim original copd indication making first single inhaler triple develop immunologicalbased medicines alter course therapy approved asthma copd us inflammatory disease extending leadership eosinophildriven diseases nucala remain company biologic treatment approved us patients hypereosinophilic benlysta specifically developed approved adult syndrome hes adding indications severe eosinophilic paediatric systemic lupus erythematosus sle chronic asthma sea eosinophilic granulomatosis polyangiitis incurable autoimmune disease applied egpa approval followed granting fda regulatory approval across several geographies including priority review makes nucala first targeted biologic us europe china benlysta lupus nephritis treatment patients rare lifethreatening disease inflammation kidneys caused sle lead also applied us european authorisation nucala endstage kidney disease followed positive data patients suffering chronic rhinosinusitis nasal pivotal blissln study supported fda granting polyps crswnp common debilitating condition breakthrough therapy designation priority review characterised high eosinophils levels cause benlysta lupus nephritis benlysta first treatment difficulty breathing sleeping maintaining sense smell approved us lupus nephritis treatment taste application followed positive results approved sle lupus nephritis pivotal synapse study nucala marked first time progressed otilimab phase iii study patients ra antiil biologic reported positive phase iii data chronic systemic inflammatory condition characterised crswnp also submitted regulatory applications pain joint swelling stiffness disability study europe use nucala patients egpa hes followed earlier encouraging results anti gmcsf believe nucala may also potential benefit antibodys phase ii baroque trial also started phase ii patients copd elevated eosinophil counts proof concept study otilimab treating severe phase iii copd trial ongoing pulmonary covidrelated disease see recognising patients respiratory diseases continue anaemia require novel therapeutic options investigational consistent intent bring new therapeutic options longacting interleukin il antagonist sea moved patients significant unmet medical need phase iii february developing daprodustat treatment anaemia due human rhinovirus hrv common respiratory chronic kidney disease ckd received pathogen associated flareups copd asthma first regulatory approval daprodustat marketed duvroq replicate hrv takes pik kinase japan patients anaemia due ckd approval lung therefore inhibiting pk could prevent hrvdriven followed positive results phase iii programme japan exacerbations associated patient burden gsks duvroq oral hypoxiainducible factor prolyl hydroxylase firstinclass pik inhibitor gsk started inhibitor new class drug encourages body make phase study determine safety pharmacokinetic red blood cells thereby treating anaemia associated profile ckd oral daily medicine duvroq offers greater ensure focus medicines greatest convenience current injectionbased standard care potential terminated progression antiil receptor nearly million people japan ckdrelated severe asthma anaemia year initial data proofofconcept study gsk committed helping patients ckdlinked anaemia copd candidate vaccine showed meet around world robust programme evaluating primary endpoint efficacy safety daprodustat daily three times week dosing regimens trials evaluating wide spectrum patients ckd including patients dialysis receiving hemodialysis peritoneal dialysis programme track data expected gsk annual report innovation continued covid solutions also support manufacture successfully fighting covid pandemic require covid vaccines february announced one solution working many fronts support production curevacs current first minimise impact generation covid vaccine candidate manufacturing million doses also ongoing contributing unique adjuvant technology help dialogue manufacturers see support develop multiple proteinbased covid vaccines covid vaccine production simultaneously developing preventative therapeutic medicines codeveloping novel mrna vaccine candidates therapeutic treatments essential patients wait partnering leading healthcare companies covid vaccination people vaccinated research institutions central approach event variations virus vaccines partial efficacy april announced covid several partnerships develop covid vaccines partnership clinicalstage immunology company vir contributing pandemic adjuvant technology biotechnology identify accelerate therapeutic use adjuvant particular importance preventative antibody therapies virus pandemic may reduce amount vaccine protein required per dose allowing additional doses produced within six months agreement vir vir therefore protecting people also enable gsk antibody early treatment covid enhanced immune response patients high risk hospitalisation moved global phase iii trial treatment identified antibodies isolated pledged supply covid pandemic adjuvant patient severe acute respiratory syndrome governments institutions responsible price either sars virus resulting antibodies activity standalone adjuvants part adjuvanted vaccine coronaviruses including sarscov dualaction reinvest profits made sales adjuvant antibodies found potential block covid pandemic phase support coronavirus clear virus provide high barrier resistance achieve related research longterm global pandemic high concentrations lungs ideal properties treat preparedness potentially prevent covid infection results early april announced collaboration sanofi treatment study vir expected early combines sprotein covid antigen approved antibody treatment could available early pandemic adjuvant technology together sanofi first half february cometpeak secured supply agreements us uk eu canada phase ii study evaluating intramuscular formulation statement intent covax global initiative vir lowrisk adults mild moderate covid aims ensure equitable international distribution effective initiated covid vaccines part commitment make clinical development programme vir includes vaccine approved available globally december evaluation subtrial us national institutes announced delay development programme due healths accelerating covid therapeutic interventions antigen concentration addressed partner vaccines activ programs clinical trial hospitalised started new phase ii study february adults covid also studied combination july announced collaboration medicago eli lillys cov antibody lowrisk patients mild develop another covid candidate vaccine phase moderate covid expect data clinical testing began month vaccine combining first half innovative plantbased antigen gsks adjuvant second monoclonal antibody vir gsk trials moved phase iiiii clinical development collaboration vir along vir november phase iii portion due start march investigated potential covid treatment announced another adjuvanted covid vaccine ukbased agile initiative patients mild moderate collaboration february sk bioscience covid phase ibiia clinical trial began entered phase testing early collaboration develop adjuvanted covid following review marketed medicines vaccine chinabased clover pharmaceuticals pipeline products identify agents might able treat stopped early covid virus secondary complications started also february announced new collaboration phase ii proof concept oscar study otilimab german biotechnology company curevac jointly treating severe pulmonary covidrelated disease develop next generation mrna vaccines covid february announced results study potential multivalent approach address showed primary endpoint reach statistical multiple emerging variants one vaccine believe significance across ages efficacy analysis age could important next phase pandemic showed potentially important clinical benefit patients years older based public health need decided expand oscar study confirm potentially important findings gsk annual report strategic report governance remuneration financial statements investor information innovation continued advanced technologies partnerships january announced collaboration eligo french biotech company investigate potential therapeutic application advanced technologies central solution acne precise modulation skin rd approach made significant investments microbiome composition using combination crispr transformational technologies changing way technology bacteriophages medicines vaccines discovered including human genetics genomics artificial intelligencemachine learning partnerships aiml build core capabilities broad achieved substantial milestones establishing portfolio platform technologies cell therapy adjuvants london ai hub two new collaborations human genetics recently mrnabased vaccines altering genomics ai hub team use biomedical information way medicines vaccines developed ai methods advanced computing platforms unlock new making investments help us accelerate pace meaning sizeable genetic clinical data use design develop novel medicines vaccines dedicated hub work partner leading companies ai institutions including nvidia silicon valley startup advanced technologies cerebras also supporting phd studentships covid demonstrated advanced technology university cambridge 's new centre ai medicine accelerating enabling innovation entire industry provide gsk talent pipeline coming five unprecedented collaborations companies years shape next generation practitioners role research institutes gsk long history leveraging establishing ecosystem partners unique accelerating technological expertise achieving industry together discover design medicines innovative combinations partnering leading vaccines higher probability success companies institutions experts gsks adjuvant technology platforms play central role vaccine innovation year also formed new fiveyear research adjuvant key component many vaccine pipeline collaboration one worlds leading genetics assets including rsv older adult candidate vaccine functional genomic centres broad institute cambridge also drives success licensed shingrix vaccine massachusetts additionally december announced made pandemic adjuvant technology available ahren innovation capital colead series collaborations potentially significant contribution investment adrestia therapeutics ukbased biotechnology strengthen global response covid company using cuttingedge molecular biology develop also progressed novel vaccines technologies precision medicines adrestias disease rebalancing platform bioconjugation central staphylococcus aureus uses synthetic viability identify phenotypic molecular candidate vaccine adenovirusvector chad core imbalances disease basis novel drug discovery paediatric rsv asset gsk also entering multiyear agreement adrestia five projects develop portfolio joint year agreed strategic mrna technology projects partners investigate human genetic collaboration clinical stage biotechnology company links disease help identify highquality curevac built relationship february genetically validated medicines agreement curevac jointly develop next generation mrna vaccines covid mrna technology new ai genomics collaborations complement cuttingedge platform development new vaccines extend important existing gsk partnerships include medicines shown proof concept agreement university california establish high efficacy levels two covid vaccines mrna laboratory genomics research lgr stateoftheart technology potential transform vaccine development laboratory evolving advancing crispr vaccines industry number although genomics technologies improve drug discovery enabling us diseases enables specific proteins antigens identify potential treatments enhance rd productivity produced bodys cells enabling human immune initiated three projects genetics disease system prevent fight disease technology could allow two oncology third neurodegeneration lgr us discover vaccines faster produce building stateoftheart crispr library enable efficiently scale continued evolution sophistication technology transform drug discovery time strengthening original agreement curevac covers research inhouse resources automated biology ability development manufacturing commercialisation interrogate cell biology heidelberg rd site cellzome five mrnabased vaccines monoclonal antibodies mabs targeting infectious disease pathogens curevacs integrated collaboration andme established helping mrna platform complements gsks selfamplifying mrna us identify new generation disease targets validated sam vaccine capabilities builds growing strengths human genetics identified novel targets mabs innovation aligned overall rd focus across number therapy areas collaboration science immunology phase study test sam year also started first gskandme rabies antigen advancing started phase study test clinical trial potential new immunooncology treatment sam covid model vaccine start march gsk gsk collaborations continue additional earlystage clinical study using sam explore potential genetics genomics include expected start later march open targets finngen altius uk biobank gsk annual report innovation continued pipeline overview assets development latestage pivotal phase iiiiiregistration benlysta rituximab sle letetresgeneautoleucei nyes tcr ss cabotegravir la hiv prep vir covid daprodustat hifphi anaemia la antiil antagonist asthma nucala copdnasal polyps shingrix immunocompromised vaccine blenrep bcma adc multiple myeloma bexsero infants vaccine us zejula parp inhibitor ovarian lung cancer mmr vaccine us dostarlimab pd antagonist dmmrmsih ec rotarix liquid vaccine us bintrafusp alfa tgf trapantipdl btc menabcwy vaccine otilimab agmcsf inhibitor ra rsv maternal vaccine gepotidacin uuti gc covid medicago vaccine feladilimab icos receptor agonist hnscc rsv older adults vaccine proof concept phase ibii maturation inhibitor hiv menveo liquid vaccine hbv aso hbv rsv paediatric vaccine linerixibat ibati cholestatic pruritus pbc therapeutic hbv vaccine prmt inhibitor cancer malaria fractional dose vaccine cobolimab tsr tim antagonist nsclc shigella vaccine leucyl trna inhibitor tb covid sanofi vaccine tsr lag antagonist cancer first time humanpom phase iib ccl inhibitor oa pain cdnyeso tcr cancer sting agonist cancer tgfbrnyeso tcr cancer hpgd synthase inhibitor dmd proteosome inhibitor visceral leishmaniasis crk inhibitor visceral leishmaniasis tg inhibitor celiac disease broadly neutralising antibody hiv mtb inhibitor tb type prmt inhibitor cancer ethionamide booster tb trpv blocker dme vir covid cd cancer c difficile vaccine ripk psoriasis sam rabies model vaccine fimh antagonist uuti aureus vaccine maturation inhibitor hiv covid sk bioscience vaccine plk inhibitor viral copd exacerbations sam covid model vaccine advanced indications shown asset inlicence alliance relationship otilimab covid therapy phase ii ec endometrial cancer gc gonorrhoea third party blenrep phase iiiiii earlier lines hbv hepatitis b hnscc head neck additional indications also investigation therapy multiple myeloma approved squamous cell carcinoma nsclc non gsk contributing pandemic adjuvant agent l pm bca l l p c imll alu ryn g b ic la ian rc ye r c h oa la n gs te iso pr oth mri pis r covid vaccines collaborations btc biliary tract cancer copd chronic mechanism prep preexposure prophylaxis icos hnscc phase iiiii study obstructive pulmonary disease ra rheumatoid arthritis sle systemic lupus registrational potential dmd duchennemuscular dystrophy erythematosus ss synovial sarcoma dme diabetic macular edema tb tuberculosis uuti uncomplicated phase iii study dmmr deficient mismatch repair urinary tract infection gsk annual report strategic report governance remuneration financial statements investor information innovation continued consumer healthcare joint venture pfizer brought together two consumer trend particularly respiratory health category complementary brand portfolios making us number one increasing preference natural remedies reflecting globally terms market share overthecounter otc trend increasing consumer concerns impact air medicines therapeutic oral health vitamins minerals pollution everyday health launched otrivin breathe clean supplements joint venture also established rd centres europe naturalsbased saline spray enables cleaner excellence richmond us focused otc breathing washing impurities like airborne pollutants wellness weybridge uk oral health suzhou pollen viruses trapped nose help restore noses china dedicated hub locally relevant innovation natural filtering function cough cold introduced natural ingredientbased cough relief extension theraflu delivered firstmarket launches new spain portugal liquid lozenge formats innovations across categories total rolled also launched robitussin naturals incorporates recent innovations new markets included herbal extracts aid cough relief us sensodyne sensitivity gum polident cushion comfort filed new invention patent applications consumers increasingly taking control wellbeing granted european us patents across see multivitamins important meeting nutritional categories needs insight told us challenge swallowing big pills representing usage barrier address delivering bestinclass innovation launched minis version power brand centrum combine deep human understanding trusted science us size regular pill minis deliver innovations meet needs consumers platform used future innovations june successfully launched voltaren arthritis pain first otc prescriptionstrength nonsteroidal antiinflammatory launched number major locally relevant innovations nsaid topical gel arthritis pain help nearly million outside useurope china consumer research people us osteoarthritis since launch voltaren boosted understanding health needs different arthritis pain accounted category growth genders built insights introduction adult topical pain relief segment us genderspecific formulations caltrate leading calcium supplement china key local star brand within research shows consumers want take vitamins minerals supplements category innovation medicines possible yet many use ibuprofen aimed increasingly health wellbeing conscious paracetamolacetaminophen work different ways yearold demographic risk bone treating headaches muscle aches arthritis related injuries typical consumers calcium joint pain launched advil dual action us supplements india gap topical first formulation combine ibuprofen paracetamol gels pain relief market fastacting product provides acetaminophen single product scientifically backed longlasting relief launched iodex ultragel product provide greater efficacy individual components harnesses brand 's trusted strong local heritage oral health continued roll pronamel intensive voltaren formulation clinically proven provide deeper enamel repair launching additional markets since penetration affected areas longlasting relief launching us households tried product innovation successful launch across going buy two years innovation indian topical gels cream category past five years generated annual global retail value sales million external partnerships also launched sensodyne sensitivity gum new look beyond business fuel innovation markets following first introduction innovation pipeline build knowledge capability available markets generated assessed opportunities partnership across million retail value sales since first launch categories many projects due diligence phase range sustainable products packaging device technology based nicholas hall 's db global otc database basis consumption manufacturers ' price gsk annual report performance delivered guidance year offsetting significant impact covid adult vaccinations strong sales performance key growth drivers hiv respiratory oncology consumer healthcare effective cost control pharmaceuticals vaccines consumer healthcare total turnover billion total turnover billion total turnover billion aer cer aer cer covid aer cer pro sales new specialty adversely impacted adult forma cer cer pharmaceuticals billion vaccination particular excluding brands divested aer cer shingrix launched new selfpay review strong commercial execution markets china belgium strong progress joint venture key growth products including netherlands japan sweden integration launches hiv oncology strong performance europe exceeded target raising respiratory reflecting robust demand billion noncore accelerated digital capabilities germany brand divestments supporting enhanced hcp strengthened bexseros track deliver synergies engagement strong supply profile compelling realworld million annual cost savings performance despite disruption evidence multiple settings covid pandemic strong flu sales across regions overall strong supply performance read read read pages pharmaceuticals performance remain industry leaders respiratory rapid indication pharmaceuticals turnover year million expansion including hypereosinophilic syndrome approval aer cer respiratory sales nucala us increased uptake therapys home aer cer million growth trelegy administration options launches france spain nucala relvarbreo hiv sales flat aer japan reinforced leadership eosinophildriven diseases cer million growth juluca nucala delivered almost billion sales growth dovato partly offset declines tivicay triumeq aer cer trelegy ellipta markets new specialty product sales billion increased market share chronic obstructive pulmonary aer cer sales established pharmaceuticals disease positive early signals launches asthma declined aer cer million us japan hiv twodrug regimen therapies dovato juluca doubled sales oncology sales million aer cer million hiv portfolio grew launches strong launches zejula blenrep strengthened cabenuva rukobia paediatric tivicay pd immuno commercial capabilities zejula parp inhibitor continued inflammation benlysta grown consistently grow market share sales increased aer cer expanding market saw doubledigit growth end million blenrep firstinclass antibcma treatment year benlystas indication us expanded multiple myeloma approved august sales include lupus nephritis million see group financial review detail new specialty products comprises pharmaceuticals excluding established pharmaceuticals gsk annual report strategic report governance remuneration financial statements investor information performance continued building specialty capability entered longterm partnership samsung reflecting shift portfolio innovative specialty biologics access additional largescale manufacturing care products including oncology continued invest capacity supply innovative assets capacity capabilities areas particularly quality supplement existing biopharma manufacturing network experience medical commercial teams vary extent depending needs partnership new hires oncology initially involve production benlysta first commercial supply expected gsk specialty care rolled revised incentive programme products coming online thereafter sales representatives countries evolved approach aims drive personal accountability competitiveness strong business performance requires efficient reliable allowing us attract retain best salespeople supply chain improving competitiveness build engagement performance sales teams supply chain creating one logistics routetomarket implemented programme upholding pharmaceutical vaccines products simplifying responsible sales marketing standards manufacturing footprint central functions completed divestment sites verona italy transforming interactions hcps patients mississauga canada also announced divestment customer patient focus central successful poznan manufacturing site poland closure performance continued strengthen gsks boronia facility australia intention sell vemgal connection heighten profile healthcare india site network changes expected complete professionals hcps help meet patients needs restrictions inperson meetings place throughout much year sales teams continued robust supply performance engage customers adapting interactions reflect hcp productivity levels increased contributing preference local guidance using online digital average rise per annum past three years tools enhance engagement alongside regular customer reflects progress made driving operational efficiency dialogue digital solutions core successful commercial digital automation technologies performing launches virtual meetings educational activities strongly safety quality compliance measures continuing despite pandemic ensure deliver service levels measured ontime infull improved hcps want leveraging data analytics shape remaining top quartile industry interactions example launched app maintained supply continuity service levels despite sales representatives combines insights multiple data impact covid thousands manufacturing sources inform next actions line hcps priorities supply employees continuing work gsk locations lockdown regulatory inspections pharmaceuticals china response patient insights developed sites satisfactory onestop shop patient support app allows medication ordered directly gsk online retail giant digital transformation alibaba rather pharmacies app integrated resilience flexibility supply chain reflects wechat messaging social media mobile payment continuing investment becoming digital datadriven app connects gsk chinas patient support programmes organisation made significant progress disease education content accelerating digital competency capability developing new ways working contributed business continuity collectively measures enabled us maintain grow maintained productivity many people across share voice key markets organisation worked home covid restrictions investing specialtyready competitive supply chain drove operational efficiency unlocked opportunities supply chain transformation progressing line improve performance measures included applying shift portfolio innovative specialty care products advanced analytics drive efficiencies across business despite disruption caused covid introduced supply chain management manufacturing several new products including firstmarket launches commercial operations digital value stream map example cabenuva rukobia blenrep duvroq ongoing enabled endtoend visibility supply chain enabling investments facilities people manufacturing partnerships users track specific brands sites interest fuelling continue support rapid launch specialty medicines faster decision making continue harness data learn accelerating delivery across portfolio impact commercial activities committed million expand next generation appropriate prescribing unlock smarter faster biopharma manufacturing facility upper merion pennsylvania interactions customers parallel accelerated development technological scientific capability people following expansion rockville maryland biopharma manufacturing facility preparations track start commercial operations gsk annual report performance continued vaccines performance continue adjust manufacturing network meet vaccines turnover declined aer cer future needs including investments support growth million primarily driven adverse impact covid existing products well pipeline assets pandemic hepatitis vaccines dtpacontaining vaccines prioritising investments manufacturing technologies synflorix bexsero together divestment rabipur digital capabilities investments allow us transform encepur decline partly offset higher sales data insights across manufacturing supply quality influenza vaccines across regions growth shingrix resulting improved productivity effective use sales billion aer cer together working capital strong performance cervarix china first quarter year sites gdll vaccines performance across regions affected lower hungary marburg germany passed us food drug demand due limited visits healthcare practitioners administration fda inspections may fda approval points vaccination pandemic government singapore site meant strategic vaccines sites stayathome directives areas lockdowns lifted fdaapproved wellness visits vaccination rates recovered paediatric digital performance vaccination near precovid levels end q advance towards goal becoming digital adolescent adult immunisations improved slower datadriven organisation continue harness new pace us backtoschool vaccinations disrupted technologies develop better efficient ways working schools universities delayed reversed inperson tuition businesswide example deploying robotic elongated backtoschool vaccination season automation bots across vaccines organisation including q adult wellness visits returned prior year levels manufacturing quality rd deployed bots end q supported seasonal flu vaccination end increasing efficiency cost savings declined late q pandemic conditions worsened despite shortterm impact vaccination rates remain year delivered several data analytics confident demand particularly shingrix products help improve scientific productivity optimise remains key growth driver manufacturing processes boost commercial performance global company committed supplying vaccines worldwide growth strategy focused improving second half started digital manufacturing geographic presence two largest vaccines markets execution system production lines sites us represents sector china currently use paper batch recording system deployed next three four years benefits see group financial review detail including operational efficiency leadtime reduction supply performance improvements compliance yield robustness system vaccines business manufacturing sites across feed making datadriven decisions manufacturing nine countries global network gives us strategic supply supply capability enabled us produce deliver improving commercial teams performance million doses achieve best ever ontime datarich technology platforms optimising numerous processes infull delivery supply metric ensuring critical vaccines tender allocation targeted marketing also available patients pandemic extended awardwinning digital tool myvaccinationhub increased shingrix bexsero output followed additional helps parents track childrens vaccination records investment supply network including bringing new national markets addition gsk working production capacity onstream bexsero continued health technology company philips pregnancy efforts improve yield productivity throughput baby apps educate parents importance expanded supply capacity remain track vaccination potential reach almost million parents begin manufacturing shingrix new facility day across globe huge step forward giving improved supply performance shingrix allowed us target audience access factual medically approved announce launch countries earlier anticipated information partnership already live brazil canada switzerland poland spain germany italy australia russia mexico internal data gsk annual report strategic report governance remuneration financial statements investor information performance continued consumer healthcare performance also completed sale horlicks reported basis sales grew aer cer consumer health food drink brands hindustan unilever million full year largely driven limited receiving required regulatory approvals inclusion pfizer portfolio partly offset brands part agreement hindustan unilever limited sell divestedunder review distribute otc oral health brands india distribution arrangement although retain brand ownership proforma basis sales declined cer grew year sold stake hindustan unilever limited cer excluding brands divestedunder review reflecting part transaction always intended underlying strength brands across portfolio sell stake appropriate time timing categories strong growth ecommerce successful sale enabling us generate greater financial return execution meeting evolving consumer demand result originally anticipated pandemic meeting consumer needs amid behaviour shifts portfolio everyday health products gives us industry among many farreaching impacts covid leading positions across number categories including pain accelerated certain consumer trends already relief respiratory therapeutic oral health vitamins minerals underway one trend increasing supplements growth strategy based prioritised convergence digital health including rapid investment nine global power brands local stars expansion digital commerce overall global brands concentrated key geographies digital commerce business grew previous year operating model critical successful implementation throughout outperformed peers gaining market strategy growth joint venture share key brands focus markets us continued progress rolling new marketing grew ahead categories example gaining market operating model allows us develop bestinclass leading position toothpaste amazon topical pain brand programmes strategic brand market choices voltaren also made great strides towards relevant globally locally building executing improving customer experiences including launching differentiated pipeline accelerating speedtomarket first directtoconsumer online store chapstick us heart innovation strategy innovation operating since launch store acquired new model also launched sets practically customers sold sticks ahead achieved plans data capture conversion continued see group financial review detail improve consumer experience grow first party data ahead expected us leveraging strong progress joint venture integration new insights back business made significant progress integrating two businesses make consumer healthcare joint broadly increased investment digital venture markets completed legal capability across business improve overall speed closes enabling legacy pfizer employee efficiency included accelerating digital population formally move gsk leadership transformation marketing functions advancing roles confirmed markets completed systems capability new areas rd supply chain cutovers operating one order one invoice data key enabler growth particular area focus customers markets completed cutovers allows us better understand consumers account global sales customers make smarter decisions created dedicated data team made data scientists innovation remain track deliver synergies million annual specialists user experience designers data apprentices cost savings drawn areas build data strategy governance processes readiness network rationalisation logistics infrastructure advertising future standalone company team also focused marketing met target realising billion building data literacy across business enable us extract divestments noncore brands process still value data accelerate digital ongoing thermacare included manufacturing transformation site albany georgia key divestment lifted integration restrictions two businesses europe also investing datarelated technology including artificial intelligence machine learning across rd despite operating complex joint venture integration supply chain marketing teams allow us majority officebased teams worked remotely operate efficiently accelerate speedtomarket seen faster decisionmaking effective meetings greater collaboration focused whats needed consumers reflected increase survey results around clarity single point accountabilities effective decisionmaking rise favourability based nicholas hall 's db global otc database basis consumption manufacturers ' price straight talk conversations internal data gsk annual report performance continued continue enhance digital capability literacy recognising critical importance purposedriven people launched digital commerce leadership created new virtual ninemonth academy online learning platform training modules development programme senior leaders playbooks planning frameworks resources help gsk consumer healthcare help identify sense embed core digital commerce learnings behaviours personal collective purpose accelerate growth since launch august employees across ambitions also plan invest development countries completed training platform people use first line leader programmes academy complements digital accelerator programme build capability around colleagues new rolled europe middle east leadership roles africa region following successful launch asiapacific prioritising safety supply programme designed drive sales unprecedented challenges digital commerce promote digital first culture continued drive decisionmaking closer consumer integrating external digital experts teams regional accountability across supply chain another trend accelerated pandemic fact accelerated approach start covid consumers proactive managing health pandemic responding agility speed changing wellness vitamins minerals supplements category consumer demand upholding commitment safety biggest beneficiary sales vitamins first priority pandemic ensure minerals supplements brands grew high teens per wellbeing employees continuing operate cent particularly strong performances power brand manufacturing sites increased safety measures centrum local stars emergenc us caltrate support critical production employees including china three grew double digits year adjusting shift patterns minimise employees overlap contact hcps significantly influence health behaviours tracing protocols regionally driven support packages consumers heightened result covid example groceries site lunches safe transport consumers increasingly relying upon doctors dentists despite operating unprecedented circumstances pharmacists trustworthy source selfcare continued deliver products really matter consumers guidance expert fieldbased representatives built additional capacity indemand products continued strengthen relationships hcps within fell two broad categories products like panadol weeks covid outbreak accelerated adoption provide symptomatic relief immunity remote detailing virtual conferences roundtables boosting properties like emergenc saw expert fieldbased representatives across world fully operational new ways working regional perspective continued deliver world pharmacist day september partnered high level service customers apac emea international pharmaceutical federation raise awareness usa challenges continue meet high level area common interest minimising impact air service customers expect caused pollution peoples health wellbeing developed significant growth immunity brands also supply targeted digital campaign pharmacists key countries disruptions precautionary product recalls creation social media assets drive awareness addressed increase demand putting engagement around topic campaign reached place significant extra capacity internally one million pharmacists engagement contract manufacturing organisations also continue content seven times industry average improve supply chain resilience network partnership also allowed us reach pharmacists continuing drive culture quality improvement previously able laid foundations building additional sources supply continuity us build longerterm relationships finished products critical raw materials leadership engagement announced plans build capacity focus quality leadership driven appointments manufacturing sites civac mexico guayama puerto formal development programmes increased efforts rico pulogadung indonesia cape town south support employees physical mental wellbeing africa part streamlining network closed contributed positive survey score employees site sligo ireland announced closure site feeling actively encouraged support health wellbeing carlisle us also ceased production joint venture integration process created san jose site costa rica sale site expected new diverse consumer healthcare leadership team completed following divestments broad industry experience legacy gsk pfizer thermacare business outside north america vesterlens businesses alongside talent wider fmcg sector naturprodukter dietary supplements also announced also improved depth talent selected closure site cluj romania divestment legacy businesses key roles nutrition business hindustan unilever included sites nabha rajahmundry sonepat india gsk annual report strategic report governance remuneration financial statements investor information trust trust one three longterm priorities crucial purpose enabling us add value shareholders society progress committed ambitious new partnered launch billion formed partnerships better environmental sustainability goals amr action fund aiming bring prepare future pandemics net zero impact climate net two four novel antibiotics ensure access future covid positive impact nature patients treatments vaccines including strong performance fda ema approved age trinity challenge esg benchmarks appropriate formulation tivicay industry commitment licensed tb candidate children living hiv weighing bill melinda gates foundation vaccine bill melinda least kg four weeks engagement gates medical research institute age covax facility continued development set new aspirational targets record response gender race ethnicity employee survey engagement improve representation vp score level introduced mandatory inclusion diversity training employees trust priority focuses broad range esg aspects external benchmarking supports ability create value society djsi ranked nd pharmaceuticals industry group shareholders stakeholders particularly investors dow jones sustainability index increasingly focused companies manage esg factors atmi ranked st access medicine index value creation risk management perspective ftsegood member ftsegood index since see risk management strong trust esg performance ensures remain attractive investors helps cdp scored cdp water b cdp carbon recruit retain talent mitigates risk builds trust named cdp supplier engagement leader stakeholders influence operating environment sustainalytics leading position sustainalytics see stakeholder engagement msci aa rating trust commitments esg areas vigeo eiris ranked st pharmaceuticals sector gsk make biggest difference set approach reporting commitments worked independent third party trust section report progress conduct materiality assessment identify esg issues commitments online publish detailed relevant stakeholders business information contribution sdgs esg commitments help us respond challenges opportunities performance summary un global compact within industry broader society see pages communication progress global reporting initiative contribute many un sustainable development index sustainability accounting standards board index goals sdgs especially goal ensure healthy lives assurance statements promote wellbeing ages gskcom esg performance summary contribution sdgs corporate responsibility cr committee oversees progress commitments company addressing evolving views expectations broad range stakeholders gsks corporate executive team senior management also oversee implementation trust commitments report regularly cr committee see pages gskcom gsk materiality assessment gsk annual report trust continued science technology covid pandemic showed vital importance early gsk path bharat announced product using science technology innovate tackle transfer agreement malaria vaccine significant global impact disease prepare future pandemics step ensuring longterm sustainable supply vaccine tafenoquine krintafelkozenis single dose radical cure new medical innovations treatment p vivax malaria developed partnership commitment develop differentiated highquality medicines malaria venture prevalence p vivax peaks needed medicines vaccines consumer healthcare children aged two six years old presented data products improve health showing tafenoquine effective preventing relapse four months children adolescents age use cuttingedge science technology discover develop innovative medicines vaccines consumer healthcare hiv products see rd pages including june us fda approved firstever dispersible tablet developing innovations combat covid formulation dolutegravir tivicay pd fda approval began producing dispersible tablets financial risk global health rd support rapid rollout tivicay pd first integrase inhibitor available oncedaily tablet oral suspension children commitment improve global health impact hiv weighing least kg four weeks age rd infectious diseases affect children fda also passed updated dosing recommendations young people developing countries focusing already approved tivicay mg filmcoated tablet paediatric hiv malaria tuberculosis hiv patients weighing kg help close working translate scientific discoveries impactful gap hiv treatment options available adults solutions worlds vulnerable patients children approval january ema also appropriate transfer innovation technology granted marketing authorisation tivicay mg dispersible organisations right capability geographic reach tablets included updated dosing recommendations partner others optimise development tivicay mg filmcoated tablets children hiv candidate medicines vaccines technologies drive publicprivate partnership clinton health access need access initiative unitaid two generic manufacturers also pursue early discovery global health research mylan macleods continue expedite development particularly neglected tropical diseases two registration market entry generic formulations paediatric established scientific research centres focused developing dolutegravir resourcelimited settings key milestone new vaccines medicines global health research recently achieved mylan macleods submitted new vaccines global health institute gvgh drug applications scored dolutegravir mg dispersible pharma rd unit tres cantos respectively tablet tentative approval fda presidents emergency plan aids relief pepfar scheme mylan gskcom using science global health received tentative fda approval november tuberculosis fastest generic manufacturers filed shortest gap gsk joined project accelerate new treatments originator approval generic medicine approval tuberculosis pantb collaboration aiming develop pantb regimen one thats effective forms tb including health security drugresistant strains work identify best possible combination medicines make tb treatments shorter better commitment help world better prepare safer current standard care multidrug regimen future disease outbreaks pandemic potential tackle antimicrobial resistance developed tb candidate vaccine phase iib trial demonstrated potential reduce pandemic preparedness active pulmonary tb half adults latent tb infection taken broad approach developing covid january licensed vaccine bill melinda solutions see details gates medical research institute continued development applying science find covid innovations also believe many areas could help improve malaria future pandemic preparedness rtss vaccine first vaccine help protect children deadliest form malaria p falciparum joined industry commitment expand global whocoordinated pilot implementation programme access covid diagnostics therapeutics vaccines led national ministries health partnership facilitated bill melinda gates foundation collaborating path gsk ongoing ghana kenya aligning resources across industry government malawi since april gsk dispatched enable faster path current covid crisis million vaccine doses children also lay foundation strong pandemic preparedness reached least one dose rtss far ecosystem future gsk annual report strategic report governance remuneration financial statements investor information trust continued became founding member trinity challenge partnered major biopharmaceutical collaboration alongside google microsoft facebook others companies european investment bank collective vision safeguard lives livelihoods wellcome trust launch billion amr action fund one billion people using data analytics better fund aims bring two four novel antibiotics patients predict prevent outbreaks epidemics pandemics gskcom industry covid joint communique trained healthcare professionals across countries appropriate use antibiotics addressing antimicrobial resistance amr amr represents one gravest threats global public working amr industry alliance health gsk playing leading role industrys response setting new global limits antibiotic discharges ranking first among large pharmaceutical companies also audited improved needed antibiotic supply access medicine foundations amr benchmark chain includes gsk factories supplier factories countries track ensure factory rd projects targeting priority pathogens discharges negligible conform alliances standards including pathogens deemed critical urgent end currently gsk 's factories us centers disease control prevention cdc suppliers factories fully compliant fifteen relate vaccines continue see vaccination major pathway fight amr see gskcom preparing future disease threats details pipeline affordability availability making products affordable available developing countries use innovative pricing structures people around world responsible pricing strategic extend product reach see pages tiered pricing access programmes partnerships model vaccines based four widelyrecognised world bank gross national income country classifications high pricing uppermiddle lowermiddle lowincome countries commitment improve health millions tier price ceilings floors progressively decrease people year making products available tiers high lowincome countries responsible prices sustainable business medicines lowincome countries file patents medicines enforce historic patents allows generic us pricing new products reflects value companies manufacture supply generic versions gsk delivered patients healthcare systems wider society medicines countries compared available alternatives supports innovation meet future healthcare needs gskcom pricing access strategies average net price discounts rebates product reach allowances products us decreased annually past five years average list commitment use access strategies reach price rose combined average net price million underserved people developing countries pharmaceutical vaccines portfolio us fell products average list price rose since set product reach target products offer various types patient support including patient reached million people assistance programmes coupon copay programmes commitment gavi reimbursement support help ensure appropriate access tiered pricing principles mean reserve lowest medicines provided prescribed medicines vaccines prices organisations gavi gsk one vaccines lowincome uninsured largest suppliers vaccines gavi since underinsured medicare part patients gsk supplied million doses vaccines viiv healthcares patient assistance programs foundation partnership allowed us introduce rapidly scale europe engage many stakeholders develop access new vaccines might otherwise taken years approaches ensure sustainable healthcare systems reach children lowincome countries confirmed continued access innovative medicines example ongoing supply cervarix gavi support continued pricing zejula medicine ovarian cancer reflects efforts protect girls human papillomavirus value delivers patients caregivers payers society provided pneumococcal vaccine synflorix eight demonstrating costeffectiveness predictable budget gavieligible countries one former gavi country discounted price reaching estimated million children rotarix vaccine rotavirus reached million calculated across gsk viiv healthcare products children across gavieligible countries four former year cagr calculated jan dec gavi countries addition oral polio vaccine supplied total excludes reach albendazole donations assessed unicef polio eradication reached almost million people gsk annual report trust continued voluntary licensing viiv healthcare positive action launched new viiv healthcares voluntary licensing agreements allow strategy vision continues explore generic manufacturers produce sell lowcost single innovative ways supporting peoplecentric community fixed dose combination products containing dolutegravir led interventions help meet un fast track targets adults generic manufacturers children ending aids viiv healthcares positive action covers countries adults children childrens fund reached people agreements large majority manufacturers via million people benefited partnership medicines patent pool end least million comic relief focused combatting malaria people living hiv across countries developing contributed million projects world access generic dolutegravircontaining product africa south east asia improving malaria awareness licensing agreements corresponds prevention efforts getting treatment patients least people living hiv antiretrovirals low since partnership save children amref health middleincome countries africa care international gsk invested training product donations frontline health workers work communities low since donated billion albendazole middleincome countries alone trained tablets including million investment approximately health workers reaching three million people partnered save children since supports efforts eliminate lymphatic filariasis lf control directly reached people health intestinal worms soiltransmitted helminths schoolage services health messaging programme activities children far benefited patients countries around world countries eliminated lf gsk supported gates ceo roundtable public health problem publicprivate collaboration train community health workers across six countries subsaharan africa tech support global response covid donated enabled community health programmes first year million gsk products antibiotics oral health programme reached people trained products multivitamins countries community health workers partnership americares direct relief ihp uk partnership smile train helps children cleft lip map international units medicines palate lead full healthy lives benefitting donated humanitarian emergency response young people free surgeries gskcom pricing access strategies pre postsurgery cleft care forms support healthcare access contributed million community initiatives includes cash product donations volunteering time commitment partner improve disease employees help improve healthcare access also prevention awareness access healthcare services provided support healthcare workers pandemic million people detail found gskcom exceeded target reaching million people gskcom prevention awareness infrastructure covid community partnerships giving response viivhealthcarecom positive action programmes modern employer positive employee experience critical attract retain inclusion diversity id motivate best people want employees commitment accelerate progress id empowered feel good keep growing including aspirational targets female ethnically diverse representation senior roles end engaged people recognition disability confident employer commitment achieve maintain competitive lgbt indices employee engagement score believe inclusion diversity id leads business survey employees annually get feedback success unleashing enormous potential people innovation performance trust strengthening ability respond differing needs culture longterm priorities may record patients consumers heart id agenda people took time feedback overall engagement lies fundamental commitment equity employment score jumped rise since survey practices support create inclusive workplace feel proud work gsk employees participate annual training programme facilitate inclusion dialogues invest leadership programmes ensure leaders understand health worker data estimated based reach responsibilities partner programmes level funding final data expected available april gsk annual report strategic report governance remuneration financial statements investor information trust continued corporate executive team cet members lead four race ethnicity uk diversity councils covering race ethnicity gender disability svpvp director manager employees lgbt working senior leaders members black asian employee resource groups minority ethnic measure progress monitor two questions asian employee survey participants said black authentic self gsk feel mixed respected work also added new question manager feedback tool one asks white employees rate whether actions manager demonstrates commitment inclusion diversity uk actively respond indicated team leaders scored average prefer say due rounding sum data may marginally different race ethnicity totals committed equality representation means uk aspire increase ethnically diverse vp constantly strive ensure workforce reflects leaders least end communities work hire specifically aspire specifically focused increasing percentage increase percentage leaders identify black vp leaders expect monitor ethnically diverse countries meet threshold ensures yearonyear growth target date expect confidentiality anonymity data disclose employee see growth across identified groups race ethnicity level communicate countrywide aspiration increase representation ethnically diverse support aspirations commitment equality leaders us uk satisfied threshold representation focused recruiting developing provide disclosures current representation diverse talent includes setting appropriate ambitious set aspirations targets ethnically diverse candidates early talent programmes us uk launching new global disclosures reflect gsks representation development programme accelerating difference ethnically december employees actively voluntarily diverse employees senior roles also disclosed race ethnicity introducing policy requires diverse shortlist qualified race ethnicity us candidates including ethnically diverse representation defined appropriately country svpvp director manager employees ethnically diverse gender american indian percentage women management continues rise alaska native gsk proud report achieved asian important landmark global percentage female managers presently equal black african american greater percentage nonmanagers currently hispanic latinx senior management roles vp native hawaiian pacific latest hamptonalexander review found gsk ranked islander top quartile ftse companies based proportion two races women board female representation white within ftse sector analysis gsk ranked nd pharmaceuticals sector rd insufficient data report fewer three employees us employees actively respond identify race women management ethnicity category indicated prefer say due rounding sum data may marginally different totals svpvp aspire increase representation ethnically diverse director vp leaders least us end manager specifically focused increasing management percentage black african american hispanic employees gender number latinx vp leaders expect monitor male female total yearonyear growth target date expect board see growth across identified groups management employees senior managers defined companies act strategic report directors report regulations gsk annual report trust continued increased global gender aspiration vp mental health training available employees roles higher end importantly managers completed encourage everyone pursuing steps within countries operate open ask help access support need enable encourage employees voluntarily self employees completed energy disclose gender identity resilience programmes via online training development published fourth annual uk gender pay gap report platform participated covidfocused resilience gender pay gap permanent ukbased gsk webinars virtual mindfulness sessions also employees mean outperforming national average introduced personalised digital health platform countries longstanding commitment fair includes subscription mental health app equal pay conduct countrybased reviews ensure individual selfsupport measure organisational stress markets clear guidance tools support ensure pay via platform focus mental health support required equity unexplainable differences detected address employee safety compensation processes overall reportable injury illness rate fell per disability hours worked reduced signatories uk department international numbers employees driving based gsk sites due developments charter change joining organisations pandemic contributed decrease common aim ensure rights freedoms dignity despite extensive safety programmes tragically inclusion people disabilities gsk also signed experienced two employee fatalities one manufacturing valuable pledge involves continuing invest site canada another road traffic accident india workplace accessibility building inclusivity skills additional workrelated fatality belgium people improving products packaging accessibility involving construction worker gsks direct developing measurable threeyear strategic disability supervision conducted extensive investigations confidence plan causes fatality ensure could take actions lgbt reduce risk similar tragic incidents occurring goal recognised global lgbt indices two developed safety improvement plan consecutive years lgbt rights group stonewall strengthen existing safety practices recognised gsk top global employers list approximately employees drive company business also ranked top uk stonewall index help employees drive safely run driver safety employee resource group lgbt employees allies programme combines online learning practical named best uk us gsk named best road safety activities drivers place work lgbtq equality fourth year running countries enrolled programme human rights campaigns corporate equality index founding member proud science alliance collective people development lgbtq networks work together raise bar want people keep developing throughout lgbtq inclusion across health life sciences sector career every employee opportunity discuss agree development plan manager health wellbeing development employees accessed training resources internal development portal year redesigned rolled commitment leading company new virtual first line leader training programme support employee health wellbeing personal development provide targeted development leaders stages careers established four leadership health wellbeing accountabilities motivate focus care develop gsks executive team overseen covid response support purpose performance driven culture including health wellbeing engagement employees primary focus support developed strong also updated one manager feedback tool help health safety framework aligned site needs specific role managers see well need focus types certain activities provided training development every manager expected complete monitored confirmed covid cases process involves selfassessment survey recoveries workforce daily basis developed team answer questions managers minimum standards returning workplace provided participated one employees provided clear expectations wearing personal protective feedback managers rating scale equipment employee testing temperaturescreening average managers scored team make workplace safe possible enabling employees return sites committed recruiting developing people start careers currently people supported employees working home ergonomic graduate mba programmes globally advice equipment provided online training remote apprenticeships countries working continued ensure sufficient employee assistance support employees well dependants g skcom employee engagement learning development gsk annual report strategic report governance remuneration financial statements investor information trust continued responsible business operating responsible business means transparent living values expectations science data delivering reliable supply employee survey showed making good highquality products protecting valuesdriven culture progress living values expectations issues responded swiftly transparently reducing employees agreeing work environment encouraged environmental impact ethical behaviour face pressures meet business objectives reliable supply also conducted joint review commercial practices commit quality safety reliable supply antibribery corruption audit team sales force products patients consumers incentives review findings highlighted strong patient focus pride working gsk review also identified ensuring highquality reliable supply products opportunities better embed values expectations patients consumers priority us see pages daily work reach employees manage continuity supply especially important pandemic every gsk employee complementary worker required complete living values expectations mandatory robust quality management systems support continuous training annually employees improvement helping us maintain high standards product complementary workers completed training quality safety complying relevant regulations focused protecting gsk content included topics including good manufacturing practice good antibribery corruption abac code conduct laboratory practice good pharmacovigilance practice information security privacy independent thirdparty speak good clinical practice external regulatory integrity lines reporting concerns human safety inspections many carried virtually due pandemic information adverse event reporting training helps manufacturing sites local operating companies identify manage risks appear daytoday roles gsk addresses inspection findings however minor robust processes ensure corrective preventive mandatory abac training continued action plans implemented timely manner employees contract workers completed training focuses principles assist carried quality audits suppliers employees identify mitigate abac risk audits clinical studies run behalf gsk recognise report mitigate conflicts interest identify areas require improvement engage relevant third parties develop improvement plans reporting investigating concerns track progress significant issues identified anyone inside outside gsk raise concerns speak remain unresolved may choose suspend terminate independent third party integrity lines work third party confidentially anonymously without fear retaliation take every concern seriously review every pharmacovigilance report understand whether formal investigation needed detecting assessing understanding preventing adverse investigations show employee breached effects drugrelated problem important policies take appropriate disciplinary action evaluating safety pharmaceutical products continue work partners maintain high standards respect employees accused misconduct safety medical governance apply rigour initiated formal investigations policy safety standards potential covid related violations relating behaviour workplace result solutions employees disciplined dismissed voluntarily left received documented warning prevent manufacture distribution counterfeit instances action short documented warning gsk products continue work international law taken end cases awaiting enforcement agencies played key role anti investigation disciplinary decision counterfeiting actions china resulted closure eight locations manufactured millions counterfeit employees disciplined breakdown types goods including toothpaste brands policy violation g skcom patient safety reliable supply behaviour workplace good manufacturing distribution practices ethics values mandatory training completion commitment operate ethical valuesdriven marketing promotional activities culture issues responded swiftly expenses transparently high expectations employees live employee subject multiple allegations disciplinary actions values act concerns extend policy violation types fit categories specified expectation third parties gsk annual report trust continued human rights data engagement committed respecting human rights throughout commitment use data responsibly transparently global operations continue deepen understanding improve patient scientific engagement human rights impacts associated activities responsible data use improved visibility labour rights risks committed using data responsibly transparently supply chain support external experts includes managing data carefully sharing results identified raw materials commodities sometimes clinical studies integrating patient insights product linked modern slavery prioritising due development providing healthcare professionals diligence activities similar risk assessment indirect relevant accurate information need suppliers progress evolved privacy approach better align membership pharmaceutical supply chain external expectations privacy design framework initiatives human rights labour subcommittee ensure dataowners consider privacy right start supported delivery human rights modern slavery activities established specialised privacy review panel training sessions suppliers india china also assess appropriateness secondary use personal information engaged stakeholders brazil better understand rd ensure protect individuals rights freedoms forced labour risks certification schemes associated carnauba wax used tablet coatings presented annual code conduct training mandatory findings suppliers employees globally includes module privacy reinforces understanding everyone gsk personally progress priority human rights areas responsible correct handling personal information access healthcare research practices patient safety also provide training new hires everyone filling environment health safety privacy found key privacy role undergoes certification international relevant sections report website association privacy professionals requires ongoing g skcom human rights modern slavery act statement privacy education maintain working third parties also critical partner transcelerate consortiums want ensure third parties work share effort create harmonised approach pharmaceutical values ethical business standards third industry support exchange data internationally party oversight tpo programme embedded clinical trial transparency globally continue refine part longstanding commitment data transparency risk assessments completed tpo programme clinical studies published clinical study third parties identified high risk reports summaries results positive undergone detailed independent assessments ecovadis negative studies clinical study register help ensure continuity suppliers also share anonymised patientlevel data studies throughout covid pandemic conducted supplier external researchers financial checks offering support suppliers financial health listed studies data sharing via wwwvivliorg deteriorated example relaxing payment terms wwwclinicalstudydatarequestcom continued work thirdparty suppliers gskcom online gsk privacy notice gsk clinical study register reduce ehs risks conducted audits ehs patient scientific engagement ethics countries physical visits possible virtual expanded priority conducted number patient panels across suppliers priority suppliers wide variety different disease areas also significant spend support significant established process seek patient feedback design revenue andor medically rd critical business clinical trials provide proactive support help suppliers build continued increase focus improving safety improvement plans build overall capability diverse representation clinical trials represent use range tools assess suppliers management real world population terms age race ethnicity gender ehs risks including use ecovadis desktop assessments approach characterises populations burden site virtual audits set clear ehs requirements disease barriers access engages communities suppliers discontinue work suppliers advocacy groups also provide training support consistently fail meet requirements continually staff increasingly research collaborators review ehs performance suppliers part internal enrolling diverse populations clinical trials ehs governance oversight processes read approach engaging hcps see code hcp engagement gskcom ethics values gskcom clinical trial diversity patient engagement engaging hcps gsk annual report strategic report governance remuneration financial statements investor information trust continued environment latest available data categories absolute scope emissions decreased vs commitment net zero impact climate per billion revenue represents reduction per net positive impact nature billion revenue since baseline year mainly set two ambitious new climate nature goals reduction carbon intensity products november start reporting purchased updated data emissions milk annual report horlicks reduced emissions metered dose inhalers new climate goal means aim net zero scope ellipta dry powder inhalers dpi lifecycle carbon carbon emissions part climate footprint around times lower propellantbased goal accredited caligned emissions inhaler certified carbon footprint trelegy reduction targets covering scopes science ellipta working carbon trust recertified carbon based targets initiative also joined reinforcing footprints ellipta products support efforts commitment renewable electricity ev reducing promote low carbon inhalers wherever possible impact sales fleet recognise suppliers efforts reduce nature goal underpinned ambitious targets focuses environmental impacts annual supplier water reduction water stewardship compliance waste environmental sustainability awards see winners reduction circularity including eliminating plastics api gskcom emissions reduction adoption biodiversity action plans also expanded climate resilience analyses see measurement carbon andor land use improved nature task force climaterelated financial based solution programmes part invest disclosures framework guidelines introduced new projects protect restore landuse align targets related carbon published gskcom science based targets nature approach measure new net zero targets joined race zero impact nature seek accredit target global un campaign aims build momentum around methodology finalised shift decarbonised economy ahead next climate seek deliver goals taking action priority summit cop impact areas working key external partners including g skcom new environmental approach supplier awards suppliers customers see gskcom full set carbon emissions plus intensity ratios per regulations targets last year report previous targets set tonnes coe scope emissions gskcom new environmental approach scope emissions carbon scope emissions available overall value chain carbon footprint made scope report emissions operations scope uk scope emissions emissions supplier base logistics energy used use products mostly metered dose inhalers scope emissions sales revenue tonnes report progress new carbon targets co em final year reporting progress scope emissions targets set targets set fte tonnes co efte baseline reduce operational carbon emissions scope scope emissionsbn available reduce value chain carbon emissions scope revenue million tonnes report per billion revenue source electricity co ebn revenue renewable sources total energy used gwh reduced scope emissions uk energy used gwh approximately compared since largely transformed use renewable electricity scope sbtiaccredited target aims baseline scope target commits us reducing absolute purchase green certificates means scope emissions baseline electricity used sourced renewably exceeding figures expected available later interim target achieving also saw one year 's treatment use propellantbased inhalers results reduction scope emissions national lockdowns reduced carbon footprint kg coe compared kg coe using ellipta dry powder inhalers need driving salesforce carbon emissions calculated according greenhouse gas protocol continued installing improving use existing corporate accounting reporting standard revised edition gsk uses marketbased scope emissions reporting purposes reports scope renewable energy site energy efficiency programme emissions across categories see esg performance summary continues identify opportunities reduce energy gsk asks dnv provide limited assurance isae energy scope consumption example installed new heat exchanger selected scope carbon emissions water waste wastewater mayenne site france transfers heat previously data methodologies reporting measurements provided esg performance summary kpi definitions pages lost chilling water uses provide hot water demand site gsk annual report trust continued water joined action sustainable derivatives aim reduce total water use highrisk site enabled us trace palm oil volume back set baseline mill level seven highrisk water sites following network changes around materials use manufacture products saw last highrisk water vaccine sites consumer derived biobased sources healthcare horlicks sites leave network result large animalderived ambition move nonanimal derived volumes water used water stress areas removed andor sustainable alternatives materials operations seven remaining highrisk water sites take time ensure efficacy safety products track achieve reduction target compromised water challenges simply volumetric reduction see gskcom new responsible sourcing good water stewardship means reducing amount water biodiversity targets use improving water quality minimising discharges working community stakeholders address local gskcom new environmental approach water challenges plastic sites compliant water set target consumer healthcare business stewardship standard meeting target eliminate problematic unnecessary plastics reduce continue work towards reaching plastic footprint tonnes ensure packaging recyclable quality safety permits introduced new targets related water published gskcom joined un ceo water mandate also joined un water consumer healthcare business developed design resilience coalition sustainability tool enable us design new products sustainable way minimising plastic use gskcom new environmental approach example tool launched first waste sustainable plasticfree toothbrush germany end sites stopped sending also continued efforts reduce single use hazardous nonhazardous waste landfill companywide plastic footprint removed million single use validation year ambition completed plastic items equivalent tonnes plastic since first half achievement excludes waste reduction programme began end asbestos must sent landfill see gskcom new target relating pharmaceuticals also commitment ensure waste repurposed environment beneficial use site parma italy example implemented initiatives increase gskcom new environmental approach amount solid waste sent incineration energy recovery pharmaceuticals environment concentrate hazardous waste stream preventing committed ensuring active pharmaceutical incineration around tonnes contaminated water ingredients apis adversely affect people programmes increased amount waste environment key partner new project repurposed beneficial use site innovative medicines initiative imi focused reduced overall waste prioritisation risk evaluation medicines see gskcom new waste reduction circularity environment premier multistakeholder project targets make environmental data apis accessible stakeholders gskcom new environmental approach committed ensuring api emissions responsible sourcing manufacturing including might contribute carried risk assessment helped us antimicrobial resistance amr kept levels identify highestrisk materials supply chain negatively impact human health environment result assessment developing responsible carry environmental testing pharmaceuticals sourcing plans highrisk materials use data risk assessments evaluate potential committed moving towards deforestationfree sourcing harm use data set safe discharge targets key commodities purchased directly gsk indirectly manufacturing supply chain reducing amr risk behalf early expanded scope see deforestationfree sourcing policy cover soy cattlederived see gskcom new target relating pharmaceuticals products rubber well palm oil paper packaging environment made first submission cdp forests covering sourcing palm oil paper packaging paper gskcom new environmental approach packaging majority carton supply chains forest stewardship council programme endorsement forest certification pefc certified see kpi definitions esg performance summary exceptions gsk annual report strategic report governance remuneration financial statements investor information risk management gsk wellembedded risk management framework reviewed continually board committees provide oversight framework assisted risk oversight compliance council risk management framework enables gsks board year developed risk management identify evaluate manage principal risks line framework moving annual quarterly upwards reporting longterm priorities sets effective hierarchy risk principal risks emerging risks external insights management compliance boards within enabled risk oversight compliance council businesses promotes tone top establishes oversee risk dynamic way also made reporting risk culture oversees effective cascade data driven key risk indicators enabling agile escalation information internal controls principal risk management strategies addition risks mitigations risk overseen cet risk owner ensure proportionate relating covid incorporated within controls place clear plans assigned address significant risks complement pandemic risks gaps businesses risk owners provide reporting identified managed cet risk mitigation risk oversight compliance three new risks escalated standalone council board committees principal risks environmental sustainability nonpromotional gsk considers current emerging risks part engagement transformation thirdparty oversight ceased risk management framework emerging risks defined principal risk implementation matured threeyear horizon may yet residual risk effectively managed within business adequate information impact likelihood relevant principal risk cet agreed maintain emerging risks thus may undertake investigation current principal risks including list principal risks emerging list current principal risks following pages risk assessments performed part remit order significance full risk definitions risk management compliance boards levels mitigating activities please see pages organisation risks associated proposed separation cet conducts formal annual risk review consider gsks consumer healthcare business current emerging risks whether significant separation consumer healthcare business dependent included principal risks list review number factors outside gsks control including supported extensive analysis external trends required shareholder regulatory approvals favourable insights senior level interviews recommendations conditions public equity markets public private risk management compliance boards debt markets changes applicable law regulation risk management framework complements values therefore certainty separation expectations speak processes ensuring completed proposed risks associated business activities actively addition separation completed effectively identified mitigated also provides reasonable assurance either gsk consumer healthcare assurance material misstatement loss conduct realise expected benefits separation separation annual confirmation exercise across businesses adversely affect gsk consumer healthcare validate key risks well managed actions value liquidity respective shares place address gaps reinforces accountability leaders risks associated covid potential impact covid pandemic gsk 's board oversight extended beyond audit risk trading performance principal risks committee include involvement corporate assessed mitigation plans put place date responsibility committee science committee report pandemic anticipated impacted committees considered gsks risks strategies used group performance year primarily demand address drew annual business vaccines result ongoing containment measures unit risk assurance update reports strategy papers impacting customers ' ability willingness access significant risks cets annual risk review vaccination services across regions anticipate governments ' prioritisation covid vaccination programmes continue impact vaccines business continue monitor situation closely continues viability statement see dynamic uncertain situation ultimate severity duration impact unknown point including potential arc report see impacts trading results clinical trials supply continuity principal risks uncertainties see employees situation could change time internal control framework see assurance covid pandemic material adverse impact future results group gsk annual report risk management continued risk assessment mitigation activities patient safety macro risk level unchanged remains challenging politicisation drug vaccine safety efficacy context covid could provoke distrust alter public reporting restrictive privacy regulations impact manage safety data create complications gsks exposure also unchanged operational risk stabilised embedding pharmacovigilance organisational efficiencies offset challenges accompanying fastpaced development medicines vaccines covid mitigate risks apply wellestablished safety governance risk management framework ensure safeguarding patients throughout lifecycle gsk products product quality macro risk remains despite concerns potential drug shortages associated covid ongoing evaluation products presence nitrosamines increased focus data integrity requirements gsk 's exposure remains unchanged quality oversight processes place monitor maintain strong compliance profile throughout pandemic governance control strategies developed deployed timely completion nitrosamine assessments continued invest technology digital platforms strengthen controls around good data management practices financial controls macro risk level increased external environment remaining challenging due political uncertainty increasing societal expectations role auditor reporting increased fraud attempts challenging financial markets informed mainly covid pandemic evolving political responses gsks risk exposure remained stable due resilience focus personnel continue implement transformational programmes leverage technology centralise processes strengthen controls maintain effective tax treasury strategies antibribery macro risk level bribery corruption increased continued see legal corruption abac frameworks similar uk us develop elsewhere rigorous standards aided improved technology increased enforcement focus thirdparty intermediaries impact covid businesses gsks abac risk exposure maintained continue improve abac programme ensure appropriate controls training capability building awareness raising strong monitoring use data analytics continue understand assess risk exposure money laundering wider corruption mitigate existing risk commercial covid increased macrolevel risk industry gotomarket model boosting practices importance different channel activities eg internet based consumers promoting pricing connecting commercialising also increased risk downward price pressure due international reference pricing aggressive healthcare budget controls tighter reimbursement gsks risk exposure level remains stable due mature robust control environment continue evolve commercial practices invested new technologies support virtual customer engagement maintain proportionate controls training monitoring employees engage healthcare organisations professionals consumer healthcare improvements digital sales marketing control framework mitigating emerging risks nonpromotional macro environment nonpromotional activities scientific engagement hcps patients stable despite impacted complexity dynamic nature engagement disease areas treatments increasing diversity engagement platforms significant increase virtual engagements since pandemic gsks exposure increased modernised adapted practices applied internal principles policies designed mitigate risk rapidly evolving environment evolved employee training people understand risk associated nonpromotional activities conduct compliance gsks values policies local laws regulations gsk annual report strategic report governance remuneration financial statements investor information risk management continued risk assessment mitigation activities privacy macro risk continues increase priority gsk markets us china india instituting new enforcing existing privacy laws court rulings invalidating privacy mechanisms international companies relied including euus privacy shield covid highlighted fragmented nature regulatory environment gsks exposure remains unchanged due continued efforts embed privacy framework markets evolution risk mitigation business advancing privacy strategy centrallydriven mitigation approach one business proactively embeds privacy design standards research macro risk level increased due covid pandemic created continuity practices challenges rd particularly human subject research disruption global clinical trial programmes introduced additional risks gsks exposure remains unchanged offsetting external impacts pandemic risk mitigation actions embed monitor additional business continuity measures controls ongoing planned work enhance monitor culture quality continuing environment macro risk level increased although regulators stakeholders expectations health safety broadly new regulations control spread covid workplace ehs added significant complexity comply existing ehs regulations gsks risk exposure increased due adjustment work practices enable covid control measures transition period significant organisational change factors require us refocus applying ehs fundamentals environmental macro risk level increased investors regulators stakeholders increasingly sustainability expect companies understand reduce environmental impacts across value chain mitigate impacts climate change could operations supply chains gsks risk exposure unchanged set ambitious new environmental sustainability targets implemented detailed water resilience assessments increased task force climaterelated financial disclosures tcfd analysis continued monitor trends physical reputational regulatory risks climate change impacts information macro risk level continues rise large multinationals increase digital footprints security threats hackers become ever sophisticated year covid also added measurable increase threats targeting healthcare industry gsks risk exposure increased gsks cybersecurity programme continues rapid improvement controls increase cyber threat intelligence capabilities protect critical information systems including operational technology networks gsk continues strengthen cybersecurity information protection capabilities targeting pharmaceutical vaccine intellectual property leveraging cybersecurity well third party service availability means disruption intensified supply continuity macro risk level remains high due ongoing impact covid pandemic product supply potential increasing protectionism countries brexit uncertainties also continues gsks risk exposure increased elevated risk supply issues bioscience materials glass vials filters industrywide concern arising rapid ramp covid vaccines therapeutics driving increased demand components transformation macro risk level increasing due covid introduced uncertainty external global environment necessitating temporary measures certain countries protect employment gsks risk exposure level remains unchanged transformation separation projects progressed planned throughout workforce engagement priority gsk annual report risk management continued climaterelated financial disclosure provide update gsks voluntary disclosure risks extreme weather events flooding wildfires accordance recommendations taskforce storms may impact supply chains manufacturing climaterelated financial disclosure tcfd initiative operations shortterm basis one three years financial stability board promotes disclosure reviewed annually addressed business continuity climate change risk plans scenario analyses continue inform focus consider address potential longerterm impacts november committed ambitious new seven years climate change environmental sustainability goals climate nature aim net zero climate impact net positive two scenarios considered impact nature goals build longterm businessasusual assumed little mitigation ambition since reduce impact environment leading c warming see lowcarbon assumed global temperature governance increase limited well c rapid board overall accountability management changes legislation technology gsks principal risks includes environmental scenarios based internationally recognised data sustainability support cet boards sets consider potential physical risks changing corporate responsibility committee crc oversees gsks climate flooding water stress well risks environmental sustainability principal risk progress associated transition lowcarbon economy environmental targets crc supported work international climate policy impacts carbon pricing members cet including ceo president analysis evaluated implications gsks manufacturing global affairs president pharmaceuticals supply chain facilities suppliers raw materials providers well attend committees meetings impacts patient consumer use product year crc reviewed approved assessment consider actions gsk might recommendations companys new sustainability goals take mitigate adapt findings crc reviewed contribution biopharma analysis physical transition risks showed consumer part business goals crc scenarios likely financial risks discussed impact climate change nature loss would need managed none would materially impact human health recognising new goals consistent business model key impacts scenarios company purpose strategy floodrelated disruptions manufacturing sites regis simard president pharmaceuticals supply chain supply chain member cet management responsibility environmental sustainability responsible governance water stress leading increased expenditure disruption risk oversight ensures effective framework manufacturing sites supply chain place use manage risks across higher temperatures affecting quality availability businesses well delivering commitments made raw materials strategy increased costs fossil fuels impact carbon trust one three longterm priorities reducing pricing energy emissions environmental impact important part trust priority findings build initial assessment gain better understanding climate change might using develop approach performing climate impact business built data reported risk scenario analysis well action plans help mitigate undertaking scenario analyses consider longterm longerterm risks embed sustainability strategy risks climate change four additional products support environmentally sustainable decisions across vaccines pharmaceuticals consumer internal carbon pricing capital investments piloted healthcare businesses means taken combination using shadow price per tonne reflecting current best work completed developed climate practice evaluate impact governance required scenario analyses supply chains cover approximately view implementation across group aim revenue stream ensure organisations assets become carbon efficient time scenarios based ippc representative concentration pathways iea world energy outlook new policy scenario current policy scenario sustainable development scenario data sets wwf wri water stress flood risk modelling gsk annual report strategic report governance remuneration financial statements investor information risk management continued risk management established transformation office review environmental sustainability includes climate change assess monitor progress towards new goals risks became standalone principal risk business commitments including key performance indicators specific dedicated environmental sustainability scope carbon emissions percentage enterprise risk plan put place details renewable electricity across operations proportion see risk management risk plan covers sales force vehicles electric vehicles expectations gsk addressing impact detail progress making towards achieving environment environment increasing impacts targets found environment section operational resilience access energy water public response cdp climate water natural resources used products along questionnaires anticipated cost increases regulatory changes environmental taxes next steps committed continuing embed climate risk internal control framework established assessments mitigation activities business environmental sustainability including appointment plan review aggregate analysis dedicated senior leaders environmental sustainability identify hotspots opportunities continue ensure governance processes place effective reducing value chain carbon emissions bring performance reducing carbon emissions energy transparency impact scenarios financial water waste continue delivered managed assessments future annual reports mature programmes enhanced including ecodesign considerations products packaging metrics targets new target net zero impact climate net positive impact nature aim deliver goals taking action priority impact areas working key external partners including suppliers customers full set targets contribute goals available gskcom accredited science based targets initiative set scope targets line decarbonisation required keep global temperature increases c joined race zero demonstrate commitment transition low carbon economy ahead cop held uk joined aligns commitment source electricity use renewable resources joined ev aligns commitment decarbonise fleet sales vehicles also committed moving towards deforestationfree sourcing key commodities working partners roundtable sustainable palm oil rainforest alliance gsk annual report risk management continued viability statement accordance provision revision downside scenarios consider gsks cash flows code gsk assessed prospects company sustainability dividends funding strategy insurance provision longer period months required recovery well key financial ratios period going concern provision directors confirm metrics subject sensitivity analysis reasonable expectation gsk continue operate involves flexing number main assumptions underlying meet liabilities fall due next three years forecasts individually combination along directors assessment made reference mitigating actions could realistically taken avoid gsks current position prospects strategy reduce impact occurrence underlying risk boards risk appetite gsks principal risks following hypothetical downside scenarios managed detailed pages evaluated strategic report scenario business performance risks include key board reviews internal controls risk management performance risks including lower sales new products policies approves governance structure code greater adverse impact generic competition conduct also appraises approves major financing competitive launches gsk products well investment licensing decisions evaluates monitors possible supply manufacturing challenges performance prospects gsk whole focus largely improving longterm financial performance scenario external macroeconomic risks scenario delivery company three business strategies reflects incremental risks business driven outside aligned innovation performance trust priorities factors intense competition increased pricing pressure us europe well potential board reviews gsks strategy makes significant capital impact material negative changes macroeconomic investment decisions longterm time horizon based healthcare environment multiyear assessment return capital performance company three business units market scenario principal risks scenario includes severe opportunity pharmaceutical vaccines consumer assessment potential loss impact principal risks sectors approach aligned gsks model achieving related patient safety product quality supply chain continuity balanced growth investing high quality innovative products environmental sustainability well antibribery patients consumers healthcare providers however corruption consequent regulatory actions fines since many internal external parameters become could fundamentally threaten operations increasingly unpredictable longer time horizons gsk would include potential severe impact coronavirus focuses detailed bottomup plan threeyear cycle materialise supply chain disruptions risks managed mitigating activities described pages plan reviewed least annually directors approve business forecasts showing expected financial impact directors believe threeyear assessment period scenario put option exercise scenario evaluates viability statement appropriate aligns additional funding requirements assuming earliest potential companys well established business planning processes exercise outstanding put option held partner balance longterm nature investments hiv business pharmaceutical vaccines consumer sectors future separation consumer healthcare joint venture assessment period analysis nearterm pfizer approved board likely occur within business performance realistically visible period covered viability assessment plan stress tested series robust operational considered scenario concluded principal risk downside scenarios part boards material impact viability group resultant separate review risk include potential risks associated companies threeyear period assessment ongoing coronavirus pandemic considered threeyear review also makes certain assumptions within plan stress test downside scenarios normal level capital recycling likely occur considers plan assumes healthcare systems consumer trends whether additional financing facilities required approach normality second half vaccines respective level funding flexibility headroom business plan assumes disruption first results stress testing show certain combinations half given governments prioritisation coronavirus hypothetical scenarios could increase funding vaccination programmes resurgence late demands gsk require mitigating changes pandemic expected impact adult adolescent groups funding strategy however light liquidity immunisations including shingrix notably us strong available group based analysis directors recovery contribution growth shingrix assumed reasonable expectation even second half stress tested severe stress tests company able continue potential risks principally delays business recovery operation meet liabilities fall due threeyear period assessment gsk annual report strategic report governance remuneration financial statements investor information risk management continued impact brexit uk left eu january brexit transition retesting certification uk completed period ended december trade relevant marketing authorisation transfers updated packaging cooperation agreement tca place uk secured additional warehousing products eu overriding priority preparing uks exit continue support employees obtaining settled status eu maintain continuity supply equivalent uk europe complying medicines vaccines consumer healthcare products new tax customs requirements introduced new people uk eu postbrexit operating model borders trade terms place uk implemented continue work closely eu northern ireland governments uk eu well third expenditure date brexit preparations parties effective implementation tca line projections mainly attributed setting ensure life sciences sector continues thrive retesting medicines consumer products eu deliver innovation patients uk eu continue anticipate subsequent ongoing costs gsk welcomes medicinal products annex tca arising brexit could approximately million particular inclusion mutual recognition good per year ongoing costs due impact customs manufacturing practice gmp inspections however due duties increased logistics costs traverse new borders lack agreed mutual recognition batch testing part cost duplicate testing release products new model conduct retesting certification continue understand technical implications medicines consumer products europe required tca implementation corresponding guidance preparing meet phasedin requirements assumptions underlying forecasts could change consequent adjustments nonfinancial information statement following aligns nonfinancial reporting requirements contained sections ca cb companies act description business model human rights policy due diligence outcomes create value human rights summary principal risks data engagement principal risks uncertainties social matters third parties viability statement global health audit risk committee report anticorruption bribery health security nonfinancial key performance affordability availability living values expectations indicators reporting investigating concerns employees antibribery corruption key performance indicators employee engagement environmental matters policies diversity wellbeing development carbon water waste public policies codes gender pay gap standards available gskcom living values expectations board diversity gsk annual report group financial review section reporting framework approach tax financial performance adjusting items cash generation conversion financial position resources treasury policies critical accounting policies strategic report governance remuneration financial statements investor information group financial review reporting framework total adjusted results costs ordinary course smaller scale restructuring group financial review discusses operating legal charges expenses retained within total financial performance group cash flows financial adjusted results position resources results year adjusted results include benefits major restructuring compared primarily results preceding year programmes exclude significant costs significant total results legal major restructuring transaction items total reported results represent groups overall regarded complete picture groups financial performance performance presented total results exclusion adjusting items may result adjusted gsk also uses number adjusted nonifrs measures earnings materially higher lower total earnings report performance business adjusted results particular significant impairments restructuring nonifrs measures may considered addition charges legal costs excluded adjusted earnings substitute superior information presented higher total earnings accordance ifrs adjusted results defined nonifrs measures defined gsk undertaking number major restructuring programmes response significant changes groups gsk believes adjusted results considered together trading environment overall strategy following material total results provide investors analysts acquisitions costs cash noncash stakeholders helpful complementary information programmes provided individual elements understand better financial performance position approved meet accounting recognition criteria group period period allow groups result charges may incurred number years performance easily compared majority following initiation major restructuring programme peer companies measures also used management planning reporting purposes may group also initiated twoyear separation preparation directly comparable similarly described measures programme prepare gsk separation two new used companies leading companies biopharma consumer healthcare gsk encourages investors analysts rely time time group divests noncore investments single financial measure review gsks annual reports products businesses records profit loss including financial statements notes entirety disposal adjusting item notable divestment year disposal horlicks consumer adjusted results healthcare brands adjusted results exclude following items total results significant legal charges expenses arising together tax effects items settlement litigation government investigations amortisation intangible assets excluding computer software normal course materially larger capitalised development costs regularly occurring individual matters also include certain impairment intangible assets excluding computer major legacy matters software goodwill reconciliations total adjusted results providing major restructuring costs include impairments information key adjusting items tangible assets computer software specific set five years boardapproved programmes structural set pages significant scale costs individual related gsk provides earnings guidance investor community projects exceed million including integration costs basis adjusted results line peer companies following material acquisitions expectations investor community supporting easier transactionrelated accounting adjustments related comparison groups performance peers gsk significant acquisitions able give guidance total results reliably proceeds costs disposals associates products forecast certain material elements total results businesses significant legal charges net insurance particularly future fair value movements contingent recoveries expenses settlement litigation consideration put options given rise government investigations operating income significant adjustments driven external factors royalty income items currency movements capital markets separation costs prepare separation gsk two companies impact enactment us tax cuts jobs act gsk annual report group financial review continued reporting framework continued historical record adjusting items reconciliations total adjusted operating profit last five years summarised follows total operating profit intangible asset amortisation intangible asset impairment major restructuring transactionrelated items divestments significant legal items separation costs us tax reform adjusted operating profit analysis impact transactionrelated items operating profit last five years follows novartis consumer healthcare joint venture put option contingent consideration former shionogiviiv healthcare jv including shionogi preferential dividends viiv healthcare put options pfizer preferential dividends contingent consideration former novartis vaccines business release fair value uplift acquired pfizer inventory adjustments transactionrelated items full reconciliations total adjusted results set pages explanations adjusting items reported noncontrolling interests viiv healthcare viiv healthcare also agreed pay additional future cash trading profit allocations consideration shionogi contingent future sales viiv healthcare subsidiary group performance products developed joint operating results turnover operating profit profit tax venture principally dolutegravir ifrs business included within group income statement combinations gsk required provide estimated portion earnings allocated noncontrolling fair value contingent consideration time interests owned shareholders line acquisition required update liability latest respective equity shareholdings pfizer shionogi estimate fair value subsequent period end shareholders including gsk also entitled liability contingent consideration recognised preferential dividends determined performance balance sheet date acquisition million certain products shareholder contributed subsequent remeasurements reflected within relative performance products changes time operating incomeexpense within adjusting items proportion overall earnings viiv healthcare income statement period december allocated shareholder change particular liability discounted stood increasing proportion sales dolutegravircontaining million posttax basis products favourable impact proportion cash payments settle contingent consideration preferential dividends allocated gsk adjusting items made shionogi viiv healthcare quarter based allocated shareholders based equity interests actual sales performance relevant products gsk entitled approximately total earnings previous quarter payments reduce balance sheet adjusted earnings viiv healthcare liability hence recorded income statement remeasurements liabilities preferential dividends cash payments made shionogi viiv healthcare allocated pfizer shionogi included within million operating incomeexpense liability required recorded fair value acquisitionrelated arrangements estimated future payments significant timing consideration acquisition shionogis interest difference charges recorded total former shionogiviiv healthcare joint venture income statement reflect movements fair value shionogi received equity stake viiv healthcare liability actual cash payments made settle liability gsk annual report strategic report governance remuneration financial statements investor information group financial review continued reporting framework continued cash payments reflected cash flow statement however q gsk notified shionogi partly operating cash flows partly within investing irrevocably given right accordingly recognised activities tax relief payments reflected liability put option groups balance sheet groups adjusting items part tax charge part q initial value million q payment relating original estimate fair shionogi irrevocably agreed waive put option value contingent consideration acquisition result gsk derecognised liability put option shionogiviiv healthcare joint venture million groups balance sheet directly equity value reported within investing activities cash flow statement liability million derecognised part payment relating increase gsk also call option shionogis shareholding liability since acquisition reported within operating cash viiv healthcare original agreements flows exercisable sixmonth windows commencing movements contingent consideration payable shionogi gsk irrevocably agreed waive first follows two exercise windows last sixmonth window remains call option fair value value accounting purposes contingent consideration beginning year free cash flow remeasurement income statement free cash flow defined net cash inflow operating cash payments operating cash flows activities less capital expenditure property plant cash payments investing activities equipment intangible assets contingent consideration contingent consideration end year payments net finance costs dividends paid non contingent consideration payable posttax basis controlling interests plus proceeds sale property shionogi december million december plant equipment intangible assets dividends million expected paid within one year received joint ventures associates used management planning reporting purposes exit rights discussions presentations investment analysts pfizer may request ipo viiv healthcare time rating agencies free cash flow growth calculated either gsk consent ipo offering reported basis reconciliation net cash inflow completed within nine months pfizer could require gsk operations free cash flow set acquire shareholding original agreements gsk unconditional right long made subsequent cer aer growth distribution shareholders withhold consent order illustrate underlying performance groups exercise pfizer put option result accordance practice discuss results terms constant exchange ifrs gsk recognise liability put option rate cer growth represents growth calculated balance sheet however q gsk notified exchange rates used determine results overseas pfizer irrevocably given right accordingly companies sterling remained unchanged recognised liability put option groups balance used comparative period cer represents growth sheet q initial value million constant exchange rates aer represents growth consistent revised treatment end q actual exchange rates gsk also recognised liabilities future preferential proforma growth dividends anticipated become payable pfizer shionogi acquisition pfizer consumer healthcare business groups balance sheet completed july closing balances liabilities related pfizers group presented proforma growth rates cer shareholding follows turnover adjusted operating profit operating profit business taking account transaction proforma growth rates cer calculated comparing reported results pfizer put option calculated applying exchange rates used pfizer preferential dividend comparative period results adjusted include equivalent seven months results july original agreements shionogi could also former pfizer consumer healthcare business consolidated requested gsk acquire shareholding viiv healthcare us included pfizers us gaap results sixmonth windows commencing gsk unconditional right long made return capital employed subsequent distribution shareholders withhold return capital employed calculated total profit consent exercise shionogi put option taxation percentage average net assets year result gsk recognise liability put option net debt balance sheet please see note net debt calculation net debt gsk annual report group financial review continued approach tax understand responsibility pay appropriate amount ongoing public focus tax affairs tax fully support efforts ensure companies multinational companies included major project appropriately transparent tax affairs organisation economic cooperation development managed tax important element economic oecd addressing tax challenges digitalisation contribution bring countries operate economy gsk welcomes oecds efforts identify engage artificial tax arrangements without longterm sustainable consensusdriven solution business commercial substance seek avoid tax tax challenges resulting digitalisation active use tax havens transactions would fully providing relevant business input assist successful disclose tax authority zero tolerance approach delivery aims project order create long tax evasion facilitation tax evasion lasting stable certain business environment taxpayers governments multilateral consensusbased substantial business employment presence approach grounded clearly defined accepted principles many countries around globe pay significant critical incentive innovate must diluted amount tax including corporation business taxes well tax associated employees time continued focus tax reform driven responsibility shareholders financially oecds base erosion profit shifting beps project efficient deliver sustainable tax rate part ec initiatives fiscal state aid investigations approach look align investment strategies introduction mandatory disclosure rules outputs countries already substantial economic activity oecd beps project clarified important principle government policies promote regimes tax paid profits throughout supply chain attractive business investment rd activity profitmaking activity takes place gsk subject transparent intent available relevant tax payers taxation throughout supply chain examples include uk patent box research gsk supports beps proposals particular development expenditure credit implementation oecds recommendations country tax risk countries operate managed country reporting including exchange data robust internal policies processes training compliance tax authorities data validated existing programmes board directors audit risk information held taxpayers support ability ensure committee responsible approving tax policies multinational groups pay appropriate amount tax risk management arrangements part wider internal uk left eu january brexit transition control framework seek develop cooperative period ended december trade relationships tax authorities based mutual respect cooperation agreement tca place uk transparency trust appropriate also provide eu complying new tax customs requirements constructive business input tax policy matters advocating introduced new borders trade terms reform supports economic growth job creation place uk eu ukeu tca needs patients agreed december due complexity group corporate tax charge million interaction uk continuity free trade agreements million profits tax million full impact taxes fully quantifiable later million representing effective tax rate direct tax implications expected limited made cash tax payments indirect tax implications may significant including million year million addition example additional customs duty products covered taxes pay profits pay duties levies ukeu tca irrecoverable indirect tax costs transactional employment taxes gsk well prepared additional administrative complexity tax arrangements new borders around adjusted tax rate uk great britain ensure continuity supply wider rate benefitted cancellation uk approach brexit set government reduction uk corporation tax rate resulting increase value balance sheet tax strategy set detail within public policies tax assets subject material changes product mix section website details corporate tax material changes tax regulations laws countries charges year set operate groups average effective adjusted tax rate medium term expected around groups total tax rate lower adjusted tax rate mainly due tax effect disposal horlicks consumer healthcare brands unilever subsequent disposal shares received hindustan unilever gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial performance group turnover bn total results group set proforma bn aer growth cer growth cer growth growth turnover turnover cer turnover cost sales selling general administration research development royalty income operating incomeexpense operating profit net finance costs total operating profit bn share aftertax profits associates bn aer growth cer growth joint ventures profit taxation taxation profit taxation year profit attributable shareholders earnings per share p earnings per ads us adjusted results group set reconciliations total results adjusted results set adjusted operating profit bn growth proforma pro bn aer growth cer growth cer growth forma growth turnover turnover cer cer turnover cost sales selling general administration research development royalty income adjusted gsk uses number adjusted nonifrs measures report operating performance business adjusted results profit nonifrs measures may considered addition adjusted substitute superior information presented profit accordance ifrs adjusted results nonifrs attributable measures defined pages shareholders adjusted earnings per share p gsk annual report group financial review continued financial performance continued group turnover pharmaceuticals group turnover business turnover bn growth growth cer bn aer growth cer growth pharmaceuticals vaccines group turnover consumer healthcare corporate unallocated turnover proforma growth group turnover geographic region growth growth cer pharmaceuticals turnover us growth growth europe cer international respiratory hiv immunoinflammation group turnover million year aer oncology cer proforma basis group turnover established pharmaceuticals cer cer excluding impact divestments vaccines brands divested review consumer healthcare pharmaceuticals turnover year million pharmaceuticals turnover year million aer cer respiratory sales aer aer cer respiratory sales aer cer million growth trelegy nucala cer million hiv sales flat aer relvarbreo hiv sales flat aer cer cer million sales established pharmaceuticals million growth juluca dovato partly offset declined aer cer million tivicay triumeq sales established pharmaceuticals declined aer cer million vaccines turnover declined aer cer million primarily driven adverse impact towards end first quarter additional demand related covid pandemic hepatitis vaccines dtpacontaining covid pandemic positive impact growth vaccines synflorix bexsero together divestment hiv respiratory products effect broadly reversed rabipur encepur decline partly offset higher second quarter saw lower levels new patient sales influenza vaccines across regions shingrix prescriptions us europe reduced market growth europe china us together strong demand allergy antibiotic products international performance cervarix china europe effects continued seen second half year reported consumer healthcare sales grew aer cer million full year largely driven us sales grew aer cer continued growth inclusion pfizer portfolio partly offset brands nucala trelegy benlysta zejula hiv twodrug divestedunder review proforma basis sales declined regimens partly offset decline tivicay triumeq cer grew cer excluding brands divestedunder established products including impact generic review reflecting underlying strength brands across albuterol substitutes portfolio strong growth ecommerce successful europe sales declined aer cer growth execution meeting evolving consumer demand result respiratory hiv oncology offset decline established pandemic pharmaceuticals sales impacted generic competition lower demand antibiotics covid pandemic period approximately one percentage point decline due impact oneoff uk relenza contract comparator gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial performance continued international declined aer cer respiratory us dolutegravir sales flat aer cer benlysta growth partly offset lower established europe dolutegravir sales grew aer cer following pharmaceuticals sales included impact weaker recent launches dovato combined sales twodrug allergy season generic competition avolve japan regimens million us million slower market growth covid pandemic period europe growth offsetting decline triumeq government mandated changes increasing use international dolutegravir sales declined aer grew generics china cer driven tivicay tender business respiratory oncology total respiratory sales aer cer sales zejula parp inhibitor asset acquired tesaro strong growth regions international respiratory sales grew q million year aer aer cer including nucala aer cer driven volume growth compared prior year cer relvarbreo aer cer million blenrep treatment patients relapsed refractory europe respiratory sales grew million aer multiple myeloma approved launched us cer us respiratory grew aer cer europe q reported sales million including trelegy nucala us relvarbreo sales grew aer cer mainly due effect prior period immunoinflammation rar adjustment sales benlysta year aer cer million including sales subcutaneous formulation sales nucala million year grew million aer cer aer cer us sales aer cer million europe sales million grew aer duvroq patients anaemia due chronic kidney disease cer international sales million grew launched japan q reported sales aer cer international region million trelegy sales aer cer million established pharmaceuticals driven growth regions us new asthma sales established pharmaceuticals year indication approved launched q sales million aer cer aer cer million europe sales grew established respiratory products declined aer aer cer international trelegy cer million advairseretide ventolin asthma approved japan quarter sales grew impacted generic substitutes us europe million year flovent experienced price pressure us relvarbreo sales aer cer international region allergy sales impacted market million year us relvarbreo grew contraction generic launch japan aer cer mainly due effect prior period remainder established pharmaceuticals portfolio rar adjustment europe international relvarbreo declined aer cer million lower continued grow aer cer aer demand antibiotics covid pandemic period cer respectively impact government mandated changes increasing hiv use generics markets including japan france china hiv sales million flat aer cer strong comparator including european contract year dolutegravir franchise grew aer cer delivering sales million remaining portfolio sales million total hiv sales declined aer cer reduced overall growth total hiv one percentage point sales dolutegravir products million twelve months tivicay delivered sales million aer cer triumeq sales million aer cer twodrug regimens juluca dovato delivered sales million twelve months combined growth offsetting decline threedrug regimen triumeq gsk annual report group financial review continued financial performance continued vaccines following categories declines related pandemic impacts unless stated otherwise turnover bn meningitis bn aer growth cer growth meningitis sales grew aer cer million bexsero sales declined aer cer million reflecting lower demand us international partly offset group turnover lower us returns rebates menveo sales declined aer grew cer million primarily driven higher demand europe lower us returns rebates partly offset lower demand us competitive pressure international us bexsero menveo grew market share influenza fluarixflulaval sales million aer vaccines turnover cer primarily reflecting robust demand across growth growth regions resulting strong government recommendations cer prioritised flu vaccination covid pandemic meningitis conditions together reversal prior year returns influenza provision us shingles established vaccines shingles shingrix grew aer cer million primarily driven strong performance europe reflecting robust vaccines turnover declined aer cer underlying demand germany launch shingrix china million primarily driven adverse impact also contributed sales growth us decline demand covid pandemic hepatitis vaccines dtpacontaining q q due lower adult wellness visits vaccines synflorix bexsero together divestment vaccination rates partially offset strong uptake rabipur encepur decline partly offset higher q return growth expected q sales influenza vaccines across regions shingrix supported coadministration seasonal flu vaccination growth europe china us together strong programmes performance cervarix china established vaccines vaccines performance across regions affected lower sales dtpacontaining vaccines infanrix pediarix demand due limited visits healthcare practitioners boostrix declined aer cer infanrixpediarix points vaccination pandemic government sales declined aer cer million reflecting stayathome directives areas lockdowns lifted lower demand us unfavourable yearonyear us wellness visits vaccination rates recovered paediatric cdc stockpile movements together supply constraints vaccination near precovid levels end q competitive pressures europe adolescent adult immunisations improved slower pace us backtoschool vaccinations disrupted boostrix sales aer cer million schools universities delayed reversed inperson tuition primarily due lower vaccination rates across regions elongated backtoschool vaccination season hepatitis vaccines declined aer cer q adult wellness visits returned prior year levels million adversely impacted us europe lower end q supported seasonal flu vaccination demand travel restrictions together competition declined late q pandemic conditions worsened returning market us synflorix sales declined aer cer million primarily due lower demand international supply constraints emerging markets rotarix sales flat aer grew cer million reflecting improved supply emerging markets higher demand europe partly offset lower channel inventory us mmrv vaccines sales grew aer cer million largely driven improved supply increased market shares europe gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial performance continued consumer healthcare quarterly performance volatile year direct result covid pandemic sales proforma cer excluding brands divestedunder review first turnover bn proforma quarter given accelerated purchases flat second quarter bn aer growth cer growth cer growth reversed third quarter final quarter year group turnover oral health oral health sales grew aer cer million sensodyne continued outperform lowdouble digit growth reflecting underlying brand strength successful innovation including sensodyne sensitivity gum strong consumer uptake traditional retail ecommerce channels us gum health continued deliver double digit growth consistent trends throughout year whilst denture care declined lowsingle digits given challenging market conditions consistent prior quarters consumer healthcare turnover growth growth pain relief cer pain relief grew aer cer million oral health proforma basis sales grew midsingle digits driven pain relief successful rx otc switch voltaren us panadol vitamins minerals supplements increased midsingle digits increased consumption respiratory health earlier year offsetting brand decline final quarter digestive health advil delivered improved performance us second half year ended year lowsingle digits brands divestedunder review vitamins minerals supplements vitamins minerals supplements doubled aer cer million proforma basis sales growth growth continued grow highteens per cent consistent cer prior quarters due strong performance centrum caltrate us emergenc particularly strong category growth europe reflected continued consumer focus health wellness international consistent previous quarters result covid pandemic combined businesss ability proforma growth successfully quickly adapt execute deliver meet reported basis sales grew aer cer consumer needs million full year largely driven inclusion respiratory health pfizer portfolio partly offset brands divestedunder respiratory health sales grew aer cer review million proforma basis sales declined proforma basis sales declined cer grew midsingle digits driven lower cold flu season cer excluding brands divestedunder review reflecting final quarter offset benefit increased underlying strength brands across portfolio consumption first quarter due covid categories strong growth ecommerce successful pandemic result robitussin contac theraflu execution meeting evolving consumer demand result declined full year allergy nasal product performance pandemic mixed flonase growth lowsingle digits overall results benefited strong growth vitamins otrivin declining midsingle digits minerals supplements well continued growth oral digestive health health pain relief digestive health although digestive health brands grew aer cer respiratory health sales cer full year million proforma basis sales declined benefited increased consumption first quarter lowsingle digits growth digestive health products offset sales declines throughout rest year decline skin health products nonstrategic particularly pronounced fourth quarter result brands smokers health products flat year historically weak cold flu season gsk annual report group financial review continued financial performance continued cost sales growth adjusted sga costs although flat aer grew growth growth cer proforma basis costs reduced cer cer reflected benefits restructuring including oneoff total cost sales benefits restructuring postretirement benefits adjusted cost sales continuing benefit restructuring pharmaceuticals total cost sales percentage turnover consumer healthcare support functions reduced variable percentage points lower aer percentage points spending across three businesses result lower cer terms compared primarily covid lockdowns tight control ongoing costs reflected lower unwinding fair market value uplift particularly nonpromotional spending across three inventory arising completion consumer healthcare businesses partly offset increased investment joint venture pfizer q promotional product support particularly new launches vaccines respiratory hiv excluding adjusting items adjusted cost sales percentage turnover flat aer research development percentage points lower cer compared growth growth proforma basis adjusted cost sales percentage cer turnover percentage points lower cer total research development compared reflected favourable product adjusted research development mix pharmaceuticals contribution total rd expenditure million turnover restructuring savings pharmaceuticals vaccines aer cer including increase major integration savings consumer healthcare partly offset restructuring costs intangible impairments adjusted rd adverse product mix vaccines continued adverse pricing expenditure million turnover higher pressure pharmaceuticals principally established aer higher cer proforma basis respiratory adjusted rd expenditure grew cer compared selling general administration pharmaceuticals adjusted rd expenditure growth growth million aer cer primarily driven cer significant increase investment oncology reflecting total selling general progression number key programmes including blenrep administration feladilimab bintrafusp alfa well progression adjusted selling general covid treatment programmes vir otilimab administration partly offset reduction investment research total selling general administration sga costs several specialty primary care programmes daprodustat percentage turnover percentage points trelegy hiv well efficiency savings lower aer percentage points lower cer implementation one development programme compared reflected lower significant legal pharmaceuticals vaccines part separation transaction costs offset increased major restructuring costs preparation restructuring programme reductions variable separation costs spending result covid lockdowns excluding adjusting items adjusted sga adjusted rd expenditure vaccines million costs percentage turnover percentage aer cer reflecting efficiency savings points lower aer percentage points implementation one development programme lower cer basis proforma basis adjusted sga reductions variable spending result covid costs percentage turnover percentage lockdowns adjusted rd expenditure consumer healthcare points lower cer compared million royalty income royalty income million million aer cer primarily reflecting genericisation transderm scop consumer healthcare lower sales gardasil gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial performance continued operating incomeexpense reduction proforma adjusted operating profit reflects net operating income million adverse impact reduction sales vaccines million primarily reflected net profit disposal result covid pandemic investment rd including horlicks consumer healthcare brands significant increase oncology partly assets million q reversal tesaro acquisition initiation several covid million embedded derivative gains value programmes continuing price pressure principally shares taken prior years partly offset related established respiratory including impact launch loss sale shares hindustan unilever q generic version advair us february million operating income also included investments promotional product support particularly new increase profit milestone income number launches vaccines hiv respiratory offset asset disposals reduced promotional variable spending across three businesses result covid lockdowns oneoff partly offset accounting charges million benefit q restructuring postretirement million credits arising remeasurement benefits continuing benefit restructuring contingent consideration liabilities related pharmaceuticals consumer healthcare support functions acquisitions former shionogiviiv healthcare joint venture tight control ongoing costs particularly non former novartis vaccines business liabilities promotional spending across three businesses pfizer put option pfizer shionogi preferential dividends viiv healthcare included remeasurement contingent consideration cash payments made charge million million contingent shionogi companies reduce balance sheet liability consideration liability due shionogi primarily arising hence recorded income statement total changes sales forecasts exchange rate assumptions contingent consideration cash payments amounted unwind discounting million million included cash payments made shionogi million operating profit million total operating profit million compared million reflected profit disposal adjusted operating profit business horlicks consumer healthcare brands pharmaceuticals operating profit million resultant sale shares hindustan unilever well aer cer turnover decrease cer increased income asset disposals partly offset operating margin percentage points lower higher remeasurement charges contingent aer percentage points lower cer consideration liabilities basis primarily reflected significant increase oncology rd well continued impact lower prices including excluding adjusting items adjusted operating impact launch generic version advair us profit million lower aer february investment new product support higher cer turnover increase cer adjusted targeted priority markets partly offset reduced operating margin percentage points lower promotional variable spending result covid aer percentage points lower cer basis lockdowns continued benefit restructuring tight proforma basis adjusted operating profit control ongoing costs lower cer turnover decrease cer adjusted proforma operating margin vaccines operating profit million aer percentage points lower cer basis cer turnover decrease cer operating margin percentage points lower aer percentage points lower cer basis primarily driven negative operating leverage covid related sales decline investment behind key brands gsk annual report group financial review continued financial performance continued consumer healthcare operating profit million profit tax aer cer turnover increase cer taking account net finance costs share profits proforma basis operating profit million cer associates profit taxation million compared lower turnover decrease cer operating margin million percentage points higher aer percentage points higher cer basis taxation proforma operating margin percentage points higher cer basis higher margin driven higher normal sales growth q due covid uk current year charge synergy delivery pfizer integration rest world current year charge partially offset impact divestments increased chargecredit respect prior periods targeted promotional investment total current taxation net finance costs total deferred taxation taxation total profits finance income charge million represented effective tax rate interest income total results reflected different fair value movements tax effects various adjusting items including disposal horlicks consumer healthcare brands unilever subsequent disposal shares received hindustan unilever tax finance expense adjusted profit amounted million represented interest expense effective adjusted tax rate unwinding discounts provisions remeasurements fair value movements issues related taxation described note finance expense lease liabilities financial statements taxation group continues believe finance expense made adequate provision liabilities likely arise periods open yet agreed tax authorities ultimate liability matters may vary total net finance costs million compared amounts provided dependent upon outcome million adjusted net finance costs agreements relevant tax authorities million compared million increase reflects lower interest income overseas cash postclosing noncontrolling interests divestment horlicks consumer healthcare allocation total earnings noncontrolling interests nutrition products india number countries amounted million million increase premium paid early repayment refinancing bond debt primarily due increased allocation consumer healthcare q fair value gain interest rate swaps profits million million following comparator partly offset reduced interest expense completion new consumer healthcare joint venture lower debt levels refinancing lower rates pfizer july included unwind fair value uplift acquired inventory major restructuring costs share aftertax profits associates joint ventures partly offset reduced allocation viiv healthcare share aftertax profits associates million profits million million including increased million included oneoff adjustment charges remeasurement contingent consideration liabilities million reflect gsks share increased tax profits innoviva primarily result nonrecurring income tax allocation adjusted earnings noncontrolling interests benefit amounted million million increase allocation primarily reflected increased allocation consumer healthcare profits million million following completion new consumer healthcare joint venture pfizer july partly offset reduced allocation viiv healthcare profits million million lower net profits groups entities noncontrolling interests primarily consumer healthcare india following horlicks consumer brands disposal gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial performance continued earnings per share outlook total earnings per share eps p compared p delivered strategic priorities increase eps primarily reflected net profit planned continue increase investment pipeline disposal horlicks consumer healthcare brands build topline momentum key growth drivers largely well increased income asset disposals partly offset complete readiness separation assuming healthcare systems higher remeasurement charges contingent consideration consumer trends approach normality second half liabilities higher major restructuring charges oneoff benefit year expect pharmaceuticals revenue grow flat lowsingle increased share aftertax profits associate digits consumer healthcare revenue grow low innoviva midsingle digits excluding brands divestedunder review market growth vaccines business adjusted eps p compared p anticipate disruption first half year given aer cer cer increase adjusted governments prioritisation covid vaccination programmes operating profit resurgence late pandemic expected reduction primarily resulted higher noncontrolling impact adult adolescent immunisations including shingrix interest allocation consumer healthcare profits reduced notably us despite shortterm impact remain share aftertax profits associates resulting non confident demand products expect strong recurring income tax benefit innoviva recovery contribution growth shingrix second half year expect vaccines revenue grow flat dividends lowsingle digits reflecting factors guidance range board declared four interim dividends resulting total decline mid highsingle digit per cent adjusted dividend year pence line dividend declared eps cer see note financial statements dividends guidance include impact intended change dividend policy uk corporation tax rate effective gsk recognises importance dividends shareholders april announced march please see aims distribute regular dividend payments note post balance sheet events determined primarily reference free cash flow expectations guidance targets regarding future generated business funding investment performance dividend payments read together necessary support groups future growth cautionary statement regarding forwardlooking statements board currently intends maintain dividend assumptions related guidance inside back current level p per share subject material cover change external environment performance expectations biopharma investor update june plan set detail growth prospects financial outlook new biopharma company medium term including detailed review pipeline building recent years alongside provide details new distribution policy reflects optimised capital structure investment priorities focused delivering sustainable longterm shareholder value anticipate new policy deliver competitive attractive returns informed appropriate earnings payout ratios investment cycle well covered free cash flow importantly expected growth potential expect aggregate distributions gsk lower present new policy implemented dividends paid respect gsk annual report group financial review continued adjusting items divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal separation adjusted results amortisation impairment restructuring related items costs results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information group financial review continued adjusting items continued major restructuring integration total cash payments made million within pharmaceuticals sector highly regulated million million existing combined manufacturing operations supply chains long life restructuring integration programme million cycle business mean restructuring programmes million million major particularly involve rationalisation closure restructuring programme including settlement certain manufacturing rd sites likely take several years charges accrued previous quarters million complete million relating consumer healthcare joint venture integration programme million relating major restructuring costs related specific separation preparation restructuring programme boardapproved major restructuring programmes excluded adjusted results major restructuring analysis major restructuring charges business programmes including integration costs following material follows acquisitions structural significant scale costs individual related projects exceed million ordinary course smallerscale restructuring pharmaceuticals costs retained within total adjusted results vaccines total major restructuring charges incurred consumer healthcare million million analysed follows corporate central functions non non total major restructuring charges cash cash total cash cash total analysis major restructuring charges income major statement line follows restructuring programme incl tesaro cost sales consumer selling general administration healthcare joint venture integration research development programme operating incomeexpense separation total major restructuring charges preparation restructuring benefit year major restructuring programme programme billion benefit consumer combined healthcare joint venture integration billion restructuring benefit separation preparation restructuring integration programme billion programme major restructuring programme including tesaro expected cost billion period cash charges million separation preparation cash costs billion noncash costs billion programme primarily arose restructuring vaccines expected deliver annual savings around manufacturing rd functions part building one million rates savings development organisation pharmaceuticals vaccines intended fully reinvested help fund targeted increases well restructuring commercial pharmaceuticals rd commercial support new products administrative functions noncash charges million completion consumer healthcare joint venture related writedown assets sites pfizer expected realise substantial cost synergies pharmaceuticals supply chain generating total annual cost savings billion cash charges million consumer healthcare expected cash costs billion noncash charges joint venture programme primarily related severance expected billion plus additional capital expenditure integration costs commercial integration consumer billion cost savings intended healthcare largely completed manufacturing reinvested business support innovation integration well underway growth opportunities major restructuring programme incurred cash charges million relation severance costs restructuring manufacturing organisation rd administrative functions well integration tesaro noncash charges million writedowns disposal sites gsk annual report group financial review continued adjusting items continued group initiated q twoyear separation million charge relating contingent consideration preparation programme prepare separation gsk former shionogiviiv healthcare joint venture represented two companies new gsk biopharma company increase valuation contingent consideration due rd approach focused science related immune shionogi result million unwind discount system use genetics new technologies new million primarily adjustments sales forecasts well leader consumer healthcare updated exchange rate assumptions million credit relating viiv healthcare put options pfizer preferential programme aims dividends represented decrease valuation put drive common approach rd improved capital option result adjustments multiples sales forecasts allocation updated exchange rate assumptions align improve capabilities efficiency global viiv healthcare contingent consideration liability fair valued support functions support new gsk ifrs potential impact covid pandemic optimise supply chain product portfolio remains uncertain december including divestment noncore assets strategic assumed significant impact longterm review prescription dermatology underway value liability position remains review prepare consumer healthcare operate standalone amount liability updated future quarters company information impact pandemic becomes available explanation accounting noncontrolling interests programme continues target delivery billion viiv healthcare set annual savings billion total costs estimated billion billion expected divestments significant legal charges items cash costs proceeds anticipated divestments divestments items included gain year largely expected cover cash costs programme million arising net profit disposal horlicks consumer healthcare brands transactionrelated adjustments million q reversal million transactionrelated adjustments resulted net charge embedded derivative gains value shares taken million million included net prior years partly offset related loss sale million accounting charge remeasurement shares hindustan unilever q million contingent consideration liabilities related acquisitions divestments items also included milestone income former shionogiviiv healthcare joint venture former gains number asset disposals certain novartis vaccines business liabilities pfizer put adjusting items charge million million option pfizer shionogi preferential dividends viiv significant legal matters included settlement existing healthcare matters well provisions ongoing litigation significant legal cash payments million million chargecredit contingent consideration former shionogiviiv separation costs healthcare joint venture including shionogi q group started report additional costs preferential dividends prepare consumer healthcare separation viiv healthcare put options pfizer preferential dividends estimated million excluding transaction costs contingent consideration former novartis vaccines business release fair value uplift acquired pfizer inventory adjustments total transactionrelated charges gsk annual report strategic report governance remuneration financial statements investor information group financial review continued adjusting items continued proforma growth reconciliations tables set reconciliations reported cer growth rates proforma cer growth rates reported margin percentages proforma margin percentages adjustment include january july results pfizer reported consumer proforma growth rate healthcare growth rate cer business cer group turnover adjusted cost sales adjusted selling general administration adjusted research development adjusted operating profit consumer healthcare turnover oral health pain relief vitamins minerals supplements respiratory health digestive health brands divestedunder review operating profit proforma financial information used basis proforma growth rates calculated follows january july results gsk pfizer reported consumer proforma results healthcare results business bn bn bn group turnover adjusted cost sales adjusted selling general administration adjusted research development adjusted operating profit consumer healthcare turnover oral health pain relief vitamins minerals supplements respiratory health digestive health brands divestedunder review operating profit gsk annual report group financial review continued cash generation conversion summary consolidated cash flow statement set reconciliation net cash inflow operating activities free cash flow reconciliation net cash inflow operating activities closest equivalent ifrs measure free cash flow net cash inflow operating activities shown net cash inflowoutflow investing activities net cash outflow financing activities increase cash bank overdrafts net cash inflow operating activities purchase property plant equipment cash bank overdrafts beginning year purchase intangible assets increase cash bank overdrafts proceeds sale property plant equipment exchange adjustments proceeds disposal intangible assets cash bank overdrafts end year interest paid cash bank overdrafts end year comprise interest received cash cash equivalents dividends associates joint ventures cash cash equivalents reported assets contingent consideration paid reported held sale investing activities overdrafts contribution noncontrolling interests distributions noncontrolling interests capital expenditure financial investment free cash flow cash payments tangible intangible fixed assets future cash flow amounted million million long term expect future cash generated disposals realised million million operations sufficient fund operating debt cash payments acquire equity investments amounted servicing costs normal levels capital expenditure obligations million million primarily relating existing licensing agreements expenditure arising vir biotechnology curevac ag sales equity restructuring programmes routine outflows including investments realised million million tax pension contributions dividends subject mainly relating proceeds arising sale principal risks uncertainties discussed pages shares hindustan unilever acquired result may time time additional demands disposal horlicks consumer healthcare finance acquisitions including potentially acquiring brands increased ownership interests viiv healthcare business minority shareholders hold put options access free cash flow multiple sources liquidity short longterm capital free cash flow amount cash generated group markets financial institutions needs addition meeting obligations contingent consideration cash flow operations interest tax dividends paid noncontrolling interests capital expenditure property plant equipment investment appraisal capital allocation intangible assets strong framework capital allocation including board govern allocation capital businesses utilise consistent cash return invested free cash inflow capital croic methodology prioritise investment across total cash payments shionogi relation viiv group whole effectively compare healthcare contingent consideration liability year returns businesses allocate capital million million million also consider impact eps recognised cash flows operating activities credit profile relevant million recognised contingent consideration paid within investing cash flows payments deductible tax purposes gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial position resources property plant equipment business sciencebased technologyintensive highly assets regulated governmental authorities allocate significant noncurrent assets financial resources renewal maintenance property plant equipment property plant equipment minimise risks interruption right use assets production ensure compliance regulatory standards goodwill number processes use hazardous materials intangible assets investments associates joint ventures total cost property plant equipment investments december million net book value deferred tax assets million land buildings represented derivative financial instruments million plant equipment million noncurrent assets assets construction million invested total noncurrent assets million new property plant equipment mainly related large number projects renewal current assets improvement expansion facilities various worldwide inventories sites support new product development launches well current tax recoverable improve efficiency existing supply chains property trade receivables mainly held freehold new investment financed derivative financial instruments liquid resources december contractual liquid investments commitments future capital expenditure million cash cash equivalents believe property plant facilities adequate assets held sale current needs total current assets observe stringent procedures use specialist skills total assets manage environmental risks activities environmental liabilities issues sometimes dating operations modified current liabilities discontinued reported environment note financial statements legal proceedings shortterm borrowings contingent consideration liabilities right use assets trade payables right use assets amounted million december derivative financial instruments compared million january current tax payable decrease year reflected impact depreciation shortterm provisions disposals million million respectively partly total current liabilities offset additions million noncurrent liabilities goodwill longterm borrowings goodwill increased million december corporation tax payable million deferred tax liabilities pensions postemployment benefits intangible assets provisions intangible assets include cost intangibles acquired derivative financial instruments third parties computer software net book value intangible assets december contingent consideration liabilities million million decrease noncurrent liabilities primarily reflected amortisation impairment losses net total noncurrent liabilities reversals year million total liabilities net assets total equity gsk annual report group financial review continued financial position resources continued investments associates joint ventures trade payables held investments associates joint ventures december trade payables carrying value december million million compared million million market value december december increase primarily reflected impact million million largest higher customer return rebate accruals see note investments innoviva inc book value financial statements trade payables december million million provisions market value million see note carried deferred tax provisions shortterm financial statements investments associates joint noncurrent provisions million december ventures million provisions yearend investments included million million related legal held investments carrying value disputes million million related december million million major restructuring programmes provision made highest value investments held december legal disputes indemnified disposal liabilities curevac ag acquired year employee related liabilities costs restructuring book value december million crispr programme extent balance sheet date legal therapeutics book value million constructive obligation existed could reliably estimated million lyell immunopharma inc pensions postemployment benefits book value december million account pension postemployment million investments included equity arrangements accordance ias net deficits stakes companies research million million pension collaborations provide access biotechnology arrangements million million developments potential interest interests companies unfunded postemployment liabilities see note arise business divestments financial statements pensions postemployment derivative financial instruments assets benefits held current derivative financial assets fair value noncurrent liabilities million million noncurrent derivative noncurrent liabilities amounted million financial assets held fair value million december million million majority financial instruments related foreign exchange contracts designated contingent consideration liabilities designated accounting hedges december contingent consideration amounted million million current derivative financial assets related december million derivative embedded agreement divest horlicks million million represented estimated nutritional brands unilever plc see note present value amounts payable shionogi relating viiv information healthcare million million represented estimated present value contingent consideration payable inventories novartis related vaccines acquisition inventory million increased million liability due shionogi included million respect preferential dividends liability preferential dividends trade receivables due pfizer december million trade receivables million decreased million explanation accounting non million controlling interests viiv healthcare set deferred tax assets total contingent consideration payable posttax deferred tax assets amounted million basis december million million million december expected paid within one year consideration payable expected paid number years derivative financial instruments liabilities result total estimated liabilities discounted held current noncurrent derivative financial liabilities present values posttax basis using posttax discount rates fair value million million primarily related foreign exchange contracts designated shionogiviiv healthcare contingent consideration liability designated accounting hedges discounted novartis vaccines contingent consideration liability discounted partly partly gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial position resources continued maturity profile bond debt equivalent gbp bonds eur bonds usd bonds net debt cash liquid investments billion billion held centrally december analysis cash gross debt effects hedging cash cash equivalents liquid investments follows cash cash equivalents reported assets held sale borrowings repayable within one year cash liquid investments borrowings repayable one year gross debt fixed net debt floating december net debt billion compared noninterest bearing billion december comprising gross debt net debt billion cash liquid investments billion includes billion equivalent notes swapped floating fixed rates via interest net debt decreased due billion proceeds rate swaps horlicks consumer brands disposal including shares movements net debt hindustan unilever billion billion assets plus billion business asset disposals together billion free cash flow partly offset cash net debt beginning year divested billion dividends paid shareholders implementation ifrs billion billion additional investments net debt beginning year adjusted december gsk shortterm borrowings increase cash bank overdrafts including overdrafts lease liabilities repayable within increasedecrease liquid investments months billion loans billion repayable increase longterm loans subsequent year net repayment shortterm loans repayment lease liabilities december gsks cash liquid investments debt subsidiary undertakings acquired held follows exchange movements movements bank balances deposits net debt end year bank balances deposits reported assets held sale us treasury treasury repo money market funds liquidity funds cash cash equivalents liquid investments government securities gsk annual report group financial review continued financial position resources continued interest rate benchmark reform total equity interest rate benchmark reform amendments ifrs december total equity increased ias ifrs issued iasb september million december million amendments modify specific hedge accounting summary movements equity set requirements allow hedge accounting continue affected hedges period uncertainty hedged items hedging instruments affected current interest total equity beginning year rate benchmarks amended result ongoing implementation ifrs interest rate benchmark reforms total equity beginning year adjusted december group directly exposed total comprehensive income year interest rate benchmark reform held interest rate dividends shareholders derivatives referenced libor matured end recognition interest consumer healthcare floating rate bonds due mature joint venture end ordinary shares issued changes noncontrolling interests group closely monitored market output various industry working groups managing sharebased incentive plans transition new benchmark interest rates includes tax sharebased incentive plans announcements made libor regulators including contributions noncontrolling interests financial conduct authority fca us commodity distributions noncontrolling interests futures trading commission regarding transition away total equity end year libor including gbp libor usd libor share purchases euribor sterling overnight index average rate december gsk held million shares sonia secured overnight financing rate sofr treasury shares million shares cost euro shortterm rate str respectively fca million million made clear end longer deducted retained earnings seek persuade compel banks submit libor exception usd libor ordinary shares repurchased period january intercontinental exchange ice benchmark administration march company expect iba fcaregulated authorised administrator make ordinary share repurchases remainder libor announced consult intention cease usd libor iba intends subject confirmation million treasury shares transferred following consultation one week two month usd employee share ownership plan esop trusts shares libor settings cease end held trusts satisfy future exercises options usd libor panel cease end june awards group share option award schemes group undertaking interest rate benchmark transition proportion shares held trusts respect programme identify potential exposures within business awards rules scheme require us satisfy deliver smooth transition appropriate alternative exercises market purchases rather issue benchmark rates new shares shares held trusts matched options awards granted december esop trusts held million million gsk shares future exercise share options share awards carrying value million million deducted reserves market value shares million million gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial position resources continued contractual obligations commitments reached agreement trustees financial commitments summarised note uk pension schemes make additional contributions financial statements commitments assist eliminating pension deficit identified part december actuarial funding valuation table following table sets contractual obligations includes commitment excludes normal ongoing commitments december fall due annual funding requirement uk approximately payment million information pension obligations total yr yrs yrs yrs see note financial statements pensions postemployment benefits loans interest loans contingent liabilities lease obligations contingent liabilities set note financial future finance charges statements contingent liabilities intangible assets following table sets contingent liabilities comprising property plant equipment discounted bills performance guarantees letters credit investments items arising normal course business purchase commitments expected expire pensions total total yr yrs yrs yrs commitments respect loans future interest payable guarantees loans disclosed taking account effect contingent liabilities derivatives total entered number research collaborations normal course business provided various develop new compounds pharmaceutical companies indemnification guarantees respect business disposals terms arrangements include upfront fees legal disputes subsequently arisen equity investments loans commitments fund specified provision made outflow resources considered levels research addition often agree make probable reliable estimate made likely payments future milestones achieved outcome dispute included note agreements relate compounds early financial statements provisions stages development potential obligation make provide outcome tax legal disputes milestone payments continue number years outflow resources considered probable compounds move successfully development reliable estimate outflow may made december process generally closer product marketing disputes provision approval greater probability success amounts made possible make reliable estimate shown within intangible assets represent maximum potential outflow funds might required settle would paid milestones achieved include disputes possibility outflow billion relates externalised projects remote discovery portfolio decrease commitments ultimate liability matters may vary significantly result reduction outstanding loan amounts provided dependent upon negotiations commitments relevant tax authorities outcome litigation proceedings relevant discussed principal risks uncertainties pages note financial statements legal proceedings gsk annual report group financial review continued treasury policies report sterling pay dividends sterling cash interest rate risk management flows role treasury monitor manage gsks objective minimise effective net interest cost groups external internal funding requirements financial balance mix debt fixed floating interest rates risks support strategic objectives gsk operates time policy interest rate risk management limits global basis primarily subsidiary companies net amount floating rate debt specific cap reviewed manage capital ensure subsidiaries able agreed less annually board operate going concerns optimise returns foreign exchange risk management shareholders appropriate balance debt objective minimise exposure overseas equity treasury activities governed policies approved operating subsidiaries transaction risk matching local annually board directors recently currency income local currency costs possible october treasury management group tmg foreign currency transaction exposures arising external meeting chaired chief financial officer takes place internal trade flows selectively hedged gsks internal regular basis review treasury activities members trading transactions matched centrally manage receive management information relating activities intercompany payment terms reduce foreign currency risk treasury operations possible manage cash surpluses borrowing objective gsks treasury activities minimise requirements subsidiary companies centrally using forward posttax net cost financial operations reduce volatility contracts hedge future repayments back originating order benefit earnings cash flows gsk uses variety currency financial instruments finance operations derivative order reduce foreign currency translation exposure financial instruments manage market risks seek denominate borrowings currencies operations derivatives principally comprise foreign exchange principal assets cash flows primarily forward contracts swaps used swap denominated us dollars euros sterling borrowings borrowings liquid assets currencies required swapped currencies required group purposes well interest rate swaps used manage exposure financial risks changes borrowings denominated swapped foreign interest rates currencies match investments overseas group assets may treated hedge relevant assets forward derivatives used exclusively hedging purposes relation contracts major currencies also used reduce exposure underlying business activities trading groups investment overseas group assets tmg speculative instruments reviews ratio borrowings assets major currencies capital management regularly gsks financial strategy implemented groups counterparty risk management financial architecture supports gsks strategic priorities set global counterparty limits banking regularly reviewed board manage capital investment counterparties based longterm credit ratings structure group appropriate mix debt moodys standard poors usage limits equity continue manage financial policies credit actively monitored breach limits would profile particularly targets shortterm credit ratings reported cfo immediately p maintaining single longterm ratings consistent targets addition relationship banks credit ratings reviewed regularly changes ratings occur gsks longterm credit rating standard poors changes made investment levels authority limits stable outlook moodys investor services moodys appropriate banking counterparty limits reviewed negative outlook shortterm credit ratings least annually p standard poors moodys respectively liquidity risk management gsks policy borrow centrally order meet anticipated funding requirements cash flow forecasts funding requirements monitored tmg regular basis strategy diversify liquidity sources using range facilities maintain broad access financial markets day sweep cash number global subsidiaries central treasury accounts liquidity management purposes gsk annual report strategic report governance remuneration financial statements investor information group financial review continued critical accounting policies group consolidated financial statements prepared us medicaid programme stateadministered accordance ifrs adopted pursuant regulation ec programme providing assistance certain poor applies european union also vulnerable patients medicaid drug rebate ifrs issued international accounting standards program established reduce state federal board iasb following accounting policies approved expenditure prescription drugs patient board described note financial statements protection affordable care act became law accounting principles policies participate providing rebates states accruals medicaid rebates calculated based specific required make estimates assumptions terms relevant regulations patient protection affect amounts assets liabilities revenue expenses affordable care act reported financial statements actual amounts results could differ estimates cash discounts offered customers encourage prompt payment accrued time critical accounting policies relate following areas invoicing adjusted subsequently reflect actual turnover experience taxation note record accrual estimated sales returns applying legal disputes notes historical experience customer returns amounts invoiced together marketrelated information contingent consideration note stock levels wholesalers anticipated price increases pensions postemployment benefits note competitor activity information judgements estimates made reconciliation gross turnover net turnover us areas given note financial statements key pharmaceuticals business follows accounting judgements estimates turnover margin margin margin respect turnover accounting policy largest gross turnover business us pharmaceuticals us market complex arrangements rebates discounts marketdriven segments allowances following briefly describes nature government arrangements existence us pharmaceuticals business mandated arrangements certain indirect customers state programmes whereby customer able buy products cash discounts wholesalers reduced prices chargeback represents customer returns difference invoice price wholesaler prior year adjustments indirect customers contractual discounted price prior year items accruals estimating chargebacks calculated based items terms agreement historical experience total deductions product growth rates net turnover customer rebates offered key managed care marketdriven segments consist primarily managed care group purchasing organisations direct indirect medicare plans negotiate contract pricing customers arrangements require customer honoured via rebates chargebacks mandated segments achieve certain performance targets relating value consist primarily medicaid federal government product purchased formulary status predetermined market programmes receive governmentmandated pricing via shares relative competitors accrual customer rebates chargebacks rebates estimated based specific terms agreement historical experience product growth rates gsk annual report group financial review continued critical accounting policies continued increased deductions governmentmandated may become involved significant legal proceedings state programmes gross turnover net turnover respect possible make reliable estimate reconciliation primarily reflected higher rebates expected financial effect could result chargebacks respiratory products advair ultimate resolution proceedings cases particular year advair accounted us appropriate disclosure cases would included pharmaceuticals turnover approximately total annual report provision would made deduction rebates returns position could change time therefore respiratory portfolio whole including established assurance losses result outcome respiratory products accounted approximately legal proceedings exceed material amount total deduction year amount provisions reported groups financial statements balance sheet accruals rebates discounts allowances returns us pharmaceuticals vaccines businesses like many pharmaceutical companies faced managed combined basis december various complex product liability antitrust patent litigation total accrual amounted million million well investigations operations conducted various governmental regulatory agencies throughout year monthly process operated monitor inventory levels general counsel group head groups legal wholesalers abnormal movements process uses function senior vice president head global gross sales volumes prescription volumes based third party litigation group responsible litigation data sources information received key wholesalers government investigations routinely brief chief executive aim maintain inventories consistent level officer chief financial officer board directors year year based pattern consumption significant litigation pending group basis us pharmaceuticals vaccines inventory governmental investigations group levels wholesalers distribution channels meetings appropriate detail status significant december estimated amount litigation government investigations review matters approximately four weeks turnover calculation uses number claims notified us information third party information accuracy totally potential claims yet notified assessment validity verified believed sufficiently reliable claims progress made settling claims recent settlement purpose levels potential reimbursement insurers legal disputes meetings also include assessment whether respect accounting policy legal disputes sufficient information available us able make following briefly describes process reliable estimate potential outcomes disputes determine level provision necessary often external counsel assisting us various litigation accordance requirements ias provisions matters investigations also assist briefing contingent liabilities contingent assets provide board senior management following discussions anticipated settlement costs outflow resources matters possible make reliable estimate considered probable reliable estimate may made amount provision may required likely outcome dispute legal expenses level provision legal disputes reviewed arising claims group adjusted appropriate matters discussed note financial statements legal proceedings strategic report strategic report approved board directors march iain mackay chief financial officer march gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn corporate governance section chairmans governance statement board corporate executive team board architecture board roles responsibilities board activity principal decisions purpose values culture boards approach engagement board performance board committee information board committee reports section statement directors report ggsskk aannnnuuaall rreeppoorrtt chairmans governance statement last years governance statement explained primary education focus science objective ensure clarity given critical importance strengthening pipeline board management gsks execution strategy board benefitted devoting higher proportion operational priorities aligned longterm priorities time understanding science behind strategy innovation performance trust powered culture testing application important board agreed metrics measure delivery working understanding key strategic themes upon boards annual cycle meetings ensures major rd strategy based themes components strategy reviewed course complemented board rd science thematic deep dives year focus fundamentals strategy human genetics immune system ai ml well covid pandemic impacted dominated gain deeper understanding covid vaccines lives majority board different technology reviews run dr hal barron adapted well operating virtually invested significant time cso supported science committee scientific assessing responding impact pandemic medical experts board also receives regular updates management board established framework hal progress strengthening pipeline consider three key areas people continuity solutions evolution rd organisation operations support corporate responsibility incredibly talented scientists science committees board considered impact covid organisation initiatives treatments governance architecture solutions undertook review appropriateness clear priorities board enabled vaccines business technology platform ensure allocation oversight responsibility innovation would continue fully competitive post performance trust priorities committees covid world means every meeting focused directly issues really matter gsk resilience decisionmaking boards resilience tested individually team benefits alignment board covid imperative remaining fast agile committees start became evident year decisionmaking deeply impressed progressed particular changes remit science management board stepped embraced corporate responsibility committees challenge six scheduled meetings january one establishment transformation separation committee took place face face since march board enabled greater focus oversight challenge full details committee meetings virtual like committees activities set later report rest organisation adjust lack physical would like highlight certain key areas work contact including crucial informal interactions help transformation separation committee committee build relationships trigger ideas evolve thinking complex established ensure board could devote sufficient topics charlie bancroft joined board may yet attention issues surrounding creation attend physical meeting induction far taken place biopharma consumer healthcare businesses reviews entirely virtually decisions around physical separation corporate finance thought carefully board organise listing locations committee also mindful virtual meetings engage spend time together build separating cost base two businesses creating maintain high quality engagements operate effectively independent competitively structured cost bases pleased observe close quarters efficient fit purpose therefore also oversees boards commitment fully aligned executive managements restructuring programmes ensure desired continuous communication sense urgency agility benefits delivered remarkable achievement desire maintain speed decision making helped notwithstanding covid major programmes ensuring continue support management timely track execution strategic priorities gsk annual report strategic report governance remuneration financial statements investor information corporate responsibility committee committee board succession planning central guiding companys esg agenda reviewed pleased lynn elsenhans agreed stay supported managements aggressive approach year stepping board executing e aspects esg included agm help continuity leadership reviewing endorsing new level ambition corporate responsibility committee work separation environmental sustainability setting new goals facilitate smooth transition successor current achieve net zero impact climate net positive impact covid environment nature review inclusion diversity honour lead highperforming collegiate included disclosing targets workforce race ethnicity unified board formal governance planning separation rebasing gender diversity targets begin second half include committee played key role guiding overseeing building towards creation two new boards enter managements response covid reviewed critical period intention maintain continuity implications production risk scale partnering cohesion current board highly focused geographic allocation access pricing maximising value shareholders beyond point separation even convinced strong commitment esg business necessity longterm value evaluation driver company benefits stakeholders busy year pleased jan hall believe well placed regard future able complete followup independent board review help us improve boards effectiveness science committee committee continues support conclusions review set later report oversight scientific assumptions drive distinctive rd strategy evolved cso biopharma year company continued operate explained earlier guides educates board comply requirements financial reporting scientific perspective council 's uk corporate governance code copy code found wwwfrcorguk year cso team sought build foundations set continuing strengthen pipeline look forward connecting agm year organically collaborations business development may updating time progress thank committees review underlying scientific assumptions continued support provision scientific technical assurance business development transactions critical support sir jonathan symonds board chairman march gsk annual report board board composition board diversity international experience composition gender executive male global nonexecutive female us europe tenure nonexecutive ethnicity emap years black asian minority ethnic years white years years ee information sir jonathan symonds cbe skills experience nonexecutive chairman jon extensive international financial life sciences governance experience jon served independent nonexecutive director hsbc holdings plc april age deputy group chairman august retirement board february nationality british previously chairman hsbc bank plc chief financial officer novartis ag partner appointed september managing director goldman sachs chief financial officer astrazeneca plc partner kpmg governance experience includes roles nonexecutive director chair n audit committees diageo plc qinetiq group plc nonexecutive chair proteus digital health inc jon fellow institute chartered accountants england wales external appointments nonexecutive director rubius therapeutics inc nonexecutive director genomics england limited previously served chairman member european round table industry dame emma walmsley skills experience chief executive officer prior appointment gsks ceo emma ceo gsk consumer healthcare joint venture gsk novartis creation march emma joined gsk age loreal worked years variety roles paris london new york shanghai nationality british emma previously nonexecutive director diageo plc appointed january emma holds classics modern languages oxford university chief executive officer april external appointments independent director microsoft inc honorary fellow royal society chemistry iain mackay skills experience chief financial officer prior joining gsk iain group finance director hsbc holdings plc position held eight years chartered accountant iain worked asia us europe hsbc age general electric schlumberger dowell price waterhouse iain previously trustee nationality british british heart foundation chair audit risk committee appointed january iain holds business studies accounting holds honorary doctorate chief financial officer april aberdeen university scotland iain member institute chartered accountants scotland external appointments member court university aberdeen chair remuneration committee member group chair financial reporting committee dr hal barron skills experience chief scientific officer prior joining gsk hal president rd calico llc california life company alphabet funded company uses advanced technologies increase understanding lifespan biology president rd prior hal executive vice president head global product development chief age medical officer roche responsible products combined portfolio roche nationality american genentech genentech senior vice president development chief medical officer appointed january hal nonexecutive director chair science technology committee juno chief scientific officer president therapeutics inc march acquired celgene corporation rd april external appointments associate adjunct professor epidemiology biostatistics university california san francisco nonexecutive board director grail inc early cancer detection healthcare company advisory board member verily life sciences llc subsidiary alphabet inc key committee chair n nominations corporate governance audit risk r remuneration science c corporate responsibility transformation separation gsk annual report strategic report governance remuneration financial statements investor information board continued charles bancroft skills experience independent nonexecutive director charlie wealth financial management experience global biopharma charlie retired successful career bristol myers squibb bms march age held number leadership roles commercial strategy finance beginning career nationality american bms held positions increasing responsibility within finance organisation appointed may commercial operational responsibility latin america middle east africa canada japan several pacific rim countries appointed chief financial officer chief financial officer executive vice president global business operations executive vice president head integration strategy business development charlie successfully steered bms period strategic transformation including recent bn acquisition celgene charlie also served member board colgatepalmolive company march external appointments board member kodiak sciences inc board member biovector inc advisory board member drexel universitys lebow college business board determined charlie recent relevant financial experience agreed appropriate qualifications background audit committee financial expert manvinder singh vindi banga skills experience senior independent nonexecutive vindi many years commercial experience track record delivering outstanding performance highly competitive global consumerfocused businesses director prior joining gsk vindi spent years unilever plc last role amongst several senior age positions president global foods home personal care businesses member nationality british unilever executive board vindi sat prime minister indias council trade industry appointed september board governors indian institute management iim senior independent nonexecutive director ahmedabad vindi also recipient padma bhushan one indias highest civilian honours may vindi nonexecutive director confederation british industry cbi thomson reuters corp chairman supervisory board mauser group chairman kalle gmbh n r senior independent director marks spencer group plc external appointments partner clayton dubilier rice director high ridge brands co nonexecutive director economist newspaper limited member holdingham international advisory board board member international chamber commerce united kingdom member governing board indian school business hyderabad member global leadership council sad business school oxford member indo uk ceo forum chair board trustees marie curie dr vivienne cox cbe skills experience independent nonexecutive director vivienne wide experience business gained energy natural resources publishing sectors also deep understanding regulatory organisations government workforce engagement director vivienne worked bp plc years britain continental europe posts including age executive vice president chief executive bps gas power renewable business nationality british alternative energy unit vivienne previously nonexecutive director bg group plc rio appointed july tinto plc lead independent director uk governments department international development vivienne appointed commander order british empire new year honours services uk economy sustainability r c external appointments senior independent director pearson plc chairman supervisory board vallourec non executive director stena ab advisory board member african leadership institute vice president energy institute advisory board member montrose associates chair rosalind franklin institute vice chair sad business school oxford member global leadership council patron hospice st francis lynn elsenhans skills experience independent nonexecutive director lynn wealth experience running global business significant knowledge global markets gsk operates age lynn served chair president chief executive officer sunoco inc prior nationality american joining sunoco president chief executive officer lynn worked royal dutch appointed july shell joined held number senior roles including executive vice president global manufacturing lynn previously nonexecutive c n director first tee greater houston flowserve corporation texas medical center trustee united way greater houston external appointments nonexecutive director chair governance corporate responsibility committee baker hughes company board director chair audit committee saudi aramco advisory board member johns hopkins university whiting school engineering member audit committee leadership network key committee chair n nominations corporate governance audit risk r remuneration science c corporate responsibility transformation separation gsk annual report board continued dr laurie glimcher skills experience independent nonexecutive director laurie brings scientific public health expertise boards deliberations wealth global publicly listed pharmaceutical business experience scientific medical expert addition number senior leadership positions held harvard medical school harvard age school public health laurie also served stephen suzanne weiss dean professor nationality american medicine weill cornell medical college attending physician new york presbyterian appointed september hospitalweill cornell medical center laurie stepped board bristolmyers squibb bms serving years board laurie previously nonexecutive director waters corporation cofounder chair scientific advisory board quentis therapeutics inc external appointments professor medicine harvard medical school ceo president attending physician danafarber cancer institute member us national academy sciences national academy medicine member scientific steering committee parker institute cancer immunotherapy independent director analog devices inc member scientific advisory boards repare therapeutics inc abpro therapeutics kaleido biosciences inc dr jesse goodman skills experience independent nonexecutive director jesse brings scientific public health expertise boards deliberations wealth experience spanning science medicine vaccines regulation public health proven record scientific medical expert addressing pressing public health needs academic federal sectors age jesse previously served senior leadership positions us food drug administration fda nationality american including recently fdas chief scientist previously deputy commissioner science appointed january public health director center biologics evaluation research cber jesse played leadership role developing fdas regulatory science medical countermeasures c initiatives worked collaboratively industry academia government global public health regulatory partners prepare respond major public health threats including emerging infectious diseases disasters terrorism led fdas response west nile virus hn influenza pandemic served senior leadership team white house medical countermeasure review jesse previously member scientific advisory committee regulatory legal working group coalition epidemic preparedness innovations cepi external appointments professor medicine attending physician infectious diseases georgetown university directs georgetown university center medical product access safety stewardship compass board member formerly president united states pharmacopeia usp board member scientific counselors infectious diseases centers disease control prevention cdc board member intellia therapeutics inc member us national academy medicine judy lewent skills experience independent nonexecutive director judy extensive knowledge global pharmaceutical industry corporate finance judy joined merck co served chief financial officer age retired judy served nonexecutive director dell inc quaker oats company motorola inc nationality american held nonexecutive directorships purdue pharma inc napp pharmaceutical holdings limited appointed april certain mundipharma international limited companies n r external appointments nonexecutive director thermo fisher scientific inc nonexecutive director motorola solutions inc trustee rockefeller family trust life member massachusetts institute technology corporation member american academy arts sciences business advisory board member twoxar advisory board member path inc board determined judy recent relevant financial experience agreed appropriate qualifications background audit committee financial expert urs rohner skills experience independent nonexecutive director urs broad business legal background extensive senior level experience multinational companies age urs served chairman number boards recently credit suisse prior joining nationality swiss credit suisse urs served chairman executive board ceo prosieben appointed january prosiebensat media ag followed number years private practice major law firms switzerland us admitted bars canton zurich switzerland r n state new york us external appointments chairman board governance nominations committee credit suisse group ag chairman member board trustees credit suisse research institute credit suisse foundation vicechairman governing board swiss bankers association key committee chair n nominations corporate governance audit risk r remuneration science c corporate responsibility transformation separation gsk annual report strategic report governance remuneration financial statements investor information corporate executive team skills experience dr hal barron hal joined gsk cet see board biographies pages chief scientific officer president rd roger connor roger joined cet appointed president gsk global vaccines president global vaccines addition leadership vaccines business responsible gsks global procurement organisation roger also member gavi board vaccine alliance represents international federation pharmaceutical manufacturers associations ifpma constituency previously president global manufacturing supply vice president office ceo corporate strategy roger joined gsk astrazeneca roger holds degree mechanical manufacturing engineering queens university belfast masters manufacturing leadership cambridge university chartered accountant diana conrad diana appointed senior vice president human resources hr member cet senior vice president april previously senior vice president hr pharmaceuticals rd played key strategic role leader rd people culture agenda support human resources hr transformation diana joined gsk canadas hr team held several roles increasing responsibility becoming senior vice president hr consumer healthcare prior joining gsk held hr roles companies including ge capital gennum corporation zenon environmental laboratories diana honours bachelor arts mcmaster university canada james ford james joined cet appointed senior vice president general counsel senior vice president joined gsk served general counsel consumer healthcare general counsel global pharmaceuticals vice president corporate legal acting head global ethics general counsel compliance prior gsk james solicitor clifford chance dla holds law degree university east anglia diploma competition law kings college qualified solicitor england wales attorney new york state bar james based london practised law lived us singapore hong kong james cochair us based civil justice reform group director european general counsel association nick hirons nick appointed cet senior vice president global ethics compliance senior vice president responsible compliance risk management corporate security investigations nick joined gsk international auditor later head audit assurance global ethics compliance combined five audit functions independent team common riskbased methodology nick relocated china establish governance model china business created consistent approach compliance nick fellow chartered institute management accountants sally jackson sally joined cet march senior vice president global communications ceo senior vice president office responsible communications government affairs three global businesses markets well employee engagement across group also global communications ceos chief staff prior sally senior vice president office ceo cfo ceo office previously served head investor relations joined gsk sally holds degree natural sciences university cambridge iain mackay iain joined gsk cet see board biographies pages chief financial officer brian mcnamara brian joined cet appointed ceo gsk consumer healthcare ceo gsk consumer healthcare joined gsk head europe americas gsk consumer healthcare following creation previous joint venture gsk novartis previously head novartis otc division brian began career procter gamble brian board member consumer goods forum former chairman board member global selfcare federation gscf earned undergraduate degree electrical engineering union college new york mba finance university cincinnati gsk annual report corporate executive team continued skills experience luke miels luke joined gsk cet president global pharmaceuticals responsible president global pharmaceuticals commercial portfolio medicines vaccines luke also cochairs portfolio investment board hal previously worked astrazeneca executive vice president european business prior executive vice president global product portfolio strategy global medical affairs corporate affairs head asia roche based shanghai singapore prior held roles increasing seniority roche sanofiaventis us europe asia luke holds bachelor science degree biology flinders university adelaide mba macquarie university sydney david redfern david joined cet chief strategy officer responsible corporate development chief strategy officer strategic planning previously senior vice president northern europe responsibility gsks pharmaceutical businesses region senior vice president central eastern europe joined gsk david appointed chairman board viiv healthcare limited nonexecutive director aspen pharmacare holdings limited board bachelor science degree bristol university chartered accountant regis simard regis joined cet became president pharmaceuticals supply chain president pharmaceuticals responsible manufacturing supply gsks pharmaceutical products also leads quality environment health safety sustainability corporate level regis joined supply chain gsk site director france rising become senior vice president global pharmaceuticals manufacturing current role previously held senior positions sony konica minolta tyco healthcare member board viiv healthcare mechanical engineer holds mba karenann terrell karenann joined gsk cet chief digital technology officer responsible chief digital technology officer technology digital data analytics strategy previously worked walmart chief information officer prior baxter international chief information officer daimler chrysler corporation karenann began career general motors became nonexecutive director pluralsight llc earned graduate postgraduate degrees electrical engineering kettering purdue universities respectively phil thomson phil joined cet appointed president global affairs responsibility president global affairs groups strategic approach reputation policy development stakeholder engagement global health previously phil senior vice president communications government affairs phil chairman whitehall industry group board member chinabritain business council earned degree english history russian studies durham university emma walmsley emma joined gsk cet see board biographies pages chief executive officer deborah waterhouse deborah appointed cet january became chief executive officer ceo viiv healthcare viiv healthcare april deborah joined gsk recently senior vice president primary care within companys us business prior led us vaccines business strong track record performance specialty primary care deborah led hiv business uk heading hiv centre excellence pharma europe held international roles general manager australia new zealand senior vice president central eastern europe gsk annual report strategic report governance remuneration financial statements investor information board architecture enhanced corporate governance framework improve effectiveness board way works support corporate executive team cet delivering transformation biopharma business planned separation consumer healthcare gsks internal control risk management arrangements described pages integral part corporate governance framework board chief science committee corporate responsibility transformation executive committee separation committee officer r ead r ead read corporate nominations corporate audit risk committee remuneration committee executive governance committee team r ead r ead read see roles membership board committee attendance scheduled board committee meetings nominations corporate corporate transformation board governance audit risk remuneration science responsibility separation total number scheduled meetings members attended attended attended attended attended attended attended sir jonathan symonds emma walmsley iain mackay dr hal barron charles bancroft vindi banga dr vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent urs rohner number adhoc meetings charles bancroft joined board audit risk committee may numbers brackets denote number meetings eligible attend gsk annual report board roles responsibilities leadership independent oversight rigorous challenge chairman nonexecutive directors jonathan symonds provide strong independent element board leads manages business board constructively support challenge management provides direction focus scrutinise performance meeting agreed ensures clear structure effective operation deliverables board committees shape proposals strategy offer specialist advice sets board agenda ensures sufficient time management allocated promote effective debate support sound letter appointment setting terms decision making conditions directorship ensures board receives accurate timely clear devote time necessary proper information performance duties meets nonexecutive director annual expected attend meetings required basis discuss individual contributions independence statement performance together training development needs board considers nonexecutive directors shares peer feedback provided part identified pages independent board evaluation process assessed circumstances set meets regularly nonexecutive directors provision code reviews independently executive directors continuing independence commitment judy maintains dialogue shareholders lewent served board nine governance company years lynn elsenhans july served board nine years chairmans role description available gskcom described pages chief executive officer senior independent director emma walmsley vindi banga responsible management group acts sounding board chairman trusted three businesses intermediary directors develops groups strategic direction together nonexecutive directors leads consideration approval board annual review chairmans performance taking implements agreed strategy account views executive directors supported members cet discusses results chairmans effectiveness maintains continual active dialogue review chairman shareholders respect companys performance leads search appointment process makes recommendation board new chairman chief executive officers role description available gskcom acts additional point contact shareholders maintains understanding issues concerns major shareholders briefings company secretary investor relations senior independent nonexecutive directors role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chairs annual agenda planning ensures information made available board members timely fashion supports chairman designing delivering board inductions coordinates continuing business awareness training requirements nonexecutive directors undertakes internal board committee evaluations request chairman advises directors board practice procedures corporate governance matters chairs groups disclosure committee operates boardapproved appointments policy reflects board external appointment requirements code point contact shareholders corporate governance matters gsk annual report strategic report governance remuneration financial statements investor information board activity principal decisions board discharges responsibilities annual programme meetings papers presentations board committees focus oversight performance driving companys strategic direction designed either facilitate effective decision making categorised awareness input andor decision aid boards oversight business awareness items business considered mission critical gsks longterm success highlighted areas focus longterm priorities link strategy boards oversight execution strategy included mc receiving discussing reports pharmaceuticals vaccines consumer healthcare p c mc holding joint board cet strategy day discuss plans two successor businesses beyond p c separation receiving quarterly reports chief executive officer ceo chief financial officer cfo chief p c scientific officer cso mc discussing scrutinising future ready plans transforming biopharma consumer healthcare p mc scrutinising approving major collaborations third parties develop vaccines treatments covid p mc approving business development transactions strategic partnerships third parties including mrna p technology collaboration curevac following review vaccines technology reviewing approving divestment nonstrategic consumer healthcare brands p performance boards focus performance included evaluating ceos performance setting objectives p c mc setting annual budget plan forwardlooking threeyear forecast p annual talent succession plan review p c scrutinising groups financial performance p reviewing risks impacts covid groups business performance p c reviewing quarterly financial results dividend proposal earnings guidance investor materials results p announcements confirming viability going concern statements p approval statutory accounts p science boards focus science included briefings key elements rd strategy mc review rd science x technology x culture strategy mc receiving updates progress key rd assets including impact covid p mc receiving approving appropriate number business development transactions strengthen pipeline governance boards focus governance included receiving reports committees receiving reports external auditor p approving appointment new nonexecutive director audit committee financial expert successor p audit risk committee chair establishing new committee focus transformation separation approving annual report form f receiving reports corporate governance regulatory developments company secretarys report considering conclusions agreeing actions boards external evaluation p mc setting boards priorities p c reviewing modern slavery statement gender pay gap positioning mc annual review boards enterprise risk responsibility framework enterprisewide risks cultural receiving updates cultural transformation progress p c transformation boards consideration stakeholder impacts included stakeholders reviewing boards governance architecture p c considering reports workforce engagement director p c discussing reports annual employee survey results p c reviewing stakeholder perception research p c mission critical items mc link longterm priorities innovation p performance trust c culture gsk annual report board activity principal decisions continued board members consider interests gsks key stakeholders decisions could potentially affect papers considered board committees seek highlight relevant stakeholder impacts proposals consideration whether positive negative support duty decisionmaking process selected examples principal decisions board considered stakeholder perspectives set stakeholder groups boardcommittee section principal decision made decisions regarded stakeholder interests duties considered boardcommittees business development science committee board stakeholders science committee considered collaborations deals reviewed several business development patients consumers scientific merits business including covid opportunities covid employees investors development opportunities prior collaborations leading boards review approval duties concluded transactions included longterm results strategic collaboration curevac workforce business access mrna platform capability relationships supplement gsk 's sam technology following review vaccines technology tb consortium collaboration develop novel treatment tb partnership ideaya biosciences synthetic lethality emerging field precision medicine oncology collaboration vir biotechnology identify potential covid treatment options partnerships sanofi medicago clover three potential covid vaccines using different technologies arrangements considered context potential help gsk deliver transformational medicines patients commercial model audit risk committee arc stakeholders arc recommended limited sfi changes china considered recommended hcps medical experts programme changes board selected markets board changes healthcare employees investors approval professionals hcp engagement governments regulators safeguard key stakeholder interests sales force incentive sfi programme patients consumers new programme implemented china selected markets nonexecutive director controlled phases across markets review reflected growing shift gsks briefing workshop robustness programmes portfolio innovative specialty care held part arc governance arrangements presented products aim increase review process enabled arc end competitiveness build board meet china initial phased roll new pharmaceuticals leadership sfi programme team discuss examined changes means countrys commercial policy risk management attracting retaining best sales compliance culture force talent china duties increasing sales forces longterm results accountability performance focus workforce business enhancing quality dialogue relationships reputation hcps china helping us serve patients better arc agreed robust governance arrangements underpin changes including realtime monitoring advanced data analytics uphold ethical valuesled approach hcp engagement gsk annual report strategic report governance remuneration financial statements investor information board activity principal decisions continued boardcommittee stakeholder groups principal decision made decisions regard stakeholder interests section duties considered boardcommittees covid solutions corporate responsibility committee stakeholders committee recommended pandemic preparedness considered gsks approach hcps medical board approved proposals investment covid solutions vaccines experts employees fully aligned purpose strategy adjuvant therapeutics pricing investors governments areas business focus supply allocation regulators non governmental organisations agreed proposal commit profits multilateral organisations sales covid vaccines patients consumers pandemic investment pandemic preparedness committee pleased agree gsks covid solutions approach principles working partnership taking global approach committing access supporting future pandemic preparedness approach seeks strike balance generating economic return rewarding innovation investing business acting responsibly towards key stakeholders supporting global response pandemic new environmental corporate responsibility committee stakeholders committee recommended sustainability goals received considered proposal investors employees board agreed stepchange scale review develop existing governments regulators pace addressing impact environmental sustainability targets nongovernmental environment committing goal net organisations zero impact climate positive impact ambitious new targets firmly multilateral organisations nature across value chain aligned expectations environmental sustainability across key stakeholder duties contribute protecting groups focus climate change longterm results restoring healthy planet improve peoples damage nature workforce business health linking goals actions relationships community remove carbon improve biodiversity committee agreed addressing environment reputation restore local water basins expectation would positively impact demonstrate nature positive approach gsks reputation employee engagement giving back take equity position mitigate exposure financial supply chain risk inclusion corporate responsibility committee stakeholders committee supported proposal diversity received considered proposal investors employees board agreed greater transparency employee governments regulators report employee race ethnicity data race ethnicity data aspirations nongovernmental annual report accompanied supports aspiration organisations headline aspirational statement increase percentage leaders multilateral organisations detailed external disclosure us identify ethnically diverse duties uk data specific aspirational increase global gender longterm results targets delivery end aspiration workforce business relationships community increase global gender aspiration committee noted environment reputation vp roles higher strategic commitment end modern employer key component trust priority strong employee experience critical attracting retaining key talent deliver innovation performance trust priorities underpinned culture part broader efforts area race ethnicity gender proposal consistent approach inclusion diversity id focuses ensuring workforce reflects communities work hire disclosing gender diversity data aspiration setting globally gsk annual report purpose values culture boards role promote gsks sustainable success year boards discussion culture centred drive longterm growth shareholders add value employees experience gsk ways working stakeholders strategic report pages particularly backdrop covid pandemic demonstrates work achieve goals also considered progress evolving gsks culture corporate governance report pages explains insights reflections key external stakeholders governance arrangements support strategy audit risk corporate responsibility committees innovation performance trust priorities underpinned meanwhile considered respective risk compliance culture aspects culture change performance line trust priority purpose gsks purpose improve quality human life helping culture change complex global organisation gsk people feel better live longer underpinned takes time sustained effort board recognises values patient focus integrity respect transparency tone top drives companys culture purpose values source great pride cet must role models words actions board management employees help attract behaviours setting template employees board members retain talented individuals want part group seek lead example instance alongside rest contributes society also strengthen relationships workforce take following key gsk training patients consumers key awareness modules stakeholders help us take new medicines living values expectations explores gsks vaccines consumer healthcare products patients values expectations culture application consumers around world operations ways working culture antibribery corruption board responsible setting group culture plays key role delivering high standards business inclusion diversity conduct promoting longterm success unlocking way people lived worked protecting value gsks expectations courage accountability covid pandemic crucial role leaders development teamwork fundamental culture played described continued make good progress evolving culture increase pace performance focus way recent race ethnicity challenges us reinforced work discussed focus inclusion diversity core element culture confident work date realise board receives regular updates gsks ceo cso progress promoting inclusion cfo head human resources global businesses diversity agenda set strategic progress aligning strategy performance values report corporate responsibility based culture assesses progress culture shift committee chairs report mainly results gsks regular employee surveys culture dashboard tracks four indicators progress namely code conduct embodies values expectations kept review board refreshed regularly appointing promoting right people available gskcom leadership capability corporate standards employee policies aligned employee engagement values expectations include longstanding speak arrangements enable employees raise ways working matters confidentially anonymously without fear reprisal head human resources regularly updates board board audit risk committee reviews speak progress indicators reports provided gsks global ethics compliance board supports gsks culture change seeking gec team speak channels reports managed appoint promote right people enhancing governance independent third party cases investigated controls processes uphold incentivise right gec behaviours training developing employees details enable culture change invest reward workforce see pages gsk annual report strategic report governance remuneration financial statements investor information boards approach engagement gsks engagement main stakeholder groups key stakeholder perspectives board cet including patients shareholders consumers customers strategy day employees levels organisation across business development analysis justifications enterprise summarised pages strategic report board committee evaluations way board considered key stakeholders interests remuneration policy reviews wider workforce discussions decision making set pay perspective holistic view board discharges duty culture succession planning updates read conjunction workforce engagement director updates section statement areas annual governance meeting crossreferences annual report annual general meeting principal decisions made board committees pages employee survey reports stakeholders quite rightly high expectations us briefings annual strategy meetings dynamic operating environment presents many challenges annual budget business planning process opportunities responding prospects board corporate governance regulatory development updates seeks ensure well remaining commercially successful meet stakeholders expectations uphold workforce reputation maintain licence operate build trust ensure identify respond expectations well established strong engagement mechanisms effectively board engages many stakeholders directly colleagues described two key well means governance channels help communicate workforces views influence importance different stakeholder groups boardroom vary depending matter considered indeed feedback gsks global employee survey different stakeholders interests conflict requiring work workforce engagement director dr vivienne balanced judgment board cox regularly gathers explains colleagues views stakeholder engagement feedback helps us identify board outlines overleaf emerging issues enables board consider gsks chairman nonexecutive directors also regularly activities context relevant important meet employees around group report back stakeholders ensuring deliver purpose advance board towards goal becoming one worlds innovative bestperforming trusted healthcare companies overall employee engagement score global employee survey one operating key performance principal board committees cet delegated indicators published years survey powers enables build detailed understanding conducted spring backdrop impacts companys actions plans stakeholders intensifying covid crisis significant business change engagement briefings insights shared resulted engagement score highest since board appropriate surveys inception increase since board primarily receives intelligence stakeholder previous survey september perspectives work corporate responsibility board pleased see improvements survey committee covered scores across innovation performance trust improve understanding stakeholder matters priorities powered culture revealed following board members encouraged meet individually trends employee sentiment employees shareholders key stakeholders purpose deeper connection purpose induction afterwards ongoing basis patientconsumer positive changes culture encouraged report board experiences contributing engaged productive happy relevant material workforce stronger performance employee feedback board also learned stakeholder views consistent key benefits general ceos board reports agreement workforce contribution recognised strong support rationale monthly stakeholder perception reports behind gsks covid response emphasis business updates people business continuity solutions retaining focus critical innovation performance trust priorities reactions gsks covid response built around powered culture people business continuity solutions gsk annual report boards approach engagement continued performance leaderdriven care people led new performance choice initiative employees generally felt valued supported respected enables combination facetoface collaboration crisis helped form stronger digital working first wave participants sign connections leaders appreciated initiative officebased employees including office greater regularity communication open honest workers laboratories factories need informal style onsite setting new work parameters employees worked managers work necessity employees much flexible line objectives performance requirements got jobs done many working around wider team preferences commitments home reacted well leaders openness sharing challenges support clear accountabilities pace also positive flexible working patterns similar appreciation recognition management assembling right company 's flexibility around childcare needs teams appropriate expertise irrespective holidays support employee health wellbeing level people company respond rapidly collaboratively fastchanging issues opportunities workforce engagement director two years since became gsks first workforce session synthesised feedback engagement director role privilege nonattributed report next board meeting carry much enjoyed meeting wide variety last october chairman pleasure meet employees across group different businesses virtually leaders members gsks race ethnicity geographies employee resource groups talked boards plan visits agreed year however due support ceos ambition actions improve inclusion covid needed creative embraced diversity wideranging conversation particular technology switched virtual meetings nonetheless discussed commitment transparent meetings insightful provided helpful ethnic representation workforce leadership employee perspectives progress evolution set public aspirational targets focus everyone gsk gsks culture improving ratio details company 's inclusion diversity work newly published aspirations years schedule included lets talk sessions teams see develop role aim incorporate employees oncology us commercial consumer annual discussion selection gsks employee healthcare rd marketing artificial intelligence resource groups machine learning rd development rd well dialogue race ethnicity employee resource pleased report general employees groups finally observed annual senior leaders virtual met broadly supportive gsks culture changes meeting key benefits delivered value advantages working large company strong purpose companys lets talk sessions wellestablished virtual employee response covid crisis received particular support voice channel direct conversations however many workforce continue deal session received briefing business challenges working remotely continue enquire head human resources included workforce data staying resilient motivated mentally well gsk survey data insights business meeting context business whole wider group employees raised impact restructurings excitement opportunities lets talk sessions followed consistent format separation two companies could bring enabled directly compare feedback gathered also natural trepidation understandable different parts workforce year participants covid permitting hope able engage represented diverse crosssection employees within employees facetoface sometime team keen hear employees meantime virtual route enabling carry us time new role look forward continuing provide platform company could bring recent perspectives compare employees views perspectives boardroom gsk organisations experienced introduced role explained passionate employee engagement purpose conversation dr vivienne cox would feedback ground rules nonexecutive director managed line values expectations ensure participants comfortable express anonymised views kept groups small could get know participants encourage share views gsk annual report strategic report governance remuneration financial statements investor information boards approach engagement continued shareholders holistic view work relationships future focus audit risk committee board seeks directly engage private retail discuss remuneration policy practices proposals institutional shareholders several ways include regular communications agm annual governance meeting well received thoughtful incisive meeting via work investor relations team questions put attending board members chairman sir jonathan symonds company secretary gsks external audit partner shareholder feedback shared victoria whyte subsequently rest board year ceo emma walmsley cfo iain year usual annual governance meeting slides mackay also gave quarterly results presentations institutional available gskcom event investors analysts media webcast teleconference annual general meeting available gskcom year agm may held registered emma iain conduct continual active dialogue office due covid restrictions public gatherings institutional shareholders performance plans broadcast agm shareholders invited join objectives regular meetings emma held ask questions vote meeting electronically individual meetings major shareholders hosted details found group meetings actual potential major shareholders unfortunately due covid pandemic unable meanwhile iain held individual meetings group hold agm planned held instead meetings registered office closed meeting attended chairman jon maintains active dialogue shareholders company secretary line minimum including fund portfolio managers well seeing quorum shareholder meetings uk governments governance professionals enables build full lockdown requirements board members joined picture major shareholders insights perspectives telephone ideal agm format priority gsk following introductory meetings held protect shareholders employees board general catchup meetings range uphold gsks governance could continue provide investors comprising approximately third companys healthcare patients need share register wrote shareholders early april explain annual governance meeting arrangements encourage submit proxy votes board holds annual governance meeting responses shareholder questions submitted advance institutional shareholders key investment industry bodies agm published website proposed proxy advisory firms resolutions approved shareholders majorities ranging year due covid chairman hosted virtual event december joined senior independent board keen provide channel meaningful director workforce engagement director committee chairs engagement shareholders would conventional gsks external audit partner shared following key gsk agm therefore held shareholder webcast immediately information investors meeting attended board members webcast chairman ceo gave updates changes board committees increased shareholders able question chairman ceo cfo focus board imperatives management oversight cso questions could also lodged board increased importance corporate responsibility members answer afterwards science committees webcast offered shareholders including strong board oversight progress towards separation could ordinarily attend agm opportunity engage via transformation separation committee board shareholders could join telephone online thoughtful rapid response covid focusing answers given broad range questions employees business usual activities potential including submitted advance recording treatments vaccines webcast qa summary available gskcom employee feedback positive changes gsks culture appear supporting engaged productive happy workforce stronger performance continued evolution gsks approach environmental social governance esg matters emphasis social esg reporting gsks modern employer approach including focus inclusion diversity response board organisation issues gsk annual report board performance board evaluates performance action points committees every year evaluation normally carried meeting review evaluation board split externally every third year last one facilitated three groups appropriate mix executive non jan hall business advisory company executive directors review consider report connection gsk board felt due consideration discussion following action points would helpful conduct evaluation improve performance agreed check progress implementation key measures consideration would continue given stop agreed board previous years review unnecessary tasks free time focus preparation priorities precondition creating shareholder met chairman advance evaluation value prime importance update board operating gsks future consideration would also given making best use priorities agree reviews objectives scope boards time virtual meetings incorporating timetable company secretary also provided opportunities unstructured discussions possible advance access board committee materials information board would continue discuss approach separation course year interviews november december conducted science committee would look deepen confidential detailed virtual interviews board understanding rds resources allocated selected cet members company secretary gsks desire enhance root cause analysis external auditor independent remuneration adviser undertaken incidents issues occurred seek views boards effectiveness ensure could avoided future part meetings reflected agreed discussion guideline groups approach improving performance sent participant beforehand included key topics board committees financial reporting councils guidance review board committees focused progress board effectiveness relevant requirements embedding enhanced ways working agreed uk corporate governance code although limit review boards governance feedback participant could give architecture involved virtual interviews committee review members conducted behalf respective review sought focus progress made committee chairs committee considered operate board focused continue evolve effectively maintain optimal effectiveness committee successful delivery two companies separation beyond chairs mindful continuing prepare full oral reports evaluation results suggested next steps included update whole board work appropriate summary report compiled discussed initially important issues would highlighted comment chairman ceo senior independent director chairman sid review presented board december sid sought feedback chairman 's covered following main areas effectiveness performance directors individually collectively review results effectiveness review noted overall review board discussed chairman sid board organisation agenda information board dynamics challenge input future strategy development performance delivery review also highlighted proposals board committees better explore resolve tough questions would heart making board even effective gsk annual report strategic report governance remuneration financial statements investor information board performance continued progress board evaluation progress conclusions board evaluation review set areas focus progressachievements meetings organisation board committee presentations organised around brief summary improve balance presentation discussion create key issues questions addressed majority allotted time debate time given qas discussion decisions board dynamics individual contributions board committee agendas papers presentations facilitate even greater individual contributions creating discussion evolved organised allow time board members provide time insights perspectives matters critical board priorities committees board committee terms reference updated new transformation review remit attendees boards committee meetings separation committee established board march ensure fit purpose beyond risk exercise completed board terms reference agree board committee ensure deeper oversight review relevant board committee updated reflect agreed reallocation groups enterprise risks enterprise risk oversight responsibilities strategy performance board committee agendas organised emphasise conduct deep dives key strategic areas ensure focus allocate time discussing mission critical input decision papers supporting management execute agreed strategy reinforce focus strategic execution board knowledge board benefitted greater insight gsks rd strategy deepen boards knowledge understanding latest scientific several rd science theme deep dives year specifically human developments genetics covid vaccines mrna technology ai ml stakeholders board aligned cet delivering mission critical items within business board continue focus key areas benefit key stakeholders focus cet namely strengthening rd pipeline growth transformation delivery gsks trust business priority externally maintain strong relationships communication information continuing area focus see shareholders key stakeholders seek input keep well informed progress succession planning charles bancroft joined board arc may complete appointment audit risk committee arc chairs succeed judy lewent arc chair march annual report successor published governance board approved company announced ambitious new build gsks commitment environmental social environmental sustainability goals net zero impact climate governance esg matters net positive impact nature search undertaken seek successor lynn elsenhans chair corporate responsibility committee lynn agreed serve another year retires board may see details gsk annual report board committee information board committee written terms reference approved board reviewed least annually ensure comply latest legal regulatory requirements reflect best practice developments following summary role committee lists membership current full terms reference board committee available gskcom number committee meetings committee members ' attendance described details committee members ' skills experience included biographies board pages accordance frcs code board determined judy lewent charles bancroft recent relevant financial experience also agreed appropriate qualifications background audit committee financial experts defined sarbanesoxley act determined independent within meaning securities exchange act amended board committee board committee role membership comprises report audit risk reviews financial reporting process integrity judy lewent chair companys financial statements external internal audit charles bancroft may process system internal control identification vindi banga management risks companys process lynn elsenhans monitoring compliance laws regulations ethical dr laurie glimcher codes practice initiates audit tenders selection appointment external auditor setting remuneration exercising oversight work corporate responsibility considers gsks trust priority oversight progress lynn elsenhans chair associated trust commitments reflect dr vivienne cox important issues responsible sustainable business dr jesse goodman growth oversight views interests internal external stakeholders reviews issues potential serious impact upon gsks business reputation science supports board understanding key strategic dr jesse goodman chair themes upon companys rd strategy based dr laurie glimcher external transactions performing depth judy lewent reviews underlying scientific assumptions give board technical assurance also undertakes depth risk oversight rd related risks nominations reviews structure size composition board sir jonathan symonds chair corporate governance appointment members board committees vindi banga appointment corporate officers makes lynn elsenhans recommendations board appropriate plans judy lewent assesses orderly succession executive nonexecutive urs rohner directors reviews management 's succession plan ensure adequacy responsible reporting board overseeing monitoring corporate governance arrangements making recommendations board ensure companys standards arrangements consistence existing corporate governance standards emerging best practice also reviews companys conflicts interest transformation advises assists board transformation sir jonathan symonds chair separation separation company oversees associated risks charles bancroft established separating group biopharma consumer dr vivienne cox march healthcare companies vindi banga lynn elsenhans judy lewent urs rohner remuneration sets companys remuneration policy regard urs rohner chair gsks workforce remuneration gsk able recruit vindi banga retain motivate executives dr vivienne cox judy lewent remuneration policy regularly reviewed ensure consistent companys scale scope operations supports business strategy growth plans aligned wider workforce helps drive creation shareholder value chairman ceo responsible evaluating making recommendations board remuneration nonexecutive directors gsk annual report strategic report governance remuneration financial statements investor information board committee reports audit risk committee report working plan rest deliver business usual standards incorporate learnings judy lewent measures taken first quarter process plan audit risk committee plan reviewed committee first quarter pleased present report ninth throughout year approval report final one chair audit risk committee pleased confirm effective operation finance committee committee worked largely helped deliver smooth second third quarterly results recurring structured programme activities continued provide stable reporting controls understandably included impacts covid platform financial year end pandemic devised programme company part committees role assessing effectiveness secretary agree content management internal controls financial reporting committee external auditor start year adapted continues obtain regular updates progress appropriate year progresses breakdown strengthening information technology processes activities areas focus available gskcom associated infrastructure especially around user access following pages aim share insights activities management appropriate mitigating technology undertaken overseen committee year business controls place processes financial reporting controls strengthened integrity gsk 's financial statements including annual usual committee diligent reviewing throughout report quarterly results announcements enduring key year appropriateness guidance balancing focus committee committees position always developments external environment advising aim clear transparent financial disclosure board accordingly financial reporting external audit impact covid audit annual report published company onset crisis assessed covid crisis impacts fully unfolded however external auditor discussed management reported first signs covid spreading several committee significant disruption countries closely monitored potential impact audit process timetable monitored closely production results number key measures external auditor committee throughout year taken finance team presented committee continued discuss insights committee pleased financial reporting external auditor provided use analytical tools controls framework remained robust require technology help improve accelerate delivery fundamental changes beyond taking targeted audit work adjustments ensure control framework continued significant issues committee external auditor operate effectively close first quarter discuss significant issues relation financial results beyond statements committee considers periodically adjustments first quarter results included year areas particular audit focus high adapting deploying finances crisis management degree alignment committee external response formation one finance issues auditor areas attention set management taskforce address deliver critical disclosures pages areas finance organisation internal audit audit assurance aa team adapted delivering results time schedule almost assurance work take account changing business finance teams thirdparty partners working challenges travel restrictions arising covid home aa team regularly updated committee progress agreed schedule audits values reviewing accounting considerations result assurance reviews covid impact resulted additional proposed disclosures committee considered approved new ways working become settled adopting applying guidance issued financial anticipate opportunities aa reporting council frc effectively perform assurance activities remotely particularly audit covers end end processes access technology likely apply companys finance tech rd processes gsk annual report board committee reports continued sfi hcp changes fundamental success continued evolution continuing consider rationale around test new programme strong leadership drive culture robust governance arrangements underpinning incremental performance trust enforced measured changes sales force incentive sfi programme governance controls zero tolerance abuse healthcare care professional engagement hcp policy risk management internal controls enterprise risks resulted gsks growing innovative specialty care gsk wellestablished mature risk management products oncology progress building internal control framework described specialty capability transform interactions hcps committee continues scrutinise operation limited updates made hcp policy framework also reviews refinements management committee report annual report described proposes framework ensure remains fit purpose committees scrutiny recommendation board complements matters identified managed make limited changes sfi programme part work global issues management team reports cet ensure attract retain best sales force talent data analytics key risk indicators global ethics enhance quality dialogue hcps compliance gec introduced key risk indicators kris hence better serve patients enterprise risks quarterly reporting believe changes necessary secure growth tolerance kris risk oversight compliance council company deliver strategic priorities act rocc addition risks mitigations relating covid best interests patients shareholders incorporated within significant risks gec stakeholders also hired data analytics specialists enhanced data mining tools team enhance use data analytics evolution commercial model aa independent business monitoring groups committee considered sfi hcp policy changes china support innovative product launches emerging risks help guide committees emerging risk competitiveness country discussions meeting summary particular areas focus rocc recent meeting shared committee devoted significant portion time committee members uptodate risk setting robust governance arrangements underpin information front changes china including realtime monitoringadvanced data analytics uphold ethical valuesled approach cyber security resilience gsks information protection risk hcp engagement addition nonexecutive director one principal enterprise risks due criticality briefing workshop held part committees business committee continued receive quarterly consideration process enabled board meet updates monitors closely ongoing work manage china pharmaceuticals leadership team discuss continuously evolving risk indeed relevance even countrys commercial policy risk management compliance acute covid pandemic less culture week resulted entire officebased workforce moving workfromhome model addition information security rollout sfi hcp policy risks increased result increased malicious email changes carefully selected markets safeguard key malware targeting gsk phishing forms stakeholder interests sfi programme implemented social engineering tech organisation able china selected markets controlled way successfully combat contextual details following clear stagegated phases steps kept mitigation activities committee overseen review management committee year given committee emphasised risk unethical although committee recognised covid behaviour sales teams one needs monitored provided unique information security challenges closely comprehensive risk mitigation plans place threats also created significant opportunities part ongoing development programme advance security company committee seeks adopt possible best practice guidelines effective compliance programmes changes sfi programme underpinned robust internal controls continue significant focus committee given associated risks know need act swiftly things go expected gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued internal control framework aa function provides independent assurance senior board recognises obligation present fair balanced management board effectiveness risk diligent assessment gsks current position management groupwide line agreed assurance prospects reflecting responsibility accountable plan helps senior management board meet evaluating approving effectiveness gsks internal oversight advisory responsibilities fulfilling gsks controls including financial operational compliance strategic objectives building trust patients controls risk management processes stakeholders aa dual reporting line cfo committee ensure reliability financial reporting compliance laws regulations internal committee receives regular reports business units control framework comprehensive enterprisewide principal risk owners gec aa areas significant risk risk management model supports boards continuous group related internal controls reports identification evaluation management groups assess internal control environment within principal risk principal risks required frcs code area including enhancements strengthen controls following framework designed manage risk us achieving consideration reports committee reports annually business objectives board effectiveness gsks internal controls fitforpurpose framework complemented corporate authority delegated committee values expectations speak processes ensures board conducted robust assessment groups principal risks associated business activities actively risks assessment line frcs effectively controlled line agreed risk appetite code included consideration nature extent risk believe gsks framework provides reasonable board willing take achieving gsks strategic objectives absolute assurance material misstatement loss board via committee also oversaw effectiveness board mandates groups rocc senior leaders internal control environment risk management assist committee overseeing risk management processes across group whole year internal control activities also provides business approval date annual report framework risk management upward escalation gsks internal control framework risk management significant risks business unit risk board governance structure illustrated graphically gskcom structure reports rocc business unit risk management compliance boards rmcbs review groups risk management approach responsible promoting local tone top discussed risk management section strategic risk culture well ensuring effective oversight internal report pages management principal controls risk management processes risk explained principal risks uncertainties pages groups viability discussed group risk principal risk assigned risk owner drawn management section strategic report senior management accountable managing hisher principal risk including setting implementing risk mitigation plans report annually respective risk management approach progress rocc committee gec function assists rocc rmcbs gec responsible advancing enterprisewide risk management developing riskbased ethically sound working practices also actively promotes ethical behaviours enabling employees operate line values comply applicable laws regulations gsk annual report board committee reports continued significant issues relating financial statements considering gsks quarterly financial results announcements financial results annual report committee reviewed significant issues management judgements determining results reviewed management papers setting key areas risk actions taken quantify effects relevant issues judgements made management appropriate accounting required address issues financial statements significant issues considered relation financial statements year ended december set following table summary financial outcomes appropriate committee external auditor discussed significant issues addressed committee year areas particular audit focus described independent auditors report pages significant issues considered committee relation financial statements issue addressed committee going concern basis preparation committee considered outcome managements halfyearly year end reviews current financial statements forecast net debt positions various financing facilities options available group committee also considered managements review current longerterm impacts covid pandemic outbreak pandemic year end following consideration assessments included stress testing viability scenarios sources liquidity funding forecasts estimates committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including returns committee reviewed managements approach timing recognition revenue accruals rebates rar accruals customer returns rebates us pharmaceuticals vaccines accrual returns rebates billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us pharmaceuticals vaccines business determining level accrual necessary set critical accounting policies provisions legal matters including committee received detailed reports actual potential litigation internal external investigations groups legal counsel together number detailed updates investigations groups commercial commercial practices practices management outlined levels provision corresponding disclosure considered necessary respect potential adverse litigation outcomes also areas yet possible determine provision necessary amount december provision legal matters billion set note financial statements provisions provisions uncertain tax positions committee considered current tax disputes areas potential risk concurred managements judgement levels tax contingencies required december tax payable liability billion including provisions uncertain tax positions recognised groups balance sheet impairments intangible assets committee reviewed managements process reviewing testing goodwill intangible assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment charge million see note financial statements intangible assets details valuation contingent consideration committee considered managements judgement necessary increase liability relation viiv healthcare pay contingent consideration result increases sales forecasts well unwind discount updated exchange rate assumptions cash payments nearly billion year december groups balance sheet included contingent consideration liability billion relation viiv healthcare see note financial statements contingent consideration liabilities details viiv healthcare put option committee reviewed agreed accounting pfizer put option concurred managements judgement valuation put option billion december gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued auditors reappointment committee chair regularly meets independently external auditor audit partners committee also meets auditor end meeting discuss progress appropriate external auditor appointment last tender may december reviewed feedback noted areas transition year improvement implemented audit team first shareholder approval current auditor may committee satisfied first audited annual report f year ending december effectiveness auditor external audit process next audit tender required regulations auditors independence qualifications objectivity expertise resources contractual similar obligations restricting groups choice external auditor committee considers committee therefore agreed recommend company complied mandatory reappointment deloitte board forthcoming agm audit processes audit committee responsibility provisions nonaudit services competition markets authority statutory audit management operates presumption services order accountancy firms provide nonaudit services gsk effectiveness quality external audit process however external auditors skills experience committee committed ensuring gsk receives make suitable supplier nonaudit support high quality effective external audit evaluating deloittes auditrelated matters tax services may performance prior making recommendation used best interests company line gsks reappointment early committee reviewed nonaudit services policy committee must ensure effectiveness performance criteria auditor objectivity independence safeguarded agreed management beginning reviewing preapproving external auditors provision criteria set annual report services detailed criteria used judging effectiveness company policy complies frcs revised deloitte external auditor based audit approach ethical standard sarbanesoxley act strategy high quality independent audit effective observes following core policy features engaging partnership value money overriding responsibility external auditor nonaudit services deliver smooth thorough efficientlyexecuted audit available gskcom gsk nonaudit services policy key features undertaking review committee considered process nonaudit services put competitive tender financial services providers line overall quality audit groups procurement process unless skills independence deloitte experience external auditor make suitable supplier whether deloitte exhibited appropriate level challenge safeguards adequate safeguards established objectivity scepticism work independence group audit threatened deloittes length tenure taken account compromised assessing independence objectivity fee cap total fee payable nonaudit services recently appointed gsks auditor however committee exceed annual audit fee except special consider effectively assumed role auditor circumstances would clear advantage auditor undertaking additional work committee also considered feedback external prohibitions gsks policy includes whitelist permitted nonaudit audit survey committee members financial services line relevant regulations service management team corporate business unit level list prohibited survey covered preapproval nonaudit services require preapproval set effectiveness auditors challenge table ensure services approved consistent gsks nonaudit policy permissible services process integrity deloitte ensures services fall within scope services permitted preapproved committee represent transparency reporting management delegation authority preapproval committee value preapprover clarity auditors communication ways working committee chair cfo alignment audit groups investment group financial controller systems applications products sap designate group quality audit teams leadership financial controller skills experience audit team fees paid company 's auditor associates set overleaf details given note financial statements operating profit gsk annual report board committee reports continued corporate responsibility committee report audit services comparison lynn elsenhans corporate responsibility committee pleased present fifth report chair corporate responsibility committee committee committee important part boards oversight companys trust priority overseeing guiding cet delivering longterm value shareholders society role committee committee oversees gsks trust priority companys progress trust commitments audit assurance services reflect important areas responsible sustainable services including tax regulatory compliance treasuryrelated services business growth oversight views interests internal external stakeholders reviews issues could seriously impact gsks business reputation fair balanced understandable assessment need annual report fair balanced committee rolling agenda receives reports understandable one key compliance requirements cet members senior managers ensure actions companys financial statements ensure gsks annual progress gsks trust commitments considered report meets requirement wellestablished regularly includes monitoring company engages documented process governing coordination review effectively broad range stakeholders responds groupwide contributions publication runs parallel high external expectations gsk global healthcare process followed external auditor company committee supported chairman ceo general counsel presidents global affairs pharma committee received summary managements supply chain vp trust global health approach gsks annual report ensure met invited meetings cet members attend required requirements frcs code enabled committee board confirm gsks annual committee oversight principal risks relevant report whole fair balanced understandable area expertise responsibility namely product provides necessary information shareholders assess quality nonpromotional engagement supply continuity companys position performance business model environmental sustainability environment health safety strategy principal risk managed member senior management ensure appropriate controls place code conduct reporting lines clear plans address gaps details risks number wellestablished policies including see pages code conduct available gskcom together details confidential speak lines reporting key activities investigating unlawful conduct focused particularly alignment groups trust priority gsks purpose strategy company audit risk committee chair succession navigated challenges presented covid delighted welcome charles bancroft former chief purpose became aligning motivating factor financial officer bristol myers squibb designated uk employees focus proved helpful us financial expert charlie joined committee whole competence relevant sector year committee undertook deeper oversight company operates may since charlie enterprise risks relevant remit expertise working smooth transition handover involved regular reports risk owners including relevant succeeds committee chairman publication materials advice risks highlights annual report relevant audit assurance global ethics compliance outcomes privilege serve member board chair committee oversee audit risk aspects made good progress trust commitments set much change company environment originally notwithstanding impact pandemic regulation governance accounting reporting pharma companies continue follow companys progress beyond separation biopharma consumer businesses judy lewent audit risk committee chair march gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued key activities reviewed included stakeholder engagement insights committee pays close attention evolving views oversight gsks covid response global health expectations companys broad range key stakeholders long one gsks key contribution areas recent years reviews discusses regular report stakeholder company increased focus science ensure insights meeting ensure considers issues biggest impact line strengths strategy may bearing gsks reputation delivery committee oversaw companys response responsible business agenda employee insights feedback covid behalf board committee discussed relation progression companys management acutely aware need respond modern employer agenda results employee way balances interests key stakeholders survey sustainable gsk committee discussed gsk could contribute scientific technological expertise meet directly shareholders understand issues explored decisionmaking frameworks management concerns may december pleased engage around responsible pricing models access allocation number largest investors companys virtual principles partnership criteria frameworks allowed annual governance meeting included interactive gsk make rapid decisions consistent values session participants increasingly important work purpose strategy committee year environmental sustainability committee reviewed committee actively looks ensure gsks continued approved recommendations gsk set two new ambitious delivery societal shareholder needs aware goals net zero impact carbon net positive impact increasing focus environmental social governance nature committee reviewed contribution esg issues among investors strongly supports goals gsks pharmaceuticals vaccines managements approach managing esg including risk consumer healthcare businesses committee also mitigation management continues benchmark esg discussed impact climate change nature loss performance pleased see strong showing human health recognising new goals consistent area year gsk ranked second purpose strategy pharmaceuticals industry dow jones sustainability index early january came first access medicine index modern employer committee regular oversight company also maintains strong position investor ratings gsks modern employer programme several sustainalytics msci vigeo eiris discussions management race ethnicity year company continue report progress committee monitors investor expectations esg gender targets set disclose targets reporting disclosure ongoing basis gsk continues workforce race ethnicity markets sufficient align best practice reporting accordance employee data available details evolving sustainability accounting standards board see esg company 's inclusion diversity agenda see performance summary taskforce climaterelated financial disclosures see health safety health wellbeing employees extremely important gsk together communities committee aims operate committee formal oversight committee continue scrutinise monitor gsks employee health safety enterprise risk always material trust topics relevant enterprise risks also provided oversight areas committee several work management continue ensure commitments discussions management gsks health safety support trust priority evolve according external performance including detailed reports investigations expectations company strategy particularly gsk causes two workplacerelated fatalities progresses towards creation two new leading healthcare year ensure company takes appropriate action companies committee considers company well key learnings positioned support continuing delivery trust priority committee chair succession approaching end tenure board however facilitate smooth transition successor agreed stay board year agm subject reelection agm may look forward working handing successor announced lynn elsenhans corporate responsibility committee chair march gsk annual report board committee reports continued science committee report pipeline progress committee pleased observe progress made dr jesse goodman dr hal barron gsks chief scientific officer cso science committee president rd driving scientific innovation across rd another significant year committee year company continued strengthen renewed focus science deeper level advance pipeline received nine major approvals support board understanding companys including approval four new molecular entities rd strategy provide reassurance guidance oncology hiv chronic kidney disease also delivered required lifecycle innovation key medicines areas respiratory disease year committee focused three broad objectives encouraging major developments oncology pipeline including two major us food drug administration ensuring key scientific assumptions drive fda approvals companys rd strategy remain valid zejula niraparib monotherapy available providing technical assurance particularly relation firstline maintenance treatment women advanced potential transactions ovarian cancer regardless biomarker status delivering oversight research practices patient blenrep belantamab mafodotin adult patients safety enterprise risks relapsed refractory multiple myeloma second part renewed focus committee undertook common form blood cancer us deepdives strategic themes including addition viiv healthcare obtained fda approval human genetics cabenuva cabotegravir rilpivirine first complete long acting regimen treatment hiv infection adults artificial intelligence machine learning ai ml vaccines pipeline also progressing well highly vaccines promising maternal rsv vaccine candidate men oncology abcwy fiveinone vaccines meningitis candidate ai ml one exciting areas addressed entering phase iii studies committee year building capabilities business development strategic partnerships area enable gsk develop systems take advantage collaborations world leading access human genetic data building foundations set last year committee collaborations uk biobank finngen continued review scientific opportunity number significant impact future rd discovery largescale investments business transactions development processes across gsk vir biotechnology committee supported gsks assessment gsks response covid collaboration vir identify accelerate new antiviral committee oversaw companys response developing antibodies could used therapeutic preventative potential vaccines therapies covid response options fight covid future outbreaks three late included stage studies underway vir results anticipated first half partnering vaccines adjuvant multiple companies research groups across world including sanofi collaboration expanded february advance sk bioscience south korea medicago canada new therapeutics influenza respiratory diseases investigating next generation covid vaccines pantb collaboration gsk joined consortium collaboration curevac philanthropic nonprofit private sector organisations including bill melinda gates foundation accelerate developing potential therapeutic options combat development novel treatment tuberculosis tb covid potential future outbreaks important step addressing current challenges collaboration vir biotechnology innovative diagnosing treating drugresistant tb pipeline assets gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued curevac partnership role helping identify critical nominations corporate governance emerging trends science medicine committee committee report believes accessing external innovative platforms key future vaccines business jonathan symonds nominations corporate governance committee gsks strategic partnership curevac provides access innovative messenger rna mrna technology rapidly pleased present second report chair progressing platform developing new vaccines nominations corporate governance committee medicines technology could expand range diseases committee committee renamed year reflect prevented treated potentially hastening expanded role encompass corporate governance matters development manufacturing curevacs mrna technology thereby freeing time board ensuring deeper manufacturing capability complement gsks existing focus important area expertise vaccines addressing significant unmet medical work nominations corporate governance committee need transform gsk move closer separation february building existing relationship gsk committees key priorities entered collaboration curevac jointly search replacements longserving directors develop next generation mrna vaccines offer broader judy lewent lynn elsenhans protection variety different sarscov varients identify third scientific medical expert sme enable quick response new variants potentially strengthen scientific expertise board emerging future science committee ideaya biosciences collaboration gsks partnership close skills gaps ideaya synthetic lethality emerging field precision medicine oncology could help us achieve sustainable flow board changes new treatments field synthetic lethality one gsks report described search judys successor four core research areas oncology making ideaya ideal chair audit risk committee arc resulted partner charles bancrofts appointment board may charlie recently retired successful career bristol would like take opportunity thank judy lewent myers squibb brings wealth financial management member committee since inception experience global biopharma invaluable retire board agm board gsk moves next stage development valuable contributions deliberations commercial beyond handover arrangements judy charlie life sciences perspective look forward joined becomes arc chair publication annual additional scientific medical expert report described judys report pages appointed board continue committees work despite serving nine years judy continues developing specialist scientific support provide demonstrate characteristics independence carrying board role board continue role supporting cso appointed korn ferry assist search lynns overseeing rd pipeline ahead separation successor chair corporate responsibility committee gsk seeks deliver next generation innovative korn ferry also provides gsk recruitment transformational medicines vaccines patients consultancy services signatory voluntary code conduct executive search firms gender diversity dr jesse goodman best practice using broad selection criteria focusing science committee chair potential candidates following knowledge march experience commitment esg depth understanding experience broader esg agenda ideally expectations investors area using science technology address health needs experience science technology progress global health potentially gained working partnership global nongovernmental organisations experience working different stakeholder groups including governments regulators public policy organisations making products affordable available familiar issues public access medicine ethical practices patient advocacy ideally gained life sciences sector gsk annual report board committee reports continued modern employer ability contribute committed diversity boardroom gsk lead discussion diversity ethnicity familiarity committed equal opportunities employees setting monitoring high standards health levels organisation board management seek safety supporting employee health wellbeing encourage diverse inclusive culture throughout personal development company responsible business experience developing effective board needs range balance skills culture focuses organisations positive social experience knowledge ethnicity gender socialeconomic impact engagement employees suppliers backgrounds independence individuals customers communities understanding experience prepared challenge work collaboratively role responsibility organisations minimising mix needs complemented diversity personal environmental impact setting monitoring attributes including character intellect judgement honesty environmental targets safety systems courage described statement asked lynn board cet diversity targets remain post another year stepping committee responsible developing measurable board agm board confirmed despite objectives monitoring progress towards achievement impending nine years service lynn continues demonstrate assist implementation boards diversity policy characteristics independence carrying role including gender ethnic diversity board diversity objectives line measurable targets given critical importance strengthening gsks pipeline set hamptonalexander parker reviews board increased time spends rd strategy achievement respectively progress science committee focusing science targets set consistency deeper level support boards understanding provide diversity metrics october reassurance guidance required therefore diversity objectives progress achieved searching third sme appointed see least board positions exceeded objective science committee made entirely smes korn held women ferry also assisting appointment identified least cet positions met objective following selection criteria candidates held women possession scientific profile leadership across least combined cet exceeded objective geneticsartificial intelligence immunology cellgene direct report positions held therapy women relevant experience academia pharmaceuticalsbiotech least one board director met objective one board director position held ethnic minority leadership ability add value board creation committee particularly intent closing gap new gsk biopharma company gender representation increasing ethnic minority representation board cet developing strong ethical personal qualities providing good fit pipeline direct reports cet ethnic minorities diverse board representation women ethnic minorities made good progress date look forward management positions illustrated part announcing results searches diversity gsks global workforce board composition tenure diversity board seeks balance composition tenure committee met nonexecutive directors present committees refresh time receive consider succession plans management benefit experience longerserving directors executive directors ensure diverse fresh perspectives insights newer appointees pipeline potential successors also regularly reviews succession planning nonexecutive members board draw nonexecutive directors wide range industries backgrounds including pharmaceuticals sir jonathan symonds industry rd vaccines consumer products nominations corporate governance committee chair healthcare medical research academia insurance march financial services wealth experience complex organisations global reach many board members also experience longcycle industries great assistance understanding sector gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued transformation separation committee report jonathan symonds transformation separation committee pleased present first report chair transformation separation committee committee met first time may committee made senior independent director chairs audit risk remuneration corporate responsibility committees workforce engagement director invite nonexecutive directors meetings could save repetition board committee two principal functions exercising oversight future ready transformation programme particularly cost savings separation company infrastructure delivery team moves project design implementation also tracking status key risk indicators value capture technology considering optimal form separation includes consumer healthcare businesss listing location implications separation committee pleased programme making good progress full cet engagement leadership deliverables track take great pride programme continued delivered planned despite covid minor adaptions necessary programme provided opportunity fundamentally review structure cost base ways working biopharma consumer healthcare businesses including consideration increased automation different service levels real estate impacts procurement savings accelerated digitisation revisited following successful embedding new ways working outbreak pandemic committee also receives reports audit assurance compliance teams risks related achieving successful separation committee management clear gsk remain one company separation overriding emphasis driving top line growth improving margin next year look forward sharing progress committees pivotal role overseeing guiding management transformation separation gsk overseeing associated risks separating group two leading companies biopharma consumer healthcare sir jonathan symonds transformation separation committee chair march gsk annual report section statement company directors required law promote success allows build trust fully understand potential organisation benefit shareholders impacts decisions makes stakeholders wider stakeholders including employees suppliers engagement gsks main stakeholder groups including community patients shareholders consumers customers employees levels across organisation statement aligns requirements set summarised pages strategic report section section cza companies act act indicates year directors companys governance architecture processes addressed matters set section f summarised pages corporate governance act performing duties avoid duplication report summary explores board considers incorporates information areas annual report relevant matters making principal decisions contribute board considers statement focuses risks delivery gsks longterm priorities innovation opportunities strategically important gsk performance trust consistent groups size complexity information issues factors stakeholders performing duty promote gsks success board board considers relevant complying section focuses various matters including listening f act found locations outlined considering views shareholders key stakeholders board regard following matters longterm results b workforce c business relationships likely consequences decision interests groups employees importance developing groups business long term relationships suppliers customers others strategic report strategic report business model strategic report business model culture business model chairmans statement modern employer industry trends ceos statement stakeholder engagement stakeholder engagement capital allocation innovation corporate governance report key performance indicators performance board activity principal decisions risk management covid solutions purpose values culture viability statement reliable supply board 's approach engagement working third parties audit risk committee report corporate governance report risk management nominations corporate governance board activity principal decisions committee report corporate governance report purpose values culture board activity principal decisions board 's approach engagement remuneration report board 's approach engagement audit risk committee report remuneration committee chairs audit risk committee report statement corporate responsibility committee report directors ' pay wider setting gskcom gender pay gap report community environment e reputation f fairness shareholders impact groups operations desire maintain reputation high aim act fairly members community environment standards business conduct company strategic report strategic report corporate governance report trust section including culture board 's approach engagement environment trust investor information environment health safety ethics values environmental sustainability risks pages human rights reporting investigating concerns climaterelated financial disclosure antibribery corruption risk pages nonfinancial information statement corporate governance report approach tax corporate responsibility committee report corporate governance report corporate responsibility committee gskcom report responsibility reports data gskcom modern slavery statement gsk annual report strategic report governance remuneration financial statements investor information directors report directors powers determined uk legislation nominations corporate governance committee articles association contain rules reviewed register potential conflict authorisations appointment replacement directors provide register conflicts january committee directors may appointed ordinary resolution reported board conflicts appropriately members resolution board provided authorised process authorisation continued appointed board director retires next operate effectively committee recommended annual general meeting following appointment approval register conflicts board subsequently approved except described note articles also provide directors required financial statements related party transactions seek reelection annually annual general meeting end financial year director person closely accordance code associated material interest contract director cease director significance group company becomes bankrupt articles prohibit director voting resolution ceases director virtue companies act concerning appointment terms termination articles appointment independent advice suffers mental physical ill health board resolves shall cease director company agreed procedure directors take independent legal andor financial advice companys missed directors meetings continuous period expense deem necessary six months without permission board resolves indemnification directors shall cease director qualifying third party indemnity provisions defined prohibited director law companies act force benefit directors resigns offers resign board accepts offer former directors held office approval signature annual report required resign board change control essential contracts directors conflicts interest contracts arrangements directors duty companies act individually fundamental ability business avoid situation could direct operate effectively neither company party material indirect conflict interest possible conflict agreements would take effect altered terminate upon company articles provide general power board change control following takeover bid authorise conflicts agreements director would provide compensation board reviews new potential actual conflict loss office employment resulting takeover recorded company secretary directors counted except provisions companys share plans may quorum authorisation actual cause options awards granted plans vest potential conflicts nominations corporate governance takeover committee reviews register conflicts annual basis details termination provisions executive directors board subsequently approves service contracts given full version companys continuing basis directors responsible remuneration policy available wwwgskcom informing company secretary new actual investors section potential conflicts may arise changes circumstances may affect authorisation previously given even provided authorisation director absolved statutory duty promote success company actual conflict arises postauthorisation board may choose exclude director receipt relevant information participation debate suspend director board last resort require director resign gsk annual report directors ' report continued content directors report following information also incorporated directors report purposes uk companies act location annual report directors report glaxosmithkline plc year ended interest capitalised financial statements december comprises notes directors report publication unaudited financial information group financial review section pages details longterm incentive schemes remuneration report corporate governance report waiver emoluments director applicable employee engagement waiver future emoluments director applicable directors statements responsibilities non preemptive issues equity cash applicable investor information non preemptive issues equity cash applicable unlisted major subsidiary undertaking strategic report sets matters required parent company participation placing applicable disclosed directors report considered listed subsidiary strategic importance provision services controlling applicable strategic report shareholder section pages shareholder waiver dividends financial statements notes risk management objectives policies shareholder waiver future dividends financial statements notes likely future developments company agreements controlling shareholders applicable research development activities business relationships directors report diversity drawn presented accordance provision information consultations employees reliance upon english company law liabilities carbon emissions directors connection report shall subject section statement limitations restrictions provided law approved board directors march signed behalf sir jonathan symonds chairman march gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn remuneration section chairmans annual statement annual report remuneration remuneration policy summary ggsskk aannnnuuaall rreeppoorrtt remuneration report chairmans annual statement behalf remuneration committee committee performance pleased present remuneration report terms overall performance management missed annual report remuneration annual statement agreed internal budget target biopharma primarily subject advisory vote agm may due significantly lower expected vaccines sales volumes set key aspects committees work result covid pandemic disruption lockdowns turn implementation remuneration policy across adult vaccines including shingrix hepatitis dtpa reward managements performance containing vaccines synflorix bexsero however despite still continued grow shingrix sales bn overall extraordinary challenging year indeed group sales overall grew cer particular strong board pleased see continued progress growth drivers new specialty products respiratory companys strategic goals testament increased hiv oncology drove growth sales bn focus placed improving commercial execution cer group innovative products accounts despite business disruption covid half pharmaceuticals sales addition robust pandemic adult vaccinations especially shingrix effective cost control supported delivery financial guidance year delivered however group pbit target adjusted eps p cer internal pbit target missed resulted reduced lower end companys earnings guidance set bonus outcome multiple ways company beginning year covid pandemic continues work response covid set began committee pleased note managements includes contribution adjuvant determination drive deliver agreed financial guidance progress potential vaccines therapeutic assets vir despite environment confirm committee biotechnology inhouse asset otilimab make adjustments targets measures executive review ipt outcomes directors result impacts covid note total remuneration preparations create two exciting companies post separation overall pay emma walmsley ceo iain mackay continued schedule remain track despite global cfo pay dr hal barron cso disruption covid increased reflecting vesting long term incentive award granted year joined would like trust set outcomes context overall finally importance business operating responsibly performance highlighted new ambitious industry leading environmental targets climate nature innovation terms innovation cso rd introduced work also undertaken introduce organisation made significant progress inclusion diversity targets published recently employee strengthening rd biopharma pipeline rd exceeded survey saw highest response rate date targets major approvals overall employee engagement score rose assets late stage development many believe rise since survey highest score since transformational patients business inception company also topped access development deals undertaken strengthen medicines index seventh time row capabilities acquisition new antibody mrna genetic platforms technologies gsk annual report strategic report governance remuneration financial statements investor information remuneration outcomes looking ahead awards relation made accordance pension remuneration policy key decisions made committee previously reported intention align committee follows current uk executive directors pension contributions wider uk workforce january response bonus outcomes ceo cfo cso feedback shareholders following determined reference performance agreed review companys pension arrangements us financial measure group pbit committees committee also reduce pension contributions assessment individual performance cso align wider us employee base remarkably challenging year formulaic methodology january used calculate financial performance determined payment would made achieving financial remuneration policy implementation target committee considered progress committee agreed executive directors receive executive directors personal objectives year across salary increase aligned provided wider aspects companys innovation performance trust workforce respective geographies priorities believes resulting overall bonus outcomes board committee continually look ensure appropriately reflect underlying performance remuneration provisions support business strategy progress made see priorities seek engage shareholders potential vesting lti awards two thirds changes policy believe company performance share plan psp awards vested shareholders best interests make changes context based last three years performance board engaging shareholders potential equally weighted preagreed measures rd new provide oneoff additional performance incentive award product performance measure vested full reflecting cso aims support continuity management continued work strengthening rd successful delivery biopharma rd pipeline thereby proactively commercialisation newly launched products equally addressing one principal risks creation focus strong cash management generation sustainable shareholder value next years reflected full delivery adjusted free cash flow discussions ongoing resulting proposal measure disappointingly companys relative tsr would course set full ahead specific vote performance past three years resulted agm part award lapsing full overall vesting statement annual report see sets level therefore see position implementation provision determining bonus lti outcomes code continue follow approach committee carefully considered directors performance agm deem necessary exercise discretion address would like thank shareholders input anomaly performance outcomes review included engagement ahead last years agm welcome assessment performance across relevant measures feedback report ahead agm may wider context including companys trust priority specifically look forward receiving support gsk access covid government support annual report remuneration job retention schemes dividend policy maintained year company delivered financial guidance urs rohner remuneration committee chair march gsk annual report annual report remuneration glance total remuneration following shows composition total remuneration paid executive directors office december respect emma walmsley iain mackay dr hal barron usm usm usm usm usm usm usm appointed effect january fixed pay salary benefits pension performance pay annual bonus ltis earned respect three year performance period pay performance annual bonus financial performance lti outcome performance period ended december overall vesting maximum target relative rd new target tsr product threshold target adjusted group pbit performance achieved vested adjusted maximum performance target lapsed free cash flow executive directors shareholdings audited align interests executive directors share ownership vs sor multiples base salary shareholders required build maintain significant holdings shares gsk time executive emma walmsley directors required continue satisfy share ownership requirements sor holding iain mackay sor first months leaving gsk less sor months leaving gsk dr hal barron executive directors cet sor salary x x x ceo appointed effect january executive directors sor december shareholding corporate executive team members gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued total remuneration audited fixed pay pay performance annual bonus vested lti awards maximum opportunity vesting measures salary measures rd new product adjusted group pbit afcf total benefits individual objectives relative tsr remuneration three year deferral plan could b pension gsk shares psp awards read pages read pages read read total remuneration audited emma walmsley iain mackay dr hal barron fixed pay salary benefits pension total fixed pay pay performance annual bonus vesting lti awards dabp matching awards psp total pay performance total remuneration notes details mandatory bonus deferrals deferred annual bonus plan dabp set matching awards ceased longer granted dabp emma walmsleys psp vested july closing price time annual report psp figure used based upon average share price three month period december therefore published figure last year committee may specific circumstances line stated principles apply clawbackmalus determines appropriate following due consideration committee recovery sums paid clawback reduction outstanding awards vesting levels malus applied respect executive directors appointed effect january gsk annual report annual report remuneration continued total remuneration audited continued following sections provide details element total remuneration including committee implemented approved remuneration policy year fixed pay audited salary table provide analysis total benefits grossed table sets base salaries executive tax received executive directors directors last two years compared increases uk us workforce benefits benefits base salary emma walmsley change benefits available employees emma walmsley business related services iain mackay business travel dr hal barron benefits uk us employees total benefits details salary levels provided iain mackay benefits benefits available employees uk remuneration reporting regulations require company business related services add executive directors total benefits calculation business travel items deemed tax authorities taxable benefits benefit total benefits comprise dr hal barron employee benefits line policy benefits available employees employees may vary location role business related services business travel business related services provided employees assist accommodation whilst business travel enable carry role tax authority benefits deemed taxable benefit individual business expenses company meets total benefits tax arises therefore items notes shown grossed tax split three areas business related services tax regulations deem taxable benefit uk andor us business travel includes travel costs executive iain mackays benefits available employees increased year director appropriate spousepartner year mainly due full years medical benefits compared partial year benefits also include professional fees vehicle allowance associated accompanying executive director gsk reviewed methodology allocating cost certain gsk business deemed taxable benefits business travel using previous methodology dr barrons business travel executive director would totalled approximately net dr barrons place main business moved uk us accommodation whilst business travel taken together effect covid international travel resulted reduction benefit benefits gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued fixed pay audited continued pensions please see details changes pensions policy implementation addition committee determined current future uk us executive directors pension arrangements aligned wider uk us workforce appropriate january executive director member since pension arrangements emma walmsley pension contributions base salary matching contributions follows iain mackay january march based first salary april december based first salary cash supplement base salary lieu pension salary excess figures dr hal barron cso member k plan open us employees executive supplemental savings plan essp savings scheme open us executives accrue benefits k plan limits receives combined contribution rate k essp plans core contributions plus match total base salary bonus less bonus deferred dabp also member us cash balance supplemental cash balance pension plans gsk makes annual contributions base salary line us senior executives members gsks cet member defined contribution plan emma walmsley iain mackay eligible receive matching award first salaries january march first salaries april december accordance terms plan emma walmsley iain mackay receive cash payments lieu pension base salary excess january march cash payments lieu pension base salary excess april december line gsks defined contribution pension plan rates following table shows breakdown pension values set pension remuneration figures calculated accordance methodology set large mediumsized companies group accounts reports amendment regulations remuneration regulations emma walmsley iain mackay dr hal barron pension remuneration values uk defined contribution us defined benefit employer cash contributions total pension remuneration value details regarding pension values dr hal barron set table pensions figures disclosed dr hal barron member us style defined benefit plans accordance paragraph eii schedule remuneration regulations table shows accrued benefit ie annual pension accrued date accordance regulations pension remuneration calculated increase accrued benefit adjusted inflation multiplied reflect fact benefit received number years normal retirement age cash balance pension plan age additional benefit retiring early accrued pension pension remuneration december december value dr hal barron pension values us funded us unfunded total gsk annual report annual report remuneration continued pay performance audited annual bonus individual annual bonus adjusted group pbit objectives performance targets performance measures weightings follows weighting adjusted group pbit performance positioning performance measure executive directors target outcome target adjusted group pbit individual objectives threshold maximum performance targets set target respectively adjusted group pbit target outcome purposes annual bonus calculation differ adjusted group pbit disclosed elsewhere annual report primarily target outcome numbers calculated applying gsks budget exchange rates actual exchange rates following table shows actual bonuses earned compared bonus opportunity bonus opportunity bonus outcome financial individual total total target maximum performance objectives bonus bonus bonus salary salary base salary salary salary salary emma walmsley iain mackay dr hal barron table provides detail delivery adjusted group pbit financial performance strong financial leadership group challenging year delivered full year reported group sales bn aer cer vaccines sales impacted lower us adult vaccination volumes covid disruption partially offset growth drivers respiratory hiv adjusted group pbit target driven lower sales delivery supported effective cost control adjusted eps p aer cer line guidance delivery supported effective cost control gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued pay performance audited continued following table summarises performance scorecard individual objectives agreed committee executive director addition contribution financial performance individual objectives emma walmsley continued focus progress longterm ipt priorities supply chain reliability severe disruption continued robust agile commercial execution exceptional network simplification circumstances pharmaceuticals vaccines sales bn sustained progress leadership esg global health consumer healthcare bn strong growth new new environmental sustainability commitments climate specialty pharmaceuticals bn aer cer nature launched expanded plans accelerate progress shingrix bn aer cer despite impact inclusion diversity continued top quartile recognition covid disruption firstmarket launches consumer external esg ratings including st place access medicines healthcare index nd place dow jones sustainability index significant progress strengthening advancing new leadership accountabilities training new role sustainable pipeline transformational pharmaceuticals top enterprise key roles women senior vaccines major approvals pivotal study starts vice president vice president level aspiration set latestage assets development race ethnicity representation us uk covid solutions including global partnerships first progress towards purpose performance culture secondgeneration vaccines therapeutics providing accelerated covid reflected highest expertise donations support local response employee engagement rates recorded date continued focus transformation separation plans track deliver two values expectations disruption remote new competitive companies consumer healthcare jv working launch new flexible working approach pfizer commercial integration delivered remaining key leadership role preparation separation two new programme track competitive companies iain mackay strong financial leadership group challenging year adjusted eps p aer cer line delivered full year reported group sales bn aer guidance delivery supported effective cost control cer vaccines sales impacted lower us adult key leadership role preparation separation two vaccination volumes covid disruption partially new competitive companies offset growth drivers respiratory hiv strong oversight across finance tech transformation extreme covid disruption dr hal barron rd strategy strengthened advancement pipeline significant progress towards one biopharma one potential new medicines vaccine candidates development organisation implemented strong major product approvals pivotal study starts foundation single approach governance capital significant business development deals executed augment allocation pipeline including vir biotechnology curevac surface oncology employee confidence pipeline strong broad institute adrestia engagement across rd organisation research targets genetically validated continuing build gsks reputation innovation targets identified collaboration st jointly external pipeline perception significant identified target clinical development engagement major platforms media investors advanced technology capability build continues new london ai hub opened uk functional genomics network nvidia collaboration key external hires ai ml new talent key rd roles external hires malus clawback policy line disclosure guidelines neither committee details policy malus clawback please refer recoupment committee exercised malus clawback companys remuneration policy report annual report available gskcom policies committee reviews discloses whether details existing policies recruitment remuneration recoupment committee exercised malus clawback loss office termination payments please refer disclosure made matter subject remuneration policy report pages public reports misconduct fully annual report available gskcom resolved legally permissible disclose made without unduly prejudicing company therefore shareholders gsk annual report annual report remuneration continued pay performance audited continued value earned longterm incentives ltis following tables set performance achieved targets set companys lti plans also includes update performance outstanding awards line committees agreed principles measure applicable lti awards actual performance targets reviewed adjustments made appropriate ensure vesting outcome reflects genuine underlying business performance results delivered line trust business priority psp awards performance period ended december committee reviewed performance psp awards granted executive directors targets set adjusted free cash flow afcf target revised line disclosure annual report restated take account revised phasing future ready programme restructuring cash payments separation costs based detailed programme separation planning undertaken result target increased bn bn psp valued based closing share price february closing ads price vested amounts ceo cso none attributable share price appreciation performance period committee exercise discretion relation vesting awards share price changes performance achieved three years december vesting levels set table outcome vesting level performance measures relative weighting performance targets outcome maximum award rd new product rd new product sales performance measures aggregate threeyear sales new bn performance products launched threeyear performance period preceding two rd years ie target vesting maximum bn bn bn threshold bn adjusted free line companys agreed principles afcf figures included adjustments bn cash flow number material distorting items including legal settlements exchange rate performance movements special pension contributions rd original revised target target vesting maximum bn bn bn bn bn bn threshold bn bn revised target adjusted since annual report noted relative tsr ranked th tsr ranking within comparator group vesting performance maximum st nd rd rd th th threshold median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holdings sanofi vesting schedule based delivering vesting median performance comparator group ten companies median falls two companies total vesting respect awards gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued pay performance audited continued update performance ongoing lti awards committee also reviewed performance psp awards granted executive directors following charts provide estimate vesting levels taking account performance december actual vesting levels determined based performance full threeyear performance periods indications therefore regarded predictions final vesting levels afcf threshold associated vesting scales psp awards adjusted net overall impact increase bn bn award decrease bn bn award adjustments take account following items revised phasing future ready programme restructuring cash payments separation costs based detailed programme separation planning undertaken revised timing future ready programme divestments cancellation one future ready programme divestments changes targets set rd new product innovation sales previously named rd new product relative tsr performance measures awards psp award psp award ranked rd ranked rd bn threshold bn threshold maximum commercially commercially commercially median bn sensitive median bn sensitive sensitive threshold relative adjusted free rd new relative adjusted free innovation pivotal trial major regulatory tsr cash flow product tsr cash flow sales starts approval rd rd rd milestones pipeline progress estimated vesting level estimated lapsing level threshold performance award vest respect performance measure individual lti award levels appear annual report set lti awards historical vesting lti plans vesting year adjusted free rd new business lapsed total vested grant relative tsr cash flow product diversification dabp awards subject tsr performance awards subject performance measures psp awards lti awards dabp awards respect deferral bonus psp awards shown table dabp awards psp awards total bonus number face value award level number face value deferred shares award base salary shares award emma walmsley shares shares iain mackay shares shares dr hal barron ads ads face values dabp awards calculated based share price ads price closing prices february day grant nilcost options uk executive directors restricted shares us executive director performance conditions attached dabp awards reflect mandatory deferrals respect annual bonus earned face values psp awards calculated based share price ads price closing prices february day grant conditional shares based performance measures outlined performance period psp awards january december gsk annual report annual report remuneration continued directors pay wider setting internal context setting executive pay important committee good understanding wider workforce pay end annual basis meet human resources business leaders hrbls global support functions pharmaceuticals viiv healthcare vaccines consumer healthcare understand perspectives pay gsks remuneration package wider workforce met hrbls year discussed current enterprisewide themes employees wider group namely attract recruit retain key talent support ambitious business agenda working towards separation biopharma consumer healthcare businesses inclusion diversity pay reviews including delivery fair pay setting appropriate salary budgets pensions changes undertaken us proposed uk consultation also discussed different pay levelscultures different markets moving key talent markets handled finally dr vivienne cox workforce engagement director valued member committee continues bring employee perspectives committees discussions urs rohner remuneration committee chair remuneration structure employees element wider workforce pay comparison executive director cet pay salary market competitiveness salaries across company executive directors cet ordinarily assessed local market level competitiveness increases base salaries line average roles measured external market wider employee population unless change internal peers kept regular review scope individuals role responsibilities experience pensions company seeks provide appropriate pensions executive directors cet eligible benefits package aligned competitive receive benefits broadly line policy benefits market practices countries employees may vary location company operates employees based pension arrangements structured accordance executive director cet member expected retire current future uk us executive directors pension arrangements aligned wider uk us workforce january annual exception sales force participate executive directors cet participate plan bonus separate arrangements wider workforce participates based assessment combination stretching plan based performance four business financial business personal objectives financial measures three measures consumer executive directors required defer healthcare structured reflect priorities cet bonus earned shares specific business area adss appropriate three years plan designed reward employees collective clawback andor malus provisions apply contribution business achievement separate mechanisms place recognise outstanding individual performance address underperformance lti plans employees senior vice president svp vice executive directors cet granted annual president vp level participate psp psp awards performance targets executive directors cet periods performance targets periods executive directors required hold vested clawback andor malus provisions apply awards additional twoyear period svp vp employees together directors clawback andor malus provisions apply managers cet receive annual share value executive directors cet receive plan awards restricted shares share value plan awards following appointment gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors pay wider setting continued ceo pay ratios light also provided supplemental ratios lower upper lti compensation excluded believe quartile median quartile provides additional view ltis formed substantial financial year methodology p p p percentage ceos total remuneration highly variable dependent business performance ceo option total remuneration excluding lti compensation pay ratios calculated using actual earnings financial year methodology p p p ceo uk employees ceo total single figure remuneration option restated detailed report total remuneration uk fulltime equivalent employees total remuneration less vesting longterm incentive awards company december calculated line percentage change remuneration ceo single figure methodology except employer pension contributions employees defined benefit pension due emma walmsley uk employees cost complexity calculations instead change change future service rate agreed recent actuarial funding salary valuation used employees otherwise benefits reflects actual earnings received excluding annual bonus business expenses used produce percentile calculation option remuneration regulations wider uk employee population salary increase business expenses excluded reimbursed includes annual salary review well additional employees sufficiently substantial value changes year eg promotion uk employee benefits significantly impact ratios unchanged previous year changes benefit policies levels reflect gsk continues choose option changes level benefits individual may received robust statistically accurate way company result change role eg promotion uk calculate three ratios options available employee population considered relevant remuneration regulations decrease pay ratio comparison closely reflects economic environment due lower pay performance elements encountered ceo bonus psp discontinuation dabp matching awards received compared historic ceo remuneration set table base salary total pay emma walmsley benefits percentiles total remuneration annual bonus award maximum p p p vesting lti awards maximum salary total sir andrew witty pay benefits total remuneration annual bonus award maximum committee believes median pay ratio consistent vesting lti awards maximum companys pay reward progression policies base salaries employees including executive emma walmsleys total remuneration includes pay period january march became ceo directors set reference range factors including sir andrew witty received prorata payment lieu variable bonus market practice experience performance role opportunity accordance remuneration policy supplementaladditional ratios psp dabp awards sir andrew witty granted vest april accordance terms executive financial recoupment policy gsks ceo pay ratio likely vary potentially significantly time since driven largely ceo variable pay outcomes line reward principles ceo larger portion pay based performance individuals p p p means depending gsks performance ratio could increase decrease significantly committee believes senior executives significant proportion pay directly linked performance gsk annual report annual report remuneration continued directors pay wider setting continued percentage change remuneration directors allemployee share plans uk executive directors may participate hmrc approved percentage change allemployee share plans wider uk workforce ie salaryfee benefits bonus share save share reward plans uk employees participants share save plan may save executive directors month three years end period emma walmsley option buy gsk shares discount share price iain mackay start savings contract participants share dr hal barron reward plan contribute month purchase gsk nonexecutive directors shares company matches sir jonathan symonds details see charles bancroft vindi banga dilution limits dr vivienne cox awards made plans incorporate dilution lynn elsenhans limits consistent guidelines published investment dr laurie glimcher association limits rolling tenyear period dr jesse goodman plans rolling tenyear period executive judy lewent share plans granted senior executives estimated dilution existing awards made last ten years urs rohner december follows percentage changes calculated based total remuneration table executive directors total fees table nonexecutive directors gsk employee share plans iain mackay joined board january whereas received full base salary year fees nonexecutive directors include fees received cash form shares ads terms nonexecutive directors share allocation plan reduction fees usbased nonexecutive directors due reduction intercontinental travel fees year relating virtual attendance board committee meetings due covid benefits nonexecutive directors decreased significantly year due reduction travel subsistence costs incurred relation virtual attendance executive share plans board committee meetings due covid sir jonathan symonds appointed board september charles bancroft appointed board may actual limit relative importance spend pay table shows total employee pay groups dividends paid shareholders change total employee pay dividends paid year figures table reflect payments made year impact movements exchange rates set pages however dividends declared respect million million increase total employee pay based employees average number people employed share repurchases made company gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors pay wider setting continued external context comparator groups pay relative tsr committee used two pay comparator groups considering executive pay global pharmaceutical comparator group also used measure relative tsr performance primary groups used executive director follows european crossindustry comparator group global pharmaceutical comparator group emma walmsley roche holding ag linde deutsche telekom dr hal barron france us iain mackay novartis sanofi kering sanofi abbvie lvmh astrazeneca heineken switzerland amgen anheuserbusch inbev diageo basf novartis bristolmyers squibb unilever siemens vinci roche holdings eli lilly sap christian dior adidas johnson johnson uk loreal inditex bayer merck co astrazeneca novo nordisk bat safran pfizer airbus volkswagen reckitt benckiser abbvie amgen included remuneration benchmarking included relative tsr comparator group ceo total remuneration positioning performance graph reviewing ceos remuneration committee following graph sets performance company also referenced pay global pharmaceutical group relative ftse index pharmaceutical performance comparator group tenyear period december indices selected comparison purposes reflect primary index gsk constituent industry operates european crossindustry group global pharmaceutical group lower quartile median upper emma walmsleys median quartile current position remuneration includes salary expected value incentives based committees agreed benchmarking methodology gsk total return gsk pharma peers ftse total return index total return index index comprises astrazeneca bristolmyers squibb eli lilly johnson johnson merck co novartis pfizer roche holdings sanofi gsk annual report annual report remuneration continued implementation remuneration policy fixed pay pay performance salary annual bonus committee considered average increases changes operation annual bonus plan awarded employees level executive directors full details policy relation annual bonus plan uk us due consideration agreed please refer details remuneration appropriate award increases line wider policy report annual report workforce ceo cfo cso ensure bonus opportunity weighting competitiveness remuneration could maintained salary performance measures adjusted scorecard base salary change group individual wider workforce target maximum pbit objectives emma walmsley emma walmsley iain mackay iain mackay dr hal barron dr hal barron based average increase budget employees level cet setting assessing performance levels executive uk us directors committee considers performance companys trust business priority see reflects benefits groups approach esg factors significant changes provision benefits proposed inevitably targets linked directly financial strategic full details policy relation benefits plan commercially sensitive committee please refer details remuneration policy consider appropriate disclose annual bonus targets report pages annual report year may result competitive harm however details available gskcom investors section performance targets usual disclosed pension retrospective basis annual report table provides overview pension deferred annual bonus plan dabp awards arrangements ongoing executive director table provides details mandatory deferral committee previously committed reduce existing dabp annual bonus payments uk executive directors pensions align wider uk associated awards granted shares awarded workforce january committee also performance conditions must held three years determined pension contributions cso also regardless continued employment aligned wider us workforce january total bonus deferred dabp awards new ukbased usbased executive directors pension shares shares ads aligned appropriate wider workforce appointment emma walmsley iain mackay pension contribution dr hal barron emma walmsley base salary matching contributions iain mackay first salary accordance terms plan open employees performance share plan psp awards base salary lieu pension salary excess table provides details awards granted psp dr hal barron base salary less contribution k psp award essp equivalent total base salary bonus net bonus deferred dabp addition salary shares adss line wider us workforce january combined contribution rate k emma walmsley essp plans core contribution plus iain mackay match total base salary bonus net dr hal barron bonus deferred dabp awards granted february price per share per ads board engaging shareholders potential provide oneoff additional performance incentive award cso aims support continuity management delivery biopharma rd pipeline thereby proactively addressing one principal risks creation sustainable shareholder value next years discussions ongoing resulting proposal would course set full ahead specific vote agm gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued implementation remuneration policy continued lti performance measures performance measures weighting lti awards remain relative tsr continue measured gsks unchanged used awards global pharmaceutical comparator group see weightings four lti measures targets adjusted free cash flow measure grant lti measure measure weighting innovation innovation sales target bn vesting pipeline progress maximum performance relative tsr adjusted free cash flow threshold innovation trust business priority innovation sales measure recognises importance setting targets reviewing performance launching new products successfully driving lti measures committee considers reflects performance key commercial success companys trust business priority trust priority reflects pipeline progress measure increases companys approach esg factors see emphasis innovation seeks reward acceleration shareholdings versus share ownership requirement strengthening pipeline based two equally sor weighted elements key assets indications measured value holdings salary threeyear performance period sor salary march december points allocated successful assets submeasure emma walmsley based upon forecast commercial value peak year sales iain mackay end performance period dr hal barron submeasures award vest follows shares subject performance conditions excluded pivotal trial starts executive directors sor calculation end focuses mainly phase iii registrational trial starts may performance period vested shares included also include phase ii starts eg oncology part directors sor extent performance performance level points payout conditions met value holdings threshold nil calculated posttax basis threshold dr hal barron ads contributing sor include investments gsk k plan essp year reallocated funds plans gsk maximum stock fund major regulatory approvals emma walmsley dr barron currently exceed sor iain mackay joined board early currently performance level points payout threshold nil working towards satisfying sor threshold company processes place ensure executive directors sor continue satisfied leaving gsk including monitoring nominee accounts maximum executive director also agrees terms sors within service contract targets innovation sales pipeline progress measures nature commercially sensitive time grant end performance period provide full disclosure achieved gsk annual report annual report remuneration continued remuneration governance committee role membership committee focus details available incorporated remuneration policy reference report chairman ceo heads hr committee sets broad structure remuneration policy reward group financial controller company determines remuneration executive directors secretary assisted committee year chairman corporate officers adviser committee items discussed pricewaterhousecoopers llp pwc proposed remuneration policy independent adviser committee since appointed remuneration impact major group restructuring full commercial tender exercise concluded engagement shareholders consideration feedback company pwc member remuneration salary review consultants group voluntarily operates committee periodically reviews considers remuneration code conduct relation executive remuneration environment executive directors cet approving annual consulting uk code conduct found adjustments necessary regard remuneration wwwremunerationconsultantsgroupcom wider workforce year pwc connection items discussed committee members board directors however review remuneration environment including wider employee provide consulting assurance services trends executive director cet benchmarking competitiveness company line protocols agreed set gsk comparator groups committee chair pwc provided advice cet company secretary salary review recommendations committee satisfied advice objective independent pwc provided independent commentary executive director salary review recommendations matters consideration committee updates market practice legislative requirements pwcs fees annual bonus advice year charged fixed committee responsible setting specific performance time materials basis measures annual bonus assessments performance willis towers watson provided additional market data items discussed committee ceo executive directors cet bonus recommendations ceo bonus objectives shareholder votes remuneration matters lti plans votes total votes total votes total votes withheld committee responsible approving lti plan rule changes cast billion million grants assessments performance vesting lti awards remuneration report executive directors cet including interim awards agm items discussed remuneration policy lti performance outcomes vesting lti awards cet agm service contracts letters appointment confirmation lti grants cet table sets dates executive directors implementation embedding new pipeline progress measure service contracts available review companys governance areas focus registered office gskcom executive directors committee adheres robust remuneration governance service contract contains month notice period framework ensuring alignment internal actions external reportingcompliance requirements date contract effective date expiry date emma walmsley items discussed review terms reference iain mackay na committee evaluation annual review dr hal barron remuneration report proposal remuneration nonexecutive directors ned letters appointment policy available view companys registered office confirmation group budget remuneration purposes ned expected serve board end remuneration considerations committee programme agm following third anniversary appointment agm remuneration report feedback external subject election subsequent annual reelection subject remuneration environment performance target disclosure mutual agreement expected serve incentive plans remuneration report disclosures including ceo pay ratio three years normally nine years appointment annual governance meeting key committee messages line provisions code subject annual committee chair consultation employee representatives reelection setting pay wider workforce pay practices gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued nonexecutive directors fees chairman nonexecutive directors nonexecutive directors fees company aims provide chairman non nonexecutive directors fees applied executive directors fees competitive set table paid companies equivalent size complexity per annum subject limits contained articles association standard annual fee chairmans fees supplemental fees chair audit risk committee chairman paid fee per annum senior independent director takes gsk shares chairmans fees scientific medical experts reviewed appointment new chair chairs remuneration corporate concluded remained appropriate responsibility science committees workforce engagement director nonexecutive director undertaking intercontinental per meeting travel meetings nonexecutive directors continue required invest least total net fees gsk shares ads implementation nonexecutive directors policy following review engagement shareholders nonexecutive directors standard fees fees payable senior independent director committee chairs including remuneration corporate responsibility science committees last increased effect january part shareholder approval remuneration policy supplemental fee introduced effect january payable workforce engagement director payment nonexecutive director amount paid committee chair undertaking additional duties exceptional unforeseen circumstances requiring significant additional time commitment authorised changes made fees payable chair audit risk committee scientific medical experts expect make increases fees payable nonexecutive directors new policy period increases described reflect time commitments roles total fees audited audited table sets value fees benefits received nonexecutive directors form cash shares ads details nonexecutive directors share allocation plan set nonexecutive directors fees paid currency sterling converted using average exchange rate reviewed time time average exchange rates updated benefits comprise grossed cash value travel subsistence costs incurred normal course business relation attendance board committee meetings overseasbased directors includes travel meetings uk nonexecutive directors fixed fees fixed fees emoluments audited cash sharesads benefits total pay cash sharesads benefits total pay sir jonathan symonds vindi banga charles bancroft dr vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent urs rohner gsk annual report annual report remuneration continued directors interests shares audited executive directors interests shares interests executive directors company office persons closely associated pca shown table december unvested share plan interests beneficial subject total directors interests interests subject performance performance march december sharesads sharesads options sharesads shares emma walmsley iain mackay ads dr hal barron total directors interests include beneficial interests unvested share plan interests subject performance balance march includes sharesads awarded performance share plan psp deferred annual bonus plan dabp vested february march respectively less sold satisfy tax liabilities vested amounts executive directors shareholdings versus sor outlined b eneficial interests include sharesads held executive directors pcas emma walmsley includes shares purchased glaxosmithkline share reward plan iain mackay currently participate share reward plan us employee dr hal barron eligible participate share reward plan open uk employees dr barrons beneficial interests include ads notional ads held way investments gsk k plan executive supplemental savings plan essp year dr barron reallocated funds plans gsk stock fund details dr barrons membership plans found u nvested sharesads subject performance represent psp shares vested subject additional twoyear holding period emma walmsley unvested ads subject performance dr barron represent bonus deferrals described note unvested options subject performance represent bonus deferrals dabp awarded nilcost options described note figure excludes share save options held emma walmsley unvested sharesads subject performance represent unvested psp awards abp table shows bonus deferrals subsequent reinvestment dividends dabp amounts represent gross sharesads balances prior sale sharesads satisfy tax liabilities vesting deferred annual bonus plan bonus deferrals march december january shares emma walmsley iain mackay ads dr hal barron uk employees bonus deferrals dabp granted nilcost options emma walmsley iain mackay following table sets details nilcost options exercised outstanding dabp matching awards following exercise number shares date market price gain exercise dabp date grant option exercise grant price exercise emma walmsley deferral award matching award respect nilcost options awarded dabp bonus deferred executive director recorded remuneration annual bonus total remuneration table respect number shares option includes initial award amount together reinvested dividends accrued date exercise matching element dabp awarded remuneration executive director recorded total remuneration table respect year performance period ended remuneration committee granted last matching award gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors interests shares audited continued nonexecutive directors interests shares interests nonexecutive directors company office persons closely associated pca shown table share allocation plan nonexecutive directors total directors interests number sharesads beneficial dividends elected december interests reinvested december allocated march december year end year january shares sir jonathan symonds vindi banga dr vivienne cox urs rohner ads charles bancroft lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent otal directors interests include beneficial interests sharesads received part fees nonexecutive directors share allocation plan dividends received sharesads plan year january converted sharesads february beneficial interests includes sharesads held nonexecutive directors pcas sharesads allocated year nonexecutive directors share allocation plan includes dividends reinvested year directors senior management information provided compensation interests directors senior management group group purpose group defined executive nonexecutive directors members cet company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate increase accrued pension benefits net inflation aggregate payments defined contribution schemes members group awarded shares ads companys various lti plans set table align interests senior management shareholders executive directors cet members required build maintain significant holdings shares gsk time cet members required hold shares equivalent multiple two times base salary must continue satisfy share ownership requirements minimum months leaving gsk awards dividend reinvestment awards awarded shares ads shares ads deferred annual bonus plan matching awards performance share plan deferred investment awards share value plan notional shares ads executive directors eligible receive deferred investment awards participate share value plan gsk annual report annual report remuneration continued directors senior management continued march group pcas following interests shares ads company interests awarded various lti plans described note financial statements employee share schemes interests march shares ads owned unexercised options deferred annual bonus plan performance share plan deferred investment awards share value plan notional shares executive directors eligible receive deferred investment awards participate share value plan fees respect executive directors external appointments ceo emma walmsley independent nonexecutive director microsoft corporation received delivered cash stock options microsoft corporations deferred compensation plan nonemployee directors cso dr hal barron nonexecutive director grail inc private company earned fees payments past directors audited sir andrew witty dr moncef slaoui left board march mutual agreement dr patrick vallance simon dingemans left board march may voluntary leavers vesting dabp awards governed remuneration policy prevailing time past director left board table reflects value deferred bonuses accrued dividends point release sir andrew witty date vesting number shares vested dabp february dr moncef slaoui date vesting number ads vested dabp february dr patrick vallance date vesting number shares vested dabp february dabp march simon dingemans date vesting number shares vested dabp may dabp march mr simon dingemans dabp award vested may accordance delayed vesting terms recoupment policy benefits grossed costs predominantly simon dingemans postemployment home security payments loss office audited loss office payments made gsk annual report strategic report governance remuneration financial statements investor information remuneration policy summary companys remuneration policy approved may gsks annual general meeting operated intended since approval full policy available gskcom investors section executive director remuneration policy salary provide core reward role set level appropriate secure retain high calibre individuals needed deliver groups strategic priorities operation opportunity individuals role experience performance independently formal maximum limit ordinarily salary increases sourced data relevant comparator groups considered broadly line average increases wider determining salary levels gsk workforce salary increases typically take effect first quarter however increases may higher reflect change year scope individuals role responsibilities experience salary adjustments may also reflect wider market conditions salaries normally paid currency executive geography individual operates directors home country details current salary levels set annual report remuneration performance measures overall performance individual key consideration determining salary increases benefits levels set recruit retain high calibre individuals execute business strategy operation executive director based outside uk executive directors eligible receive benefits line required travel uk fulfil responsibilities policy employees may vary location role attend board meetings may subject tax include limited car allowances healthcare business travel expenses uk life assurancedeath service provided part provision accommodation uk although reality individuals pension arrangements personal financial advice represents business expense tax treatment requires contractual postretirement benefits line policy travel accommodation expenses included employees executive directors may eligible benefits business context tax liabilities receive overseas relocation allowances international covered company grossedup basis transferrelated benefits required executive directors benefit provision tailored reflect market practice uk also eligible participate allemployee share geography executive director based schemes eg share save share reward plan different policies may apply current future executive subject terms directors based different country employees opportunity order recognise high business travel requirements formal maximum limit benefits costs fluctuate role executive directors also entitled car travel depending changes provider cost individual exceptionally may accompanied spousepartner circumstances business trips benefits include expenses incurred details current benefits costs set annual ordinary course business deemed taxable report remuneration benefits individual performance measure none gsk annual report remuneration policy summary continued executive director remuneration policy continued pension pension arrangements provide competitive level retirement income pension arrangements provide competitive level retirement new executive directors uk receive date income appointment base salary contribution defined contribution plan operation matched contributions subject pension arrangements structured accordance relevant cap line implementation principles plans operated country individual likely members plan retire individual chooses become member base salary cash payment lieu pension pension plan cash lieu relevant pension contribution portion relevant cap contribution paid instead executive directors uk entitled either join defined contribution pension plan base salary cash payment lieu pension receive cash payment lieu pension contribution contribution individual member gsk legacy defined us benefit plan defined contribution plan alternative cash balance supplemental cash balance pension pension plan arrangement subsequently appointed plans providing annual contributions base salary board may remain member plan split two plans appropriate opportunity gsk k plan executive supplemental savings plan policy current executive directors essp core contributions salary bonus uk matched contributions salary bonus base salary contribution defined contribution plan new executive directors us receive matched contributions subject cash balance supplemental cash balance pension relevant cap line implementation principles plans providing annual contributions base salary members plan bonus split two plans appropriate base salary cash payment lieu pension gsk k plan essp core contributions contribution portion relevant cap salary bonus matched contributions salary bonus base salary cash payment lieu pension global contribution eligible appropriate equivalent arrangement excess january current uk executive directors usuk arrangements still role pension arrangements aligned performance measures new executive directors arrangements follows none n event change plans operated us similar value would provided successor arrangements introduced within market l ess bonus deferred dabp annual bonus incentivise recognise execution business strategy annual basis rewards achievement stretching annual financial strategic business targets delivery personal objectives operation committee may apply judgement making appropriate financial operational business targets set start adjustments bonus outcomes ensure reflect underlying year committee bonus levels determined business performance clawback andor malus provisions apply committee based performance targets described annual report individual objectives set start year opportunity committee performance objectives maximum bonus opportunity executive directors assessed committee salary threshold performance bonus payout financial measure nil target performance executive directors required defer bonus bonus payout maximum opportunity earned shares ads appropriate three years deferred bonus shares eligible dividend equivalents performance measures date vesting based combination financial targets individual strategic performance objectives majority bonus assessed financial measures weighting different measures determined year according business priorities details including measures used financial year provided annual report remuneration gsk annual report strategic report governance remuneration financial statements investor information remuneration policy summary continued executive director remuneration policy continued selection annual bonus measures annual bonus designed drive achievement majority annual bonus opportunity based gsks annual financial strategic business targets formal review performance stretching financial delivery personal objectives targets remainder bonus subject balanced scorecard strategic individual targets aligned annual bonus financial targets set reference companys key objectives financial year internal budget external consensus targets performance incentivise recognise delivery longer term business priorities financial growth share plan psp increases shareholder value compared pharmaceutical companies addition provide alignment shareholder interests retention element encourage longterm shareholding discourage excessive risk taking operation opportunity conditional awards made annually vesting dependent normal maximum award limits may granted achievement performance conditions three years psp individual one year set table subject additional twoyear holding period psp targets set reference internal budget external salary consensus targets ceo awards eligible dividend equivalents date cfo vesting release executive directors committee may adjust formulaic vesting outcome performance measures either ensure overall outcome reflects based combination financial share price related underlying business performance vesting period strategic performance conditions aligned companys strategic plan measures awards clawback andor malus provisions apply described vest threshold performance details including annual report performance targets attached psp respect year weightings targets psp awards provided annual report remuneration w e announced annual report reducing threshold vesting level tsr measure order align performance measures share ownership requirements align interests executive directors minimum executive directors required maintain shareholders required build maintain share ownership requirements end significant holdings shares gsk time first year following retirement company requirements executive director follows end second year salary ceo executive directors details policy clawbackmalus recruitment remuneration loss office termination payments please refer full remuneration policy report pages annual report available gskcom investors section gsk annual report remuneration policy summary continued scenarios future total remuneration charts opposite provide illustrations future total remuneration executive directors respect emma walmsley remuneration opportunity granted approved remuneration policy range potential outcomes provided executive director underlying assumptions set scenarios base salary used benefits figures used ie based actual amounts received dr hal barron pension figures pensions emma walmsley iain mackay based upon salaries amounts shown value psp awards based upon relevant multiples include amounts respect dividends reinvested factor fixed expected maximum maximum changes share price vesting period except share price described increase fixed excludes pay performance ie annual bonus would paid psp awards would vest iain mackay expected includes fixed pay annual bonus assumed target performance achieved psp awards amounts reflect vesting levels maximum assumed annual bonus would payable maximum level awards psp would vest full maximum share price increase elements maximum assuming fixed expected maximum maximum share price increase share price increase dr hal barron fixed expected maximum maximum share price increase fixed pay annual bonus psp share price increase gsk annual report strategic report governance remuneration financial statements investor information remuneration policy summary continued nonexecutive director remuneration policy companys remuneration policy report approved wednesday may gsks annual general meeting full policy available investor section gskcom following summary policy nonexecutive directors fees element purpose link strategy operation chairmans fees provide inclusive flat rate fee formal maximum however fees reviewed annually set reference competitive paid review chairmans performance independently sourced market data companies equivalent size committee responsible evaluating making recommendations board complexity subject limits contained fees payable chairman chairman participate discussions gsks articles association respect fees fees paid cash chairman required invest least total net fees shares ads company basic fees formal maximum chairman fees reviewed annually set reference independently sourced data chairman ceo responsible evaluating making recommendations board fees payable companys nonexecutive directors fees paid cash directors required invest least total net fees shares ads company shares ads delivered released following retirement board supplemental compensate nonexecutive directors additional fees senior independent director committee chairs scientific fees chairman taking medical experts workforce engagement director role intercontinental travel additional board responsibilities company authority pay additional fee equivalent undertaking intercontinental travel committee chair supplement effect january nonexecutive director company require significant additional time commitment exceptional unforeseen circumstances benefits facilitate execution responsibilities travel subsistence costs nonexecutive directors incurred normal duties required role course business relation meetings board committee matters gskhosted events overseasbased nonexecutive directors includes travel meetings uk event necessary business purposes whilst normal practice nonexecutive directors may accompanied spouse partner meetings events costs associated met company instances deemed taxable therefore treated benefits nonexecutive director approach recruitment remuneration following policy principles apply roles nonexecutive directors chairman nonexecutive director fee levels new nonexecutive directors set basis existing nonexecutive directors chairman company subject local laws regulations fees fees set level competitive paid paid partly shares companies equivalent size complexity fees paid partly shares event nonexecutive director different role responsibilities appointed fee levels benchmarked set reference comparable roles companies equivalent size complexity loss office chairman nonexecutive directors entitled receive payments respect fees loss office retire step board gsk annual report remuneration policy summary continued operation scope remuneration policy remuneration policy policy set pages ii policy came effect provided terms annual report intended policy payment consistent shareholderapproved gsks executive nonexecutive directors operate remuneration policy force time agreed period three years date approval companys iii time relevant individual director annual general meeting may company opinion committee payment committee wrote policy principally relation consideration individual becoming director remuneration arrangements executive directors whilst company purposes payments includes taking account possible recruitment replacement committee satisfying awards variable remuneration additional executive director operation relation award shares ads terms policy committee intends policy operate payment agreed time award granted period set entirety however may due performance share plan psp awards subject consideration seek change policy period terms psp plan rules award believes appropriate longterm granted committee may adjust amend awards success company consultation shareholders accordance provisions plan rules includes sought shareholder approval general meeting making adjustments reflect oneoff corporate events committee reserves right make remuneration change companys capital structure payments andor payments loss office including committee may also make minor amendments policy exercising discretions available connection regulatory exchange control tax administrative purposes payments notwithstanding line take account change legislation without obtaining policy terms payment agreed shareholder approval amendments agm may date companys statement consideration shareholder views first shareholderapproved directors remuneration policy came committee engages regular dialogue shareholders effect holds annual meetings gsks largest investors discuss take feedback remuneration policy practices governance matters basis preparation annual report remuneration prepared annual report remuneration approved accordance companies act large board directors signed behalf mediumsized companies groups accounts reports amendment regulations regulations accordance regulations following parts urs rohner annual report remuneration subject audit total remuneration committee chairman remuneration figures executive directors including march details element remuneration salary benefits pension annual bonus longterm incentive awards nonexecutive directors fees emoluments received year directors interests shares including interests gsk share plans payments past directors payments loss office share ownership requirements holdings opinion thereon expressed remaining sections annual report remuneration subject audit pages referred within audited sections gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap ggsskk aannnnuuaall rreeppoorrtt directors statement responsibilities directors responsible preparing annual report directors responsible keeping adequate accounting remuneration report group parent company records sufficient show explain companys financial statements accordance applicable law transactions disclose reasonable accuracy time regulations financial position group enable ensure group financial statements remuneration uk company law requires directors prepare financial report comply companies act article statements financial year directors required ias regulation also responsible safeguarding prepare group consolidated financial statements assets group hence taking reasonable steps accordance international financial reporting standards prevention detection fraud irregularities ifrs adopted pursuant regulation ec applies european union preparing group group financial statements year ended consolidated financial statements directors also december comprising principal statements elected comply ifrs issued international supporting notes set financial statements accounting standards board iasb directors pages report parent company elected prepare parent company financial statements financial statements year ended december accordance united kingdom accounting standards comprising balance sheet statement changes applicable law united kingdom generally accepted equity year ended december supporting accounting practice company law directors must notes set pages approve financial statements unless satisfied responsibilities auditor relation financial give true fair view state affairs statements set independent auditors report group profit loss period pages preparing financial statements directors financial statements year ended december required included annual report published printed select suitable accounting policies apply form made available website directors consistently responsible maintenance integrity annual report website accordance uk legislation make judgements accounting estimates governing preparation dissemination financial reasonable prudent statements access website available outside state group financial statements comply ifrs uk comparable legislation may different adopted pursuant regulation ec current directors whose names functions applies european union ifrs issued listed corporate governance section annual iasb subject material departures disclosed report confirms best knowledge explained group financial statements group financial statements prepared state regard parent company financial statements accordance ifrs adopted pursuant regulation applicable uk accounting standards ec applies european union followed subject material departures disclosed ifrs issued iasb give true fair view explained parent company financial statements assets liabilities financial position profit prepare financial statements going concern basis group unless inappropriate presume group strategic report risk sections annual report parent company continue business represent management report include fair review development performance business position company group taken whole together description principal risks uncertainties faces gsk annual report strategic report governance remuneration financial statements investor information directors statement responsibilities continued disclosure information auditor uk corporate governance code directors office date annual report board considers glaxosmithkline plc applies confirmed principles complies provisions uk corporate governance code maintained financial reporting far aware relevant audit council described corporate governance section information companys auditor unaware pages board considers taken steps ought annual report taken whole fair balanced taken director make aware understandable provides information necessary relevant audit information establish companys shareholders assess groups position performance auditor aware information business model strategy confirmation given interpreted required financial conduct authoritys listing rules accordance provisions section auditor considered directors statement companies act compliance relation points uk corporate going concern basis governance code specified review pages contain information performance annual report group financial position cash flows net debt position annual report year ended december borrowing facilities information including treasury comprising report directors remuneration risk management policies exposures market credit risk report financial statements additional information hedging activities given note financial investors approved board directors statements financial instruments related disclosures signed behalf assessed principal risks matters considered connection viability statement sir jonathan symonds directors considered appropriate adopt going concern chairman basis accounting preparing financial statements internal control march board audit risk committee reviewed assessment risks internal control framework operates gsk considered effectiveness system internal control operation group year covered annual report date approval board directors gsk annual report independent auditors report members glaxosmithkline plc report audit financial statements opinion basis opinion opinion conducted audit accordance international standards auditing uk isas uk applicable law financial statements glaxosmithkline plc parent responsibilities standards described company subsidiaries group give true auditors responsibilities audit financial fair view state groups parent statements section report companys affairs december groups profit year ended independent group parent company accordance ethical requirements relevant group financial statements properly prepared audit financial statements uk including accordance international accounting standards financial reporting councils frcs ethical standard conformity requirements companies act applied listed public interest entities fulfilled international financial reporting standards ifrss ethical responsibilities accordance adopted european union ifrss issued requirements confirm nonaudit services prohibited international accounting standards board iasb frcs ethical standard provided group parent company financial statements properly parent company noted audit risk committee prepared accordance united kingdom generally report within corporate governance section annual accepted accounting practice including frs reduced report disclosure framework believe audit evidence obtained financial statements prepared accordance sufficient appropriate provide basis opinion requirements companies act audit scope execution regards group financial statements article ias regulation structured approach audit reflect audited financial statements comprise group organised well ensuring audit effective risk focused audit approach group summarised following areas enabled us obtain consolidated balance sheet december evidence required form opinion group consolidated income statement year ended parent company financial statements consolidated statement comprehensive income risk assessment audit planning group level year ended central control common systems throughout group enabled us structure audit centrally use consolidated statement changes equity year ended data analytic tools allowed detailed understanding flow transactions enabling us focus risk consolidated cash flow statement year ended assessment design targeted audit testing procedures risk assessment procedures considered impact notes financial statements includes global pandemic account balances disclosures accounting principles policies company practices addition appointing partners parent company three businesses also partners coordinate component legal entity audits country balance sheet december global business partners met regularly relevant statement changes equity year ended management understand strategy matters arose notes financial statements includes throughout year could impacted financial accounting principles policies reporting regular meetings members internal audit internal legal counsel global ethics financial reporting framework applied compliance teams allowed us understand work preparation group financial statements applicable law review reports enhance risk assessment international accounting standards conformity audit work performed global shared service centres requirements companies act ifrss significant amount groups operational processes adopted european union issued iasb cover financial reporting undertaken shared service financial reporting framework applied centres group audit team included senior individuals preparation parent company financial statements responsible global processes coordinated applicable law united kingdom accounting standards audit work shared service centres scope group including frs reduced disclosure framework united audit ensure developed good understanding kingdom generally accepted accounting practice endtoend view key processes supported material account balances classes transactions disclosures within group financial statements gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued evaluated effectiveness internal controls application materiality financial reporting processes considered define materiality magnitude misstatement implications remainder audit work financial statements makes probable economic audit work executed component level individual decisions reasonably knowledgeable person would legal entities following components subject changed influenced use materiality planning audit procedures well assessment internal scope audit work evaluating results controls financial reporting australia belgium canada work china france germany italy japan spain switzerland based professional judgement determined united kingdom united states group audit team materiality financial statements whole follows active dialogue throughout audit component audit teams responsible audit work parent company direction supervision group audit team group financial statements financial statements included determining whether work planned materiality million million million million performed accordance overall group audit basis determining benchmark materiality strategy requirements group audit instructions determining materiality considered determined using components due restrictions overseas travel materiality metrics used investors total assets benchmark visit components year prior readers financial year satisfy oversight supervision statements particular appropriate performed remote reviews considered statutory profit tax adjusted profit videoconferencing increased frequency tax revenue net cash flows length reviews depending significance operations risk component continued attend using professional judgement planning clearance meetings components engage determined materiality local management million audit procedures undertaken group level metric parent company addition also performed statutory profit tax audit work group parent company financial adjusted profit tax statements including limited consolidation revenue net cash inflow groups results preparation financial operating activities statements certain disclosures within directors reconciliation statutory remuneration report litigation provisions exposures profit tax adjusted profit addition managements entity level oversight controls tax detailed adjusting relevant financial reporting components legal entities items section strategic report annual revenue greater total group rationale given importance parent company revenue included audit scope components metrics used investors holds groups legal entities covered audit scope subject benchmark readers financial statements investments applied concluded statutory profit profitoriented analytical procedures confirm conclusion tax primary strength significant risks material misstatement benchmark adjusted profit balance sheet key aggregated financial information tax revenue net cash measure financial inflow operating activities health important internal controls testing approach tested internal supporting benchmarks shareholders since controls financial reporting across inscope entities component materiality allocated primary concern entity level controls group level common systems inscope components ranged parent company allowed relevant controls tested centrally across million payment components able place reliance controls million dividends using benchmark total planned efficient notwithstanding range materiality allocated assets therefore controls deficiencies disclosed key audit matters across components audit appropriate metric prior years group financial section report mitigating controls existed allowed statements us continue take reliance controls planned million million audit scope addressed groups revenue groups profit tax groups total assets gsk annual report independent auditors report continued report audit financial statements continued set performance materiality level lower materiality based work performed identified reduce probability aggregate uncorrected material uncertainties relating events conditions undetected misstatements exceed materiality individually collectively may cast significant doubt financial statements whole group parent company groups parent companys ability continue going performance materiality set group parent concern period least twelve months materiality respectively audit financial statements authorised issue determining performance materiality considered factors relation reporting group applied including uk corporate governance code nothing material risk assessment including assessment add draw attention relation directors statement groups overall control environment consider financial statements whether directors considered appropriate rely controls number business appropriate adopt going concern basis accounting processes responsibilities responsibilities directors past experience audit indicated respect going concern described relevant sections low number corrected uncorrected misstatements report identified prior periods agreed audit risk committee would report committee audit differences excess million million well differences threshold view warranted reporting qualitative grounds also report audit risk committee disclosure matters identified assessing overall presentation financial statements conclusions relating going concern auditing financial statements concluded directors use going concern basis accounting preparation financial statements appropriate evaluation directors assessment groups parent companys ability continue adopt going concern basis accounting included enquiring management regarding assumptions used going concern models evaluating groups existing access sources financing including undrawn committed bank facilities reading analyst reports industry data external information determine provided corroborative contradictory evidence relation managements assumptions comparing forecasted sales recent historical financial information testing underlying data generated prepare forecast scenarios determined whether adequate support assumptions underlying forecast evaluating groups disclosures going concern requirements ias gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued key audit matters key audit matters matters professional judgement significance audit financial statements current period include significant assessed risks material misstatement whether due fraud identified matters included greatest effect overall audit strategy allocation resources audit directing efforts engagement team matters addressed context audit financial statements whole forming opinion thereon provide separate opinion matters key audit matter description scope audit responded key audit matter valuation viiv healthcare shionogi contingent audit procedures performed consideration liability performed following audit procedures amongst others recent years group completed number significant related sales forecasts transactions resulted recognition material challenged managements evidence enquiries key contingent consideration liabilities key source individuals senior leadership team commercial strategy estimation uncertainty significant liabilities team key personnel involved budgeting viiv healthcare shionogi contingent consideration forecasting process obtained objective evidence liability viiv ccl respect key inputs assumptions group completed acquisition remaining challenged us volume assumptions made management interest shionogiviiv healthcare joint venture estimate sales forecasts involved benchmarking market upon completion group recognised contingent share data external data total prescription consideration liability fair value expected future volumes new patient prescription volumes order assess payments made shionogi december sources contradictory evidence liability valued million challenged reasonableness us pricing assumptions made identified viiv ccl key audit matter management comparing forecasted returns significant estimates assumptions management makes rebates rate product current rate assessing related sales forecasts used valuing viiv ccl forecasted returns rebates comparable sensitivity valuation inputs products expected changes payer policy significant relate sales forecasts united states us certain products treatment portfolio reviewed results clinical studies undertaken year forecasts based managements assessment management key competitors order assess whether expected launch dates ability shift market practice corroborative contradictory managements prescriber behaviour towards drug regimens subsequent assumptions treatment product portfolio sales forecasts sales volumes pricing forecasts also required us significant audit effort perform appropriate audit procedures benchmarked managements sales forecasts challenge evaluate reasonableness included reports analysts considered sales forecasts forecasts total viiv basis individual product contingent consideration liabilities including viiv ccl basis disclosed key source estimation uncertainty note tested controls key inputs assumptions used group financial statements disclosures provided valuation contingent consideration liability including notes matter also discussed management review controls sales forecasts audit risk committee report within corporate treatment product portfolio used value viiv ccl governance section annual report key observations communicated audit risk committee underlying sales forecasts used valuation reasonable line internal supporting data external evidence analyst forecasts satisfied sales forecasts updated year reflect appropriately actual performance changes overall hiv treatment market approach valuing viiv ccl consistent prior periods overall satisfied valuation liability reasonable consistent ifrs gsk annual report independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation us returns rebates rar accruals audit procedures performed us group sells customers various commercial performed following audit procedures amongst others government mandated contracts reimbursement related management estimates rar accruals arrangements include rebates chargebacks right challenged managements assumptions selection return certain pharmaceutical products revenue utilisation rates focusing certain products recognition reflects grosstonet sales adjustments concluded accrual sensitive assumptions adjustments known returns rebates rar challenge included comparison historical utilisation rates accruals source significant estimation uncertainty consideration historical accuracy drivers market could material impact reported revenue changes impact ongoing generic competition three significant payer channels also referred macroeconomic impacts covid pandemic buying groups within rar accrual managed healthcare supplemented substantive analytical procedures organisations medicaid medicare part developing independent expectation accrual balance two main causes significant estimation uncertainty key segments based historical claims received adjusted reflect market changes period including utilisation rate portion total sales assessment time lag initial point sale made payer channel estimated management claim receipt compared independent recording accruals utilisation assumption expectation management evaluate challenging key assumptions used derive accrual appropriateness managements ending accrual position given influenced market demand factors outside control group considered historical accuracy managements estimates evaluated whether management appropriately updated time lag point sale point forecast assumptions selection cases exact rebate amounts known group upon receipt actual rebate claims differed amount accrued claim payer channels longest time lag result greater accrued period therefore greater level challenged appropriateness completeness estimation uncertainty estimating period end accrual periodend adjustments liability made management part ongoing review estimated accrual level estimation uncertainty also impacted significant shifts channel mix often driven changes competitive tested key controls estimation rar accruals landscape including competitor generic product launches including controls associated forecasting macroeconomic factors focus utilisation rates process monthend accrual review utilisation assumptions products deem controls level estimation uncertainty significant key observations communicated audit risk committee furthermore auditing standards presume significant fraud satisfied managements estimated liability rar risk exists revenue recognition line presumption accruals year end appropriate observed prudence also focus periodend adjustments management made assessing certain key assumptions rar accruals adjustments reflected updates made independent expectations historical accuracy prior year management initial assumptions included within estimates actual rebates satisfied forecasted rar rates view present greatest reasonable accordance requirements ifrs opportunity fraud revenue recognition notwithstanding revenue contracts customers existence internal controls us pharmaceuticals business million rar deductions made gross revenue million resulting net revenue million balance sheet accrual december combined us pharmaceuticals vaccines businesses amounted million us pharmaceuticals returns rebates disclosed key source estimation uncertainty note group financial statements disclosures provided note matter also discussed audit risk committee report within corporate governance section annual report gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation intangible assets audit procedures performed december group held million performed following audit procedures amongst others intangible assets including licences patents trademarks related future sales growth likelihood successful new brand names excluding goodwill computer product innovations profit margin levels used assessment software recoverable amount intangible intangible assets impairment assets relies certain assumptions estimates future met key individuals senior leadership team trading performance create estimation uncertainty product category leads key personnel involved assets risk material impairment identified forecasting process discuss evaluate managements using sensitivity analysis key assumptions review evidence support future sales growth rates profitability potential triggering events could indicative assumptions impairment carrying value associated assets challenged business assumptions applied management result analysis performed additional audit procedures estimating sales forecasts including macroeconomic certain indefinite life consumer healthcare intangible assets impacts resulting ongoing covid pandemic acquired pfizer involved benchmarking sales forecasts product key assumptions applied management determining compound annual growth rates external data specific recoverable amount include future sales growth rates market segments profit margin levels well likelihood successful new evaluated independent market research corroborate expected product innovations changes assumptions could lead category growth rates assessed sources impairment carrying value intangible contradictory evidence assets compared forecast sales plan data asset asset identified valuation intangible assets key internal forecasts approved senior management audit matter due inherent judgements involved board directors estimating future cash flows year increased uncertainty brought covid assessed historical accuracy managements forecasts pandemic associated lockdowns auditing estimates including consumption data estimates new sales required extensive audit effort challenge evaluate innovation reasonableness forecasts considered whether events transactions occurred disclosures relating intangible assets included balance sheet date reporting date affect note group financial statements matter conclusions reached carrying values assets also discussed audit risk committee report within associated disclosures corporate governance section annual report tested management review controls key inputs assumptions used valuation intangible assets including controls review revenue growth rates profit margins key observations communicated audit risk committee audit challenged future forecast performance consumer healthcare products including potential adverse impact covid pandemic concluded assumptions underpinning impairment review intangible assets reasonable accordance ifrs gsk annual report independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation uncertain tax positions including transfer audit procedures performed pricing support tax specialists assessed group operates numerous jurisdictions appropriateness uncertain tax provisions performing open tax transfer pricing matters exposures uk following audit procedures amongst others us overseas tax authorities give rise uncertain tax assessed challenged provisions uncertain tax positions positions range possible outcomes provisions focused work jurisdictions group contingencies management required make greatest potential exposure highest level certain judgements respect estimates tax exposures judgement required contingencies order assess adequacy tax provisions sometimes complex result assessed managements policies recognition considerations required multiple tax laws regulations measurement uncertain tax positions compliance guidance per ifric december group recorded provisions million respect uncertain tax positions involved transfer pricing specialists review transfer pricing methodology group associated approach valuation uncertain tax positions disclosed key source provisioning estimation uncertainty note group financial statements disclosures included note involved uk us international tax transfer pricing matter also discussed audit risk committee report specialists challenge conclusions reached within corporate governance section annual report management relation expected outcome financial impact considered evidence actual results recent tax authority audits enquiries thirdparty tax advice obtained tax specialists knowledge market practice relevant jurisdictions tested key controls preparation review reporting judgmental tax balances transactions include provisions uncertain tax provisions key observations communicated audit risk committee satisfied managements estimates relation uncertain tax positions related disclosures accordance ifrs work concluded management applied consistent approach estimating uncertain tax provisions judgements continue prudent appropriately recorded gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter systems impact financial reporting audit procedures performed systems within group form critical component audit scope driven level reliance placed groups financial reporting activities impact account technology obtain assurance within business process balances technology deemed relevant audit based financial data system configured automated controls andor key financial identified systems impact financial reporting reports reside within utilised specialists support key audit matter evaluation risks associated technology pervasive reliance complex technology integral testing design operation controls operation key business processes financial testing scope technology performed address reporting groups control objectives financial reporting risks reliance technology continues increase line included testing following areas business strategy increase use general controls including user access change automation across group management controls importance controls maintaining effective key financial reports system configured automated controls control environment key interdependency exists ability rely controls ability rely controls provide assurance completeness financial data system configured automated controls accuracy relevant data migrations system reports testing managements remediation previously identified continued remediation controls supporting scope deficiencies application systems risk assessment procedures included assessment implementation application systems key business impact unremediated control deficiencies determine areas year impact audit plan relevant audit plan adjusted include testing additional manual business controls context scope financial audit process controls mitigate unaddressed risk primarily relate user access security change control group continue implement programme remediation key observations communicated audit risk committee across landscape deficiencies identified prior years satisfied controls impacting groups financial extended reporting activities designed operating effectively control systems impact financial reporting discussed deficiencies identified remediated year end mitigated audit risk committee report within corporate compensating controls governance section annual report management continue make significant progress year remediating control deficiencies relating user access change management group many layers business process controls mitigate risk associated control deficiencies gsk annual report independent auditors report continued report audit financial statements continued information information comprises information included annual report financial statements auditors report thereon directors responsible information contained within annual report opinion financial statements cover information except extent otherwise explicitly stated report express form assurance conclusion thereon responsibility read information consider whether information materially inconsistent financial statements knowledge obtained course audit otherwise appears materially misstated identify material inconsistencies apparent material misstatements required determine whether gives rise material misstatement financial statements based work performed conclude material misstatement information required report fact nothing report regard summarise work relation areas information including areas upon specifically required report matters specifically required report responsibility reporting principal risks viability statement review confirmation description light knowledge set section corporate governance gathered audit considering directors statement nothing material report add processes support statements made challenging managements key draw attention respect matters judgements estimates consideration historical forecasting accuracy evaluating macroeconomic assumptions consider statements aligned relevant provisions code directors remuneration report report whether part directors remuneration report audited set section opinions matters properly prepared disclosures specified companies act prescribed companies act opinion made part directors remuneration report audited prepared accordance companies act strategic report directors report report whether consistent audited financial statements set section opinions matters prepared accordance applicable legal requirements prescribed companies act opinion based work undertaken course audit report identified material misstatements either report information reports consistent light knowledge understanding group audited financial statements prepared parent company environment obtained course audit accordance applicable legal requirements gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued reporting information responsibility reporting alternative performance measures apms apms measures defined generally accepted accounting opinion practice gaap therefore typically included financial use calculation disclosure apms statement part annual report group use apms adjusted consistent groups published definitions profit free cash flow constant currency growth rates policies quarterly annual reporting financial performance use apms groups reporting results reviewed assessed managements calculation reporting consistent guidelines produced esma metrics assess consistency groups published definitions frc policies items appropriate balance use also considered assessed whether use apms statutory metrics apms together clear groups reporting results consistent guidelines produced definitions reconciliation apms used financial regulators european securities markets authority esma reporting guidelines use apms frc alternative performance measures thematic review published november also considered whether appropriate balance use statutory metrics apms addition whether clear definitions reconciliation apms used financial reporting provided dividends distribution policy consider whether dividends policy transparent dividends opinion dividends policy appropriately paid consistent policy outlined strategic report disclosed dividends paid consistent policy responsibilities directors auditors responsibilities audit financial statements explained fully directors responsibilities statement directors responsible preparation objectives obtain reasonable assurance financial statements satisfied give whether financial statements whole free true fair view internal control directors material misstatement whether due fraud error determine necessary enable preparation financial issue auditors report includes opinion reasonable statements free material misstatement whether assurance high level assurance guarantee due fraud error audit conducted accordance isas uk always detect material misstatement exists preparing financial statements directors misstatements arise fraud error considered responsible assessing groups parent material individually aggregate could reasonably companys ability continue going concern disclosing expected influence economic decisions users taken applicable matters related going concern using basis financial statements going concern basis accounting unless directors either intend liquidate group parent company cease description responsibilities audit operations realistic alternative financial statements located frcs website wwwfrcorgukauditorsresponsibilities description forms part auditors report gsk annual report independent auditors report continued report audit financial statements continued extent audit considered audit response risks identified capable detecting irregularities including fraud result performing identified valuation us returns rebates accruals key audit matter irregularities including fraud instances noncompliance related potential risk fraud key audit matters laws regulations design procedures line section report explains matter detail also responsibilities outlined detect material describes specific procedures response key audit misstatements respect irregularities including fraud matter common audits isas uk also extent procedures capable detecting required perform specific procedures respond risk irregularities including fraud detailed management override identifying assessing potential risks related addition procedures respond risks irregularities identified included following identifying assessing risks material misstatement reviewing financial statement disclosures testing respect irregularities including fraud noncompliance supporting documentation assess compliance laws regulations considered following provisions relevant laws regulations described nature industry sector control environment direct effect financial statements business performance including design enquiring management audit risk committee groups remuneration policies key drivers directors inhouse external legal counsel concerning actual remuneration bonus levels performance targets potential litigation claims enquiring management internal audit audit risk performing analytical procedures identify unusual committee including obtaining reviewing supporting unexpected relationships may indicate risks material documentation concerning groups policies misstatement due fraud procedures relating reading minutes meetings charged identifying evaluating complying laws governance reviewing internal audit reports regulations whether aware instances correspondence regulators noncompliance addressing risk fraud management override detecting responding risks fraud whether controls testing appropriateness journal entries knowledge actual suspected alleged adjustments assessing whether judgements made fraud making accounting estimates indicative potential internal controls established mitigate risks related bias evaluating business rationale significant fraud noncompliance laws regulations transactions unusual outside normal course business discussing among engagement team including significant component audit teams involving relevant internal also communicated relevant identified laws regulations specialists including tax valuations pensions industry potential fraud risks engagement team members specialists regarding fraud might occur significant component audit teams remained alert financial statements potential indicators fraud indications fraud noncompliance laws regulations throughout audit obtaining understanding legal regulatory frameworks group operates focusing report legal regulatory requirements laws regulations direct effect financial statements provisions uk companies act opinions matters prescribed pensions legislation tax legislation companies act fundamental effect operations group including good clinical practice fda regulations general opinion part directors remuneration report data protection requirements antibribery corruption audited properly prepared accordance policy foreign corrupt practices act companies act opinion based work undertaken course audit information given strategic report directors report financial year financial statements prepared consistent financial statements strategic report directors report prepared accordance applicable legal requirements gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued light knowledge understanding group directors remuneration parent company environment obtained companies act also required report course audit identified material opinion certain disclosures directors remuneration misstatements strategic report directors report made part directors remuneration report audited agreement accounting corporate governance statement records returns listing rules require us review directors statement nothing report respect matters relation going concern longerterm viability part corporate governance statement relating groups matters required compliance provisions uk corporate governance address code specified review auditor tenure based work undertaken part audit following recommendation audit risk committee concluded following elements corporate effect january appointed governance statement materially consistent financial board directors audit financial statements year statements knowledge obtained audit ended december subsequent financial periods directors statement regards appropriateness period total uninterrupted engagement firm adopting going concern basis accounting years material uncertainties identified set consistency audit report additional report directors explanation assessment groups audit risk committee prospects period assessment covers audit opinion consistent additional report period appropriate set audit risk committee required provide directors statement fair balanced understandable accordance isas uk annual report set use report boards confirmation carried robust report made solely parent companys members assessment emerging principal risks set body accordance chapter part pages companies act audit work undertaken section annual report describes review might state parent companys members effectiveness risk management internal control matters required state auditors report systems set pages purpose fullest extent permitted law section describing work audit risk committee accept assume responsibility anyone set pages parent company parent companys members body audit work report opinions matters required report formed exception parent company passed resolution accordance adequacy explanations received accounting records section companies act senior companies act required report statutory auditors name stated opinion received information explanations require audit adequate accounting records kept parent company returns adequate audit received branches visited us parent company financial statements deloitte llp agreement accounting records returns statutory auditor london united kingdom nothing report respect matters march gsk annual report consolidated income statement year ended december notes turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit finance income finance expense profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p consolidated statement comprehensive income year ended december profit year comprehensive incomeexpense year items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries fair value movements cash flow hedges tax fair value movements cash flow hedges reclassification cash flow hedges income statement deferred tax reversed reclassification cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement lossesgains defined benefit plans tax remeasurement defined benefit plans comprehensive incomeexpense year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report strategic report governance remuneration financial statements investor information consolidated balance sheet december notes noncurrent assets property plant equipment right use assets goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings contingent consideration liabilities trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings corporation tax payable deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments contingent consideration liabilities noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity financial statements pages approved board march signed behalf sir jonathan symonds chairman gsk annual report consolidated statement changes equity year ended december shareholders equity share share retained noncontrolling total capital premium earnings reserves total interests equity december implementation ifrs implementation ifrs december adjusted profit year comprehensive income year total comprehensive income year distributions noncontrolling interests contribution noncontrolling interests derecognition noncontrolling interests consumer healthcare joint venture dividends shareholders realised profits disposal equity investments share associates joint ventures realised profits disposal equity investments shares issued writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december reported adjustment noncontrolling interest december revised implementation ifrs december adjusted profit year comprehensive income year total comprehensive income year distributions noncontrolling interests changes noncontrolling interests dividends shareholders recognition interest consumer healthcare jv realised losses disposal equity investments shares issued shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive expenseincome year total comprehensive income year distributions noncontrolling interests contributions noncontrolling interests changes noncontrolling interests dividends shareholders realised profits disposal equity investments share associates joint ventures realised profits disposal equity investments shares issued shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december analysis reserves presented part note movements equity gsk annual report strategic report governance remuneration financial statements investor information consolidated cash flow statement year ended december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments contingent consideration paid purchase businesses net cash acquired disposal businesses investments associates joint ventures proceeds disposal interests associates increasedecrease liquid investments interest received dividends associates joint ventures equity investments net cash inflowoutflow investing activities cash flow financing activities issue share capital purchase noncontrolling interests increase longterm loans repayment shortterm notes repayment ofincrease shortterm loans repayment lease liabilities interest paid dividends paid shareholders distributions noncontrolling interests contributions noncontrolling interests financing cash flows net cash outflow financing activities increase cash bank overdrafts cash bank overdrafts beginning year exchange adjustments increase cash bank overdrafts cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents cash cash equivalents reported assets held sale overdrafts gsk annual report notes financial statements presentation financial statements description business composition group gsk major global healthcare group engaged list subsidiaries associates opinion creation discovery development manufacture directors principally affected amount profit net marketing pharmaceutical products vaccines overthe assets group given note principal group counter otc medicines healthrelated consumer companies products gsks principal pharmaceutical products include financial period medicines following therapeutic areas respiratory hiv financial statements cover financial year immunoinflammation oncology antivirals central nervous january december comparative figures system cardiovascular urogenital metabolic antibacterials financial years january december dermatology appropriate january december compliance applicable law ifrs accounting principles policies financial statements prepared accordance financial statements prepared using international accounting standards conformity historical cost convention modified revaluation certain requirements companies act international items stated accounting policies going financial reporting standards adopted pursuant regulation concern basis ec applies european union financial statements prepared accordance financial statements also prepared groups accounting policies approved board accordance international financial reporting standards described note accounting principles policies issued iasb information application accounting policies including areas estimation judgement given note composition financial statements key accounting judgements estimates consolidated financial statements drawn sterling functional currency glaxosmithkline plc preparation financial statements conformity accordance ifrs accounting presentation financial generally accepted accounting principles requires management statements comprise make estimates assumptions affect reported amounts assets liabilities disclosure contingent consolidated income statement assets liabilities date financial statements consolidated statement comprehensive income reported amounts revenues expenses consolidated balance sheet reporting period actual results could differ estimates consolidated statement changes equity parent company financial statements financial statements parent company consolidated cash flow statement glaxosmithkline plc prepared accordance notes financial statements uk gaap uk accounting presentation company balance sheet presented accounting policies given pages accounting principles policies consolidation group ability exercise joint control consolidated financial statements include rights net assets entities entities accounted joint ventures group ability assets liabilities results cash flows exercise joint control arrangement rights company subsidiaries including esop trusts specified assets obligations specified liabilities groups share results net assets associates arrangement arrangement accounted joint joint ventures operation group ability exercise groups share assets liabilities revenue expenses significant influence entities accounted joint operations associates results assets liabilities associates joint ventures incorporated consolidated financial statements entities consolidated made financial statements using equity method accounting december year groups rights assets liabilities revenue expenses entities group power direct joint operations included consolidated financial relevant activities affect returns group statements accordance rights obligations generally control financial operating interests acquired entities consolidated date policies accounted subsidiaries group acquires control interests sold deconsolidated date control ceases gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued transactions balances subsidiaries eliminated consolidation assets liabilities including related profit tax taken sales subsidiaries goodwill overseas subsidiaries associates joint products sold customers outside group ventures translated sterling rates exchange relevant proportion profits transactions joint ruling balance sheet date results cash flows ventures joint operations associates also deferred overseas subsidiaries associates joint ventures products sold third parties transactions non translated sterling using average rates exchange controlling interests recorded directly equity deferred exchange adjustments arising opening net assets tax relief unrealised intragroup profit accounted profits year retained overseas subsidiaries extent considered recoverable associates joint ventures translated sterling less business combinations exchange differences arising related foreign currency business combinations accounted using acquisition borrowings hedge groups net investment accounting method identifiable assets liabilities contingent operations taken separate component equity liabilities acquired measured fair value acquisition date translating sterling assets liabilities results consideration transferred measured fair value cash flows overseas subsidiaries associates joint includes fair value contingent consideration ventures reported currencies hyperinflationary fair value contingent consideration liabilities economies adjustments made material reflect reassessed balance sheet date changes current price levels loss net monetary assets charged recognised income statement payments contingent consolidated income statement consideration reduce balance sheet liability result revenue recorded income statement turnover part payment relating original estimate group receives revenue supply goods external fair value contingent consideration acquisition customers orders received majority contracts reported within investing activities cash flow statement gsk enters relate sales orders containing single part payment relating increase performance obligations delivery pharmaceutical liability since acquisition date reported within operating vaccine consumer healthcare products average cash flows duration sales order less months consideration transferred together non product revenue recognised control goods controlling interest exceeds fair value net assets passed customer point control passes liabilities contingent liabilities acquired excess determined customer arrangement generally recorded goodwill costs effecting acquisition occurs delivery customer charged income statement period product revenue represents net invoice value including fixed incurred variable consideration variable consideration arises goodwill capitalised separate item case sale goods result discounts allowances given subsidiaries part cost investment case accruals estimated future returns rebates revenue joint ventures associates goodwill denominated recognised full highly probable significant currency operation acquired reversal amount cumulative revenue recognised cost acquisition fair value net occur methodology assumptions used estimate assets acquired difference recognised directly rebates returns monitored adjusted regularly income statement light contractual legal obligations historical trends past experience projected market conditions equity subsidiary acquired uncertainty associated returns rebates resolved noncontrolling interest recognised either fair value revenue adjusted accordingly noncontrolling interests share net assets subsidiary casebycase basis changes groups operating income royalty income ownership percentage subsidiaries accounted gsk enters development marketing collaborations within equity outlicences groups compounds products foreign currency translation parties contracts give rise fixed variable foreign currency transactions booked functional consideration upfront payments development milestones currency group company exchange rate ruling salesbased milestones royalties date transaction foreign currency monetary assets income dependent achievement development liabilities retranslated functional currency milestone recognised highly probable rates exchange ruling balance sheet date exchange significant reversal amount cumulative revenue differences included income statement recognised occur usually related event occurs salesbased milestone income recognised highly probable sales threshold reached gsk annual report notes financial statements continued accounting principles policies continued salesbased royalties licence intellectual property certain cases incurred reported ibnr actuarial recognised relevant product sale occurs technique used determine estimate addition provision made legal expenses arising revenue time recognition revenue claims received disputes payment customer expected one year impact material amount consideration group may become involved legal proceedings discounted using appropriate discount rates respect possible make reliable estimate expected financial effect could result value added tax sales taxes excluded revenue ultimate resolution proceedings cases expenditure appropriate disclosure cases would included expenditure recognised respect goods services provision would made received supplied accordance contractual terms costs associated claims made group third provision made obligation exists future liability parties charged income statement respect past event amount incurred obligation reliably estimated manufacturing startup costs validation achievement normal pensions postemployment benefits production expensed incurred costs providing pensions defined benefit schemes calculated using projected unit credit method spread advertising promotion expenditure charged income period benefit expected derived statement incurred employees services consistent advice qualified shipment costs intercompany transfers charged cost actuaries sales distribution costs sales customers included pension obligations measured present value selling general administrative expenditure estimated future cash flows discounted rates reflecting restructuring costs recognised provided yields highquality corporate bonds pension scheme assets appropriate respect direct expenditure business measured fair value balance sheet date reorganisation plans sufficiently detailed well costs postemployment liabilities calculated advanced appropriate communication similar way defined benefit pension schemes spread affected undertaken period benefit expected derived research development employees services accordance advice research development expenditure charged qualified actuaries service cost providing retirement income statement period incurred benefits employees year together cost development expenditure capitalised criteria curtailment charged operating profit year recognising asset met usually regulatory filing actuarial gains losses effect changes actuarial made major market approval considered assumptions recognised statement comprehensive highly probable property plant equipment used income year arise research development capitalised depreciated accordance groups policy groups contributions defined contribution plans charged income statement incurred environmental expenditure environmental expenditure related existing conditions employee share plans resulting past current operations incentives form shares provided employees current future benefit discernible charged income share option share award schemes statement group recognises liability sitebysite fair values options awards calculated basis reliably estimated liability includes grant dates using blackscholes option pricing model groups portion total costs also portion charged income statement relevant vesting periods potentially responsible parties costs probable able satisfy respective shares group provides finance esop trusts purchase cleanup obligation recoveries reimbursements company shares meet obligation provide shares recorded assets virtually certain employees exercise options awards costs running esop trusts charged income statement shares held legal disputes esop trusts deducted reserves transfer provision made anticipated settlement costs legal made reserves retained earnings disputes group outflow resources vesting periods related share options awards reflect considered probable reliable estimate made ultimate proceeds receivable employees exercise likely outcome respect product liability claims related certain products provision made sufficient property plant equipment history claims made settlements enable management property plant equipment ppe stated cost make reliable estimate provision required cover purchase construction less provisions depreciation unasserted claims impairment financing costs capitalised within cost qualifying assets construction gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued depreciation calculated write cost less residual leases applicable december value ppe excluding freehold land using straightline leasing agreements transfer group substantially basis expected useful life residual values lives benefits risks ownership asset treated reviewed appropriate adjusted annually normal finance leases asset purchased outright expected useful lives major categories ppe assets included ppe computer software capital elements leasing commitments shown freehold buildings years obligations finance leases assets held finance leasehold land buildings lease term years leases depreciated basis consistent similar owned plant machinery years assets lease term shorter interest element equipment vehicles years lease rental included income statement leases disposal ppe cost related accumulated operating leases rental costs charged depreciation impairments removed financial income statement straightline basis lease term statements net amount less proceeds taken goodwill income statement goodwill stated cost less impairments goodwill leases applicable january deemed indefinite useful life tested group recognises right use assets lease impairment least annually arrangements lessee rights use assets fair value interest acquired entitys owned third parties lease agreements capitalised assets liabilities contingent liabilities exceeds inception lease recognised consolidated consideration paid excess recognised immediately balance sheet gain income statement corresponding liability lessor recognised lease intangible assets obligation within short longterm borrowings carrying intangible assets stated cost less provisions amount subsequently increased reflect interest amortisation impairments lease liability reduced lease payments made licences patents knowhow marketing rights separately calculating discounted lease liability leases acquired acquired part business combination annual payments million implicit rate amortised estimated useful lives generally lease used available incremental borrowing exceeding years using straightline basis rate lease specific adjustment used neither time available use estimated useful lives available leases annual payments less determining amortisation charge take account patent million incremental borrowing rate used lives applicable well value obtained incremental borrowing rate calculated rate interest periods nonexclusivity asset lives reviewed gsk would able borrow similar term appropriate adjusted annually similar security funds necessary obtain similar asset similar market contingent milestone payments recognised point contingent event becomes probable development finance costs charged income statement costs incurred group associated acquired produce constant periodic rate charge remaining licences patents knowhow marketing rights written balance obligations accounting period income statement incurred unless criteria variable rents part lease liability right recognition internallygenerated intangible asset met use asset payments charged income usually regulatory filing made major market statement incurred shortterm lowvalue leases approval considered highly probable capitalised lease rentals also charged income acquired brands valued independently part fair value statement incurred businesses acquired third parties brand nonlease components accounted separately value substantial longterm brands lease components plant equipment leases either contractual legal nature sold separately separately accounted land buildings vehicle leases rest businesses acquired brands amortised estimated useful lives years except modifications reassessments occur lease liability considered useful economic life indefinite right use asset remeasured costs acquiring developing computer software right use assets title expected pass gsk internal use internet sites external use capitalised point future depreciated basis consistent intangible fixed assets software site supports similar owned assets cases right use assets significant business system expenditure leads depreciated shorter useful life asset creation durable asset erp systems software amortised lease term seven ten years computer software three five years gsk annual report notes financial statements continued accounting principles policies continued impairment noncurrent assets investments carrying values noncurrent assets reviewed investments comprise equity investments impairment either standalone basis part larger investments limited life funds group elected cash generating unit indication assets designate equity investments measured fvtoci might impaired additionally goodwill intangible assets initially recorded fair value plus transaction costs indefinite useful lives intangible assets yet remeasured subsequent reporting dates fair value available use tested impairment annually unrealised gains losses recognised provision impairment charged income statement comprehensive income year concerned disposal equity investment gains losses impairments goodwill reversed impairment losses deferred comprehensive income transferred noncurrent assets reversed directly retained earnings investments limited life funds change estimates used determine recoverable amounts measured fvtpl initially recorded fair value extent revised recoverable amounts remeasured subsequent reporting dates fair value exceed carrying values would existed net unrealised gains losses recognised income depreciation amortisation impairments statement recognised dividends equity investments distributions funds investments associates joint ventures joint recognised income statement groups right operations receive payment established investments associates joint ventures carried purchases sales investments accounted consolidated balance sheet groups share net trade date assets date acquisition postacquisition retained profits losses together goodwill arising trade receivables acquisition group recognises rights assets trade receivables measured accordance liabilities revenue expenses joint operations business model portfolio trade receivables held group portfolios three business inventories models ifrs due factoring arrangements place inventories included financial statements lower collect contractual cash flows measured amortised cost cost including raw materials direct labour direct costs sell contractual cash flows measured fvtpl related production overheads net realisable value collect sell contractual cash flows measured cost generally determined first first basis fvtoci trade receivables measured amortised cost prelaunch inventory held asset high carried original invoice amount less allowances probability regulatory approval product expected credit losses point provision made carrying value recoverable amount provision reversed point expected credit losses calculated accordance high probability regulatory approval determined simplified approach permitted ifrs using provision matrix applying lifetime historical credit loss experience trade financial instruments receivables expected credit loss rate varies depending financial assets whether extent settlement trade financial assets measured amortised cost fair value receivables overdue also adjusted appropriate comprehensive income fvtoci fair value reflect current economic conditions estimates future profit loss fvtpl measurement basis conditions purpose determining credit loss rates determined reference business model customers classified groupings similar loss managing financial asset contractual cash flow patterns key drivers loss rate nature characteristics financial asset financial assets business unit location type customer trade receivables month expected credit loss ecl allowance recorded initial recognition trade receivable determined reasonable subsequent evidence significant increase credit risk expectation recovery written firstly asset allowance increased reflect full lifetime expected credit loss allowance available ecl realistic prospect recovery asset income statement written subsequent recoveries amounts previously provided expected credit losses recognised income statement written credited income statement longterm financial assets measured amortised cost fair value receivables discounted effect material comprehensive income apart equity investments gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued cash cash equivalents changes fair value derivatives designated fair value cash held deposit accounts measured amortised cost hedges recorded income statement together investments money market funds held fair value changes fair value hedged asset liability profit loss funds fail solely payments taxation principal interest sppi test current tax provided amounts expected paid applying tax rates enacted substantively borrowings enacted balance sheet date borrowings initially recorded amount proceeds received net transaction costs borrowings subsequently deferred tax provided full temporary differences arising carried amortised cost difference tax bases assets liabilities carrying proceeds net transaction costs amount due amounts financial statements deferred tax assets redemption recognised charge income recognised extent probable future taxable statement period relevant borrowing profits available temporary differences utilised deferred tax provided temporary derivative financial instruments differences arising investments subsidiaries associates derivative financial instruments used manage exposure joint ventures except timing reversal market risks principal derivative instruments used temporary difference controlled probable gsk foreign currency swaps interest rate swaps foreign temporary difference reverse foreseeable exchange forward contracts options group future deferred tax provided using rates tax hold issue derivative financial instruments trading enacted substantively enacted balance sheet date speculative purposes uncertain tax position identified management derivative financial assets liabilities including derivatives make judgement probable outcome embedded host contracts separated assuming relevant tax authority full knowledge host contract classified heldfortrading situation assessed economic outflow measured fair value changes fair value derivative probable arise provision made best estimate instruments qualify hedge accounting liability estimating liability gsk applies recognised immediately income statement riskbased approach takes account appropriate hedge accounting probability group would able obtain compensatory adjustments international tax treaties derivatives designated hedging instruments classified estimates take account specific circumstances inception hedge relationship cash flow hedges net dispute relevant external advice investment hedges fair value hedges discounting changes fair value derivatives designated cash flow time value money material balances hedges recognised comprehensive income discounted current values using appropriate discount rates extent hedges effective ineffective portions unwinding discounts recorded finance income recognised profit loss immediately amounts deferred finance expense comprehensive income reclassified income statement hedged item affects profit loss net investment hedges accounted similar way cash flow hedges key accounting judgements estimates preparing financial statements management required estimates make judgements items gross turnover reduced rebates discounts allowances recognised financial statements estimates product returns given expected given assumptions affect amounts assets liabilities vary product arrangements buying groups revenue expenses reported financial statements arrangements purchasing organisations dependent actual amounts results could differ estimates upon submission claims time initial following considered critical accounting recognition sale accruals made time sale judgements key sources estimation uncertainty estimated rebates discounts allowances payable returns made based available market information turnover historical experience reported group turnover million million gsk annual report notes financial statements continued key accounting judgements estimates continued us pharmaceuticals business largest estimates complex arrangements rebates discounts allowances group open tax issues number revenue us pharmaceuticals turnover million authorities management makes judgement whether million recording deductions sufficient information able make reliable estimate million million rebates discounts outcome dispute insufficient information available allowances returns balance sheet accruals rebates provision made discounts allowances returns us pharmaceuticals sufficient information available estimating potential tax vaccines businesses managed combined basis liability gsk applies riskbased approach takes december total accrual amounted account appropriate probability group would million million nature able obtain compensatory adjustments international accruals practicable give meaningful tax treaties estimates take account specific sensitivity estimates due large volume variables circumstances dispute relevant external advice contribute overall rebates chargebacks returns inherently judgemental could change substantially revenue accruals time dispute progresses new facts emerge significant variability final outcomes december group recognised provisions group applies constraint measuring variable element million respect uncertain tax positions within revenue revenue recognised suitably million due number uncertain tax positions held cautious amount objective constraint ensure number jurisdictions relate highly probable significant reversal revenue practicable give meaningful sensitivity estimates occur uncertainties resolved constraint applied making suitably cautious estimates inputs factors affecting tax charge future years set assumptions used estimating variable consideration note taxation gsk continues believe made amounts estimated may fully reflect adequate provision liabilities likely arise open final outcome amounts subject change assessments open issues exist ultimate liability dependent upon amongst things types buying matters may vary amounts provided group product sales mix constraints applied dependent upon outcome negotiations relevant recognising revenue mean risk material downward tax authorities necessary litigation proceedings adjustment revenue next financial year low legal disputes level accrual rebates returns reviewed legal costs year million adjusted regularly light contractual legal million december provisions legal obligations historical trends past experience projected disputes amounted million million market conditions market conditions evaluated using estimates wholesaler thirdparty analyses market research data management makes judgement whether sufficient internallygenerated information reasonably possible information able make reliable estimate likely could significant adjustment within next outcome dispute legal expenses arising months recognise additional revenue actual outcomes claims group insufficient information better cautious constrained estimates revenue available provision made disclosure claim recognised full highly probable significant given reversal amount cumulative revenue recognised occur amount turnover recognised year estimated provisions take account specific performance obligations satisfied previous periods set circumstances dispute relevant external advice note turnover segment information inherently judgemental could change substantially time indication level sensitivity estimate dispute progresses new facts emerge details status various uncertainties involved significant future events could cause assumptions unresolved disputes set note legal proceedings accruals based change could materially affect future results group companys directors taken legal advice established provisions taking account relevant taxation facts circumstances matter accordance tax charge year million accounting requirements respect product liability claims million december current tax payable related certain products sufficient history claims million million noncurrent corporation made settlements enable management make reliable tax payable million million current estimate provision required cover unasserted claims tax recoverable million million gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued key accounting judgements estimates continued group may become involved legal proceedings respect pensions postemployment benefits possible make reliable estimate judgement expected financial effect practicable give surplus defined benefit scheme arises meaningful range outcomes could result ultimate potential surplus arise committed future resolution proceedings cases appropriate contributions rights trustees prevent group disclosure cases would provided provision obtaining refund surplus future considered would made contingent liability quantified determining whether necessary restrict amount ultimate liability legal claims may vary amounts surplus recognised three uk schemes provided dependent upon outcome litigation surplus combined surplus million december proceedings investigations possible settlement negotiations million gsk made judgement position could change time therefore amounts meet requirements recoverability assurance losses result outcome estimates legal proceedings exceed amount provisions costs providing pensions postemployment reported groups financial statements material amount benefits assessed basis assumptions selected contingent consideration management assumptions include future earnings income statement charge contingent pension increases discount rates expected longterm rates consideration million million return assets mortality rates disclosed note december liability contingent consideration pensions postemployment benefits amounted million million discount rates derived aa rated corporate bond yields amount million million related except countries deep market corporate acquisition former shionogiviiv healthcare joint venture bonds government bond yields used sensitivity analysis provided note pensions post employment benefits reduction discount estimates rate would lead increase net pension deficit contingent consideration included consideration approximately million increase annual payable business combination recorded fair value pension cost approximately million similarly date acquisition fair values generally based increase discount rate would lead decrease net riskadjusted future cash flows discounted using appropriate pension deficit approximately million decrease posttax discount rates fair values reviewed annual pension cost approximately million regular basis least annually changes reflected selection different assumptions could affect future results income statement see note contingent consideration group liabilities new accounting requirements year group implemented amendment ifrs interest rate benchmark reform phase amendments business combinations issued october ifrs ias ifrs ifrs ifrs issued amendment clarifies definition business august effective january permits simplified initial assessment whether acquired phase amendments address issues arise set activities assets group assets rather implementation reforms including replacement business amendment material impact one benchmark alternative one practical expedient results financial position group provided change contractual cash flows financial assets liabilities including lease liabilities covidrelated rent concessions amendment ifrs accounted prospectively revising effective interest issued may introduces practical expedient rate addition hedge accounting discontinued ifrs leases permits lessee elect assess solely ibor reform whether covidrelated concession respect rent due periods june lease modification amendments expected material impact amendment applicable annual reporting periods beginning results financial position group june earlier application permitted gsk annual report notes financial statements continued exchange rates group uses average exchange rates prevailing period translate results cash flows overseas subsidiaries joint ventures associates sterling period end rates translate net assets entities currencies influence translations relevant exchange rates average rates period end rates us us euro euro yen yen turnover segment information operating segments reported based financial information provided chief executive officer responsibilities corporate executive team cet gsk reports results four segments pharmaceuticals pharmaceuticals rd vaccines consumer healthcare individual members cet responsible segment groups management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis corporate unallocated turnover costs includes results certain consumer healthcare products held sale number markets order meet antitrust approval requirements together costs corporate functions revenue recognised year performance obligations satisfied previous periods totalled million million included million million impacting turnover arising changes prior year estimates rar returns rebates accruals million million milestone income million million royalty income recognised current year turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover pharmaceuticals turnover therapeutic area respiratory hiv immunoinflammation oncology established pharmaceuticals vaccines turnover category meningitis influenza shingles established vaccines gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued turnover segment information continued us operations pharmaceuticals vaccines businesses made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers gsk reviewed presentation consumer healthcare products january adopted revised detailed disclosure category sales closely aligned consumer healthcare industry standard definitions comparative information revised onto consistent basis revised revised consumer healthcare turnover category oral health pain relief vitamins minerals supplements respiratory health digestive health brands divestedunder review segment profit pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment profit corporate unallocated costs reconciling items segment profit operating profit operating profit finance income finance costs profit disposal interest associates share aftertax profits associates joint ventures profit taxation taxation profit taxation year reconciling items segment profit operating profit comprise items specifically allocated segment profit include impairment amortisation intangible assets major restructuring costs include impairments tangible assets computer software transactionrelated adjustments related significant acquisitions proceeds costs disposals associates products businesses significant legal charges expenses settlement litigation government investigations operating income royalty income items separation costs depreciation amortisation segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report notes financial statements continued turnover segment information continued ppe intangible asset goodwill impairment segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment ppe intangible asset impairment reversals segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment reversals corporate unallocated impairment reversals reconciling items segment impairment reversals total impairment reversals total impairment reversals net operating assets segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale excluding cash cash equivalents net assets pharmaceuticals segment includes shionogiviiv healthcare contingent consideration liability million million pfizer put option million million gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued turnover segment information continued geographical information uk regarded groups country domicile turnover location customer uk us rest world external turnover noncurrent assets location subsidiary uk us rest world noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables operating incomeexpense fair value remeasurements equity investments disposal businesses assets fair value remeasurements contingent consideration recognised business combinations remeasurement viiv healthcare put option liabilities preferential dividends remeasurement consumer healthcare put option liability fair value adjustments derivative financial instruments incomeexpense disposal businesses assets included net profit disposal horlicks consumer healthcare nutritional brands two subsidiaries india bangladesh million reflected reversal million embedded derivative gains value shares taken prior years partly offset related million loss shares hindustan unilever limited including fair value remeasurement losses acquisition consideration divestment gsk consumer healthcare limited india subsequent disposal operating income also included increase profit milestone income number asset disposals profit disposal rabies tickborne encephalitis vaccines million gain arising increase value shares hindustan unilever limited subsequently received million including fair value movements related derivatives fair value remeasurements contingent consideration recognised business combinations included million related acquisition former shionogiviiv healthcare joint venture million related vaccines acquisition novartis together fair value movements related hedging contracts gsk annual report notes financial statements continued operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals depreciation right use assets impairment right use assets amortisation intangible assets impairment intangible assets net reversals impairment property plant equipment held sale net reversals impairment intangible assets held sale net reversals impairment goodwill allocated disposal group net reversals net foreign exchange lossesgains inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories shortterm lease charge lowvalue lease charge variable lease payments operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration net foreign exchange gains include net loss million million gain nil arising reclassification exchange liquidation disposal overseas subsidiaries included within operating profit major restructuring charges million million million see note major restructuring costs fees payable companys auditor associates audit parent company consolidated financial statements including attestation sarbanesoxley act audit companys subsidiaries total audit services taxation compliance audit related assurance services services total auditrelated nonaudit services assurance services provided auditor related agreed upon procedures assurance services outside statutory audit requirements addition fees paid auditor respect gsk pension schemes audit services fees million million nil also paid auditors respect audits certain companys subsidiaries acquired year gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities increase wages salaries included impact movements exchange rates group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance cost sharebased incentive plans analysed follows share value plan performance share plan share option plans cash settled plans average monthly number persons employed group including directors year number number number manufacturing selling general administration research development average monthly number group employees excludes temporary contract staff numbers group employees end financial year given financial record compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans information remuneration directors given sections annual report remuneration labelled audited within pages gsk annual report notes financial statements continued major restructuring costs within pharmaceuticals sector highly regulated manufacturing operations supply chains long lifecycle business mean restructuring programmes particularly involve rationalisation closure manufacturing rd sites likely take several years complete major restructuring costs related specific boardapproved major restructuring programmes including integration costs following material acquisitions structural significant scale costs individual related projects exceed million existing combined restructuring integration programme incorporates previous major change programme pharmaceuticals restructuring programme restructuring integration programme following novartis transaction programme substantially complete july boardapproved major restructuring programme designed significantly improve competitiveness efficiency groups cost base savings delivered primarily supply chain optimisation reductions administrative costs february board approved major restructuring plan generate synergies integration pfizer consumer healthcare business gsks consumer healthcare business january board approved twoyear separation preparation programme prepare separation gsk two companies total restructuring costs million incurred following areas restructuring costs prepare separation gsk two companies restructuring following integration pfizer consumer healthcare business gsk consumer healthcare continued implementation restructuring programme started july simplify operating models improve resource allocation pharmaceutical consumer healthcare supply chains continued transformation central functions including gsk technology platforms interfaces deliver greater digital synergies simplification applications staff reductions analysis costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash charges cash costs provision reversals million million million reflected provision releases mainly combined restructuring integration programme asset impairments million noncash charges million principally comprised fixed asset writedowns manufacturing facilities accelerated depreciation asset lives shortened supply chain manufacturing network result major restructuring programmes charges settled cash include site closure costs consultancy project management costs analysis major restructuring charges programme follows cash noncash total separation preparation programme consumer healthcare joint venture integration programme major restructuring programme including tesaro combined restructuring integration programme cash noncash total consumer healthcare joint venture integration programme major restructuring programme including tesaro combined restructuring integration programme gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued major restructuring costs continued analysis major restructuring charges income statement line follows cost sales selling general administration research development operating expense finance income finance income arising financial assets measured amortised cost financial assets measured fair value profit loss net gains arising forward element forward contracts net investment hedge relationships finance expense finance expense arising financial liabilities amortised cost derivatives fair value profit loss net losses arising financial instruments mandatorily measured fair value profit loss retranslation loans reclassification hedges comprehensive income unwinding discounts provisions finance expense arising lease liabilities finance expense finance expense arising derivatives fair value profit loss relates swap interest expense figure finance expense arising lease liabilities related interest arising finance leases previous leasing standard ias originally reported finance expense finance expense included million charge interest relating historical income tax settlements gsk annual report notes financial statements continued associates joint ventures groups share aftertax profits losses associates joint ventures set share aftertax profits associates share aftertax lossesprofits joint ventures december group held one significant associate innoviva inc summarised income statement information respect innoviva set groups share aftertax profits associates comprehensive income includes profit million comprehensive income nil respect innoviva results innoviva included summarised income statement information represent estimated earnings innoviva relevant periods based publicly available information balance sheet date innovivas turnover arises royalty income gsk relation relvarbreo ellipta anoro ellipta trelegy ellipta sales turnover profit taxation total comprehensive income aggregated financial information respect gsks share associated undertakings joint ventures set share turnover share aftertax losses share comprehensive income share total comprehensive incomeexpense groups sales associates joint ventures nil million million gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued taxation groups tax charge sum total current deferred tax expense taxation charge based profits year uk current year charge rest world current year charge chargecredit respect prior periods current taxation deferred taxation gsk made payments million uk corporation tax hmrc amounts uk corporation tax include various business taxes borne uk gsk year deferred tax credit reflected origination current year expenses offset taxable profits future periods probable relates primarily unwind deferred tax liabilities intangible assets recognition current year tax losses reversal temporary differences also included uplift tax carrying value certain consumer healthcare brands result acquisition novartis interest former consumer healthcare joint venture significant prior year credits reflected impact settlement number open issues tax authorities period following table reconciles tax charge calculated uk statutory rate group profit tax actual tax charge year reconciliation taxation group profits profit tax uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits fair value remeasurement nontaxable put options tax losses benefit recognised permanent differences disposals acquisitions permanent differences reassessments prior year estimates changes tax rates tax chargetax rate gsk substantial business presence many countries around globe impact differences overseas taxation rates arose profits earned countries tax rates higher uk statutory rate significant us belgium germany india japan adverse impact partly offset benefit intellectual property incentives uk patent box belgian patent income deduction regimes provide reduced rate corporation tax profits earned qualifying patents claim incentives manner intended relevant statutory regulatory framework changes tax rates included credits relation uk reduction corporation tax rate cancelled india tax treatment dividends changed effect april uk credit partly reversed expense future benefit provided formerly enacted corporation tax rate permanent differences disposals acquisitions reflects tax impact disposal horlicks consumer healthcare brands unilever subsequent disposal shares received hindustan unilever groups tax rate also influenced reassessment open issues tax authorities various jurisdictions reassessment prior year estimates includes current deferred tax future tax charges therefore effective tax rate may affected factors acquisitions disposals restructurings location rd activity tax regime reforms resolution open matters continue bring tax affairs date around world gsk annual report notes financial statements continued taxation continued tax items charged equity statement comprehensive income current taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements equity investments deferred taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements equity investments total creditcharge equity statement comprehensive income items charged statement comprehensive income except tax sharebased payments issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets line current oecd guidelines base transfer pricing policy arms length principle however different tax authorities may seek attribute profit activities undertaken jurisdiction potentially resulting double taxation group also open items several jurisdictions concerning matters deductibility particular expenses tax treatment certain business transactions gsk applies risk based approach determine transactions likely subject challenge probability group would able obtain compensatory adjustments international tax treaties calculation groups total tax charge therefore necessarily involves degree estimation judgement respect certain items whose tax treatment finally determined resolution reached relevant tax authority appropriate formal legal process december group recognised provisions million respect uncertain tax positions million decrease recognised provisions driven reassessment estimates utilisation provisions uncertain tax positions following settlement number open issues tax authorities various jurisdictions whilst ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate group continues believe made appropriate provision periods open yet agreed tax authorities provision deferred tax liabilities million december million made respect taxation would payable remittance profits certain overseas subsidiaries whilst aggregate amount unremitted profits balance sheet date approximately billion billion majority unremitted profits would subject tax including withholding tax repatriation uk legislation relating company distributions provides exemption tax overseas profits subject certain exceptions deferred tax provided temporary differences million million arising unremitted profits management ability control future reversal consider reversal probable continued focus tax reform expected future years driven oecds project address tax challenges arising digitalisation economy may result significant changes established tax principles increase tax authority disputes turn could adversely affect gsks effective tax rate could result higher cash tax liabilities gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued taxation continued movement deferred tax assets liabilities pensions share accelerated post option net capital intangible contingent intragroup employment tax award temporary allowances assets consideration profit benefits losses schemes differences total january exchange adjustments creditcharge income statement creditcharge statement comprehensive income equity acquisitions disposals rd credits utilisation december exchange adjustments chargecredit income statement creditcharge statement comprehensive income equity acquisitions disposals rd credits utilisation december deferred tax liabilities provided relation intangible assets predominately relate temporary differences arising assets liabilities acquired part historic business combinations acquisitions disposals includes deferred tax liabilities million related pfizer consumer healthcare business acquisition million related tesaro acquisition group continues recognise deferred tax assets future obligations respect contingent consideration amounts payable minority shareholders payments tax deductible point time payment made deferred tax asset recognised intragroup profits arising intercompany inventory eliminated within consolidated accounts intragroup profits eliminated individual entities tax returns temporary difference arises reverse point time inventory sold externally deferred tax asset million million recognised tax losses relates trading losses deferred tax assets recognised probable future taxable profit available utilise losses supported product level forecasts net temporary differences included accrued expenses tax deduction available paid basis deferred tax asset liabilities recognised balance sheet follows deferred tax assets deferred tax liabilities unrecognised unrecognised deferred tax deferred tax tax losses asset tax losses asset unrecognised tax losses trading losses expiring within years years available indefinitely december capital losses expiring available indefinitely december gsk annual report notes financial statements continued earnings per share pence pence pence basic earnings per share diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paid pence paid pence first interim july july july second interim october october october third interim january january january fourth interim april april april total ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued property plant equipment plant land equipment assets buildings vehicles construction total cost december implementation ifrs december adjusted exchange adjustments additions business combinations additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december exchange adjustments additions business combinations additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december depreciation december implementation ifrs december adjusted exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december impairment december implementation ifrs december adjusted exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december gsk annual report notes financial statements continued property plant equipment continued weighted average interest rate capitalised borrowing costs year disposals writeoffs year included number assets nil net book value longer use business impairment losses principally arose decisions rationalise facilities calculated based fair value less costs disposal fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate specific segment country currency risk assets continue used group generally assessed part associated cash generating unit value use basis value use calculations posttax cash flows include impact future uncommitted restructuring plans improvements impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately net impairment losses charged cost sales million million rd million million sga million million included million million arising major restructuring programmes reversals impairment arose subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales million million computer software reclassified assets construction intangible assets becoming ready use right use assets land plant buildings equipment vehicles total net book value january exchange adjustments additions business combinations additions depreciation disposals impairments reclassifications net book value december exchange adjustments additions depreciation disposals impairments reclassifications net book value december total cash outflow leases amounted million significant lease commitments leases commenced yearend analysis lease liabilities set note net debt gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued goodwill cost january exchange adjustments additions business combinations note transfer tofrom assets held sale cost december net book value january net book value december goodwill allocated groups segments follows pharmaceuticals vaccines consumer healthcare net book value december recoverable amounts cash generating units assessed using fair value less costs disposal model fair value less costs disposal calculated using discounted cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific segment country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy details relating discounted cash flow models used impairment tests pharmaceuticals vaccines consumer healthcare cash generating units follows valuation basis fair value less costs disposal key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates region period specific projected cash flows five years terminal growth rate discount rate terminal growth rate discount rate pharmaceuticals pa vaccines pa consumer healthcare pa terminal growth rates exceed longterm projected growth rates relevant markets reflect impact future generic competition take account new product launches goodwill monitored impairment segmental level case valuations indicated sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill consumer healthcare cash generating unit also comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion details indefinite life brands given note intangible assets gsk annual report notes financial statements continued intangible assets licences patents computer amortised indefinite life software brands etc brands total cost january exchange adjustments capitalised development costs capitalised borrowing costs additions business combinations additions disposals asset writeoffs transfer assets held sale reclassifications cost december exchange adjustments capitalised development costs additions business combinations additions disposals asset writeoffs transfer assets held sale reclassifications cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december impairment january exchange adjustments impairment losses reversal impairments disposals asset writeoffs transfer assets held sale impairment december exchange adjustments impairment losses reversal impairments disposals asset writeoffs transfer assets held sale reclassification impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year net book value computer software included million million internally generated costs carrying value december intangible assets impairments charged reversed year following impairments reversals million million patent expiry dates groups significant assets relevant set pages gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development licences patents amortised brands etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development note acquisitions disposals gives details additions business combinations year book values largest individual items follows tesaro assets meningitis portfolio dolutegravir benlysta lamisil merck assets bms assets fluarixflulaval okairos stiefel trade name others tesaro assets comprise zejula currently marketed monotherapy well combination therapies meningitis portfolio includes menveo bexsero men abcwy menjugate lamisil moved licences patents amortised brands etc following decision start amortisation gsk divested breathe right brand year indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business pfizer consumer healthcare business book values major brands follows advil voltaren centrum caltrate otrivin preparation h robitussin nexium fenistil chapstick emergenc theraflu panadol lamisil sensodyne breathe right others gsk annual report notes financial statements continued intangible assets continued brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factors could limit useful lives accordingly amortised brand tested annually impairment amortised intangible assets tested indicators impairment arise testing applies fair value less costs disposal methodology generally using posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate specific segment country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions exchange rates assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment intangible assets investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals distributions received net fair value movements comprehensive income movements profitloss tax recognised consolidated income statement december group held one significant associate december innoviva inc december group owned million shares innoviva biopharmaceutical company listed nasdaq innoviva partnered gsk development long acting beta agonist vilanterol currently receives royalty income sales products contain component namely relvarbreo ellipta anoro ellipta also economic interest royalties paid gsk sales trelegy ellipta remaining economic interest royalties held theravance biopharma inc group holds common stock investment innoviva market value million december million summarised balance sheet information based information published post balance sheet date respect innoviva set december december noncurrent assets current assets current liabilities noncurrent liabilities net assets carrying value groups investment innoviva analysed follows interest net assets associate goodwill fair value adjustments carrying value december gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued investments investments investments designated investments designated investments measured measured measured measured fvtoci fvtpl fvtoci fvtpl january additions net fair value movements comprehensive income net fair value movements profit loss disposals settlements december investments comprise noncurrent equity investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments recent financing rounds discounted cash flows underlying net assets net fair value movements include impact exchange losses million comprehensive income nil profit loss losses million million respectively investments include listed investments million million gsk elected designate majority equity investments measured fair value comprehensive income fvtoci significant investments held december curevac ag group holds common stock crispr therapeutics ag group holds lyell immunopharma inc group holds andme inc group holds turning point therapeutics inc group holds investments fair value december million million million million million million million million million respectively investments include equity stakes companies gsk research collaborations companies provide access biotechnology developments potential interest june gsk issued us us notes exchangeable option note holders time maturity notes june shares held gsk theravance biopharma inc upon exchange notes gsk expects deliver shares may option certain circumstances deliver cash combination theravance biopharma shares cash theravance biopharma shares measured fvtoci fair value december million disposal equity investments measured fvtoci accumulated fair value movements reclassified fair value reserve retained earnings investments fair value million million disposed year cumulative gain investments tax million million certain investments investments funds limited lives investments acquired intention sell measured fair value profit loss fvtpl additions disposals investments measured fvtpl include acquisition shares hindustan unilever limited merger gsks indian listed consumer healthcare entity hindustan unilever subsequent divestment shares noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables amounts receivable insurance contacts held cash surrender value movements profit loss within receivables million million million million classified financial assets million million classified fair value profit loss remaining balance million million expected credit loss allowance immaterial december gsk annual report notes financial statements continued inventories raw materials consumables work progress finished goods trade receivables trade receivables net loss allowance accrued income prepayments interest receivable employee loans advances receivables trade receivables included nil nil due associates joint ventures receivables included nil nil due associates joint ventures loss allowance january exchange adjustments charge year subsequent recoveries amounts provided utilised december total trade receivables balance million million considered credit impaired million million expected credit loss allowance applied amount purchased originated credit impaired within receivables million million million million classified financial assets nil nil classified fair value profit loss remaining balance million million expected credit loss allowance million million recognised december charge reported profit loss year discussion credit risk practices please refer note gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued cash cash equivalents cash bank hand shortterm deposits addition nil million cash cash equivalents reported assets held sale see note assets held sale cash cash equivalents included billion billion available general use due restrictions applying subsidiaries held restrictions include exchange controls taxes repatriation assets held sale property plant equipment right use assets lease liabilities goodwill intangibles inventory cash cash equivalents noncurrent assets disposal groups transferred assets held sale expected carrying amounts recovered principally disposal sale considered highly probable held lower carrying amount fair value less costs sell included within assets held sale inventory written fair value less costs sell million million valuation methodology used significant inputs based observable market data therefore valuation classified level fair value hierarchy intangible assets million transferred intangibles year intangible assets held sale remaining december million impairments exchange movements assets divested year assets held sale december primarily comprised disposal group thermacare acquired pfizer part consumer healthcare business divested meet antitrust requirements disposal group horlicks consumer healthcare nutritional products india number countries divestments disposal groups completed gsk annual report notes financial statements continued trade payables trade payables wages salaries social security viiv healthcare put option payables deferred income customer return rebate accruals accruals trade payables included million million due associates joint ventures group provides limited supplier financing arrangements certain customers amounts involved december material revenue recognised year included deferred income january million million customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers included million million respect us pharmaceuticals vaccines fully described group financial review accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual amounts paid changes arrangements future events could cause assumptions accruals based change could affect future results group pfizers put option shareholding viiv healthcare currently exercisable pfizer may request ipo viiv healthcare time either gsk consent ipo offering completed within nine months pfizer could require gsk acquire shareholding amount liability put option held gross redemption basis derived internal valuation viiv healthcare business utilising discounted forecast future cash flow multiplesbased methodologies table shows indicative basis income statement balance sheet sensitivity pfizer put option reasonably possible changes key assumptions increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued net debt listing exchange current assets liquid investments cash cash equivalents cash cash equivalents reported assets held sale shortterm borrowings commercial paper bank loans overdrafts drawn bank facility euribor euro medium term note london stock exchange euro medium term note london stock exchange libor us us medium term note new york stock exchange euribor euro medium term note london stock exchange euro medium term note london stock exchange lease liabilities longterm borrowings us us medium term note new york stock exchange libor us us medium term note new york stock exchange euribor euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange exchangeable us us medium term note new york stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange longterm borrowings lease liabilities net debt gsk annual report notes financial statements continued net debt continued current assets liquid investments classified financial assets amortised cost december included us treasury notes government bonds effective interest rate liquid investments december approximately approximately liquid investment balances december earning interest floating rates amount million million liquid investment balances december earning interest fixed rates amount nil million balances reported within cash cash equivalents original maturity three months less effective interest rate cash cash equivalents december approximately approximately cash cash equivalents december earning interest floating fixed rates amounted million million respectively million million noninterest bearing holdings amounted million million gsks policy regarding credit quality cash cash equivalents set note financial instruments related disclosures shortterm borrowings gsk billion billion us commercial paper programme million million issue december billion billion gsk billion euro commercial paper programme newly established nil issue december gsk billion threeyear committed facility billion billion day committed facility three year committed facility agreed september extended one year september day committed facility agreed september facilities undrawn december weighted average interest rate commercial paper borrowings december weighted average interest rate current bank loans overdrafts december average effective preswap interest rate notes classified shortterm december rate reflects upcoming maturities libor coupon note may zero coupon euribor note september longterm borrowings yearend gsk longterm borrowings billion billion billion billion fell due five years average effective preswap interest rate notes issue december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates ranging pledged assets group held pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions lease liabilities maturity analysis discounted lease liabilities recognised group balance sheet follows rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total lease liabilities gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service pension costs defined benefit schemes accounting purposes calculated using projected unit credit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years remeasurement movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females us mortality rates calculated using pri white collar table adjusted reflect recent experience rates projected using mp allow future improvements life expectancy gsk annual report notes financial statements continued pensions postemployment benefits continued average life expectancy assumed individual age projected apply individual age follows uk us male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment physical asset allocation strategy three four uk plans adjusted returnseeking assets liabilitymatching assets returnseeking assets liabilitymatching assets buyin insurance contract purchased cover substantially obligations uk plan december value insurance contract million million asset allocation us plans currently set returnseeking assets liabilitymatching assets pension plans exposed risk arises estimated market value plans assets might decline investment returns might reduce estimated value plans liabilities might increase line agreed mix returnseeking assets generate future returns liabilitymatching assets better match future pension obligations group defined overall longterm investment strategy plans investments across broad range assets main market risks within asset hedging portfolio credit risk interest rates longterm inflation equities property currency bank counterparty risk plan liabilities series future cash flows relatively long duration ias basis cash flows sensitive changes expected longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation corresponds increase liabilities increase discount rate corresponds decrease liabilities interest rate risk credit rate risk us partially hedged targets based accounting measure plan liabilities uk plans interest rate inflation hedging strategy place targets based economic measure plan liabilities furthermore plans also currently hedge portion equity exposure staggered maturity profile uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme addition group operates number postretirement healthcare schemes principal one us following period consultation impacted employees announced december uk defined benefit plans would closed future accrual effective march result post closure accrued benefits active participants revalued line inflation rpi legacy glaxo wellcome plans cpi legacy smithkline beecham plans subject relevant caps arrangement rather capped pay increases addition defined benefit plan participants still active april receive defined pension contribution effect closure defined contribution enhancement together result one cost million announced september us cash balance pension plans would closed future accrual january change resulted credit million june september two amendments made retiree healthcare plans us resulting credit million group applied following financial assumptions assessing defined benefit liabilities uk us rest world pa pa pa pa pa pa pa pa pa rate increase future earnings na discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate sensitivity analysis detailing effect changes assumptions provided analysis provided reflects assumption changes material impact results group gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement losses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income amounts included within past service costs uk included million million million augmentation costs arose major restructuring programmes together charge million relation impact closure defined benefit schemes future accrual past service costs uk included charge million relation estimated impact guaranteed minimum pension gmp equalisation gmps minimum pension entitlements members schemes elected contract state earnings related pension scheme uk high court ruling required equalisation benefits earned included gmps order address gender inequality arising gmps different men women past service credit million us reflected closure cash balance pension plans january amendments retiree healthcare plan us resulted credit million past service costs postretirement benefits gsk annual report notes financial statements continued pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised assets held sale postretirement benefits recognised pensions postemployment benefits pension schemes deficit postretirement benefits event plan windup gsk believes uk pension scheme rules provide company right refund surplus assets following full settlement plan liabilities result net surplus uk defined benefit pension schemes recognised full fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets multiasset funds comprise investments pooled investment vehicles invested across range asset classes increasing diversification within growth portfolio value funds asset class quoted market price million million assets category comprises cash mark market values derivative positions indexlinked gilts held part uk repo programme included government bonds related loan million december million nil deducted within assets gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements fair values assets assets january exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments additions business combinations interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments additions business combinations interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december group made special funding contributions uk pension schemes million million nil nil nil million us schemes gsk reached revised agreement trustees uk pension schemes make additional contributions eliminate pension deficits identified within schemes december actuarial funding valuation based funding agreements additional contributions eliminate pension deficit expected million included within note commitments funding commitment supersedes previous agreement made contributions based government bond yield curve approach selecting discount rate rate chosen included allowance expected investment returns reflected asset mix schemes employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements defined benefit obligations obligations january exchange adjustments service cost past service costcredit interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments additions business combinations service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments disposals service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december defined benefit pension obligation analysed follows funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter december us postretirement healthcare scheme obligation million million million postretirement benefits unfunded gsk annual report notes financial statements continued pensions postemployment benefits continued movement net defined benefit liability follows january exchange adjustments additions business combinations service cost past service cost interest cost settlements curtailments remeasurements return plan assets excluding amounts included interest gain change demographic assumptions lossgain change financial assumptions experience gainslosses employer contributions expenses december remeasurements included within postretirement benefits detailed gain change demographic assumptions lossgain change financial assumptions experience gains defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension post retirement costs detailed information determined taking account duration liabilities overall profile plan memberships increase decrease discount rate decreaseincrease annual pension cost increasedecrease annual postretirement benefits cost decreaseincrease pension obligation decreaseincrease postretirement benefits obligation increase decrease decreaseincrease annual pension cost increasedecrease annual postretirement benefits cost decreaseincrease pension obligation decreaseincrease postretirement benefits obligation increase decrease inflation rate increasedecrease annual pension cost increasedecrease pension obligation year increase life expectancy increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation increase annual postretirement benefits cost increase postretirement benefits obligation gsk annual report notes financial statements continued provisions legal major employee restructuring related disputes programmes provisions provisions total january exchange adjustments charge year reversed unused unwinding discount utilised reclassifications movements transfer pension obligations december settled within one year settled one year december legal disputes group potential settlement discussions number group involved substantial number legal disputes amounts provided disputes including notification possible claims set based current assessment progress note legal proceedings provisions legal disputes estimates million amount provided disputes include amounts relating product liability antitrust december settled within one year government investigations contract terminations self december expected million insurance million provision made legal disputes reimbursed third parties discussion net charge year million including reversals legal issues see note legal proceedings estimated insurance recoveries primarily related provisions product liability cases commercial disputes major restructuring programmes various government investigations group four major restructuring programmes progress combined restructuring discount provisions increased million integration programme substantially complete increased million discount calculated major restructuring programme consumer using riskadjusted projected cash flows riskfree rates healthcare joint venture integration programme return separation preparation programme programmes respect product liability claims related certain products focused primarily simplifying supply chain processes provision made sufficient history claims rationalising groups manufacturing network restructuring made settlements enable management make reliable pharmaceuticals commercial operations integrating estimate provision required cover unasserted claims pfizer consumer healthcare business preparing ultimate liability matters may vary amounts separation gsk two new companies provided dependent upon outcome litigation restructuring provisions primarily include severance costs proceedings investigations possible settlement management made formal decision eliminate negotiations certain positions communicated nature groups business number groups employees affected appropriate consultation matters may subject negotiation litigation procedures completed appropriate provision many years litigation proceedings including various made staff severance payments paid immediately appeal procedures often take many years reach resolution pension augmentations arising staff redundancies outofcourt settlement discussions also often million million charged protracted indemnified disputes result provision year transferred pensions obligations provision charge corresponding receivable million relates defined benefit plans million relates defined contribution schemes shown note pensions postemployment benefits gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued provisions continued employee related provisions given nature provisions amounts likely employee related provisions include obligations certain settled many years medical benefits disabled employees spouses provisions us december provision benefits included provisions insurance provisions amounted million million employee million million number benefits reflect variety provisions severance costs provisions including vehicle insurance regulatory matters jubilee awards longservice benefits contingent consideration liabilities consideration certain acquisitions includes amounts contingent future events development milestones sales performance group provided fair value contingent consideration follows shionogi viiv novartis healthcare vaccines total january remeasurement income statement cash payments operating cash flows cash payments investing activities december remeasurement income statement cash payments operating cash flows cash payments investing activities movements december remeasurement income statement cash payments operating cash flows cash payments investing activities december contingent consideration payable december million million expected paid within one year consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccines business expected paid number years result total estimated liabilities discounted present values shown shionogiviiv healthcare contingent consideration liability discounted novartis vaccines contingent consideration liability discounted commercialised products pipeline assets shionogiviiv healthcare novartis vaccines contingent consideration liabilities calculated principally based forecast sales performance specified products lives products table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuations contingent consideration liabilities shionogi shionogi viiv novartis viiv novartis healthcare vaccines healthcare vaccines increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts increase discount rate decrease discount rate increase probability milestone success decrease probability milestone success cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report notes financial statements continued noncurrent liabilities accruals deferred income payables payables includes number employeerelated liabilities including employee savings plans contingent liabilities december contingent liabilities gsk present obligation result past event comprising guarantees discounted bills items arising normal course business amounted million million contingent liabilities arise group present obligation arising past event december million million financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible make reliable estimate potential outflow funds might required settle disputes possibility outflow remote descriptions significant legal disputes group party set note legal proceedings commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions interest loans future finance charges leases commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted increase intangible commitments mainly attributable number new rd collaborations including curevac ideaya biosciences surface oncology gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation payment million due table includes commitment excludes normal ongoing annual funding requirement uk approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued share capital share premium account share ordinary shares p premium number share capital issued fully paid january issued employee share schemes december issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes ordinary shares acquired esop trusts december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes gsk annual report notes financial statements continued movements equity retained earnings reserves amounted million december million million loss million million million related associates joint ventures cumulative translation exchange equity follows net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets december reported adjustment exchange movements overseas net assets december revised exchange movements overseas net assets reclassification exchange movements liquidation disposal overseas subsidiaries december exchange movements overseas net assets reclassification exchange movements liquidation disposal overseas subsidiaries december analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries fair value movements cash flow hedges reclassification cash flow hedges income expense tax fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement losses defined benefit plans tax remeasurement losses defined benefit plans comprehensive expenseincome year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries fair value movements cash flow hedges reclassification cash flow hedges income expense tax fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive expenseincome year gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued movements equity continued non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements cash flow hedges reclassification cash flow hedges income expense tax fair value movements cash flow hedges deferred tax reversed reclassification cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive incomeexpense year information net investment hedges provided part note financial instruments related disclosures analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january exchange adjustments transferred retained earnings year disposal equity investments net fair value movement year writedown shares held esop trusts december exchange adjustments transferred retained earnings year disposal equity investments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december exchange adjustments transferred retained earnings year disposal equity investments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million gsk annual report notes financial statements continued noncontrolling interests total noncontrolling interests includes following individually material noncontrolling interests noncontrolling interests individually material viiv healthcare gsk holds viiv healthcare subgroup giving rise material noncontrolling interest summarised financial information respect viiv healthcare subgroup follows turnover profit taxation comprehensive incomeexpense total comprehensive income noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net liabilities net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities decreaseincrease cash bank overdrafts year financial information relates viiv healthcare group standalone basis impact grouprelated adjustments primarily related recognition preferential dividends profit taxation million million million stated charging preferential dividends payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable consideration expected paid number years following amounts attributable viiv healthcare group included gsks financial statements share profit year attributable noncontrolling interest dividends paid noncontrolling interest noncontrolling interest consolidated balance sheet gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued noncontrolling interests continued consumer healthcare joint venture gsk holds consumer healthcare subgroup giving rise material noncontrolling interest summarised financial information respect consumer healthcare subgroup follows turnover profit taxation comprehensive expenses total comprehensive incomeexpenses noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets net cash inflow operating activities net cash inflowoutflow investing activities net cash outflow financing activities increase cash bank overdraft yearperiod financial information relates consumer healthcare joint venture standalone basis year ended december period formation july december impact grouprelated adjustments classification cash pooling accounts group companies outside consumer healthcare joint venture major restructuring charges following amounts attributable consumer healthcare joint venture included gsks financial statements share profit yearperiod attributable noncontrolling interest dividends paid noncontrolling interest noncontrolling interest consolidated balance sheet gsk annual report notes financial statements continued related party transactions december gsk owned million shares innoviva inc biopharmaceutical company listed nasdaq gsk began recognising innoviva associate september royalties due gsk innoviva year million million december balance payable gsk innoviva million million loan million medicxi ventures lp remained due gsk december loan due index ventures life vi jersey lp repaid year gsk increased investment kurma biofund ii fcpr million apollo therapeutics llp million investments also made medicxi ventures lp million part joint venture agreement qura therapeutics llc group obligation fund joint venture million per quarter april june agreement extended second fiveyear period april gsk joint venture partner committing additional financial support amount million december outstanding liability due qura million cash distributions received investments medicxi ventures lp million index venture vi jersey lp million aggregate compensation directors cet given note employee costs acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given business acquisitions gsk completed one smaller business acquisition acquired pfizer biotech corporation taiwan part pfizers consumer healthcare business previously recognised part consumer healthcare joint venture september non cash consideration million represented goodwill million cash million assets acquired million less noncontrolling interest million net liabilities million total net assets acquired intangible assets property plant equipment inventory trade receivables cash cash equivalents trade payables noncontrolling interest goodwill noncash consideration settlement promissory note total consideration business disposals april gsk completed divestment horlicks consumer healthcare nutrition products india number countries excluding bangladesh unilever merger gsks indian listed consumer healthcare entity hindustan unilever indian listed public company gsk received equity stake hindustan unilever million cash gsk disposed equity stake hindustan unilever may divestment bangladesh closed june total cash consideration received million cash divested part disposal india bangladesh consumer healthcare entities million gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued acquisitions disposals continued profit disposal businesses year million calculated follows horlicks divestment total consideration cash consideration receivable including currency forwards purchase adjustments equity investment hindustan unilever limited total net assets disposed goodwill intangible assets property plant equipment inventory cash cash equivalents net liabilitiesassets total costs transaction costs derivative reclassification exchange comprehensive income total gain disposals exposure share price movements embedded agreement merge gsks indian listed consumer healthcare entity hindustan unilever limited part divestment horlicks nutrition products india number countries recognised derivative signing agreement completion transaction million recorded cost table derecognition derivative asset largely reflects fair value gains recognised income statement prior periods associates joint ventures year gsk made investments associates million million paid cash cash flows associates joint business business ventures acquisitions disposals investments cash consideration receivedpaid net deferred consideration transaction costs cash cash equivalents acquireddivested cash inflowoutflow gsk annual report notes financial statements continued acquisitions disposals continued business acquisitions pfizer consumer healthcare business acquisition pfizers consumer healthcare business completed july gsk pfizer contributed respective consumer healthcare businesses new consumer healthcare joint venture noncash transaction whereby gsk acquired pfizers consumer healthcare business return shares joint venture gsk equity interest majority control joint venture pfizer equity interest group control consumer healthcare joint venture consolidated within groups financial statements number territories legal completion acquisition occurred regulatory constraints however consumer healthcare joint venture obtained control majority businesses territories july consolidated net assets businesses date cases entitled benefits trading businesses delayed territories noncontrolling interest consumer healthcare joint venture calculated applying proportionate goodwill method represents pfizers share net assets joint venture excluding goodwill goodwill billion expected deductible tax purposes recognised goodwill represents potential synergies arising combining acquired businesses gsks existing business together value workforce acquired total transaction costs recognised acquisition amounted million since acquisition july sales billion arising pfizer consumer healthcare business included group turnover business acquired beginning year estimated group turnover would approximately billion higher business integrated groups existing activities practicable identify impact group profit period tesaro inc january gsk acquired tesaro inc oncology focused biopharmaceutical company cash consideration billion billion order strengthen groups pharmaceutical pipeline transaction costs amounted million goodwill billion none expected taxdeductible recognised goodwill represents potential synergies arising combining acquired businesses gsks existing business together value workforce acquired acquisition january december sales billion arising tesaro business included group turnover business integrated groups existing activities practicable identify impact group profit period fair value assets acquired business combinations including goodwill set table amounts related pfizer consumer healthcare business acquisition provisional subject change pfizer consumer healthcare business tesaro net assets acquired intangible assets property plant equipment right use assets inventory trade receivables assets including cash cash equivalents trade payables net deferred tax liabilities liabilities term loan noncontrolling interest goodwill total consideration settled shares gsk consumer healthcare joint venture cash consideration paid fair value investment joint venture converted subsidiary total consideration gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued acquisitions disposals continued noncontrolling interest million represents pfizers share fair value pfizer consumer healthcare business excluding goodwill total noncontrolling interest initially recognised consolidated statement changes equity million also includes pfizers share book value gsk consumer healthcare business disposals gsk made number business disposals net cash consideration received year million profit disposal businesses year million calculated follows total cash consideration receivable net subsidy payable net assets disposed goodwill intangible assets property plant equipment inventory cash cash equivalents net assets transaction costs reclassification exchange comprehensive income noncontrolling interest divested transaction signed yet completed gain embedded derivative transaction signed yet completed transaction costs total profit disposal transaction signed yet completed december december gsk agreed divest horlicks consumer healthcare nutrition brands unilever plc form merger glaxosmithkline consumer healthcare limited hindustan unilever limited total consideration valued approximately billion glaxosmithkline consumer healthcare limited public company listed national stock exchange nse bombay stock exchange bse gsk held stake following merger glaxosmithkline consumer healthcare limited hindustan unilever limited public company listed nse bse gsk would million hindustan unilever limited shares group entered forward foreign exchange contracts relation transaction contracts value billion designated cash flow hedge part foreign exposure arising transaction contracts value billion designated net investment hedges inr eur assets addition exposure share price movements forward purchase shares hindustan unilever limited recognised embedded derivative embedded derivative asset position fair value million december million associates joint ventures year gsk made investments million associates joint ventures million paid cash cash flows associates joint business business venture acquisitions disposals investments cash consideration paidreceived net deferred consideration received transaction costs cash cash equivalents acquireddivested cash outflowinflow gsk annual report notes financial statements continued business acquisitions business acquisitions business disposals gsk made number small business disposals year net cash consideration million cash flows associates associates joint joint business venture venture disposals investments disposals cash consideration net deferred consideration received cash inflowoutflow adjustments reconciling profit tax operating cash flows profit tax tax profits share aftertax profits associates joint ventures finance expense net finance income depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets profit sale investments associates profit sale equity investments gain novartis consumer healthcare joint venture put option hedging business acquisition costs changes working capital decrease inventories increase trade receivables increase trade payables increasedecrease receivables contingent consideration paid see note noncash increase contingent consideration liabilities increase payables increasedecrease pension provisions sharebased incentive plans fair value adjustments cash generated operations gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued reconciliation net cash flow movement net debt net debt previously reported implementation ifrs net debt beginning year adjusted increase cash bank overdrafts increasedecrease liquid investments increase longterm loans repayment shortterm notes repayment ofincrease shortterm loans repayment lease liabilities debt subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year january profit reclass december exchange loss ifications cash flow analysis changes net debt liquid investments cash cash equivalents cash cash equivalents ahfs overdrafts debt due within one year commercial paper europeanus medium term notes bank facilities lease liabilities debt due one year europeanus medium term notes bank facilities lease liabilities net debt analysis changes liabilities financing activities debt due within one year debt due one year derivative financial instruments financing items interest payable total liabilities financing activities ifrs january implement debt profit reclass december ation exchange acquired loss ifications cash flow analysis changes liabilities financing activities debt due within one year debt due one year derivative financial instruments financing items interest payable total liabilities financing activities information significant changes net debt see note net debt gsk annual report notes financial statements continued financial instruments related disclosures objective gsks treasury activity minimise facilities undrawn december gsk posttax net cost financial operations reduce volatility considers level committed facilities adequate given benefit earnings cash flows gsk uses variety current liquidity requirements financial instruments finance operations derivative repayment additional bank facilities agreed financial instruments manage market risks support transactions completed none remain active operations derivatives principally comprise foreign exchange december june billion drawn forward contracts swaps used swap support acquisition novartis remaining stake borrowings liquid assets currencies required group consumer healthcare joint venture billion repaid purposes well interest rate swaps used november billion repaid may manage exposure financial risks changes interest rates financial instruments reduce uncertainty gsk billion euro medium term note programme foreign currency transactions interest payments december billion notes issue programme group also billion derivatives used exclusively hedging purposes billion notes issue december relation underlying business activities trading us shelf registration gsks borrowings mature dates speculative instruments capital management put option owned pfizer viiv healthcare gsks financial strategy supports groups strategic exercisable reviewing liquidity requirements gsk considers priorities regularly reviewed board gsk manages sufficient financing options available put capital structure group appropriate mix option exercised debt equity market risk capital structure group consists net debt interest rate risk management billion see note net debt total equity objective gsks treasury activity minimise including items related noncontrolling interests effective net interest cost balance mix debt fixed billion see consolidated statement changes floating rates time equity total capital including provided noncontrolling interests billion groups main interest rate risk arises borrowings investments floating rates refinancing maturing fixed group continues manage financial policies credit rate debt changes interest rates affect future profile particularly targets shortterm credit ratings cash flows fair values financial instruments policy p maintaining single longterm ratings consistent interest rate risk management limits net amount targets groups longterm credit rating floating rate debt specific cap reviewed agreed standard poors stable outlook moodys less annually board investor services moodys negative outlook groups shortterm credit ratings p standard majority debt issued fixed interest rates poors moodys respectively changes floating rates interest significantly affect groups net interest charge includes liquidity risk management borrowings interest rate swaps place gsks policy borrow centrally order meet anticipated removes impact associated periodic repricing funding requirements strategy diversify liquidity shortterm borrowings including bank facilities exposed sources using range facilities maintain broad access risk future changes market interest rate financial markets majority cash liquid investments december gsk billion borrowings repayable within one year held billion cash interest rate benchmark reform cash equivalents liquid investments billion interest rate benchmark reform amendments ifrs held centrally gsk access shortterm finance ias ifrs issued iasb september billion billion us commercial paper amendments modify specific hedge accounting programme million million issue requirements allow hedge accounting continue december billion billion gsk affected hedges period uncertainty access shortterm finance billion euro hedged items hedging instruments affected current commercial paper programme newly established interest rate benchmarks amended result nil issue december gsk billion ongoing interest rate benchmark reforms threeyear committed facility billion billion december group directly exposed day committed facility three year committed facility interest rate benchmark reform held interest rate agreed september extended one year derivatives referenced libor matured end september day committed facility floating rate bonds due mature agreed september end gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued group closely monitored market output group considers maximum credit risk december various industry working groups managing million december transition new benchmark interest rates includes million total groups financial announcements made libor regulators including assets exception investments comprising financial conduct authority fca us commodity equity investments bear equity risk rather credit futures trading commission regarding transition away risk see details groups total financial libor including gbp libor usd libor assets december gsks greatest concentration euribor sterling overnight index average rate credit risk billion legal general sonia secured overnight financing rate sofr investment management class gbp liquidity fund aaaaaa euro shortterm rate str respectively fca billion legal general investment made clear end longer management class gbp liquidity fund aaaaaa seek persuade compel banks submit libor change estimation techniques exception usd libor significant assumptions made current reporting intercontinental exchange ice benchmark administration period assessing loss allowance financial assets iba fcaregulated authorised administrator amortised cost since adoption ifrs start libor announced consult intention reporting period cease us libor iba intends subject confirmation following consultation one week two month us treasuryrelated credit risk libor settings cease end gsk sets global counterparty limits gsks banking us libor panel cease end june investment counterparties based longterm credit ratings moodys standard poors usage group undertaking interest rate benchmark transition limits actively monitored programme identify potential exposures within business deliver smooth transition appropriate alternative gsk actively manages exposure credit risk reducing benchmark rates surplus cash balances wherever possible part gsks strategy regionalise cash management concentrate foreign exchange risk management cash centrally much possible table sets groups objective minimise exposure overseas credit exposure counterparties rating liquid operating subsidiaries transaction risk matching local investments cash cash equivalents derivatives currency income local currency costs possible foreign currency transaction exposures arising external gross asset position derivative contract internal trade flows selectively hedged gsks internal considered purpose table although isda trading transactions matched centrally intercompany agreements amount risk net position payment terms managed reduce foreign currency risk counterparty table e sets groups possible gsk manages cash surpluses financial assets liabilities offset basis borrowing requirements subsidiary companies centrally december million cash categorised using forward contracts hedge future repayments back held unrated subinvestment grade rated counterparties originating currency lower bbbbaa million cash transit order reduce foreign currency translation exposure remaining exposure concentrated overseas banks used group seeks denominate borrowings currencies local cash management investment purposes including principal assets cash flows primarily million nigeria held united bank africa zenith denominated us dollars euros sterling borrowings bank stanbic ibtc bank million halk bank swapped currencies required uk million btv austria million banco itau brazil million banco de la nacion panama million borrowings denominated swapped foreign hatton national bank sri lanka million hua nan currencies match investments overseas group assets bank taiwan million banco popular puerto may treated hedge relevant assets forward rico million bank balances deposits held contracts major currencies also used reduce exposure bbbbaa rated counterparties million held groups investment overseas assets see net bbbbaa rated counterparties including balances investment hedges section note details deposits million hdfc bank india million credit risk state bank india banks used local credit risk risk counterparty default investment purposes contractual obligations resulting financial loss group gsk measures expected credit losses cash cash arises cash cash equivalents favourable equivalents function individual counterparty credit ratings derivative financial instruments held banks financial associated month default rates expected credit losses institutions well credit exposures wholesale retail cash cash equivalents thirdparty financial customers including outstanding receivables derivatives deemed immaterial loss experienced gsk annual report notes financial statements continued financial instruments related disclosures continued credit ratings assigned standard poors moodys respectively opinions two rating agencies differ gsk assigns lower rating two counterparty local rating agency fitch data source available ratings converted global ratings equivalent standard poors moodys using published conversion tables credit ratings form basis assessment expected credit loss treasuryrelated balances held amortised cost bank balances deposits government securities bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total gsks centrally managed cash reserves amounted new customers subject credit vetting process billion december available within three existing customers subject review least annually months includes billion cash managed vetting process subsequent reviews involve obtaining group viiv healthcare owned subsidiary information including customers status government billion cash managed group gsk consumer private sector entity audited financial statements credit bureau healthcare owned subsidiary group invested reports debt rating agency eg moodys standard poors centrally managed liquid assets bank deposits aaaaaa reports payment performance history trade references rated us treasury treasury repo money market funds industry credit groups bank references aaaaaa rated liquidity funds trade receivables consist amounts due large number wholesale retail credit risk customers spread across diverse industries outside us customer accounts geographical areas ongoing credit evaluation performed groups trade receivables balance financial condition accounts receivable appropriate credit insurance purchased factoring us line pharmaceutical companies arrangements put place group sells products small number wholesalers addition hospitals pharmacies physicians amount information obtained proportional level groups sales three largest wholesalers amounted exposure considered information evaluated approximately sales us quantitatively ie credit score qualitatively ie judgement pharmaceuticals vaccines businesses conjunction customers credit requirements december group trade receivables due determine credit limit three wholesalers totalling million trade receivables grouped customer segments million group exposed concentration similar loss patterns assess credit risk credit risk respect wholesalers one receivables financial assets assessed individually encounters financial difficulty could materially historical forwardlooking information considered adversely affect groups financial results determine appropriate expected credit loss allowance groups credit risk monitoring activities relating group believes credit risk provision wholesalers include review quarterly financial required excess allowance expected credit losses information standard poors credit ratings development see note trade receivables gsk internal risk ratings establishment periodic review credit limits gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued credit enhancements following methods assumptions used estimate group uses credit enhancements including factoring fair values significant financial instruments credit insurance minimise credit risk trade measured fair value balance sheet receivables group december million companyowned life insurance policies based cash million trade receivables insured surrender value order protect receivables loss due credit risks default insolvency bankruptcy receivables payables including put options carried amortised cost approximates carrying amount group entity assesses credit risk private customers determine credit insurance required liquid investments approximates carrying amount factoring arrangements managed locally entities cash cash equivalents carried amortised cost used mitigate risk arising large credit risk approximates carrying amount concentrations factoring arrangements nonrecourse longterm loans based quoted market prices level fair value financial assets liabilities excluding lease fair value measurement case european us liabilities medium term notes approximates carrying amount table presents carrying amounts case fixed rate borrowings floating rate bank fair values groups financial assets liabilities loans excluding lease liabilities december shortterm loans overdrafts commercial paper december approximates carrying amount short fair values financial assets liabilities included maturity instruments price would received sell asset paid transfer liability orderly transaction market participants measurement date following methods assumptions used measure fair values significant financial instruments carried fair value balance sheet investments equity investments traded active market determined reference relevant stock exchange quoted bid price equity investments determined reference current market value similar instruments recent financing rounds discounted cash flows underlying net assets trade receivables carried fair value based invoiced amount interest rate swaps foreign exchange forward contracts swaps options based present value contractual cash flows option valuation models using market sourced data exchange rates interest rates balance sheet date cash cash equivalents carried fair value based net asset value funds contingent consideration business acquisitions divestments based present values expected future cash flows gsk annual report notes financial statements continued financial instruments related disclosures continued carrying fair carrying fair value value value value notes financial assets measured amortised cost noncurrent assets b trade receivables b liquid investments cash cash equivalents items assets held sale b financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables ab financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets ab trade receivables ab held trading derivatives designated effective hedging relationship ade cash cash equivalents derivatives designated effective hedging instruments fair value movements comprehensive income ade total financial assets financial liabilities measured amortised cost borrowings excluding obligations lease liabilities bonds designated hedging relationship bonds bank loans overdrafts commercial paper borrowings total borrowings excluding lease liabilities f trade payables c provisions c noncurrent liabilities c items assets held sale c financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities ac held trading derivatives designated effective hedging relationship ade derivatives designated effective hedging instruments fair value movements comprehensive income ade total financial liabilities excluding lease liabilities net financial assets financial liabilities excluding lease liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets trade payables provisions noncurrent liabilities contingent consideration liabilities items assets held sale reconciled relevant notes pages december cash cash equivalents table included million reported assets held sale see note assets held sale gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued fair value investments gsk shares december employee share ownership plan esop trusts held gsk shares carrying value million million market value million million based quoted market price shares held esop trusts satisfy future exercises options awards employee incentive schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earnings financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies level level level total december financial assets fair value financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets trade receivables held trading derivatives designated effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value movements oci financial liabilities fair value financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities held trading derivatives designated effective hedging relationship derivatives designated effective hedging instruments fair value movements oci level level level total december financial assets fair value financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets trade receivables held trading derivatives designated effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value movements oci financial liabilities fair value financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities held trading derivatives designated effective hedging relationship derivatives designated effective hedging instruments fair value movements oci gsk annual report notes financial statements continued financial instruments related disclosures continued movements year financial instruments measured using level valuation methods presented january net losses recognised income statement net gains recognised comprehensive income settlement contingent consideration liabilities settlement contingent consideration receivables additions disposals settlements transfers level movements december net losses million million attributable level financial instruments recognised income statement included net losses million million respect financial instruments held end year losses million million reported operating income gains nil million reported finance income charges million million arose remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture million million arose remeasurement contingent consideration payable acquisition novartis vaccines business net gains million million attributable level financial instruments reported comprehensive income fair value movements equity investments included net gains million net gains million respect financial instruments held end year net gains million net gains million arose prior transfer level equity investments transferred level valuation methodology result listing recognised stock exchange year net gains losses include impact exchange movements financial liabilities measured using level valuation methods december included million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years vary line future performance specified products movements certain foreign currencies also included million million respect contingent consideration acquisition novartis vaccines business consideration expected paid number years vary line future performance specified products achievement certain milestone targets movements certain foreign currencies sensitivity analysis balances provided note contingent consideration liabilities b trade receivables noncurrent assets items assets held sale scope ifrs following table reconciles financial instruments within trade receivables noncurrent assets items assets held sale fall within scope ifrs relevant balance sheet amounts financial assets predominantly noninterest earning nonfinancial instruments include tax receivables pension surplus balances prepayments outside scope ifrs non non amortised financial financial amortised financial financial fvtpl fvtoci cost instruments instruments total fvtpl fvtoci cost instruments instruments total trade receivables note noncurrent assets note items assets held sale note trade receivables include trade receivables million million group portfolios three business models ifrs due factoring arrangements place million million held sell contractual cash flows measured fvtpl million million held either collect sell contractual cash flows measured fvtoci million million held collect contractual cash flows measured amortised cost december items assets held sale included million trade receivables measured amortised cost gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued c trade payables provisions noncurrent liabilities contingent consideration liabilities items assets held sale scope ifrs following table reconciles financial instruments within trade payables provisions noncurrent liabilities contingent consideration liabilities items assets held sale fall within scope ifrs relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities nonfinancial instruments include payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ifrs non non amortised financial financial amortised financial financial fvtpl cost instruments instruments total fvtpl cost instruments instruments total trade payables note provisions note noncurrent liabilities note contingent consideration liabilities note items assets held sale note derivative financial instruments hedging programmes derivatives used economic hedging purposes speculative investments classified held trading designated effective hedging instruments presented current assets liabilities expected settled within months end reporting period otherwise classified noncurrent group following derivative financial instruments fair value fair value assets liabilities assets liabilities noncurrent cash flow hedges interest rate swap contracts principal amount nil million net investment hedges cross currency swaps principal amount nil million current cash flow hedges interest rate swap contracts principal amount million million net investment hedges cross currency swaps principal amount million nil cash flow hedges foreign exchange contracts principal amount million million net investment hedges foreign exchange contracts principal amount million million derivatives designated effective hedging instruments noncurrent embedded derivatives current foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading total derivative instruments fair value hedges december december group designated fair value hedges gsk annual report notes financial statements continued financial instruments related disclosures continued net investment hedges december certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro singaporean sgd japanese jpy foreign operations shown table carrying value bonds included million million designated hedging instruments net investment hedges cash flow hedges group entered forward foreign exchange contracts designated cash flow hedges entered hedge foreign exchange exposure arising cash flows euro denominated coupon payments relating notes issued groups european medium term note programme buyout novartis noncontrolling interest consumer healthcare joint venture divestment horlicks nutrition brands took place refinancing existing debt maturities group manages cash flow interest rate risk using floatingtofixed interest rate swaps addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued prior years current year balance reclassified finance costs life bonds foreign exchange risk current year group designated certain foreign exchange forward contracts swaps cash flow net investment hedges foreign exchange derivative financial assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet following tables detail foreign exchange forward contracts swaps outstanding end reporting period well information related hedged items notional value foreign exchange forward contracts swaps absolute total outstanding positions balance sheet date hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessments ensure economic relationship exists hedged item hedging instrument group enters hedge relationships critical terms hedging instrument match exactly terms hedged item qualitative assessment effectiveness performed changes circumstances affect terms hedged item critical terms longer match exactly critical terms hedging instrument group uses hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationships effect counterparty groups credit risk fair value foreign exchange forward contracts swaps reflected fair value hedged item attributable changes foreign exchange rates ineffectiveness rolling cash flow hedges divestments mentioned sources ineffectiveness emerged hedging relationships ineffectiveness recorded cash flow hedges amounted gain million loss million ineffectiveness recorded net investment hedges nil included table borrowings bonds notional value us million swapped fixed interest rate eur debt cross currency interest rate swap notional carrying average foreign value value hedging instruments exchange rate currency cash flow hedges foreign exchange contracts buy foreign currency months eur gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued notional carrying average foreign value value hedging instruments exchange rate currency net investment hedges foreign exchange contracts sell foreign currency less months eur less months sgd less months jpy borrowings including cross currency interest rate swaps months eur months eur cumulative balance cash periodic change value flow hedge reserveforeign calculating hedge currency translation reserve ineffectiveness continuing hedges hedged items cash flow hedges variability cash flows highly probable forecast transaction variability cash flows foreign exchange exposure arising euro denominated coupon payments relating debt issued net investment hedges net investment foreign operations balances cash flow hedge reserve arising hedging relationships hedge accounting longer applied average foreign notional carrying exchange rate currency value value hedging instruments cash flow hedges foreign exchange contracts buy foreign currency months eur months eur sell foreign currency less months inrgbp less months inrsgd net investment hedges foreign exchange contracts sell foreign currency less months eur less months sgd less months inr less months jpy borrowings including cross currency interest rate swaps months eur months eur gsk annual report notes financial statements continued financial instruments related disclosures continued cumulative balance cash periodic change value flow hedge reserveforeign calculating hedge currency translation reserve ineffectiveness continuing hedges hedged items cash flow hedges variability cash flows highly probable forecast transaction variability cash flows foreign exchange exposure arising euro denominated coupon payments relating debt issued net investment hedges net investment european foreign operations balances cash flow hedge reserve arising hedging relationships hedge accounting longer applied following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss amount line item hedged hedge profit future cash line item hedging ineffectiveness loss flows gainslosses gainslosses hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows highly probable forecast transaction operating operating income income expense expense variability cash flows foreign exchange exposure arising finance finance euro denominated coupon payments relating debt issued income income expense expense net investment hedges net investment foreign operations finance finance income income expense expense following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss amount line item hedged hedge profit future cash line item hedging ineffectiveness loss flows gainslosses gainslosses hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows highly probable forecast transaction operating operating income income expense expense variability cash flows foreign exchange exposure arising finance finance euro denominated coupon payments relating debt issued income income expense expense net investment hedges net investment foreign operations finance finance income income expense expense gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued interest rate risk group manages cash flow interest rate risk using floatingtofixed interest rate swaps quarterly intervals difference fixed contract rates floating rate interest amounts calculated reference agreed notional principal amounts exchanged interest rate swap contracts exchanging floating rate interest fixed interest designated cash flow hedges hedge variability interest cash flows associated floating rate debt relating notes issued groups european medium term note programme interest rate swaps interest payments loan occur simultaneously amount accumulated equity reclassified profit loss period floating rate interest payments affect profit loss critical terms interest rate swap contracts corresponding hedged items qualitative assessment effectiveness performed expected value interest rate swap contracts value corresponding hedged items systematically change opposite directions response movements underlying interest rates main sources ineffectiveness hedge relationships effects groups credit risk fair value interest rate swap contracts reflected fair value hedged item attributable change interest rates sources ineffectiveness emerged hedging relationships following tables provide information regarding interest rate swap contracts outstanding related hedged items december december interest rate swap contract assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet change fair value average notional recognising fair value contracted fixed principal hedge assets rate value ineffectiveness liabilities hedging instruments less year years change value balance cash used flow hedge calculating reserve hedge continuing ineffectiveness hedges hedged items variable rate borrowings change fair value average notional recognising fair value contracted fixed principal hedge assets rate value ineffectiveness liabilities hedging instruments less year years change value balance cash used flow hedge calculating reserve hedge continuing ineffectiveness hedges hedged items variable rate borrowings gsk annual report notes financial statements continued financial instruments related disclosures continued following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss line item hedged amount profit future cash line item hedging hedge loss flows gainslosses ineffectiveness hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows finance finance income income expense expense prehedging longterm interest rates finance finance income income expense expense amount reclassified profit loss line item hedged amount profit future cash line item hedging hedge loss flows gainslosses ineffectiveness hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows finance finance income income expense expense prehedging longterm interest rates finance finance income income expense expense e offsetting financial assets liabilities financial assets liabilities offset net amount reported balance sheet legally enforceable right offset recognised amounts intention settle net basis realise asset settle liability simultaneously also arrangements meet criteria offsetting still allow related amounts offset certain circumstances bankruptcy termination contract following tables set financial assets liabilities offset subject enforceable master netting arrangements similar agreements offset december december column net amount shows impact groups balance sheet offset rights exercised gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset amount december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset balance december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party presently legally enforceable right offset amounts offset balance sheet presented separately table f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings lease liabilities total debt total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest gsk annual report notes financial statements continued financial instruments related disclosures continued g sensitivity analysis tables illustrate estimated impact income statement equity result hypothetical market movements foreign exchange interest rates relation groups financial instruments range variables chosen sensitivity analysis reflects managements view changes reasonably possible oneyear period foreign exchange sensitivity group operates internationally primarily exposed foreign exchange risk relation sterling movements us dollar euro japanese yen foreign exchange risk arises translation financial assets liabilities functional currency entity holds based groups net financial assets liabilities december weakening strengthening sterling currencies variables held constant illustrated tables tables exclude financial instruments expose group foreign exchange risk risk fully hedged another financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent depreciation us dollar cent depreciation euro yen depreciation yen equity impact shown foreign exchange sensitivity relates derivative nonderivative financial instruments hedging groups net investments european euro foreign operations cash flow hedges foreign exchange exposure arising euro denominated coupon payments relating notes issued groups european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent depreciation euro gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued tables present groups sensitivity weakening strengthening sterling relevant currency based composition net debt shown note adjusted effects foreign exchange derivatives part net debt affect future foreign currency cash flows increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent depreciation us dollar cent depreciation euro yen depreciation yen interest rate sensitivity group exposed interest rate risk outstanding borrowings investments changes interest rates affect future cash flows fair values financial instruments majority debt issued fixed interest rates changes floating rates interest significantly affect groups net interest charge although majority cash liquid investments earn floating rates interest table hypothetically shows groups sensitivity changes interest rates relation sterling us dollar euro floating rate financial assets liabilities interest rates applicable floating rate financial assets liabilities increased basis points assuming variables remained constant estimated groups finance income would increased approximately million million decrease basis points movement interest rates deemed material effect equity increasedecrease increasedecrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates gsk annual report notes financial statements continued financial instruments related disclosures continued h contractual cash flows nonderivative financial liabilities derivative instruments following tables provide analysis anticipated contractual cash flows including interest payable groups non derivative financial liabilities undiscounted basis purpose table debt defined classes borrowings except lease liabilities interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december finance trade payables charge interest lease lease liabilities debt debt liabilities liabilities net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance trade payables charge interest lease lease liabilities debt debt liabilities liabilities net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows table provides analysis anticipated contractual cash flows groups derivative instruments excluding equity options give rise cash flows embedded derivatives material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purpose table although practice group uses standard settlement arrangements reduce liquidity requirements instruments cash flows interest rate swaps shown table significant gross cash inflows gross cash ouflows gross cash inflows gross cash outflows foreign foreign foreign foreign cross exchange cross exchange cross exchange cross exchange currency forward currency forward currency forward currency forward interest rate contracts interest rate contracts interest rate contracts interest rate contracts swaps swaps swaps swaps swaps swaps swaps swaps due less one year one two years gross contractual cash flows gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued employee share schemes gsk operates several employee share schemes including share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets granting restricted share awards replaced granting options employees cost schemes readily equates potential gain made employee group also operates savings related share option schemes whereby options granted employees acquire shares glaxosmithkline plc discounted price grants restricted share awards normally exercisable end threeyear vesting performance period awards normally granted employees acquire shares ads glaxosmithkline plc circumstances may settled cash grants savingsrelated share option schemes normally exercisable three years saving accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant options historical share option schemes granted market price ruling date grant total charge sharebased incentive plans million million million amount million million million arose share value plan see note employee costs details glaxosmithkline share award schemes share value plan share value plan share awards granted certain employees cost awards vest two half three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december performance share plan performance share plan share awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted performance conditions based three equally weighted measures threeyear performance period adjusted free cash flow tsr rd new product performance awards granted performance conditions based four measures threeyear performance period adjusted free cash flow tsr rd new product performance pipeline progress fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant awards made million shares weighted fair value million ads weighted fair value december outstanding awards million shares million ads gsk annual report notes financial statements continued employee share schemes continued share options savingsrelated options purposes valuing savingsrelated options arrive sharebased payment charge blackscholes option pricing model used assumptions used model follows grant grant grant riskfree interest rate dividend yield volatility expected life years years years savingsrelated options grant price including discount share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price december na na range exercise prices options outstanding year end na na weighted average market price exercise year weighted average remaining contractual life na na years options million shares granted year savingsrelated share option scheme weighted average fair value december million savingsrelated share options exercisable share options ads options exercisable expired exercised july change effective exercise price outstanding options year employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves amortised value proceeds receivable employees exercise transfer retained earnings trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued principal group companies following represent principal subsidiaries countries incorporation group december equity share capital entities wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated england us glaxo group limited block drug company inc glaxo operations uk limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare holdings us llc glaxosmithkline consumer healthcare uk trading limited glaxosmithkline consumer healthcare lp glaxosmithkline consumer trading services limited glaxosmithkline holdings americas inc glaxosmithkline export limited glaxosmithkline llc glaxosmithkline finance plc human genome sciences inc glaxosmithkline holdings limited gsk consumer health inc glaxosmithkline research development limited pf consumer healthcare llc glaxosmithkline services unlimited gsk equity investments limited glaxosmithkline uk limited stiefel laboratories inc setfirst limited tesaro inc smithkline beecham limited viiv healthcare company viiv healthcare finance limited viiv healthcare limited viiv healthcare uk limited europe others glaxosmithkline biologicals sa belgium glaxosmithkline australia pty ltd australia glaxosmithkline sante grand public sas france glaxosmithkline consumer healthcare australia pty ltd australia laboratoire glaxosmithkline france glaxosmithkline brasil limitada brazil viiv healthcare sas france glaxosmithkline consumer healthcare ulcglaxosmithkline soins de glaxosmithkline consumer healthcare gmbh co kg germany sante aux consommateurs sri canada glaxosmithkline gmbh co kg germany glaxosmithkline inc canada gsk vaccines gmbh germany id biomedical corporation quebec canada glaxosmithkline consumer healthcare srl italy pf consumer healthcare canada ulcpf soins de sante sri canada glaxosmithkline spa italy glaxosmithkline limited china hong kong gsk vaccines srl italy sinoamerican tianjin smith kline french laboratories ltd china viiv healthcare srl italy wyeth pharmaceutical co ltd china pfizer consumer manufacturing italy srl italy glaxosmithkline asia pvt limited india gsk services sp z oo poland glaxosmithkline pharmaceuticals limited india glaxosmithkline trading services limited republic ireland glaxosmithkline consumer healthcare japan kk japan glaxosmithkline healthcare ao russia glaxosmithkline kk japan glaxosmithkline sa spain glaxosmithkline pakistan limited pakistan laboratorios viiv healthcare sl spain glaxo wellcome manufacturing pte ltd singapore gsk consumer healthcare sa switzerland glaxosmithkline korea limited republic korea glaxosmithkline llaclari sanayi ticaret turkey directly held whollyowned subsidiary glaxosmithkline plc subsidiaries associates listed principally affect figures groups financial statements glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc see pages complete list subsidiary undertakings associates joint ventures form part financial statements gsk annual report notes financial statements continued legal proceedings group involved significant legal administrative dolutegravirtivicaytriumeqdovatojuluca proceedings principally product liability intellectual property viiv healthcare received patent challenge letters tax antitrust consumer fraud governmental investigations hatchwaxman act cipla dr reddys labs significant matters tax matters apotex triumeq tivicay letters lupin described group makes provision mylan triumeq letter sandoz tivicay viiv proceedings regular basis summarised note healthcare lists two patents fda orange book tivicay accounting principles policies note triumeq one patent covers molecule dolutegravir provisions note also describes disclosure made expires october second patent claims crystal proceedings provision legal expenses form dolutegravir expires december incurred provisions related legal claims charged letters challenged laterexpiring crystal form patent selling general administration costs group several generic companies allege crystal believe information amount sought plaintiffs form patent invalid others claim crystal form patent known would meaningful respect legal invalid infringed proposed products proceedings due number factors including viiv healthcare filed patent infringement suits limited stage proceedings entitlement six generic companies parties appeal decision clarity theories liability matters mylan laurus successor damages governing law dr reddys labs resolved cases december groups aggregate provision defendants consolidated single case legal disputes including tax matters described us district court district delaware trial date note taxation million yet set assurance losses result outcome september viiv healthcare received paragraph iv legal proceedings exceed material amount letter cipla relating dovato challenging amount provisions reported groups financial crystal form patent november viiv healthcare filed statements happen could material suit cipla us district court district adverse impact results operations group delaware trial date yet set reporting period judgements incurred settlements entered january viiv healthcare received paragraph iv letter lupin relating juluca challenging crystal form intellectual property patent well patent relating combination intellectual property claims include challenges validity dolutegravir rilpivirine expires january enforceability groups patents various products february viiv healthcare filed suit lupin processes well assertions noninfringement patents additionally june cipla sent viiv patents loss cases could result loss healthcare paragraph iv letter related juluca patent protection product issue consequences july viiv healthcare filed suit cipla federal loss could significant decrease sales court delaware court yet set trial date product could materially affect future results operations february viiv healthcare filed patent infringement group litigation regarding bictegravir gilead sciences inc coreg gilead us district court district delaware gsk initiated suit teva inducing canadian federal court viiv healthcare alleges gileads infringement patent relating use carvedilol coreg triple combination hiv drug containing hiv integrase decreasing mortality caused congestive heart failure inhibitor bictegravir infringes viiv healthcares patent covering june case proceeded jury trial us district dolutegravir compounds include dolutegravirs court district delaware jury returned verdict unique chemical scaffold us canada viiv gsks favour awarding gsk lost profits reasonable healthcare seeking financial redress rather injunctive royalties total award million march relief jury trial us case set january trial judge ruled posttrial motions filed teva canadian matter fourday summary trial issue found substantial evidence trial support infringement held january april jurys finding induced infringement overturning jury court ruled gileads bictegravir compound infringe award gsk appealed october divided panel viiv healthcares canadian patent viiv healthcare court appeals federal circuit reversed appealed district courts ruling reinstated jury award gsks favour december teva filed petition rehearing viiv healthcare also commenced actions uk france en banc court granted tevas petition germany japan south korea australia gilead rehearing threemember panel issued original alleging gileads biktarvy infringes certain viiv decision oral argument took place february healthcares hiv integrase inhibitor patents infringement await courts ruling trial german action set april gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued legal proceedings continued kivexa uk longpending group action alleging seroxat june biogaran commenced proceedings france caused severe discontinuation symptoms concluded seeking revocation french supplementary protection july trial court entering judgement certificate spc covering kivexa trial date set groups favour along award costs us case action involving discontinuationtype claims also resolved product liability ppi litigation group currently defendant number product group defendant ongoing proton pump inhibitor liability lawsuits ppi litigation plaintiffs allege use ppis caused serious bodily injuries including acute kidney injury avandia chronic kidney disease endstage renal failure january avandia product liability cases january approximately prevacidhr settled two remaining us class actions brought personal injury lawsuits approximately nexiumhr thirdparty payers actions assert claims cases pending company nearly racketeer influenced corrupt organizations act rico pending multidistrict litigation mdl proceeding state consumer protection laws december district new jersey manufacturers ppis also third circuit court appeals reversed summary named codefendants mdl group filed judgements granted favour group remanded motions dismiss several hundred cases mdl court thirdparty payer cases back district court trial dates yet ruled motions first ppi bellwether trial yet set set november addition mdl cases small seroxatpaxil paxil cr number cases pending state courts seroxatpaxil paroxetine product liability matters involve zantac three general types allegations use paxil group contacted several regulatory pregnancy caused congenital malformations persistent authorities regarding detection nnitrosodimethylamine pulmonary hypertension autism ii paxil treatment ndma zantac ranitidine products based information caused patients commit suicidal violent acts iii available time correspondence regulators group failed warn patients could experience certain group made decision suspend release distribution symptoms discontinuing seroxatpaxil treatment supply dose forms zantac markets pending group reached agreements settle majority outcome ongoing tests investigations also us claims relating use paxil pregnancy precautionary action group made decision initiate january four lawsuits remain pending us voluntary pharmacyretail level recall zantac products two additional actions pending canada globally beginning six pending claims april european medicines agency ema cases five us one case canada concerning recommended suspension ranitidine medicines allegations patients took paroxetine paxil committed following publication emas recommendation attempted commit suicide acts violence dolin company communicated decision reenter market case involving suicide man allegedly took generic us fda requested manufacturers withdraw paroxetine manufactured mylan concluded favour ranitidine products market group leaving five pending matters four us group named defendant approximately one canada remaining us cases largely dormant us personal injury claims involving zantac class actions one pending canadian action carmichael group alleging economic injury thirdparty payer class action filed motion summary judgement based statute also filed federal court outside us limitations denied group appealed ruling three class actions pending group canada along oral argument took place december july class action israel appellate court reversed lower courts decision granted summary judgement groups favour plaintiff filed application leave appeal supreme court canada briefing application complete january parties await ruling gsk annual report notes financial statements continued legal proceedings continued february us product liability litigation sales marketing regulation assigned multidistrict litigation mdl status southern groups marketing promotion pharmaceutical district florida august group filed motions vaccine products subject certain governmental dismiss mdl claims based innovator liability investigations private lawsuits brought litigants preemption deficiencies pleadings december various theories law court granted groups motion innovator gsk korea proceedings fair trade laws liability generic defendants motion preemption august gsk korea indicted koreas motion defendants deficiencies pleadings monopoly regulation fair trade laws relation additionally january court granted brand government tenders hpv cervarix pcv synflorix defendants partial motion preemption dismissing plaintiffs vaccines prosecutor alleged claims seeking refunds otc zantac product court gsk korea actions least one allowed plaintiffs replead master complaints employees interfered tender process attempt cure deficiencies pleadings plaintiffs national immunisation programme using straw bidders filed notices appeal related decisions innovator liability generic preemption one employee also charged individual capacity prosecutor relation matter addition class action litigation march number wholesalers codefendants proceedings department justice doj sent group notice civil korea fair trade commission also commenced investigation opened allegations false claims act investigation gsk korea regarding matter gsk violations group related zantac june korea cooperating authorities matters doj served civil investigative demand group proceedings ongoing formalizing request documents day new mexico attorney general filed lawsuit multiple sfo secdoj anticorruption enquiries defendants including group alleging violations state previously reported following resolution investigations consumer protection false advertising statutes among uk serious fraud office sfo us securities claims exchange commission sec us department justice doj groups commercial operations zofran number countries including china sfo requested january group defendant product additional information group regarding thirdparty liability cases involving zofran two cases pending state advisers engaged company course courts rest either pending transferred investigations initiated chinas ministry public security multidistrict litigation mdl proceeding district sec doj also investigating matters massachusetts cases allege children suffered birth february sfo announced closed defects due mothers ingestion zofran andor generic investigation confirmed would taking ondansetron pregnancyrelated nausea vomiting action group sec notified group plaintiffs assert group sold zofran knowing march terminating investigation unsafe pregnant women failed warn risks matters may doj likewise informed illegally marketed zofran offlabel use pregnant women group would closing investigation without first zofran bellwether trial set october recommendation action accordingly matter parties continue await rulings court concluded motions exclude general causation experts well groups motion summary judgement first case set trial preemption motion group also defendant four proposed class actions canada gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued legal proceedings continued antitrustcompetition december trial judge granted plaintiffs class certain governmental actions private lawsuits certification motion certifying class direct purchasers brought group alleging violation competition group filed rule f motion court appeals antitrust laws third circuit challenging class certification decision april court appeals vacated lower courts uk competition markets authority investigation grant class certification remanded issue back february uk competition markets lower court analysis authority cma issued decision fining group million infringement competition act october district court heard argument connection agreements settle patent disputes plaintiffs renewed motion class certification remand group entered potential suppliers await courts decision generic paroxetine formulations commercial corporate group appealed competition appeal tribunal group historically named defendant cat delivered initial judgement upholding fine certain cases allege violations us securities laws march referred certain questions law employee retirement income security act erisa european union court justice ecj january securitieserisa class actions stiefel ecj issued judgement endorsing criteria used february group reached settlement principle cma levying fine matter returned respect claims brought us securities cat entry final judgement exchange commission sec group relating lamictal groups acquisition stiefel laboratories inc purported classes purchasers filed suit us district sec filed motion entry final judgements april court district new jersey alleging group effectively dismissing case matter teva pharmaceuticals unlawfully conspired delay generic concluded one claim brought private litigant martinolich competition lamictal resulting overcharges remains pending federal court florida matter purchasers entering allegedly anticompetitive plaintiff former stiefel employee alleges stiefel reverse payment settlement resolve patent infringement officers directors violated erisa federal state litigation separate count accuses group monopolising securities laws inducing stiefel employees sell shares market employee stock plan back stiefel greatly undervalued price without disclosing employees stiefel sold group post balance sheet events intention increase uk corporation tax rate effective april announced uk budget march deferred taxes measured using appropriate rates substantively enacted balance sheet date overall effect proposed change uk corporation tax rate applied deferred tax balance december would increase deferred tax assets approximately million gsk annual report company balance sheet uk gaap including frs reduced disclosure framework december notes fixed assets investments e current assets trade receivables f cash bank total current assets short term borrowings g trade payables h total current liabilities net current assets total assets less current liabilities provisions liabilities noncurrent liabilities j net assets capital reserves share capital k share premium account k reserves l retained earnings january profitloss year changes retained earnings l equity shareholders funds financial statements pages approved board march signed behalf sir jonathan symonds chairman glaxosmithkline plc registered number company statement changes equity year ended december share share premium retained total capital account reserves earnings equity january loss total comprehensive expense attributable shareholders distribution received glaxosmithkline consumer healthcare holdings limited total comprehensive income year dividends shareholders shares issued employee share schemes treasury shares transferred esop trusts december profit total comprehensive income attributable shareholders dividends shareholders shares issued employee share schemes treasury shares transferred esop trusts december gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap including frs reduced disclosure framework presentation financial statements accounting principles policies description business preparation balance sheet conformity glaxosmithkline plc parent company gsk major generally accepted accounting principles requires management global healthcare group engaged creation make estimates assumptions affect reported discovery development manufacture marketing amounts assets liabilities disclosure contingent pharmaceutical products including vaccines overthecounter assets liabilities date balance sheet actual otc medicines healthrelated consumer products amounts could differ estimates preparation financial statements balance sheet prepared accordance financial statements prepared using companys accounting policies approved board historical cost convention modified include revaluation described note b policies consistently certain financial instruments going concern basis applied unless otherwise stated prepared accordance financial reporting standard key accounting judgements estimates reduced disclosure framework uk accounting key accounting judgements estimates required presentation companies act december current year comparative figures december b accounting policies permitted section companies act foreign currency transactions income statement company presented foreign currency transactions recorded exchange annual report rate ruling date transaction foreign currency assets company included group financial statements liabilities translated rates exchange ruling glaxosmithkline plc publicly available balance sheet date following exemptions requirements ifrs dividends paid received applied preparation financial statements dividends paid received included financial accordance frs statements period related dividends paragraphs b ifrs sharebased actually paid received payment expenditure ifrs financial instruments disclosures expenditure recognised respect goods services received supplied accordance contractual terms paragraphs ifrs fair value measurement provision made obligation exists future liability paragraph ias presentation financial statements respect past event amount comparative information requirements respect obligation reliably estimated paragraph iv ias investments subsidiary companies paragraphs f b investments subsidiary companies held cost less ias presentation financial provision impairment also includes capital contribution statements relation movements contingent consideration ias statement cash flows impairment investments carrying value investments reviewed impairment paragraph ias accounting policies changes indication investment might accounting estimates errors impaired one assessment methods used compare paragraph ias related party disclosures carrying value investment share requirement ias disclose related party groups valuation basis overall market capitalisation transactions entered two members impairment charge recognised income statement group year concerned accounting convention standards sharebased payments balance sheet prepared using historical issuance company subsidiaries grant cost convention complies applicable uk accounting companys shares represents additional capital standards contributions company subsidiaries additional investment subsidiaries results corresponding increase shareholders equity additional capital contribution based fair value grant issued allocated underlying grants vesting period gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework continued taxation financial guarantees current tax provided amounts expected paid liabilities relating guarantees issued company applying tax rates enacted substantively behalf subsidiaries initially recognised fair value enacted balance sheet date amortised life guarantee deferred tax provided full using liability method c operating profit temporary differences arising tax bases assets fee relating audit liabilities carrying amounts financial company charged operating profit statements deferred tax assets recognised dividends extent considered recoverable future directors declared four interim dividends resulting taxable profits dividend year pence line dividend deferred tax measured average tax rates details see note group financial expected apply periods temporary statements dividends differences expected realised settled deferred tax liabilities assets discounted e fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline consumer healthcare holdings limited shares glaxosmithkline mercury limited capital contribution relating sharebased payments contribution relating contingent consideration shares glaxosmithkline consumer healthcare holdings limited received dividend specie part group reorganisation prior acquisition pfizer consumer healthcare business f trade receivables amounts due within one year uk corporation tax recoverable amounts owed group undertakings amounts due one year amounts owed group undertakings gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap including frs reduced disclosure framework continued g shortterm borrowings billion borrowing december related balance facility taken june part financing buyout noncontrolling interest consumer healthcare joint venture held novartis loan repaid may h trade payables amounts due within one year creditors contingent consideration payable amounts owed group undertakings company guaranteed debt issued subsidiary companies two receives fees aggregate company outstanding guarantees billion debt instruments billion amounts due subsidiary company relation guarantee fees recovered life bonds disclosed within trade receivables see note f provisions liabilities january charge year utilised december provisions relate number legal disputes company currently involved j noncurrent liabilities contingent consideration payable contingent consideration relates amount payable acquisition novartis vaccines portfolio current year liability included within trade payables details see note group financial statements contingent consideration liabilities gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework continued k share capital share premium account share premium ordinary shares p account number share capital issued fully paid january issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes ordinary shares acquired esop trusts december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes l retained earnings reserves profit glaxosmithkline plc year million million loss dividends paid million million effect million treasury shares transferred subsidiary company million distribution received shares subsidiary company million retained earnings december stood million million million unrealised million dividends shareholders paid realised profits company december amounted million million reserves includes capital redemption reserve reserve reflecting historical contributions shares company issued satisfy share option awards granted employees subsidiary companies group companies see pages complete list subsidiaries associates joint ventures significant shareholdings forms part financial statements gsk annual report ssttrraatteeggicic r erepporotrt ggoovveerrnnaannccee nadn dre rmeumnuernaetiroantion ffiinnaanncciaial ls stattaetmemenetsnts iinnvveessttoor ri ninfoformrmataiotnion investor information section quarterly trend pharmaceuticals turnover vaccines turnover five year record product development pipeline products competition intellectual property principal risks uncertainties share capital control dividends financial calendar annual general meeting tax information shareholders shareholder services contacts us law regulation group companies glossary terms ggsskk aannnnuuaall rreeppoorrtt financial record quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported proforma reported reported reported reported cer cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare corporate unallocated turnover total turnover cost sales selling general administration research development royalty income operating incomeexpense operating profit net finance costs share aftertax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement adjusted total turnover cost sales selling general administration research development royalty income operating profit net finance costs share aftertax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation adjusted results described gsk annual report strategic report governance remuneration financial statements investor information financial record continued quarterly trend quarterly trend continued unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported proforma reported reported reported reported cer cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare corporate unallocated turnover total turnover cost sales selling general administration research development royalty income operating incomeexpense operating profit net finance costs share aftertax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement adjusted total turnover cost sales selling general administration research development royalty income operating profit net finance costs share aftertax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation adjusted results described gsk annual report financial record continued pharmaceutical turnover therapeutic area total us europe international growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory ellipta products anoro ellipta arnuity ellipta incruse ellipta relvarbreo ellipta trelegy ellipta nucala hiv dolutegravir products tivicay triumeq juluca dovato epzicomkivexa selzentry rukobia immunoinflammation benlysta oncology zejula blenrep pharmaceuticals excluding established products established pharmaceuticals established respiratory seretideadvair flixotideflovent ventolin avamysveramyst respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals gsk annual report strategic report governance remuneration financial statements investor information financial record continued pharmaceutical turnover therapeutic area total us europe international growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory ellipta products anoro ellipta arnuity ellipta incruse ellipta relvarbreo ellipta trelegy ellipta nucala hiv dolutegravir products tivicay triumeq juluca dovato epzicomkivexa selzentry immunoinflammation benlysta oncology zejula pharmaceuticals excluding established products established pharmaceuticals established respiratory seretideadvair flixotideflovent ventolin avamysveramyst respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals gsk annual report financial record continued vaccines turnover total us europe international growth growth growth growth major products cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingles shingrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccines represents growth actual exchange rates cer represents growth constant exchange rates vaccines turnover total us europe international growth growth growth growth major products cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingles shingrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccines represents growth actual exchange rates cer represents growth constant exchange rates gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board group turnover geographic region us europe international group turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover pharmaceuticals turnover respiratory hiv immunoinflammation oncology established pharmaceuticals vaccines turnover meningitis influenza shingles established vaccines revised revised revised revised consumer healthcare turnover oral health pain relief vitamins minerals supplements respiratory health digestive health subtotal brands divestedunder review gsk annual report financial record continued five year record continued financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted financial results adjusted turnover operating profit profit taxation profit taxation pence pence pence pence pence adjusted earnings per share return capital employed return capital employed calculated total profit taxation percentage average net assets year gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record continued balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees us europe international manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported bank england pm buying rate average rate year calculated average pm buying rates day year average mar feb jan dec nov oct sep high low pm buying rate march us gsk annual report financial record continued five year record continued divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal separation adjusted results amortisation impairment restructuring related items costs results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record continued divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs profit disposal associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal us tax adjusted results amortisation impairment restructuring related items reform results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs profit disposal associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions gsk annual report financial record continued five year record continued divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition pharmaceuticals vaccines product development pipeline key nlicense alliance relationship third party nda new drug application us exception rituximab owned biogen inc approved v iiv healthcare global specialist hiv company submitted gsk pfizer inc shionogi limited shareholders phase e valuation clinical pharmacology usually conducted responsible developing delivering hiv medicines volunteers g sk contributing pandemic adjuvant covid phase ii etermination dose initial evaluation efficacy vaccines collaborations conducted small number patients bla biological licence application phase iii l arge comparative study compound versus placebo maa marketing authorisation application europe andor established treatment patients establish clinical benefit safety maa ndabla regulatory review milestones shown table achieved future filing dates included list oncology assets useu regulatory approvalssubmissions advanced indication clinic listed achieved regulatory review milestones compound mechanism action indication phase maa ndabla oncology zejula poly adpribose polymerase parp inhibitor l maintenance ovarian cancer approved oct apr niraparib prima l maintenance ovarian cancer iii combination dostarlimab l maintenance non small cell lung cancer iii nsclc blenrep adc targeting bcell maturation antigen l multiple myeloma approved aug aug belantamab dreamm mafodotin l multiple myeloma iii l multiple myeloma iii dostarlimab antiprogrammed cell death protein receptor l dmmrmsih endometrial cancer submitted mar dec pd antibody l dmmr solid tumours submitted dec l endometrial cancer iii feladilimab icos receptor agonist without cell depletion l relapsedmetastatic head neck iiiii squamous cell carcinoma hnscc bintrafusp alfa transforming growth factor beta tgf trap l biliary tract cancer btc iiiii immune checkpoint pd inhibitor letetresgene engineered tcr tcells targeting nyeso synovial sarcoma ii autoleucel pivotal cobolimab antitcell immunoglobulin mucin domain nonsmall cell lung cancer nsclc ii tsr tim antibody protein arginine methyltransferase prmt solid tumours haematological malignancies iii inhibitor antilymphocyte activation gene lag cancer tsr antibody type protein arginine methyltransferase cancer type prmt inhibitor sting cytosolic dna pathway agonist cancer cd antagonist cancer engineered tcr tcells coexpressing cda cancer cell surface receptor targeting nyeso engineered tcr tcells coexpressing cancer dntgfrii cell surface receptor targeting nyeso hiv infectious diseases rukobia hiv attachment inhibitor hiv infection approved feb jul fostemasavir cabenuva hiv integrase strand transfer inhibitor non hiv infection approved dec jan vocabria nucleoside reverse transcriptase inhibitor nnrti cabotegravir longacting regimen rilpivirine cabotegravir hiv integrase strand transfer inhibitor longacting hiv preexposure prophylaxis iii gepotidacin triazaacenaphthylene bacterial type ii topoisomerase uncomplicated urinary tract infection uuti iii inhibitor gonorrhea gc gsk annual report pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound mechanism action indication phase maa ndabla hiv infectious diseases continued vir antispike protein antibody covid iiiii leucyl trna synthetase inhibitor tuberculosis ii hbv antisense hepatitis b ii hiv maturation inhibitor hiv infection ii crk inhibitor visceral leishmaniasis hiv attachment inhibitor hiv infection hiv maturation inhibitor hiv infection fimh antagonist uncomplicated urinary tract infection uuti proteasome inhibitor visceral leishmaniasis mtb cholesterol dependent inhibitor tuberculosis ethionamide booster tuberculosis vir antispike protein antibody covid immunoinflammation benlysta b lymphocyte stimulator monoclonal lupus nephritis approved jun dec antibody us submitted eu benlysta rituximab b lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody cluster differentiation cd monoclonal antibody otilimab granulocyte macrophage colony rheumatoid arthritis iii stimulating factor inhibitor covid related acute pulmonary disease ii ccl inhibitor osteoarthritis pain rip kinase inhibitor psoriasis respiratory trelegy fluticasone glucocorticoid agonist longacting asthma approved jan sep furoate vilanterol beta agonist muscarinic us umeclidinium acetylcholine antagonist submitted eu nucala interleukin il antagonist hypereosinophilic syndrome approved soct asep us submitted eu nasal polyposis submitted soct ssep useu copd iii interleukin il antagonist asthma iii longacting pik beta inhibitor viral copd exacerbations pharmaceuticals daprodustat prolyl hydroxylase inhibitor anaemia associated chronic renal disease jnda jnda approved jun iii row linerixibat ileal bile acid transporter ibat inhibitor cholestatic pruritus pbc primary biliary cholangitis ii hematopoietic prostaglandin duchenne muscular dystrophy synthase hpgds inhibitor trpv channel blocker diabetic macular edema dme transglutaminase tg inhibitor celiac disease gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound vaccine type indication phase maa ndabla vaccines shingrix recombinant protein adjuvanted herpes zoster prophylaxis immunocompromised approved jul sep eu submitted us rotarix live attenuated pcv porcine circovirus rotavirus prophylaxis approved feb free eu variation iii us bexsero recombinant protein meningococcal b disease prophylaxis infants us iii mmr live attenuated measles mumps rubella prophylaxis us iii men abcwy recombinant protein conjugated meningococcal abcw disease prophylaxis iii adolescents rsv recombinant protein respiratory syncytial virus prophylaxis pregnant iii woman population prevent respiratory syncytial virus lower respiratory tract illness infants first months life transfer maternal antibodies recombinant protein adjuvanted respiratory syncytial virus prophylaxis older adult iii population replicationdefective recombinant respiratory syncytial virus prophylaxis paediatric ii viral vector population malaria next recombinant protein adjuvanted malaria prophylaxis plasmodium falciparum ii generation fractional dose menveo conjugated liquid formulation meningococcal acw disease prophylaxis ii adolescents shigella bioconjugated tetravalent shigella diarrhoea prophylaxis ii therapeutic hbv primeboost viral vector vaccines treatment chronic hepatitis b infections aims iii co sequentially administrated functional cure controlling resolving infection adjuvanted recombinant proteins reducing need treatment c difficile recombinant protein adjuvanted active immunization prevention primary c difficile diseases prevention recurrences sam rabies model selfamplifying mrna rabies prophylaxis aureus recombinant protein bioconjugated active immunization prevention primary adjuvanted recurrent softskintissue infections caused aureus covid recombinant protein adjuvanted covid iiiii plantderived viruslike particles vaccine medicago covid vaccine recombinant protein adjuvanted covid ii sanofi covid vaccine recombinant protein nanoparticle covid iii sk bioscience adjuvanted sam covid selfamplifying mrna covid model gsk annual report pipeline products competition continued pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu respiratory anoro ellipta umeclidinium bromide copd stiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi aerosphere formulation formulation brimica genuair arnuity ellipta fluticasone furoate asthma beclazone pulmicort budesonide gx nce nce asmanex alvesco device device formulation formulation avamysveramyst fluticasone furoate rhinitis dymista xhance nasonex fluticasone gx flixotideflovent fluticasone propionate asthmacopd beclazone pulmicort expired expired budesonide gx diskus device diskus device asmanex alvesco expired hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat yupelri nce nce braltus seebri breezhaler bretaris device device genuair formulation formulation nucala mepolizumab severe eosinophilic asthma egpa xolair cinqair expired expired hypereosinophilic syndrome fasenra dupixent relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol trifenatate budesonideformetrol gx nce nce sirdupla dulera device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expired expired fluticasone propionate budesonideformetrol gx diskus device diskus device sirdupla dulera expired hfadevice hfadevice trelegy ellipta fluticasone furoate copd trimbow vilanterol trifenatate breztri aerosphere nce nce umeclidinium bromide trixeo aerosphere enerzair breezhaler device device formulation formulation ventolin hfa albuterol sulphate asthmacopd generic companies expired hfadevice hfadevice antivirals valtrex valaciclovir genital herpes coldsores shingles prevymis valacyclovir gx expired expired valcyte central nervous system lamictal lamotrigine epilepsy bipolar disorder vimpat trokendi xr expired expired inovelon imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired seroxatpaxil paroxetine depression various anxiety trintellix aplenzin viibryd expired expired disorders zoloft cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia harnal vesomni urorec expired expired antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections generic competition commenced includes supplementary protection certificates granted multiple countries eu patent term extensions granted us data exclusivity expires eu us gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands us eu oncology zejula niraparib ovarian cancer lynparza rubraca nce nce blenrep belantamab mafodotin relapsedrefractory multiple sarclisa xpovio myeloma immunoinflammation benlysta benlysta belimumab systemic lupus erythematosus lupkynis sc iv lupus nephritis hiv juluca dolutegravir rilpivirine hivaids descovy genvoya odefsey biktarvy nce nce dovato dolutegravir lamivudine hivaids descovy genvoya odefsey biktarvy nce nce selzentrycelsentri maraviroc hivaids isentress intelence prezista nce nce tivicay dolutegravir hivaids isentress prezista symtuza reyataz nce nce biktarvy triumeq dolutegravir lamivudine hivaids descovy genvoya abacavir odefsey biktarvy nce nce vaccine products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu bexsero meningococcal groupb meningitis group b prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expired expired pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expired expired polio hepatitis b haemophilus tetanus pertussis polio pentaxim pentavac influenzae type b eu hepatitis b haemophilus hexaxim hexyon influenzae type b eu vaxelis cervarix hpv virus like human papilloma virus gardasil silgard particles vlps type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtypes vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigens virus subtypes fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w nimenrix menactra conjugate vaccine prophylaxis prepandrix derived split inactivated pandemic hn influenza aflunov vepacel influenza virus antigen prophylaxis adjuvant priorix priorix tetraab live attenuated measles mumps measles mumps rubella mmr ii mmrvaxpro expired expired varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugated pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis media shingrix zoster vaccine herpes zoster zostavax recombinant adjuvanted shingles see note financial statements legal proceedings includes supplementary protection certificates granted multiple countries eu patent term extensions granted us related compoundsindications measles mumps rubella vaccineprophylaxis b related compound varicella vaccine gsk annual report pipeline products competition continued consumer healthcare products competition brand products application markets competition oral health sensodyne toothpastes toothbrushes relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protects colgatepalmolive acid erosion elmex colgatepalmolive oral b procter gamble parodontax toothpaste dailymedicated helps stop prevent global colgate total gum health corsodyl mouthwash gel spray bleeding gums treats colgatepalmolive prevents gingivitis oral b gum enamel repair crest gum detoxify procter gamble polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser wipes dentures cleans dentures procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavities global colgate colgatepalmolive mouthwashes maintains healthy teeth gums crest procter gamble fresh breath oralb procter gamble pain relief panadol tablets caplets infant paracetamolbased treatment global except us aspirin bayer panadol cold syrup headache joint pain fever cold tylenol johnson johnson flu symptoms nurofen reckitt benckiser voltaren topical gel nonsteroidal diclofenac based global salonpas hisamitsu antiinflammatory aspirin bayer tylenol johnson johnson nurofen reckitt benckiser advil tablets caplets gel caplets ibuprofen based treatment us canada brazil tylenol tylenol pm tylenol childrens nonrespiratory liquid filled suspension headache toothache backache colombia mexico motrin motrin childrens johnson range drops childrens menstrual cramps muscular johnson aleve aleve pm bayer pains minor pain arthritis vitamins minerals supplements centrum tablets gummies vitamin supplement global nutralite infinitus cheongkwanjung capsules chewables byhealth nature made herbalife swisse caltrate tablets gummies calcium supplement global citracal bayer oscal nature made soft chews private label emergenc powder gummies immune support dietary us canada airborne reckitt benckiser supplement zicam church dwight nature made pharmavite sambucol healthcare brands international esterc american health respiratory health otrivin nasal spray nasal decongestant germany netherlands afrin bayer nasivin proctor gamble norway russia sweden tyzine johnson johnson theraflu hot liquids tablets syrups cold flu relief russia poland us tylenol cold flu johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser advil respiratory tablets allergy relief cold flu tylenol cold flu johnson johnson cold flu advil relief lemsip mucinex reckit benckiser respiratory allergy flixonaseflonase nasal spray tablets allergy relief us china uk ireland claritin bayer allegra sanofi piriton zyrtec johnson johnson robitussin syrup tablets coughcold us canada singapore mucinex reckitt benckiser philippines australia dimetapp foundation consumer healthcare digestive health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicated patch onset cold sores carmex carma labs blistex blistex incorporated retail label chapstick lip balm protect moisturise prevent global blistex burts bees carmex carma labs soothe chapped lips eos nivea beiersdorf vaseline unilever eno effervescent immediate relief antacid global except us estomazil hypermarca gelusil tums chewable tablets immediate relief antacid us alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi nicorette us lozenges gum treatment nicotine withdrawal global nicorette johnson johnson nicoderm nicotinell transdermal patches aid smoking reduction niquitin perrigo ex australia cessation gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties outline principal risks uncertainties relevant manufacturing testing approval distribution sales gsks business financial condition operations may marketing pharmaceutical vaccine consumer healthcare affect performance ability achieve objectives products affect cost product development risks believe could cause actual time required reach market likelihood results differ materially expected historical results successfully uninterrupted basis board oversight extended beyond audit risk rules regulations change government interpretation committee include involvement corporate evolves business activities develop nature responsibility committee science committee particular risk may also alter changes certain regulatory committees considered gsks risks strategies used regimes may substantial alteration failure address drew annual business unit comply applicable laws regulations could materially risk assurance update reports strategy papers adversely affect financial results significant risks corporate executive teams cets similarly global business exposes us litigation annual risk review government investigations including limited product year developed risk management liability litigation patent antitrust litigation sales framework moving annual quarterly upwards reporting marketing litigation litigation government investigations principal risks enabled risk including related provisions may make unfavourable oversight compliance council oversee risk outcomes increases related costs insurance dynamic way continued evolve report new premiums could also materially adversely affect emerging risks external environmental insights also financial results made reporting data driven key risk indicators detail status various uncertainties enabling agile risk management strategies addition significant unresolved disputes potential litigation set risks mitigations relating covid incorporated note legal proceedings within significant risks complement pandemic risks identified managed global issues management uk regulations require discussion mitigation activities team reported cet company takes address principal risks uncertainties description principal risks required comply broad range laws summary activities take manage risk across regulations apply research development businesses listed order significance patient safety risk definition collect information safety efficacy failure appropriately collect review follow report products humans clinical development gain human safety information hsi including adverse events comprehensive information realworld use products potential sources act relevant findings market safety information obtained timely manner ongoing safety surveillance activities external parties also analyse publiclyavailable clinical trial results data risk impact variety sources increasing volume safety ability effectively collect manage analyse safety data setting variable complex global regulations information associated products enables us conduct present new evolving challenges conduct robust safety signal detection activities turn ensures pharmacovigilance example must collect sensitive make decisions based uptodate riskbenefit health information develop robust product safety profiles profile products take appropriate measures ensuring adherence increasingly stringent global safeguard patients consumers effectively privacy regulations remaining vigilant threat manage risks patient safety activities serious cyberattacks repercussion could harm patients could also lead reputational damage productrelated litigation governmental result covid pandemic gsks safety investigation regulatory action including fines penalties organisation third parties quickly effectively even loss product marketing authorisation adopted new ways working impact patient safety however urgent need effective treatment context prevention covid political discourse around licence operate depends compliance global developing treatment prevention increased regulatory pharmacovigilance requirements fully accountable governmental public scrutiny industry ensures safeguarding patients complying global regulations development regulatory measures safety however augment pharmacovigilance capabilities efficacy medicines vaccines environment could using third parties continue seek innovative solutions undermine regulatory governmental public trust eg automation machine learning improved patient medicines treating covid may turn negatively safety management efficient reliable influence healthcare decisions diseases leading accurate data collection interrogation reputational damage product liability lawsuits gsk annual report principal risks uncertainties continued patient safety continued mitigating activities proposed actions discussed regulatory authorities chief medical officer cmo accountable patient include updating prescribing information safety enterprise risk human safety matters collaboration communicating healthcare providers restricting product head global safety support business prescribingavailability help assure safe use carrying unitspecific cmos crossenterprise safety governance clinical trials certain cases may appropriate board oversees implementation control framework stop clinical trials withdraw product market including risk management global safety board embedded changes central local safety subsidiary business unitspecific product safety boards ensure departments increased support core pharmacovigilance human safety addressed proactively throughout activities thirdparty vendors operating model products lifecycle tested pandemic areas improvement global policy management human safety information identified terms vendor flexibility capacity adapted requires employees immediately report issues relating quickly full operational capacity second half safety products thirdparty oversight framework year impact patient safety implementing ensures third parties risk encountering human safety new safety signal management tool leveraged automation information identified trained appropriately possible case processing preparing integration pfizer consumer healthcare safety database safety information products sources refine global pharmacovigilance collected processed reported analysed followed organisation deliver additional efficiencies including focus compliance global regulations information allows us advancing innovation automation detect safety signals products take timely action information changes products riskbenefit profile product quality risk definition gsk increasingly using new technology enhance failure gsk contractors suppliers ensure manufacture testing products example continuing deploy new electronic documentation systems appropriate controls governance quality product advanced laboratory information management tools development threat cyberattacks remains key risk integrity compliance good manufacturing practice good product quality data audit trail distribution practice regulations commercial clinical significant changes taking place gsk implement trials manufacture distribution activities new organisational alignments strategy changes compliance terms gsk product licences assessed quality organisations make sure supporting regulatory activities quality procedures governance facilitate strategy risk impact also ensuring unintended consequences increase failure ensure product quality could far reaching product quality risk implications patient consumer safety product launch mitigating activities delays drug shortages product recalls well extensive global network quality compliance regulatory legal financial consequences could professionals site senior management level aligned materially adversely affect gsks reputation financial business unit provide oversight assist results delivery quality performance operational compliance context management oversight accomplished external environment product quality remains hierarchy quality councils independent chief product challenging quality officer global product quality office oversee product quality risk across company european medicines agency ema implement two new sets requirements may ema regulations developed implemented single quality covering licensing medical devices become effective management system defines quality standards new annex guidance manufacture sterile systems businesses associated pharmaceutical medicinal products also due release gsk preparing vaccine consumer healthcare products clinical trial implement sets requirements materials system broad scope applicable throughout product lifecycle rd mature reviewing manufacturing processes products commercial supply augmented consolidation identify risks presence nitrosamine impurities numerous regulatory requirements markets across comply updated regulatory requirements work world assures meets external expectations product continue necessary mitigate quality markets supply system based identified risks internationallyrecognised principles ich q pharmaceutical quality system framework gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued product quality continued quality management system routinely updated ensure product incident committee processes place keeps pace evolving external regulatory environment investigate product issues make recommendations new scientific understanding products remediation activities including necessary recall processes part drive continually improve products protect patients consumers established operational deployment quality management system complaint process also ensures gsk responds appropriately making policies procedures simpler understand product quality issues raised patients customers implement adopting innovative tools give independent functions review triage allegations non userfriendly experience staff members regularly trained compliance misconduct received formal informal regulatory expectations learnings inspections speak channels global disciplinary enforcement existing procedures ensure continued maintenance procedures apply breaches standards current good manufacturing practice standards initiated appropriate following investigations implemented riskbased approach assessing leverage key risk indicators support risk management managing third party suppliers provide materials used activities provide gsks corporate executive team finished products contract manufacturers make risk oversight compliance council integrated products expected comply gsk standards assessment product quality performance regularly audited provide assurance financial controls reporting risk definition treasury group deals daily high value transactions mostly failure comply current tax laws incurring significant foreign exchange cash management transactions losses due treasury activities failure report accurate transactions involve market volatility counterparty risk financial information compliance accounting standards groups effective tax rate reflects locations applicable legislation activities value generate determine risk impact jurisdictions profits arise applicable tax rates noncompliance existing new financial reporting may higher lower uk statutory rate disclosure requirements changes recognition income may reflect regimes encourage innovation investment expenses could expose gsk litigation regulatory rd providing tax incentives changed could action could materially adversely affect financial affect gsks tax rate addition worldwide nature results current global pandemic significant operations means crossborder supply routes changes short notice failure comply changes necessary ensure supplies medicines numerous substance application laws governing transfer pricing countries result conflicting claims tax authorities dividends tax credits intellectual property could also profits taxed individual countries lead materially adversely affect financial results double taxation profits taxed one country complexity tax regulations also means may inconsistent application treasury policies transactional occasionally disagree tax authorities technical settlement errors counterparty defaults could lead interpretation particular area tax law tax charge significant losses included financial statements best estimate tax context liability pending audits tax authorities required laws various jurisdictions publicly expect continued focus tax reform driven disclose financial results events could materially initiatives oecd ec address tax affect groups financial results regulators routinely review challenges arising digitalisation economy together financial statements listed companies compliance domestic initiatives around world may result new revised existing accounting regulatory requirements significant changes established tax principles believe comply appropriate regulatory increase tax authority disputes regardless merit requirements concerning financial statements outcomes may costly divert management attention disclosure material information including transactions adversely impact reputation relationship key relating business restructuring acquisitions stakeholders divestitures however subject investigation potential noncompliance accounting disclosure requirements could lead restatements previously reported results significant penalties gsk annual report principal risks uncertainties continued financial controls reporting continued mitigating activities counterparty exposure subject defined limits approved financial results reviewed approved regional board credit rating individual counterparties management reviewed gsks group financial corporate compliance officer operating independently controller chief financial officer cfo allows treasury oversees treasurys role managing counterparty financial controller cfo assess evolution risk line agreed policy details mitigation business time evaluate performance plan treasury risks found pages note significant judgements reviewed confirmed senior financial instruments related disclosures management technical organisational transformation newly gsk manages tax risk robust internal policies acquired activities external risks covid processes training compliance programmes seek pandemic integrated risk assessments appropriate maintain open constructive relationships tax authorities controls reviews applied worldwide monitor government debate tax policy maintain control environment designed identify material key jurisdictions understand share errors financial reporting disclosure design informed point view regarding potential future changes operating effectiveness key financial reporting controls tax law relevant provide pragmatic constructive regularly reviewed management tested external third business input tax policy makers either directly parties minimum standard control set place industry trade bodies includes advocating reform finance locations irrespective size reviewed support economic growth job creation well management monitored independently provides us needs patients key stakeholders submit assurance controls key financial reporting significant tax decisions tax governance board disclosure processes operated effectively global meets quarterly made senior gsk finance finance risk management controls centre excellence employees provides extra support significant transformations tax affairs managed global basis team tax system deployment managementstructural professionals led global head tax work closely reorganisations also add operational resources ensure business daytoday basis global tax team processes controls maintained changes suitably qualified roles perform support introduced additional risk mitigation amending training needs provide date technical programme timelines system upgrades optimise delivery advice line responsibilities disclosure committee reporting board reviews submit tax returns according statutory time limits gsks quarterly results annual report consultation engage proactively tax authorities seek ensure tax legal advisors throughout year determines whether affairs current entering continuous audit programmes necessary disclose publicly information group advance pricing agreements appropriate stock exchange announcements keep uptodate arrangements provide longterm certainty tax latest developments financial reporting requirements authorities gsk tax treatment business working external auditor legal advisors based full disclosure relevant facts seek resolve treasury management group meets regularly seek differences interpretation tax legislation tax ensure liquidity interest rate counterparty foreign currency authorities cooperative manner exceptional cases transaction foreign currency translation risks may resolve disputes formal proceedings managed line conservative approach detailed associated risk strategies policies adopted board gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued antibribery corruption abac risk definition appropriate controls place around transactions abac risk comprises five subrisk areas payments third parties training awareness raising strong monitoring plan continue pre bribery public officials gsk posttransaction abac due diligence increase bribery commercial nonpublic entities gsk capabilities business monitoring oversight red bribery third parties acting behalf gsk flag resolution third parties review controls accountabilities government officials continue assess gsk employees receiving andor requesting bribes andor understand money laundering risk exposure undue personal benefit mitigate existing risk corruptionnoncompliance laws regulations code conduct values expectations related money laundering facilitation tax evasion commitment zero tolerance towards bribery corruption third partiesclientspartners integral mitigate risk light complexity risk impact geographic breadth risk constantly evolve failure mitigate risk could expose group oversight activities data reinforce workforce associated persons governmental investigation regulatory gsks clear expectations regarding acceptable behaviours action civil criminal liability may compromise maintain regular communications centre groups ability supply products certain government local markets contracts addition failure prevent bribery corruption abac programme built best class principles could substantial implications gsks reputation subject ongoing review development provides us credibility senior leaders might erode investor confidence basis seek manage risk top governance risk management could also lead bottom example programme comprises legal financial penalties toplevel commitment board leadership context data analytics programme create embed local key risk overall environment abac remains challenging indicators enable targeted intervention risk management countries holding individuals well corporations activities accountable increasing employer duty care programme underpinned global abac policy divergence legislation increasing political protectionism written standards address commercial social inequality pricing pressures making compliance practices give rise abac risk addition harder society holding corporations ever higher standards programme mandates enhanced controls interactions technology providing rapid anonymous avenue government officials business development dissemination previously confidential information even transactions controls abac policy establish due damaging false reports diligence requirements engagement third parties enforcement actions penalties increased across dedicated team responsible implementation globe focus use thirdparty intermediaries evolution abac programme response proposed eu legislation would require businesses carry developments internal external environment due diligence potential human rights related abac team continually works groups across environmental impacts operations supply chains enterprise address improve controls monitoring imposing legal standard care addition impact requirements teams work complemented covid businesses including disruptions independent oversight assurance audit manufacturing supply chain importexport travel assurance independent business monitoring teams etc could increase risk bribery corruption issues identified oversight assurance exercises supportive aspects external environment include investigations used identify areas specific increase transparency collaboration among enforcement intervention markets continuously improve authorities aim reducing bribery corruption programme globally advances technology also providing better periodically provide mandatory abac training employees platforms streamline processes detect potential issues relevant third parties accordance roles mitigating activities responsibilities risks face enterprisewide abac programme designed continually benchmark abac programme ensure compliance abac policies mitigate risk large multinational companies use external bribery corruption builds business standards expertise internal insights drive improvements values expectations form comprehensive practical approach compliance flexible evolving nature formal informal speak channels available report business misconduct noncompliance allegations noncompliance reviewed triaged central investigations team programme governance provided enterprise risk allocated investigation appropriate management overseen gsks abac governance board includes representation key functional areas gsk annual report principal risks uncertainties continued commercial practices pricing risk definition committed ethical responsible failure engage commercial activities consistent commercialisation products support purpose letter spirit law industry regulations improve quality human life enabling people groups requirements relating sales promotion feel better live longer accomplish purpose medicines vaccines appropriate interactions engage healthcare community various ways provide healthcare professionalsorganisations patients legitimate important information medicines vaccines transparent transfers value pricing competition promoting approved products seek ensure antitrust regulations commercial practices including hcps globally access information need trade channel activities tendering business patients consumers facts products risk impact require products prescribed recommended failure engage commercial activities consistent used manner provides maximum healthcare benefits letter spirit law industry regulations committed communicating information related groups requirements relating sales promotion approved products responsible legal ethical manner medicines vaccines appropriate interactions mitigating activities healthcare professionals hcps organisations patients strategic objectives designed ensure achieve legitimate transparent transfers value purpose continue strive new product launches pricing competition antitrust regulations commercial competitive resourced effectively ensure practices including trade channel activities business healthy proportion group sales come new products tendering could materially adversely affect ability innovations deliver strategy long term priorities additionally may result incomplete awareness riskbenefit profile establishing new products meet price expectations products possibly suboptimal treatment patients patients consumers hcps payers shareholders consumers governmental investigation regulatory action community able maintain strong global business legal proceedings brought group governmental remain relevant needs patients consumers private plaintiffs could result government values behaviours provide guide lead sanctions criminal andor financial penalties practices make decisions constantly strive right thing found misaligned values could also result deliver quality products sustain reliable supply meet reputational harm dilute trust established external customer needs seek ensure actions stakeholders reflect gsks values behaviours purpose context gsk acted enhance improve policies continue evolve business operations operate standards application data analytics channel globally highly regulated extremely competitive activities developed policies support strong biopharma industry peers may make significant growth consumer healthcare internet channels digital product innovations technical advances intensify price marketing activities using artificial intelligencepowered tools competition consumer healthcare marketplace improve oversight gsk websites partners classic retail pharmacies increasingly also improved control framework around reporting adverse online platforms face similarly robust competition events digital space upgrading customer service challenging environment achieve strategic objectives policies standards governing commercial activities must continue develop commercially viable new products undertake carried behalf deliver additional uses existing products address implemented training relevant employees support needs patients consumers hcps payers evolution activities commercial activities common pharmaceutical vaccine consumer worldwide must conform high ethical regulatory industry healthcare companies embracing opportunities standards local standards differ global ones evolving digital landscape facing uncertain market apply stringent standards conditions due global covid pandemic acquired company joint venture partner differ global continued downward price pressure major markets standards remediate legacy policies implement revisions align developing new pharmaceutical vaccine consumer healthcare products costly lengthy uncertain process consumer healthcare business harmonised policies candidate product may fail stage including procedures guide regional global commercial investment significant economic human resources practice processes clarified applicable standards competitors products pricing strategies potential operations markets operate also failure develop commercially successful products deliver reducing number export hubs five additional uses existing products could materially complemented specific control framework activity adversely affect ability achieve gsks strategic china developed specific promotion code objectives enable responsible business growth employee behaviour trained employees new code gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued commercial practices continued gsks pharmaceuticals consumer healthcare vaccines targets approach implemented businesses adopted internal control framework markets supported comprehensive training support assessment management risks business unit control monitoring framework ensure full alignment risk management compliance boards manage risks gsks valuesbased approach hcp engagement across incountry business activities oversee commercial allow fair market value payments made gsk activities monitoring programmes continue expert practitioners speak innovative medicines improve framework culture compliance vaccines countries north america europe processes asia pacific restricted time period products promotional materials activities must reviewed lifecycle controls training ensure appropriate oversight approved according policies standards across markets permitted report payments conducted accordance local laws regulations individual hcps part commitment transparency requirements seek ensure materials activities responsible disclosure fairly represent groups products services consumer consumer healthcare key driver development healthcare deployed new copy approval tool improve ethical code global selfcare federation setting controls important promotional activity necessary principles promotion healthcare practitioners event misconduct disciplined employees pharmacy staff including termination contract clawed back remuneration senior management gsk committed complying applicable sanctions laws regulations deployed programme enable continued evolve incentive programme management sanctions risk programme led gsk pharmaceuticals vaccines sales representatives better finance made various systems controls including recognise reward individual effort specialty care limited policies procedures training example capped variable pay element representatives awareness screening monitoring risk reporting compensation evaluated basis individual sales nonpromotional engagement risk definition context failure engage nonpromotional activities nonpromotional engagements diverse activities directed consistent external regulations internal policies healthcare professionals well patients payers gsk values regarding scientific engagement healthcare stakeholders aim improve patient care professionals patients including communications relating exchange provision knowledge use gsk medicines associated disease areas ii appropriate medicines vaccines related diseases non conduct interactions iii legitimacy transparency promotional engagement external stakeholder groups interactions vital gsk researchbased healthcare company necessary scientific medical advances expect risk impact nonpromotional activities scientifically sound without controls place risk could result reputational accurate conducted ethically transparently compliant damage governmental regulatory investigations eg applicable codes laws regulations however non regarding real perceived disguised promotion including promotional engagements largely unregulated therefore offlabel priorauthorisation promotion real measured risk taking rooted sound values principles perceived provision medical advice criminal investigations based decision making training communication monitoring penalties civil litigation competitor complaints affecting key managing risk enabling full appropriate financial results reducing trust general public engagement patients healthcare professionals payers regulators governments time failure engage fully appropriately could also result reputational damage patient harm financial loss gsk annual report nonpromotional engagement continued mitigating activities covid resulted significant increase virtual chief medical officer cmo oversees nonpromotional engagements eg external experts advisory boards engagement enterprise risk owner patient advocacy patient engagements congresses modernized practices applied internal gsk code practice key internal policy non principles policies rapidly changing growing promotional engagement activities activities include environment evolving employee training among others scientific interactions support medical people understand risk associated nonpromotional disease education advice seeking scientific communication activities conduct compliance gsks values research disease awareness general public policies local laws regulations training must launched revised code practice supported extended third parties support nonpromotional activities revised standard operating procedures order become ensure also understand comply risk agile innovative organisation mitigation ensure nonpromotional activities appear promotion continue build effective management monitoring systems apply key risk indicators managing nonpromotional engagement privacy risk definition mitigating activities failure collect secure use destroy personal groups chief compliance officer also chair information pi accordance data privacy laws lead privacy governance board oversees gsks overall harm individuals eg financial stress prejudice gsk data privacy operating model gsk business area eg fines operational financial reputational appointed risk owner accountable overseeing privacy risks supported privacy leaders within business risk impact countries data privacy laws require data protection noncompliance data privacy laws globally could lead officer dpo appointed gsk appointed single harm individuals gsk could also damage trust dpo eu represented supported specific gsk individuals communities business partners countries country privacy advisors government authorities chief compliance officer gsks enterprise risk owner many countries increased enforcement powers ero ero appointed delegate risk owner data protection authorities allowing impose global privacy officer gpo daytoday accountability significant fines impact crossborder data flows temporarily designing implementing control framework ban data processing many new country laws also give gpo coleads crossfunctional privacy centre individuals right bring collective legal actions excellence together global privacy counsel companies like gsk failure comply data privacy laws supported privacy officers privacy counsel multiple context country privacy advisors familiar local privacy data privacy legislation diverse limited harmonisation regulations simplification challenging multinationals standardise gsk evolved initial control framework implemented approach compliance data privacy laws eu general data protection regulation governments enforcing compliance data privacy laws comprehensive privacy control framework based global rigorously focus ethical use personal privacy principles common across global privacy landscape information growing compliance data global framework deployed countries exhibiting privacy laws due increase volume data need comprehensive framework based factors processed advances technology like robust local privacy legislation established data protection workforce protection effective privacy controls research authorities gsk footprint beyond countries covid pandemic creating unique challenges started preparations involve resource educate additionally new data privacy laws enforcement activities employees remaining undeployed countries gsk court decisions like court justice european footprint union ruling schrems ii creating uncertainties privacy centre excellence responsible international data transfers potential localisation requirements operating improving centralised global privacy control framework continuously assessing providing relevant proportionate controls aid nondeployed markets gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued pprriivvaaccyy ccoonnttiinnuueedd monitoring new changing laws adapting privacy continuously improve processes issue framework accordingly identification reporting handling monitoring privacy centre excellence involved new business deploying comprehensive training programme drive development opportunities early stage ensure greater awareness accountability managing personal appropriate due diligence performed right steps information across entire organisation taken onboarding splitting business unit certify key gsk privacy network roles accredited international privacy association research practices risk definition integrity governance data essential success research practices risk failure adequately conduct stages data lifecycle including design generation ethical sound preclinical clinical research addition recording management analysis reporting storage failure engage scientific activities retrieval rd data governed legislation consistent letter spirit law industry regulatory requirements data supporting documents groups requirements comprises following subrisks core components various stages pipeline progression nonclinical laboratory research human subject research decision making form content regulatory data integrity care welfare treatment animals human submissions publications patent filings poor data integrity biological samples management data disclosure regulatory governance could compromise gsks rd efforts filings engagement patents negatively impact reputation risk impact innate complexities interdependencies potential impacts risk include harm human subjects regulatory filings particularly given global rd footprint reputational damage failure obtain necessary regulatory ever changing increasingly stringent submission approvals products governmental investigation legal requirements continue increase complexity worldwide proceedings brought group governmental product registration supply gsk medicines patients private plaintiffs product liability suits claims damages dependent ongoing compliance maintenance loss revenue due inadequate patent protection inability licences across many geographies whose requirements supply gsk products regulatory action fines timelines differ secure management high volume penalties loss product authorisation could lifecycle changes licences renewal critical materially adversely affect financial results damage compliant supply failure maintain licences directly trust patients customers impact patients company revenue context wide variety biological materials used gsk research involving animals raise ethical concerns many discovery research development assets cases however research animals way convention biological diversity cbd nagoya investigate effects potential new medicine living protocol international community established global body humans animal research provides critical framework regulating access use genetic resources information causes mechanisms diseases nonhuman origin rd therefore remains vital part research continually support principles access benefit sharing seek ways minimise use animals genetic resources outlined cbd nagoya research development testing complying protocol also recognise importance appropriate regulatory requirements reducing impact animals effective proportionate implementation measures national used regional levels human subject research including clinical trials healthy patent rights awarded protect innovation play volunteers patients assess demonstrate important role providing competitive advantage investigational products efficacy safety evaluate market limited period time loss patent protection product approved disclose market gsks products developed rd research externally according regulations ethical principles including reducing term availability scope patent rights industry commitments could materially adversely affect financial results also work human biological samples market inadequate patent data exclusivity protection fundamental discovery development safety could lead example competition monitoring products gsk committed ensuring manufacturers generic biosimilar pharmaceutical products human biological samples managed accordance could limit opportunity rely markets future relevant laws regulations ethical principles sales growth could also materially adversely impact manner respects interests sample donors financial results gsk annual report principal risks uncertainties continued research practices continued following expiration certain intellectual property rights enhancing data integrity controls remains important generic biosimilar manufacturer may lawfully produce priority data integrity committees provide oversight competing copy product introduction generic products data integrity quality assurance teams conducting assessments typically leads rapid dramatic loss sales reduces provide independent business monitoring internal revenues margins proprietary products controls rd activities mitigating activities regulatory governance board serves global established office animal welfare ethics regulatory risk management compliance board promotes strategy oawes led chief veterinary officer compliance regulatory requirements procedures supports humane responsible care animals carries oversees groupwide written standards crossbusiness ethical reviews independent scientific reviews animal regulatory processes significant programme underway studies shares knowledge advocates replace modernise regulatory information management application nonanimal alternatives oawes provides systems across gsk framework animal welfare governance defines provides established access benefit sharing centre oversight animal care use training promotes excellence oversee requirements enforcement measures replacement refinement reduction animals research acquisition use genetic material nonhuman conducts quality assessments manages programme origin line nagoya protocol external animal diligence develops deploys strategies reproducibility experiments translatability human rd organisation maintains controls prepublication clinical end points procedures guard public disclosure advance filing patent applications addition loss patent gsks chief medical officer oversees following enterprise protection occur due lack data integrity preparing medical governance boards patent application data information legal experts human subject research board risk forum provide collaborate rd support review process new oversight human subject research sponsor patent applications support ensure conforms ethical medical research practices risk overseen enterprise scientific standards framework seeks ensure strengthened governance data disclosure board risk forum oversee across rd pharmaceuticals vaccines consumer disclosure sponsored supported human subject healthcare businesses research make information available clinical leadership research practices enterprise risk studies including summaries results whether positive owner management risk takes pragmatic approach negative information sharing streamlining risk identification global human biological samples management escalation ensuring ownership stays business hbsm governance framework oversee ethical lawful acquisition management human biological samples hbsm enterprise risk management team works minimise risks related acquisition storage use transfer disposal human biological samples gsk annual report strategic report governance remuneration financial statements investor information environment health safety risk definition mitigating activities failure management corporate executive team responsible ehs governance risk oversight ensures effective execution hazardous activities control framework place use manage risks gsks physical assets infrastructure impacts legal compliance issues relate ehs across handling processing hazardous chemicals businesses includes assigning responsibility biological agents senior managers providing maintaining controls ensuring tiered monitoring governance processes control releases substances harmful environment place within businesses individual managers seek short long term ensure ehs control framework effective well leading incidents could disrupt rd supply implemented respective business area activities harm employees harm communities harm fully compliant applicable laws regulations local environments operate adequately resourced maintained communicated monitored additionally employee personally risk impact responsible ensuring follow applicable local failure manage ehs risks could lead significant harm standard operating procedures people environment communities operate fines inability meet stakeholder expectations riskbased proactive approach articulated global regulatory requirements litigation regulatory action ehs policy detailed global ehs standards damage groups reputation could materially audit operations ensure compliance adversely affect financial results ensure hazards appropriately controlled safe design facilities plant equipment following context rigorous procedures help us provide effective barriers gsk subject health safety environmental laws protect employees health safety various jurisdictions laws impose duties protect people environment communities despite extensive safety programmes tragically operate well potential obligations remediate experienced two employee fatalities one manufacturing contaminated sites overall control framework site canada another road traffic accident india managing ehs risk effective additional workrelated fatality belgium involving construction worker gsks direct supervision conducted extensive investigations causes fatality ensure could take actions reduce risk similar tragic incidents occurring developed safety improvement plan strengthen existing safety practices gsk annual report principal risks uncertainties continued environmental sustainability risk definition mitigating activities failure management november gsk announced new commitment net zero climate impact net nature positive physical climate environmental risks goals build longterm ambition set current future regulatory requirements environmental reduce impact environment policies taxes corporate executive team cet responsible delivery performance management environmental environmental sustainability governance risk oversight objectives ensures effective framework place use leading reduced supply chain resilience product life cycle manage risks across businesses deliver management issues loss trustreputation employees commitments made gsk dedicated environmental investors customers regulators stakeholders sustainability enterprise risk plan place cets increased costs loss sales market access negative responsibilities include appointing dedicated senior leaders impacts environment resources provide maintain risk controls ensure governance processes established effective within risk impact businesses gsk recognises way respond climate change manage environmental risks impacts ability supply continue control antibiotic emissions products patients consumers could lead harm manufacturing effluents gsk facilities environment impact reputation suppliers following good operational practice meeting emission limits defined amr alliance manufacturing failure meet fastevolving regulatory requirements framework stakeholder expectations could result litigation regulatory actions may materially adversely impact financial continuously assess business resilience climate results change task force climaterelated financial disclosures framework guidelines context increasingly understood effects climate change ensure reductions carbon emissions energy water nature loss interconnected waste delivered managed mature programmes impacting human health internal external expectations including ecodesign considerations products companies address impact environment packaging increasing effects climate change operational resilience regard access energy water natural resources used products along potential cost increases regulatory changes environmental taxes gsk annual report strategic report governance remuneration financial statements investor information information security risk definition mitigating activities risk unauthorised disclosure theft unavailability global information security policy accompanying corruption gsks information key information systems standards processes supported dedicated may lead harm patients workforce customers team programme activity gsk technology security disruption business andor loss commercial risk function provides strategy direction oversight strategic advantage damage reputation regulatory includes active monitoring cybersecurity sanction enhancing global information security capabilities ongoing programme investment made risk impact following significant investments mitigation activities failure adequately protect gsks information key continue advance coming year information systems may cause harm patients workforce customers disruption business andor loss modernising cyber operations ensure timely detection commercial strategic advantage regulatory sanction response information security incidents damage reputation modernising operational technology ot address age context complexity global footprint ot environment overall information security environment challenging manufacturing rd sites difficulty keeping pace increasingly optimising security architecture mitigate risk network sophisticated cyber threats due many factors users using email externallyconnected communications including complexity large regulated organisations removeable media inappropriately whether intentionally wellresourced nature hacking activities increasing unintentionally also continuing remediate demands accountability data handled companies improve control environment privileged elevated continue reassess gsks reliance interconnectivity user rights across gsks systems third party contractors partners suppliers covid pandemic emerged another significant external factor transferring third party risk management managed impacting information security managed gsk service partner organisation process gsks critical covidrelated threats include increase ransomware sensitive information support development attacks healthcare sector hackers used solution enable us move third parties opportunity disrupt critical healthcare operations access resources remotely secure cases seize healthcare research related covid environment vaccines treatments enabling business performance high risk markets gsk operates highlyconnected information network assessing data information originating flowing holds confidential research development manufacturing international markets local laws norms represent commercial workforce financial data means heightened risk confidentiality integrity availability systems information continue gsks operational systems target cyberattacks continue consolidate information systems reduce attack points enable focused controls gsks strategic approach digital analytics increase dependency digital assets distributed data continued analysis assessment gsks critical data assets threats assets require continuous reevaluation emerging risks gsk mitigating actions already defined areas includes secure deployment operation gsk resources highrisk markets risk posed gsk data cloud potential complexity resulting agile businessled development across enterprise gsk annual report principal risks uncertainties continued supply continuity risk definition also participated eus new reporting system failure deliver continuous supply compliant finished anticipated drug shortages introduced pandemic product inability respond effectively crisis incident proactively resolve supply issues potentially timely manner recover sustain critical operations impacted hospital intensive care units risk impact mitigating activities recognise important continuity supply supply chain model adopted pharmaceuticals products patients consumers rely vaccines consumer healthcare business units designed material interruption supply could lead litigation ensure far possible supply quality security regulatory action including exclusion healthcare products around world programmes financial penalties might adversely affect supply chain governance committees within business unit groups financial results gsks international presence closely monitor inventory status delivery products partners expose workforce facilities aim ensuring customers products operations potential disruption natural events need improved links commercial forecasting eg storms earthquakes manmade events eg manufacturing made possible core commercial cycle imposition trading barriers short notice civilpolitical time reduce risk associated demand unrest terrorism cyberattacks public health fluctuations impact ability supply cost emergencies eg global covid pandemic writeoffs products exceed expiry date therefore vital robust crisis management node supply chain periodically reviewed ensure recovery plans place manage events adequate safety stock balancing working capital context endtoend supply chain particular attention placed supply chain operations subject review approval mitigating supply risks associated medicallycritical various regulatory agencies effectively provide highrevenue products key new product launches licence operate failure manufacturing distribution routinely monitor compliance external manufacturing network deliver products could lead litigation regulatory suppliers service providers identify manage risks action product recalls seizures interruption supply base practical minimise dependence supply delays approval new products suspension single sources supply critical items alternative manufacturing operations pending resolution manufacturing sourcing arrangements possible certain materials logistics issues inventory strategy aims limit impact ultimately rely materials services provided third party protect supply chain unanticipated disruption suppliers make products include active continue implement anticounterfeit systems like product pharmaceutical ingredients antigens intermediates serialisation accordance new emerging supply chain commodities components developing manufacturing requirements around world eu falsified packaging pharmaceutical vaccine consumer medicines directive healthcare products thirdparty oversight includes outsourcing operations contract manufacturing corporate policy requires business functional area clinical research organisations provide manufacturing head ensure effective crisis management business support development key products behalf continuity plans including authorised response recovery strategies key areas responsibility clear communication although undertake risk mitigation recognise routes place business disruption occurs certain events could still result delays service interruptions corporate security supports business coordinating use effective crisis management business continuity crisis management business continuity training facilitating planning ensure health safety people simulation exercises assessing preparedness recovery minimise impact supply maintaining functional capability providing assurance oversight gsks central operations event natural manmade disaster repository plans supporting critical business processes public health emergency drug shortages reported appropriate regulatory authorities us food business unit performs risk oversight drug administration transparency solicit feedback respective risk management compliance board assure risk mitigation adequate risk mitigation including identifying new emerging threats example taken coordinated approach supply performance expectations increased evaluating managing implications gsk brexit covid pandemic governments sought secure supply key medicines vaccines prioritised aligned activities help ensure maintain appropriate behind manufacture supply pandemic level readiness response capability also develop medicines suppliers leveraging strategic stocks maintain partnerships external bodies including modifying supply routes avoid disrupting availability business continuity institute un international strategy finished products disaster risk reduction helps improve business continuity initiatives disasterprone areas supports development community resilience disasters gsk annual report strategic report governance remuneration financial statements investor information transformation risk definition mitigating activities failure deliver plan successful transformation future ready office fro established fourth separation gsk two competitive standalone companies quarter accountable monitoring progress new gsk biopharma company new consumer performance risks associated creating two new healthcare leading companies reports monthly corporate executive team cet ensure enterprise oversight risk impact plan using key performance risk indicators addition failure manage increasing macro level risk due gsks chief executive officer ceo chief financial officer covid relation delivery transformation plan chief strategy officer head fro meet leaders could materially adversely affect ability deliver gsks consumer healthcare input approval key design strategy longterm priorities choices new company required overall balance context transformation separation upheld clear february gsk announced new future ready governance joint new gsk consumer healthcare programme prepare separation two companies coordination rigorous progress tracking setting new gsk biopharma company rd approach clear parameters focused science related immune system use gsk board regularly informed future ready genetics new technologies new leader consumer programme lead indicators ceo board report healthcare gsk increases investment rd new board meeting transformation separation product launches twoyear separation programme aims committee established board level support drive common approach innovation across modalities advise managements work transforming separating improved capital allocation align improve capabilities group committee chaired gsk chairman efficiencies global support functions support new includes senior independent director chairs gsk optimise supply chain portfolio audit risk remuneration corporate responsibility including divesting noncore assets prepare consumer committees healthcare operate standalone company complete outlook companies fundamentally strengthened making efficient modern automated future skills capabilities extend beyond transition timeline gsk annual report shareholder information share capital control details issued share capital number shares interests voting rights held treasury december found stated far aware note financial statements share capital share persons significant direct indirect holdings premium account company information provided company pursuant financial conduct authoritys disclosure guidance ordinary shares listed london stock exchange transparency rules dtr published regulatory lse also quoted new york stock exchange information service companys website nyse form american depositary shares ads wwwgskcom ads represents two ordinary shares details listed debt listed refer note financial statements company received notifications accordance net debt dtr following notifiable interests voting rights companys issued share capital holders ordinary shares ads entitled receive dividends declared companys annual report december march also entitled attend speak appoint proxies percentage percentage exercise voting rights general meetings company total voting total voting voting rights rights voting rights rights restrictions transfer limitations blackrock inc holding ordinary shares ads requirements dodge cox obtain approval prior transfers ordinary shares percentage total voting rights date notification company ads carry special rights regard control comprising indirect interest ordinary shares company restrictions voting rights major holding qualifying financial instruments contract shareholders voting rights per share difference shareholders known arrangements comprising indirect interest ordinary shares financial rights held person holder american depositary shares shares known agreements restrictions share company acquired disposed interests transfers voting rights shares period review shares acquired groups employee share plans exception transferred treasury satisfy awards rank equally shares issue special groups employee share plans rights trustees employee share ownership plan share buyback programme trusts waived rights dividends shares held board authorised issue allot ordinary trusts shares article companys articles association exchange controls limitations affecting holders power article authority company certain economic sanctions may make purchases shares subject shareholder force time time currently applicable laws authorities sought annual basis annual decrees regulations force uk restricting import general meeting agm shares purchased export capital restricting remittance dividends company may cancelled held treasury shares payments holders companys shares used satisfying share options grants group 's nonresidents uk similarly certain economic employee share plans sanctions may force time time programme covers purchases shares cancellation limitations relating nonresidents uk english held treasury shares accordance law companys articles association right authority renewed shareholders agm may holder vote respect companys shares company authorised purchase maximum million shares details shares purchased cancelled held treasury shares subsequently transferred treasury satisfy awards groups employee share plans disclosed note financial statements share capital share premium account determining specific share repurchase levels company considers development free cash flow year shares purchased since company confirms currently intend make market purchases company review potential future share buybacks line usual annual cycle subject return ratings criteria gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued share capital control continued market capitalisation uk us market capitalisation based shares issue excluding treasury shares gsk december billion date gsk th largest company market capitalisation ftse index share price january december increasedecrease high year low year table sets middle market closing prices companys share price decreased compares increase ftse index uk share price uk us ads price us year middle market closing share price march nature trading market following table sets periods indicated high low middle market closing prices companys ordinary shares lse ads nyse ordinary shares ads uk per share us per share high low high low march february january december november october september quarter ended december quarter ended september quarter ended june quarter ended march quarter ended december quarter ended september quarter ended june quarter ended march year ended december year ended december year ended december year ended december march gsk annual report shareholder information continued analysis shareholdings december number total total number accounts accounts shares shares holding shares held institutional corporate holders individuals corporate bodies guaranty nominees limited held treasury shares glaxosmithkline jp morgan chase bank na depositary companys american depository receipt adr programme companys ads listed nyse ordinary shares representing companys adr programme managed depositary registered name guaranty nominees limited march guaranty nominees limited held ordinary shares representing issued share capital excluding treasury shares date march number holders ordinary shares us holdings ordinary shares number registered holders ads holdings ads certain ordinary shares ads held brokers nominees result number holders record registered holders us representative number beneficial holders residence beneficial holders dividends company pays dividends quarterly continues return board intends maintain dividend cash shareholders dividend policy dividends current level p per share subject material change remain essential component total shareholder return external environment performance expectations gsk recognises importance dividends shareholders implement new distribution policy dividends company aims distribute regular dividend payments details dividends declared amounts payment determined primarily reference free cash flow dates given note financial statements generated business funding investment dividends necessary support groups future growth dividend calendar dividends per share quarter exdividend date record date payment date table sets dividend per share per ads q february february april last five years dividend per ads translated q may may july us dollars applicable exchange rates q august august october q november november january year dividend pence us q february february april q ordinary dividend receivable ads holders calculated based exchange rate april annual fee per ads per ads per quarter charged depository cumulative dividend receivable ads holders q q q gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued financial calendar results announcements event date results announcements issued lse available quarter results announcement april news service also sent us securities annual general meeting may exchange commission sec nyse issued biopharma investor update june media made available website quarter results announcement july quarter results announcement october financial reports preliminaryquarter results announcement february company publishes annual report made annual report publication februarymarch available website date publication annual report distribution march shareholders may elect receive notification email publication annual reports registering information company including share ads wwwshareviewcouk may also elect receive price available website wwwgskcom information printed copy annual report contacting registrar made available website constitute part equiniti limited annual report copies previous annual reports available website printed copies also obtained registrar see contact details annual general meeting annual general meeting agm held pm investors holding shares nominee service uk time wednesday may great west arrange nominee service appointed proxy road brentford middlesex tw gs company 's respect shareholding order attend vote registered office meeting electronically agm broadcast online registered office ads holders wishing attend meeting electronically line uk government 's covid restrictions refer agm notice details request proxy physical attendance shareholders permitted appointment depositary jp morgan chase bank na shareholders invited attend meeting electronically enable attend ask questions vote agm companys principal forum communication electronically business transacted meeting private shareholders addition formal agm ads holders reminded instruct business presentation ceo depositary way shares represented performance group future development ads voted completing returning opportunity questions asked board voting card provided depositary shares chairs boards committees workforce voted engagement director available take questions documents display relating roles articles association company directors details access agm ask questions service contracts applicable letters appointment vote electronically found notice annual directors company subsidiaries general meeting agm notice available side letters relating severance terms pension website wwwgskcom arrangements available inspection companys registered office appointment gsk annual report shareholder information continued tax information shareholders summary certain uk tax us federal income tax inheritance tax consequences holders shares ads citizens individual ukdomiciled otherwise shareholders may uk us set complete liable uk inheritance tax transfer shares ads analysis possible tax consequences purchase tax may charged amount value ownership sale securities intended shareholders estate reduced result transfer general guide holders advised consult advisers way lifetime gift disposal less full market respect tax consequences purchase ownership value case bequest death tax may charged sale shares ads consequences state value shares date shareholders death local tax laws us implications current gift disposal subject uk ukus tax conventions inheritance tax us estate gift tax estate gift tax convention would generally provide tax paid us us holders ads generally treated owners credited tax payable uk underlying shares purposes current ukus double taxation conventions relating income gains stamp duty stamp duty reserve tax income tax convention estate gift taxes estate gift uk stamp duty andor stamp duty reserve tax sdrt tax convention purposes internal revenue subject certain exemptions payable transfer code amended shares rate rounded nearest case stamp duty consideration transfer uk shareholders notwithstanding provided instrument executed summary applies uk resident shareholder pursuance agreement gave rise charge holds shares capital assets sdrt instrument stamped within six years agreement including stamped exempt sdrt taxation dividends charge cancelled sdrt already uk tax year uk resident individuals paid repaid entitled dividend tax allowance first dividends received tax year free us shareholders tax dividends excess allowance taxed summary applies shareholder citizen basic rate taxpayers higher rate taxpayers resident us domestic corporation person additional rate taxpayers otherwise subject us federal income tax net income uk resident shareholders corporation taxpayers basis respect shares ads holds shares ads note dividends payable ordinary shares generally capital assets resident uk uk tax purposes entitled exemption corporation tax hold shares purposes trade profession vocation carried uk branch taxation capital gains agency uk resident shareholders may liable uk tax gains disposal shares ads summary also address tax treatment holders subject special tax rules banks disposals individuals uk tax year taxexempt entities insurance companies dealers securities taxable capital gain accruing disposal shares ads currencies persons hold shares ads part taxed basic rate taxpayers integrated investment including straddle comprised allowable deductions individuals taxable income share ads one positions persons year exceeds basic rate income tax banding note directly indirectly companys stock following use exemptions available individual vote value address tax treatment may taxpayer annual exempt amount applicable result international income tax treaties corporation taxpayers may entitled indexation allowance applies reduce capital gains extent gains arise due inflation indexation allowance may reduce chargeable gain create allowable loss assets acquired january legislation finance act freezes level indexation allowance given calculating companys chargeable gains value would apply disposal asset december assets acquired january onwards legislation finance act removes indexation allowance disposal gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued tax information shareholders continued taxation dividends taxation capital gains gross amount dividends received treated foreign generally us holders subject uk capital gains source dividend income us tax purposes eligible tax subject us tax capital gains realised dividend received deduction allowed us corporations sale disposal shares ads gains dividends ads payable us dollars dividends longterm capital gains subject reduced rates taxation ordinary shares payable sterling dividends paid individual holders shares ads held sterling included income us dollar amount one year date shares vestedreleased calculated reference exchange rate day shortterm capital gains subject taxation rates dividends received holder subject certain whereas longterm capital gains may subject exceptions shortterm hedged positions individual rates state local tax rates capital gains eligible us holder subject us taxation maximum may also apply federal rate plus applicable state local tax information reporting backup withholding respect qualified dividends qualified dividend defined dividends payments proceeds sale shares us internal revenue service irs dividend ads paid within us certain usrelated financial meets following criteria intermediaries subject information reporting may must issued us corporation corporation subject backup withholding unless us holder incorporated us possession corporation corporation exempt recipient provides taxpayer eligible benefits comprehensive income tax treaty identification number certifies loss exemption deemed satisfactory published irs occurred nonus holders generally subject dividends type listed irs dividends information reporting backup withholding may qualify required provide certification nonus status connection payments received amounts withheld required dividend holding period met allowed refund credit holders us federal shares must owned days income tax liability provided required information furnished holding period defined day irs period begins days exdividend date day stock trades without dividend priced estate gift taxes example stocks exdividend date october estate gift tax convention us shareholder shares must held days period generally subject uk inheritance tax however us august november year order holder may subject us federal estate gift tax count qualified dividend stamp duty dividends qualified subject taxation uk stamp duty andor sdrt subject certain exemptions us federal graduated tax rates maximum rate payable transfer shares ads custodian types dividends automatically excluded depository rate amount consideration qualified dividends even meet requirements provided transferred sale value transferred include limited consideration capital gains distributions however stamp duty sdrt payable dividends bank deposits transfer agreement transfer ads dividends held corporation employee stock ownership plan esop dividends paid taxexempt corporations us state local tax rates qualified nonqualified dividends may vary would assessed addition federal tax rates communicated gsk annual report statutory disclosures shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel uk tel outside uk equiniti provides range services shareholders service offers participate dividend reinvestment plan alternative receiving cash dividends may choose drip election form downloaded drip reinvest dividends buy gsk shares wwwshareviewcouk requested contacting equiniti dividend payment direct bank dividends paid directly bank building society dividend bank mandate form account bank mandate account receive cash dividends must provide downloaded wwwshareviewcouk equiniti bank building society account details requested contacting equiniti quick secure method payment dividend payment direct bank equiniti convert dividend local currency details service costs account overseas shareholders send direct local bank account service available involved please contact equiniti countries worldwide electronic communications shareholders may elect receive electronic notifications please register wwwshareviewcouk company communications including annual report dividend payments dividend confirmations availability online voting general meetings time gsk publishes shareholder documents receive email containing link document relevant website shareview portfolio service enables create free online portfolio view please register wwwshareviewcouk share balance movements update address dividend payment instructions register votes general meetings deduplication publications mailings receive duplicate copies mailings may please contact equiniti one account please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificated online transactions please log please note market trading hours form corporate sponsored nominee online wwwshareviewcoukdealing pm uk time telephone via postal dealing service provided equiniti telephone transactions please call monday friday excluding public financial services limited uk holidays england wales outside uk lines open pm uk time monday friday excluding uk public holidays postal transactions please call request dealing form corporate sponsored nominee account convenient way manage shares without requiring application form requested share certificate service provides facility hold wwwshareviewcouk shares nominee account sponsored company contacting equiniti continue receive dividend payments attend vote companys general meetings shareholders names appear publicly available share register service free join individual savings accounts isas company arranged equiniti financial services details available wwwshareviewcouk limited provide gsk corporate isa hold gsk shares requested telephoning equiniti lines open pm dealing pm enquiries monday friday excluding public holidays england wales lines open pm monday friday excluding public holidays england wales provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued shareholders services contacts continued ads depositary contacts adr programme administered jp morgan investor relations chase bank na investor relations may contacted follows regular correspondence uk eq shareowner services great west road po box brentford middlesex tw gs st paul mn tel delivery stock certificates overnight mail us eq shareowner services crescent drive centre point curve suite philadelphia pa mendota heights mn tel us toll free wwwshareowneronlinecom tel outside us general gsk response center outside us tel us toll free depository also provides global invest direct direct share scam alert ads purchasesale dividend reinvestment plan ads receive unsolicited telephone call offering sell buy holders details enrol please visit wwwadrcom shares please take extra care caller may part call helpline number obtain enrolment pack highly organised financial scam donating shares save children uk shareholder please contact financial gsk embarked ambitious global partnership conduct authority wwwfcaorgukconsumers save children share expertise resources consumer helpline aim helping save lives one million children tel uk shareholders small number shares value makes uneconomical sell may wish consider donating tel outside uk save children donated shares aggregated lines open pm uk time monday friday except uk public sold save children use funds raised holidays pm saturdays help reach goal obtain share donation form please contact registrar equiniti managing donation sale uk shares save children free charge provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser stock exchange announcement notifications provide shareholders service receive automatic email notifications publish stock exchange announcement receive email notifications please sign announcements wwwgskcom investors section gsk annual report statutory disclosures continued us law regulation number provisions us law regulation apply section corporate responsibility company shares quoted nyse financial reports form ads sarbanesoxley requires ceo cfo complete formal certifications confirming nyse rules general nyse rules permit company follow uk reviewed annual report form f corporate governance practices instead applied based knowledge annual report form f us provided explain significant variations contains material misstatements omissions explanation contained form f based knowledge financial statements accessed sec 's edgar database via website financial information fairly present material respects nyse rules require us file annual interim written financial condition results operations cash flows affirmations concerning audit risk committee arc dates periods presented annual report statement significant differences corporate form f governance responsible establishing maintaining sarbanesoxley act disclosure controls procedures ensure material following number corporate accounting scandals information made known evaluated us congress passed sarbanesoxley act effectiveness controls procedures year sarbanesoxley wideranging piece legislation end results evaluation contained concerned largely financial reporting corporate annual report form f governance responsible establishing maintaining internal recommended sec company established control financial reporting provides reasonable disclosure committee committee reports ceo assurance regarding reliability financial reporting cfo arc chaired company secretary preparation financial statements external purposes members consist senior managers finance legal accordance generally accepted accounting principles corporate communications investor relations disclosed annual report form f external legal counsel external auditors internal experts changes internal controls financial reporting invited attend disclosure committees meetings period covered annual report form f periodically committee responsibility considering materially affected reasonably likely affect materially materiality information timely basis determining companys internal control financial reporting disclosure information responsibility disclosed based recent evaluation timely filing reports sec formal review internal control financial reporting external auditor annual report form f committee met arc significant deficiencies material times weaknesses design operation internal controls sarbanesoxley requires annual report form f financial reporting reasonably likely affect contains statement whether member arc adversely companys ability record process audit committee financial expert defined rules summarise report financial information fraud sarbanesoxley statement relevant members regardless materiality involving persons arc judy lewent charles bancroft included significant role companys internal control financial board committee information area corporate reporting governance report biographies group carried evaluation supervision pages additional disclosure requirements arise participation management including ceo section section sarbanesoxley cfo effectiveness design operation respect disclosure controls procedures internal groups disclosure controls procedures control financial reporting december inherent limitations effectiveness system disclosure controls procedures including possibility human error circumvention overriding controls procedures accordingly even effective disclosure controls procedures provide reasonable assurance achieving control objectives gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued us law regulation continued ceo cfo expect complete certifications group exports certain pharmaceutical vaccine report conclusions effectiveness disclosure consumer products iran via sales nonus entities controls procedures march following subsidiaries us entity two privately held iranian certifications filed sec part groups distributors form f group regularly receive information regarding section managements annual report internal identity distributors ' downstream customers control financial reporting intermediaries iran possible parties accordance requirements section include entities governmentowned hospitals sarbanesoxley following report provided pharmacies owned directly indirectly iranian management respect companys internal control government persons entities sanctioned connection financial reporting defined rules af df terrorism proliferation activities us securities exchange act amended group regularly receive information exchange act regarding identity distributors ' downstream customers management responsible establishing maintaining establish proportion gross revenue sales adequate internal control financial reporting potentially attributable entities affiliated iranian group internal control financial reporting designed government parties sanctioned disclosable activities provide reasonable assurance regarding reliability result group reporting entire gross revenues financial reporting preparation financial statements million net loss million group 's sales external purposes accordance ifrs iran management conducted evaluation effectiveness group also aware hospitals medical internal control financial reporting based facilities lebanon may affiliated controlled framework internal control integrated framework hezbollah groups designated united issued committee sponsoring organisations states pursuant executive order group treadway commission coso deal directly hospitals facilities instead sells distributors group unable changes groups internal control establish proportion gross revenue sales potentially financial reporting materially attributable reportable activities result group affected reasonably likely affect materially reporting entire gross revenues million net groups internal control financial reporting profits million group 's sales lebanon management assessed effectiveness internal control financial reporting december unless noted group intends continue activities conclusion filed part groups form described f addition section r exchange act us law deloitte llp audited consolidated financial generally restricts dealings us persons dealings statements group year ended december otherwise subject us jurisdiction certain countries also assessed effectiveness groups territories subject comprehensive sanctions currently internal control financial reporting auditing crimea cuba iran north korea syria well standard public company accounting oversight government venezuela though country board united states audit report filed venezuela whole group business via nonus groups form f entities owned controlled us entities section r exchange act certain jurisdictions believe group complies applicable us sanctions material respects section r exchange act requires issuers make laws complex continue evolve rapidly specific disclosure annual reports certain types dealings iran including transactions dealings governmentowned entities well dealings entities sanctioned activities related terrorism proliferation weapons mass destruction even activities prohibited us law involve us persons gsk annual report statutory disclosures continued donations political organisations political expenditure ensure consistent approach political contributions result definitions may cover legitimate business across group global policy introduced activities ordinary sense considered political voluntarily stop corporate political contributions donations political expenditure designed support political party independent election candidate period january december group make political donations eu therefore notwithstanding policy noneu organisations intend make donations eu political parties organisations incur eu political expenditure notwithstanding introduction policy accordance annually seek shareholder authorisation inadvertent federal election campaign act us continue expenditure support employeeoperated political action committee pac facilitates voluntary political donations eligible authority precautionary measure ensure gsk employees company subsidiaries inadvertently breach legislation pac controlled gsk decisions amounts recipients contributions made authorisation process expenditure participating employees exercising legal right pool year dates back agm held may following resources make political contributions introduction political parties elections subject strict limitations total us referendums act authority since us donated political organisations renewed annually gsk employee pac english law requires prior shareholder approval political contributions eu political parties independent election candidates well eu political expenditure definitions political donations political expenditure political organisations used legislation however quite broad particular definition eu political organisations may extend bodies concerned policy review law reform representation business community special interest groups concerned environment company subsidiaries might wish support gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies accordance section companies act full list subsidiaries associates joint ventures joint arrangements address registered office effective percentage equity owned december disclosed unless otherwise stated share capital disclosed comprises ordinary shares indirectly held glaxosmithkline plc percentage held class share stated less unless otherwise stated subsidiary companies registered office tax resident country incorporation name security registered address wholly owned subsidiaries alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limited ordinary great west road brentford middlesex tw gs england adechsa gmbh ii ordinary co prv provides treuhandgesellschaft ag dorfstrasse baar switzerland affymax research institute common corporation service company gateway oaks drive suite n sacramento california united states allen hanburys limited ii ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria beecham group plc p shares p shares b great west road brentford middlesex tw gs england beecham pharmaceuticals pte limited ordinary quality road jurong industrial estate jurong singapore beecham portuguesaprodutos farmaceuticos e quimicos lda ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal beecham sa ii ordinary parc de la noire epine avenue fleming wavre belgium biovesta ilalari ltd sti ii nominative bykdere caddesi levent plaza b blok levent istanbul turkey cascan gmbh co kg partnership capital prinzregentenplatz munich germany castleton investment ltd liquidation ordinary co dtos cybercity th floor standard chartered tower ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome inc merged glaxosmithkline llc dec common corporation service company little falls drive wilmington series preferred delaware united states series b preferred series c convertible preferred series c convertible preferred charles midgley limited ii ordinary cumulative preference great west road brentford middlesex tw gs england clarges pharmaceuticals trustees limited ii iv ordinary great west road brentford middlesex tw gs england colleen corporation common corporation service company little falls drive wilmington delaware united states corixa corporation common corporation service company little falls drive wilmington delaware united states coulter pharmaceutical inc ii common corporation service company little falls drive wilmington delaware united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energia solar alternativa sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain duncan flockhart australia pty limited ii iv ordinary mountain highway boronia vic australia etex farmaceutica ltda social capital avenue andres bello piso las condes santiago cp chile fipar thailand ltd liquidation ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand genelabs technologies inc common corporation service company gateway oaks drive suite n sacramento california ca united states glaxo group limited ordinary great west road brentford middlesex tw gs england glaxo kabushiki kaisha ii ordinary akasaka minatoku tokyo japan glaxo laboratories nigeria limited ii ordinary marine road apapa lagos nigeria glaxo laboratories limited liquidation ordinary baker street london wu eu england glaxo new zealand pension plan trustee limited ordinary level egenerator gridakl madden street wynyard quarter auckland new zealand glaxo operations uk limited ordinary great west road brentford middlesex tw gs england glaxo properties bv ordinary van asch van wijckstraat h lp amersfoort netherlands gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxo trustees limited liquidation ordinary baker street london wu eu england glaxo verwaltungs gmbh ordinary industriestrasse bad oldesloe germany glaxo wellcome australia pty ltd ii iv ordinary mountain highway boronia vic australia glaxo wellcome farmaceutica limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxo wellcome international bv ii iii ordinary huis ter heideweg lz zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production sas ordinary rue franois jacob rueilmalmaison france glaxo wellcome vidhyasom limited ii ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgos spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxoallenburys nigeria limited ii ordinary creek road apapa lagos pmb nigeria glaxochem pte ltd iii ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxosmithkline cambodia co ltd liquidation ordinary th floor dksh building preah monivong boulevard corner street sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room unit floor mid th east ring road chaoyang district beijing china glaxosmithkline china rd company limited equity f building huanke road pilot free trade zone shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center th floor nicosia pc cyprus glaxosmithkline gsk srl ordinary costache negri street opera center one th th floors zone district bucharest romania glaxosmithkline ireland limited ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline malta limited ordinary first floor de la cruz avenue qormi qrm malta glaxosmithkline private limited ii ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada iv quotas luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aires caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline asia pvt limited equity patiala road nabha dist patiala punjab india glaxosmithkline australia pty ltd ordinary mountain highway boronia vic australia glaxosmithkline bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands glaxosmithkline beteiligungs gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biologicals shanghai ltd ordinary niudun road pilot free trade zone shanhai china glaxosmithkline biologicals kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biologicals sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biologicals sa ordinary preference rue de l'institut b rixensart belgium glaxosmithkline brasil limitada quotas estrada dos bandeirantes rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc north market street suite wilmington delaware united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital avenue andres bello piso las condes santiago cp chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare investments ireland ordinary knockbrack dungarvan co waterford x ry ireland limited iii liquidation glaxosmithkline consumer healthcare ireland ip limited iii ordinary knockbrack dungarvan co waterford x ry ireland liquidation glaxosmithkline consumer holding bv ii ordinary van asch van wijckstraat h lp amersfoort netherlands gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline doo quotas zmja od bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ou ordinary ltsa tallinn estonia glaxosmithkline el salvador sa de cv ordinary municipio de san salvador departamento de san salvador el salvador glaxosmithkline eood ordinary g tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limited ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary ra av zona torre citibank nivel guatemala city guatemala glaxosmithkline holding ordinary drammensveien oslo norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street suite wilmington delaware united states glaxosmithkline holdings ireland limited ordinary deferred great west road brentford middlesex tw gs england glaxosmithkline holdings one limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary mountain highway boronia vic australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limited ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline inc class common class c preference mississauga road north mississauga ln l canada glaxosmithkline insurance ltd ordinary parlaville road hamilton hm bermuda glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property holdings limited ordinary b ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary deferred great west road brentford middlesex tw gs england glaxosmithkline intellectual property management limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline investment holdings limited liquidation ordinary baker street london wu eu england glaxosmithkline investment services limited liquidation ordinary baker street london wu eu england glaxosmithkline investments ireland limited iii liquidation ordinary riverwalk citywest business campus dublin ireland glaxosmithkline investments pty ltd ordinary mountain highway boronia vic australia glaxosmithkline kk ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary duntes iela riga latvia glaxosmithkline lietuva uab ordinary ukmerges st vilnius lt lithuania glaxosmithkline limited ordinary f tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline manufacturing spa ordinary via alessandro fleming verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou hamed el glaza casablanca morocco glaxosmithkline medical healthcare products limited ordinary h csorsz utca budapest hungary glaxosmithkline mercury limited ordinary great west road brentford middlesex tw gs england glaxosmithkline mexico sa de cv ordinary ordinary b calzada mexicoxochimilco colonia san lorenzo huipulco delegacion tlalpan mexico glaxosmithkline nz limited ordinary level e madden street wynyard quarter auckland new zealand glaxosmithkline oy ordinary piispansilta po box espoo fin finland glaxosmithkline peru sa ordinary av javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer brondby dk denmark gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline pharmaceutical kenya limited ordinary likoni road nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan prof khoo kay kim petaling jaya selangor malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals costa rica sa ordinary metros al este de la rotonda de la betania mercedes de montes de oca sabanilla montes de oca san jose costa rica glaxosmithkline pharmaceuticals sa ordinary ordinary b ul grunwaldzka poznan poland ordinary c ordinary glaxosmithkline pharmaceuticals sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceuticals ukraine llc chartered capital pavla tychyny avenue v kiev ukraine glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common prenticehall corporation system puerto rico inc co fast solutions llc ponce de leon avenue floor san juan puerto rico glaxosmithkline republica dominicana sa ordinary blue mall tower floor ave winston churchill santo domingo dominican republic glaxosmithkline research development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline spa ordinary viale dellagricoltura verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline services inc ii common corporation service company little falls drive wilmington delaware united states glaxosmithkline services unlimited ordinary great west road brentford middlesex tw gs england glaxosmithkline single member aebe ordinary kifissias avenue halandri athens greece glaxosmithkline sl llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline sl lp ii viii partnership great west road brentford middlesex tw gs england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia glaxosmithkline south africa pty limited ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline trading ordinary leningradskiy prospect building floor premises xv room moscow russian federation glaxosmithkline trading services limited iii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline tunisia sarl ordinary immeuble les quatres r rue du lac lochness berges du lac tunis tunisia glaxosmithkline uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa registered shares provisory stock salto cp montevideo uruguay glaxosmithkline us trading limited ordinary great west road brentford middlesex tw gs england glaxosmithkline venezuela ca ordinary urbanizacion la trinidad calle luis de camoems edif apatado posta caracas venezuela glaxosmithkline vietnam limited liability company ii iv equity capital metropolitan dong khoi street district th floor unit ho chi minh city viet nam glycovaxyn ag iv common preferred grabenstrasse schlieren switzerland preferred b preferred c groupe glaxosmithkline sas ordinary rue franois jacob rueilmalmaison france gsk australia nvd pty ltd ii iv ordinary mountain highway boronia vic australia gsk bangladesh private limited ordinary sweden tower harinnachala konabari gazipur bangladesh gsk biopharma argentina sa nominative non endorseable tucumn piso buenos aires caaa argentina ordinary shares gsk business service centre sdn bhd ordinary level quill jalan prof khoo kay kim petaling jaya selangor malaysia gsk capital bv incorporated iii ix ordinary great west road brentford middlesex tw gs england gsk capital kk ordinary akasaka minatoku tokyo japan gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk enterprise management co ltd ordinary floor lane huanke road zhongke road shanghai china gsk equity investments limited unit corporation service company interstate drive suite harrisburg pennsylvania pa united states gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued gsk finance limited ordinary great west road brentford middlesex tw gs england gsk finance plc ordinary great west road brentford middlesex tw gs england gsk india global services private limited equity shares prestige trade tower th floor palace road sampangiramnagar bangalore karnataka india gsk kazakhstan llp participationparticipating interest furmanov street almaty medeu district kazakhstan gsk pharma vietnam company limited chartered capital unit th floor metropolitan tower dong khoi street ben nghe ward district ho chi minh viet nam gsk pharmaceutical trading sa ii iv ordinary costache negri street opera center one th floor discussions room district bucharest romania gsk services sp z oo ordinary ul grunwaldzka poznan poland gsk vaccines bv ordinary hullenbergweg amsterdam cl netherlands gsk vaccines gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quotas via fiorentina siena italy gsk vaccines srl quotas via fiorentina siena italy gsk vaccines vertriebs gmbh ii ordinary rudolfdieselring holzkirchen germany hgs france sarl ii iv ordinary rue de la belle feuille boulognebillancourt france horlicks limited ordinary preference great west road brentford middlesex tw gs england human genome sciences inc common corporation service company little falls drive wilmington delaware united states id biomedical corporation quebec common boul du parc technologique qubec gp r canada instituto luso farmaco limitada ii ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal interpharma dienstleistungen gmbh ii quotas wagenseilgasse euro plaza gebude stock vienna austria jj technologies lc llc interests corporation service company shockoe slip nd floor richmond va united states laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoires paucourt ii ordinary rue franois jacob rueilmalmaison france laboratoires saintgermain ii ordinary rue franois jacob rueilmalmaison france laboratorios dermatologicos darier sa de cv ordinary calzada mexico xochimilco san lorenzo huipulco district federal ordinary b mexico mexico laboratorios farmaceuticos stiefel portugal ltda ii ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal laboratorios stiefel de venezuela sa ordinary calle luis de camoens edificio glaxosmithkline urb la trinidad caracas venezuela laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem bairro de bonsucesso municipality guarulhos sao paulo cep brazil laboratorios wellcome de portugal limitada ii ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal mixis genetics limited liquidation ordinary ordinary euro baker street london wu eu england montrose pharma company limited ii iv ordinary quota h csorsz utca budapest hungary okairos ag liquidation common preferred preferred b co obc suisse ag aeschenvorstadt basel switzerland penn labs inc ii common corporation service company little falls drive wilmington delaware united states sr one international bv ordinary van asch van wijckstraat h lp amersfoort netherlands setfirst limited ordinary preference great west road brentford middlesex tw gs england sitari pharma inc common stock corporation service company little falls drive wilmington delaware de united states smith kline french portuguesaprodutos farmaceuticos ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges lda ii portugal smithkline beecham bangladesh private limited ii ordinary topkhana road segunbagicha dhaka bangladesh smithkline beecham cork limited ordinary riverwalk citywest business campus dublin ireland smithkline beecham manufacturing limited ordinary riverwalk citywest business campus dublin ireland smithkline beecham swg limited liquidation ordinary baker street london wu eu england smithkline beecham biologicals us partnership partnership interest corporation service company little falls drive wilmington delaware united states smithkline beecham egypt llc quotas amoun street el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham interamerican corporation ii common corporation service company little falls drive wilmington delaware united states gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued smithkline beecham limited ordinary great west road brentford middlesex tw gs england smithkline beecham overseas limited ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited ii ordinary great west road brentford middlesex tw gs england smithkline beecham pension trustees limited liquidation ordinary baker street london wu eu england smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltungs gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited ii iv ordinary flushing meadows building campus sloane street bryanston south africa smithkline beecham pharmaceuticals co common corporation service company little falls drive wilmington delaware united states smithkline beecham port louis limited liquidation ordinary co cim corporate services ltd les cascades building edith cavell street port louis mauritius smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex tw gs england limited ii stiefel distributors ireland limited liquidation ordinary finisklin business park sligo ireland stiefel dominicana srl ii iv ordinary ave lope de vega torre novocentro local santo domingo dominican republic stiefel farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain stiefel gmbh co kg partnership capital prinzregentenplatz munchen germany stiefel india private limited equity wing th floorfloral deck plaza opp rolta bhavan central midc road mumbai andheri e india stiefel laboratories maidenhead ltd liquidation ordinary baker street london wu eu england stiefel laboratories legacy ireland limited ordinary unit building avenue cork airport business park cork ireland stiefel laboratories limited ii ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories pte limited ii ordinary pioneer sector singapore stiefel laboratories inc common corporation service company little falls drive wilmington delaware united states stiefel maroc sarl ii iv ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary mountain highway boronia vic australia stiefel research australia pty ltd ordinary mountain highway boronia vic australia stiefel west coast llc llc interests corporation service company little falls drive wilmington delaware united states strebor inc common corporation service company little falls drive wilmington delaware united states tempero pharmaceuticals inc series preference corporation service company little falls drive wilmington series b preference common delaware united states tesaro bio austria gmbh liqu liquidation common fleischmarkt vienna austria tesaro bio gmbh ordinary poststrasse zug switzerland tesaro bio netherlands bv shares joop geesinkweg ab amsterdamduivendrecht netherlands tesaro bio spain slu iv sharesparticipation quota severo ochoa parque tecnolgico de madrid tres cantos madrid spain tesaro bio sweden ab common co bdo malardalen ab skatt box stockholm sweden tesaro development limited shares clarendon house church street hamilton hm bermuda tesaro inc common corporation service company little falls drive wilmington delaware de united states sydney ross co ii common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states wellcome foundation investment company limited limited guarantee great west road brentford middlesex tw gs england active proposal strike ucb pharma asia pacific sdn bhd ii ordinary th floor menara symphony jalan prof khoo kay kim seksyen petaling jaya malaysia wellcome consumer healthcare limited ii ordinary great west road brentford middlesex tw gs england wellcome consumer products limited ii ordinary great west road brentford middlesex tw gs england wellcome developments pty ltd ii iv ordinary mountain highway boronia vic australia wellcome limited ordinary great west road brentford middlesex tw gs england wellcome operations pty ltd ii iv ordinary mountain highway boronia vic australia gsk pharma vietnam company limited chartered capital unit th floor metropolitan tower dong khoi street ben nghe ward district ho chi minh viet nam glaxosmithkline limited ordinary likoni road po box nairobi kenya gsk consumer healthcare export limited great west road brentford middlesex tw gs england gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less alacer corp common corporate service company dba csclawyers incorp gateway oaks drive suite n sacramento california united states amoun pharmaceutical industries co sae new monetary shares el salam city po box cairo egypt beecham enterprises inc ii common corporation service company little falls drive wilmington delaware united states biddle sawyer limited equity dr annie besant road mumbai india block drug company inc common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states block drug corporation ii common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states british pharma group limited captial great west road brentford middlesex tw gs england consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england consumer healthcare intermediate holdings limited ordinary great west road brentford middlesex tw gs england duncan consumer healthcare philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines duncan pharmaceuticals philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines exlax inc common prentice hall corporation system puerto rico inc co fast solutions llc citi tower ponce de leon avenue floor san juan puerto rico ferrosan aps shares b shares nykaer brondby dk denmark ferrosan international aps ordinary nykaer brondby dk denmark ferrosan srl registered capital c calea turzii clujnapoca cluj county romania galvani bioelectronics inc common corporation service company little falls drive wilmington delaware united states galvani bioelectronics limited ordinary b ordinary great west road brentford middlesex tw gs england glaxo saudi arabia limited ordinary po box area warehouse city first stage al khomrah jeddah saudi arabia glaxo wellcome ceylon limited ordinary ordinary b galle road kaldemulla moratuwa sri lanka glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline brasil produtos para consumo e saude quotas av das americas th floor rooms rio de janeiro rj ltda brazil glaxosmithkline consumer healthcare china co ltd ordinary floor xizangzhong road huangpu district shanghai china glaxosmithkline consumer healthcare hong kong ordinary f tower gateway canton road tsimshatsui kowloon limited hong kong glaxosmithkline consumer healthcare ireland limited ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare thailand limited ordinary th floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare uk ip limited iv ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare uk trading ordinary great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare us ip llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare ordinary nykaer brondby dk denmark glaxosmithkline consumer healthcare ab v ordinary nykaer brondby dk denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington nsw australia glaxosmithkline consumer healthcare bv ordinary van asch van wijckstraat g amersfoort lp netherlands glaxosmithkline consumer healthcare colombia sas ordinary carrera piso colombia glaxosmithkline consumer healthcare czech republic sro ordinary hvezdova c prague czech republic glaxosmithkline consumer healthcare finance limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finance ordinary great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare finland oy ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh co kg partnership capital barthstr mnchen germany glaxosmithkline consumer healthcare hellas single ordinary kifissias avenue halandri athens greece member societe anonyme gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxosmithkline consumer healthcare holdings b preference great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare holdings us llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare investments ordinary knockbrack dungarvan co waterford x ry ireland ireland limited iii liquidation glaxosmithkline consumer healthcare investments ordinary knockbrack dungarvan co waterford x ry ireland ireland unlimited company iii liquidation glaxosmithkline consumer healthcare japan kk ordinary akasaka minatoku tokyo japan glaxosmithkline consumer healthcare korea co ltd ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline consumer healthcare llc llc interests corporation service company interstate drive suite harrisburg pennsylvania united states glaxosmithkline consumer healthcare mexico ordinary calzada mexicoxochimilco colonia san lorenzo huipulco de rl de cv delegacion tlalpan mexico df mexico glaxosmithkline consumer healthcare new zealand ulc ordinary level zurich house queen street auckland new zealand glaxosmithkline consumer healthcare norway ordinary drammensveien lysaker norway glaxosmithkline consumer healthcare pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines glaxosmithkline consumer healthcare pte ltd ordinary rochester park singapore glaxosmithkline consumer healthcare sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline consumer healthcare srl ordinary via zambeletti sncbaranzate milan italy glaxosmithkline consumer healthcare saudi limited ordinary salamah tower th floor madinah road alsalamah district jeddah saudi arabia glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampangulu kelang industrial estate ampang selangor darul ehsan malaysia glaxosmithkline consumer healthcare slovakia r ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa ordinary flushing meadows building campus sloane street bryanston pty ltd south africa glaxosmithkline consumer healthcare spzoo ordinary ul grunwaldzka poznan poland glaxosmithkline consumer healthcare srl ordinary costache negri street opera center one th floor zone district bucharest romania glaxosmithkline consumer healthcare ulc class preference burrard street suite three bentall centre po box glaxosmithkline soins de sante aux consommateurs sri common vancouver bc vx l canada glaxosmithkline consumer healthcare vietnam company charter capital floor metropolitan dong khoi ben nghe ward district ho limited ii chi minh city viet nam glaxosmithkline consumer healthcare lp partnership capital corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare produtos para ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges saude e higiene lda portugal glaxosmithkline consumer nigeria plc vi ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer trading services limited ordinary great west road brentford middlesex tw gs england glaxosmithkline costa rica sa ordinary san jose este de la rotonda betania carretera sabanilla costa rica glaxosmithkline dungarvan limited ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline healthcare ao ordinary premises iii room floor presnenskaya nab moscow russian federation glaxosmithkline healthcare gmbh ordinary barthstr mnchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue v kiev ukraine glaxosmithkline pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline panama sa ordinary urbanizacion industrial juan calles b republic panama panama glaxosmithkline paraguay sa ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncion paraguay glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt glaxosmithkline sante grand public sas ordinary rue franois jacob rueilmalmaison france glaxosmithkline technology taizhou co ltd ordinary room building phase ii new drug innovation base taizhou jiangsu province china glaxosmithkline tuketici sagligi anonim sirketi nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithklineconsumer hungary limited liability membership h csorsz utca budapest hungary company gsk canada holding company limited ordinary great west road brentford middlesex tw gs england gsk ch kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk consumer health inc common corporation service company little falls drive wilmington delaware de united states gsk consumer healthcare holdings us inc common corporation service company little falls drive wilmington delaware de united states gsk consumer healthcare holdings llc iii unit corporation service company little falls drive wilmington delaware de united states gsk consumer healthcare israel ltd iv ordinary basel street petech tikva israel gsk consumer healthcare levice sro ordinary priemyselny park gena ul e sachsa levice slovakia gsk consumer healthcare sa ordinary route de i'etraz prangins switzerland gsk consumer healthcare schweiz ag ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation service company little falls drive wilmington delaware united states gsk consumer healthcare singapore pte ltd ordinary rochester park singapore gsk consumer healthcare trinidad tobago limited ordinary th floor algico plaza stvincent street port spain trinidad incorporated jan tobago gsk new zealand holding company limited ordinary great west road brentford middlesex tw gs england gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria iodosan spa ordinary via zambeletti sncbaranzate milan italy kuhs gmbh ordinary barthstr mnchen germany laboratorios viiv healthcare sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street po box el salam city cairo egypt nch nutrition consumer health ltd ii ordinary hamephalsim st petach tikva israel pt smithkline beecham pharmaceuticals shares b shares jl pulobuaran raya kav iii dd kawasan industri pulogadung jakarta indonesia pt sterling products indonesia shares b shares graha paramita building th f jalan denpasar raya blok jakarta indonesia panadol gmbh ordinary barthstr mnchen germany pf consumer healthcare llc membership interest corporation service company little falls drive wilmington delaware de united states pf consumer healthcare bv class class b van asch van wijckstraat g lp amersfoort netherlands pf consumer healthcare brazil importadora e distribuidora quota barueri avenida ceci block iii part tambore district de medicamentos ltda sao paulo brazil pf consumer healthcare canada ulc pf soins de common burrard street suite three bentall centre po box sante sri vancouver bc vx l canada pf consumer healthcare holding bv ordinary van asch van wijckstraat g lp amersfoort netherlands pf consumer healthcare poland spzoo ordinary rzymowskiego street warsaw poland pf consumer healthcare singapore pte ltd ordinary rochester park singapore pf consumer ireland company limited ordinary riverwalk national digital park citywest business park dublin ireland pf consumer taiwan llc interests orange street corporate trust center wilmington delaware united states pfizer biotech corporation ordinary f sec zhong xiao w rd taipei taiwan pfizer consumer healthcare ab ordinary vetenskapsvagen se sollentuna sweden pfizer consumer healthcare gmbh ordinary linkstrasse berlin germany pfizer consumer manufacturing italy srl quota stock via nettunese aprilia prov di latin italy pfizer laboratories pfe pty ltd common flushing meadows building campus sloane bryanston south africa pfizer pfe colombia sas common carrera piso colombia phivco jersey ii limited iii dissolved dec ordinary ifc st helier je st jersey united kingdom phivco jersey limited iii dissolved dec ordinary ifc st helier je st jersey united kingdom gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued phivco llc llc interests corporation service company little falls drive wilmington delaware united states phivco llc llc interests corporation service company little falls drive wilmington delaware united states prism pch limited voting shares non voting great west road brentford middlesex tw gs england shares pt glaxo wellcome indonesia shares b shares jl pulobuaran raya kav iii dd kawasan industri pulogadung timur jakarta indonesia pt gsk consumer healthcare indonesia ordinary graha paramita building th f jalan denpasar raya blok kuningan jakarta selatan indonesia pt bina dentalindo liquidation ordinary gedung graha ganesha lantai jl raya bekasi km jakarta timur indonesia shionogiviiv healthcare llc ii common interests corporation service company little falls drive wilmington delaware united states sinoamerican tianjin smith kline french laboratories ordinary cheng lin zhuang industrial zone dong li district tianjin ltd china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lanka smithkline beecham research limited ordinary great west road brentford middlesex tw gs england smithkline beecham sa ordinary ctra de ajalvir km alcala de henares madrid spain smithkline beechambiomed ooo participation interest leningradskiy prospect building floor premises xiv room moscow russian federation staffordmiller ireland limited ordinary clocherane youghal road dungarvan co waterford ireland staffordmiller limited liquidation ordinary baker street london wu eu united kingdom noncumulative non redeemable preference sterling drug malaya sdn berhad ordinary lot jalan enggangampang hulu kelang industrial estate selangor darul ehsan ampang malaysia sterling products international incorporated ii common corporation service company little falls drive wilmington delaware united states stiefel consumer healthcare uk limited ordinary great west road brentford middlesex tw gs england stiefel egypt llc ii quota amoun street po box el salam city cairo egypt stiefel laboratories ireland limited iv ordinary finisklin business park county sligo ireland treerly health co ltd capital contribution unit room east zhujiang road tianhe district guangzhou city prc china viiv healthcare south africa proprietary limited ii iv ordinary flushing meadows building campus sloane street bryanston south africa viiv healthcare bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands viiv healthcare company common corporation service company little falls drive wilmington delaware united states viiv healthcare finance limited liquidation ordinary baker street london wu eu england viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary redeemable great west road brentford middlesex tw gs england preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limited ii ordinary f tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare kk ordinary akasaka minatoku tokyo japan viiv healthcare limited class shares deferred great west road brentford middlesex tw gs england class b shares class c shares class class class e cumulativepreference viiv healthcare pty ltd ordinary mountain highway boronia vic australia viiv healthcare puerto rico llc llc interests centro international de mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota viale dellagricoltura verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc ii participation interest leningradskiy prospect building floor premises xiv room moscow russian federation gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued viiv healthcare trading services uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited liquidation ordinary ifc st helier je st jersey united kingdom viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada viiv healthcare venture llc llc interests corporation service company little falls drive wilmington delaware united states viivhiv healthcare unipessoal lda quota rua dr antonio loureiro borges arquiparque miraflores alges portugal vog au pty ltd ii ordinary redeemable hughes avenue ermington nsw australia preference winster pharmaceuticals limited ii ordinary association avenue ilupeju industrial estate lagos po box nigeria wyeth consumer healthcare llc membership interest ct corporation system n nd st suite harrisburg pennsylvania united states wyeth pharmaceutical co ltd registered capital baodai west road suzhou jiangsu province china wyeth pharmaceuticals company vii capital contribution state road kilometer guayama puerto rico associates apollo therapeutics llp partnership interest stevenage biosciences catalyst gunnels wood road stevenage hertfordshire sg fx england glaxosmithkline landholding company inc common chino roces avenue city makati philippines index ventures life vi jersey lp partnership interest esplanade st helier jersey je wg channel islands innoviva inc common shares old bayshore highway suite burlingame ca united states kurma biofund ii fcpr partnership interest rue royale paris france longwood fund lp partnership interest prudential tower suite boylston street boston medicxi ventures lp partnership interest esplanade st helier jersey je wg channel islands joint ventures chiron panacea vaccines private limited ii equity shares th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india qualivax pte limited ordinary robinson road singapore quell intellectual property corp llc membership interest corporation service company little falls drive wilmington delaware united states qura therapeutics llc units corporation service company little falls drive wilmington delaware united states significant shareholdings axon therapies inc common shares co coridea llc west th street new york delaware series preference usa gladius pharmaceuticals corporation series shares boulevard west cartier quest laval qc hv b global farm sa shares cazadores de coquimbo piso munro argentina b shares c shares shares e shares f shares longwood fund ii lp partnership interest prudential tower suite boylston street boston neuspera medical inc series preference daggett dr san jose ca united states series b preference sanderling ventures vii lp partnership interest el camino real suite san mateo ca sr one capital fund ib lp partnership interest corporation service company little falls drive city wilmington county new castle delaware vhsquared limited series preference shares copley hill farm cambridge rd babraham cambridge cb gn united kingdom gsk annual report statutory disclosures continued group companies continued following uk subsidiaries take advantage audit exemption set within section companies act period ended december unless otherwise stated undertakings listed owned either directly indirectly glaxosmithkline plc company name security registered address number uk registered subsidiaries exempted audit burroughs wellcome international limited ordinary great west road brentford middlesex tw gs england cellzome limited ordinary great west road brentford middlesex tw gs england clarges pharmaceuticals limited ordinary preference great west road brentford middlesex tw gs england domantis limited ordinary great west road brentford middlesex tw gs england edinburgh pharmaceutical industries limited ordinary preference shewalton road irvine ayrshire ka ap scotland sc eskaylab limited p ordinary great west road brentford middlesex tw gs england glaxo wellcome uk limited ordinary great west road brentford middlesex tw gs england glaxochem uk unlimited ordinary ordinary b great west road brentford middlesex tw gs england ordinary c glaxosmithkline consumer healthcare uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare sri lanka holdings ordinary great west road brentford middlesex tw gs england limited glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england gsk consumer healthcare export limited ordinary great west road brentford middlesex tw gs england gsk limited ii ordinary great west road brentford middlesex tw gs england gsk new zealand holding company limited ordinary great west road brentford middlesex tw gs england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap scotland sc pf consumer healthcare uk limited ordinary great west road brentford middlesex tw gs england phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limited ordinary great west road brentford middlesex tw gs england smith kline french laboratories limited ordinary great west road brentford middlesex tw gs england smithkline beecham export limited ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative great west road brentford middlesex tw gs england nonredeemables ordinary smithkline beecham investments limited ordinary great west road brentford middlesex tw gs england smithkline beecham marketing technical services ordinary great west road brentford middlesex tw gs england limited smithkline beecham nominees limited ordinary great west road brentford middlesex tw gs england stiefel laboratories uk ltd ordinary eurasia headquarters concorde road maidenhead berkshire sl england tesaro uk limited ordinary baker street london wu eu england wellcome foundation limited ordinary great west road brentford middlesex tw gs england viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england company effective ownership viiv healthcare overseas limited phivco uk ii limited phivco uk limited company effective ownership glaxosmithkline consumer healthcare uk limited glaxosmithkline consumer healthcare sri lanka holdings limited gsk consumer healthcare export limited gsk new zealand holding company limited accordance section c companies act company guarantee debts liabilities uk subsidiary undertakings december total sum debts liabilities million million key directly owned glaxosmithkline plc ii ormant entity iii ax resident uk iv entity expected disposed removed v incorporated sweden vi consolidated subsidiary accordance section companies act grounds dominant influence vii principal business address puerto rico viii exempt provisions regulations partnership accounts regulation accordance exemptions noted regulation regulation ix incorporated netherlands gsk annual report strategic report governance remuneration financial statements investor information glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ads gsk adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties novartis transaction threepart interconditional transaction novartis ag involving consumer healthcare vaccines oncology businesses completed march ordinary share fully paid ordinary share capital company profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity gsk exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance code gsk annual report index remuneration policy summary investor relations accounting principles policies key accounting judgements estimates acquisitions disposals key performance indicators adjustments reconciling profit tax operating legal proceedings cash flows major restructuring costs affordability availability modern employer annual general meeting movements equity approach tax net debt assets held sale new accounting requirements associates joint ventures nominations committee report audit risk committee report noncontrolling interests business model noncontrolling interests viiv healthcare cash cash equivalents nonexecutive directors fees cash generation conversion nonfinancial information statement ceos statement notes financial statements chairmans statement operating profit chairmans governance statement intangible assets chairmans remuneration annual statement investments climaterelated financial disclosure noncurrent assets commitments noncurrent liabilities consolidated balance sheet operating incomeexpense consolidated cash flow statement provisions consolidated income statement culture consolidated statement changes equity longterm priorities consolidated statement comprehensive income pensions postemployment benefits consumer healthcare performance consumer healthcare products competition pharmaceuticals contingent consideration liabilities pharmaceutical products competition contingent liabilities intellectual property corporate executive team pipeline corporate governance post balance sheet events corporate responsibility committee report presentation financial statements critical accounting policies principal group companies data engagement principal risks uncertainties directors senior management property plant equipment directors interests shares quarterly trend directors report reconciliation net cash flow movement net debt directors statement responsibilities registrar dividends related party transactions donations political organisations reliable supply political expenditure remuneration governance earnings per share remuneration report employee costs reporting framework employee share schemes responsible business environment right use assets ethics values risk management exchange rates science technology finance expense science committee report finance income section statement financial calendar share capital control financial instruments related disclosures share capital share premium account financial performance shareholder information financial position resources shareholder services contacts financial statements glaxosmithkline plc prepared stakeholder engagement uk gaap taxation five year record tax information shareholders glossary terms board goodwill trade payables group companies trade receivables group financial review transformation separation committee report impact brexit treasury policies independent auditors report trust industry trends turnover segment information innovation us law regulation inventories vaccines investments associates joint ventures vaccine products competition intellectual property viability statement gsk annual report gsk glaxosmithkline plc incorporated english brand names brand names appearing italics throughout report public limited company december trade marks either owned andor licensed gsk associated companies trade marks formed merger glaxo wellcome plc property respective owners smithkline beecham plc gsk acquired two acknowledgements printing english companies december part printed sustainably uk pureprint carbonneutral company fsc chain custody iso merger arrangements certified environmental management system recycling dry waste shares listed london stock exchange paper printed innovation premium fsc certified paper new york stock exchange pulps used totally chlorine free manufacturing mill iso environmental management certification mills energy produced biomass fuels sourced local forestry read wwwgskcom fossil fuels used carbon emissions measured offset using world land trusts carbon balanced scheme download pdfs nnual report f orm f cautionary statement regarding factors include limited discussed groups guidance assumes successful delivery forwardlooking statements principal risks uncertainties pages groups integration restructuring plans also assumes groups reports filed furnished us annual report impacts integration investment programmes following securities exchange commission sec including covid pandemic forwardlooking statements creation consumer healthcare joint venture document written information released made behalf group speak pfizer delivered successfully material costs oral statements made public future date made based upon knowledge investment new product launches rd behalf group may contain forwardlooking information available directors date factored expectations given given potential statements forwardlooking statements give groups annual report development options groups pipeline outlook c n ih nu hv e tr ee eyr yse n dtn u ot r ee n c wx wap loe r l ec ri dlt pa e stt r n e si oo ui jsn f ecy ts cr h tco h tr e sl pf e lt ar ne ns thc c ia bis e pot em r l iie eo ecn vf e tf l u eo sb r u ty c ar u rt g h r ae etv e e te f n n c nefs dx c ph ot ea sn tct h e r p tone n tr pu f oo tr g amb le e ra er n c uf e l n soo f u sif r ea r b tn ou us ai tn oe e na c pou nr ge ch es ie l tr e ie nu e oe f au dro e j ur se tp ero e dr r et eh sfie un le tsd c anh fea ntacy h oni eb g ui e ne n n csa ts e ef n n e c oa eut ne x dr r g ce b u h mgiy aid na rged cn esd hc e nai n tn hda e dul ud om tea k het ea c n gond uror p ii dv one arg cn nn l tu cr ii odfi e nc e id sa tt n ah gi xn e vnv ri eae nts w ep nce n words terms similar meaning connection information document constitute constant currency basis discussion future operating financial offer sell invitation buy shares glaxosmithkline notice regarding limitations performance particular include statements plc invitation inducement engage director liability english law relating future actions prospective products product investment activities past performance relied approvals future performance results current upon guide future performance nothing uk companies act safe harbour limits anticipated products sales efforts expenses annual report construed profit forecast liability directors respect statements outcome contingencies legal proceedings omissions directors report see dividend payments financial results assumptions related guidance strategic report remuneration report accordance legal regulatory obligations outlining guidance group made english law directors would liable including market abuse regulations certain assumptions healthcare sector company third party one uk listing rules disclosure transparency different markets group operates reports contained errors result recklessness rules financial conduct authority group delivery revenues financial benefits current knowing misstatement dishonest concealment undertakes obligation update forwardlooking portfolio pipeline restructuring programmes material fact would otherwise liable pages statements whether result new information future inclusive comprise events otherwise reader however consult group made planning assumptions directors report pages inclusive comprise additional disclosures group may make healthcare systems consumer trends approach strategic report pages inclusive comprise documents publishes andor files sec normality second half year expect remuneration report drawn readers wherever located take note turnover flat low single digit growth presented accordance reliance upon disclosures accordingly assurance given pharmaceuticals vaccines businesses low english company law liabilities directors particular expectation met investors midsingle digit growth consumer healthcare excluding connection reports shall subject cautioned place undue reliance forward brands divestedunder review planning assumptions limitations restrictions provided law looking statements sw ue mll e ns e mar ti en rg ias l g inu ti ed ra run pc te oa nn sd od svi ud pe pn ld oe fx p ec gat ri oo un ps website forwardlooking statements subject assumptions products material mergers acquisitions disposals gsks website wwwgskcom gives additional information inherent risks uncertainties many relate material litigation investigation costs company group notwithstanding references make factors beyond groups control precise save already recognised annual report gsks website none estimate group cautions investors number provisions made share repurchases information made available website constitutes important factors including document company change groups shareholdings part annual report shall deemed could cause actual results differ materially viiv healthcare assumptions also assume material incorporated reference herein expressed implied forwardlooking statement changes healthcare environment guidance factors divestments product exits announced date including product divestments planned connection formation consumer healthcare joint venture pfizer noncore divestments planned fund cash costs separation preparation restructuring programmefront cover technology help us find patterns genetic data faster combining genetics tools like functional genomics artificial intelligence help us understand really causing disease could help double success rates new treatments interventions image created using anonymised realworld clinical trial data formatted produce visualisations unexpected natural groupings patterns within dataset give us new insight patients best respond new medicines search us head office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel registered number wwwgskcom